



- (51) **International Patent Classification:**
A61K 47/48 (2006.01) *A61P 35/00* (2006.01)
C07K 16/30 (2006.01)
- (21) **International Application Number:** PCT/EP2016/058371
- (22) **International Filing Date:** 15 April 2016 (15.04.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:** 1506393.6 15 April 2015 (15.04.2015) GB
- (72) **Inventors; and**
- (71) **Applicants :** VAN BERKEL, Patricius Hendrikus Cornelis [NL/CH]; ADC Therapeutics Sàrl, Rue Saint Pierre 2 c/o Michael Forer, 1003 Lausanne (CH). HOWARD, Philip Wilson [GB/GB]; c/i MedImmune Limited, Riverside Building, Granta Park, Cambridge Cambridgeshire CB1 7PH (GB).
- (74) **Agents:** ANDREWS, Robert et al.; Mewburn Ellis LLP, City Tower, 40 Basinghall Street, London Greater London EC2V 5DE (GB).

- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES




Figure 1

(57) **Abstract:** Site-specific antibody-drug conjugates are described, in particular conjugates comprising an antibody which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and pyrrolbenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.

WO 2016/166299 A1

SITE-SPECIFIC ANTIBODY-DRUG CONJUGATES

The present disclosure relates to site-specific antibody-drug conjugates. Conjugates comprising pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker to the antibody which binds PSMA are described.

Background

Antibody-drug conjugates

Antibody therapy has been established for the targeted treatment of patients with cancer, immunological and angiogenic disorders (Carter, P. (2006) *Nature Reviews Immunology* 6:343-357). The use of antibody-drug conjugates (ADC), i.e. immunoconjugates, for the local delivery of cytotoxic or cytostatic agents, i.e. drugs to kill or inhibit tumor cells in the treatment of cancer, targets delivery of the drug moiety to tumors, and intracellular accumulation therein (Junutula, *et al.*, 2008b *Nature Biotech.*, 26(8):925-932; Dornan *et al* (2009) *Blood* 114(13):2721-2729; US 7521541; US 7723485; WO2009/052249; McDonagh (2006) *Protein Eng. Design & Sel.* 19(7): 299-307; Doronina *et al* (2006) *Bioconj. Chem.* 17:114-124; Erickson *et al* (2006) *Cancer Res.* 66(8):1-8; Sanderson *et al* (2005) *Clin. Cancer Res.* 11:843-852; Jeffrey *et al* (2005) *J. Med. Chem.* 48:1344-1358; Hamblett *et al* (2004) *Clin. Cancer Res.* 10:7063-7070).

The present inventors have developed particular antibody-drug conjugates in which the antibody moiety is modified so as to increase the safety and efficacy of the ADC.

Site-specific conjugation

In ADCs cytotoxic drugs have typically been conjugated to the antibodies in a non-site-specific manner via lysine side chains or by reducing interchain disulfide bonds present in the antibodies to provide activated native cysteine sulfhydryl groups.

Site-specific conjugation of drug to antibody has also been considered with a view to provide ADC populations with high homogeneity and batch-to-batch consistency with respect to drug-to-antibody ratio (DAR) and attachment site. Site-specific attachment has typically been achieved by substituting a native amino acid in the antibody with an amino acid such as cysteine, to which a drug moiety can be conjugated (see Stimmel *et al.*, *JBC*, Vol. 275, No. 39, Issue of September 29, pp. 30445–30450 – conjugation of an IgG S442C variant with bromoacetyl-TMT); also Junutula *et al.*, *Nature Biotechnology*, vol.26, no.8, pp.925-932). Junutula *et al.* report that site-specific ADCs in which drug moieties were attached to

specific cysteine residues engineered into the antibody sequence exhibited comparable efficacy and reduced systemic toxicity compared to non-specifically conjugated ADCs.

Other studies have investigated the biological characteristics of ADCs comprising cytotoxic drug moieties conjugated to antibodies at specific sites. For example, WO2013/093809 discusses a number of engineered antibody constant regions, a sub-set of which are exemplified as part of conjugates to cytotoxic drugs such as monomethyl auristatin D (MMAD). WO2011/005481 describes engineered antibody Fc regions for site-specific conjugation, including exemplification of biotin-PEG2-maleimide to a number of the engineered antibodies. WO2006-065533 describes antibody Fc regions in which one or more of the 'native' interchain-disulphide-forming cysteines present in the heavy and/or light chain is substituted with another amino acid, so as to leave the complementary cysteine sulphhydryl available for conjugation to a drug moiety.

Strop et al., Chemistry & Biology 20, 161-167, February 21, 2013 assessed the stability and pharmacokinetics of a number of site-specific ADCs which differed from each other only in the location of the site used to conjugate the drug to the antibody. The authors report that for the tested ADCs the conjugation site influences the ADC stability and pharmacokinetics in a species-dependent manner.

The present inventors have developed particular antibody-drug conjugates in which the drug moiety is conjugated in a site-specific manner.

Summary

The present inventors have found that antibody-drug conjugates where the Drug unit (D^L) is conjugated to particular interchain cysteine residues have unexpected and advantageous properties. In particular, these newly developed ADCs have advantageous manufacturing and pharmacological properties which are described herein.

Accordingly, in a first aspect – in order to increase the efficacy and efficiency of conjugation of Drug unit (D^L) to the desired interchain cysteine residue(s) – the antibody of the conjugates described herein comprises one or more substitution of an interchain cysteine residue by an amino acid that is not cysteine.

The antibody of the conjugates described herein retains at least one unsubstituted interchain cysteine residue for conjugation of the drug moiety to the antibody. The number of retained interchain cysteine residues in the antibody is greater than zero but less than the total

number of interchain cysteine residues in the parent (native) antibody. Thus, in some embodiments, the antibody has at least one, at least two, at least three, at least four, at least five, at least six or at least seven interchain cysteine residues. In typical embodiments, the antibody has an even integral number of interchain cysteine residues (e.g., at least two, four, six or eight). In some embodiments, the antibody has less than eight interchain cysteine residues.

AbLJ

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.120.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbHJ

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprise heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14 and 103 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbBJ

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. In some embodiments, the cysteine at position 102 in SEQ ID NO: 120 is also substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.120.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. In some embodiments, the cysteine at position 102 in SEQ ID NO: 120 is also substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.120.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbDJ

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprises light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprises heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprises heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments, some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 103, 106 and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

The present inventors have further found that antibody-drug conjugates wherein the antibody comprises specific mutations, or combinations of mutations, in the heavy chain have unexpected and advantageous properties. In particular, the present inventors have identified antibody mutations in the heavy chain which reduce the toxicity and increase the serum half-lives of the ADCs they are incorporated into, as compared to otherwise identical ADCs comprising antibodies which lack the specific mutations.

For example, in the IgG1 isotype the present inventors have identified the Leucine residues at positions 234 and 235 in the EU index set forth in Kabat (residues L117 and L118 in SEQ ID NO.110) as residues which, when substituted by an amino acid that is not leucine, allow for ADCs with advantageous properties.

Accordingly, in a second aspect the antibody of the conjugates described herein comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid (that is, an amino acid that is not identical to that found in the 'wild-type' sequence). Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted by any other amino acid.

In some embodiments the antibody is an IgG1 isotype and the leucine at position 234 in the EU index set forth in Kabat and/or the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine. Preferably both the leucines at position 234 and 235 in the EU index set forth in Kabat are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

For example, in some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments the antibody is an IgG3 isotype and the leucine at position 234 in the EU index set forth in Kabat and/or the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine. Preferably both the leucines at position 234 and 235 in the EU index set forth in Kabat are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

For example, in some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments the antibody is an IgG4 isotype and the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine, such as alanine. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

For example, in some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

The modifications described in the first aspect can be advantageously combined in the same antibody with the modifications described in the second aspect.

Accordingly, in a third aspect the antibody of the conjugates described herein:

- (1) comprises one or more substitution of an interchain cysteine residue by an amino acid that is not cysteine and retains at least one unsubstituted interchain cysteine residue for conjugation of the drug moiety to the antibody; and
- (2) comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid (that is, an amino acid that is not identical to that found in the 'wild-type' sequence).

AbLJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii)

comprise light chains each having an amino acid substitution of the interchain cysteine residue κ LC214 or λ LC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 in SEQ ID NO: 110 and/or the leucine at position 118 in SEQ ID NO: 110 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. Preferably both the leucines at position 117 and 118 in SEQ ID NO: 110 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 in SEQ ID NO: 130 and/or the leucine at position 165 in SEQ ID NO: 130 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130. Preferably both the leucines at position 164 and 165 in SEQ ID NO: 130 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 in SEQ ID NO: 140 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

AbHJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, (iii) comprise heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 in SEQ ID NO: 110 and/or the leucine at position 118 in SEQ ID NO: 110 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 117 and 118 in SEQ ID NO: 110 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 in SEQ ID NO: 130 and/or the leucine at position 165 in SEQ ID NO: 130 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 164 and 165 in SEQ ID NO: 130 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 in SEQ ID NO: 140 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

AbBJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine

located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 in SEQ ID NO: 110 and/or the leucine at position 118 in SEQ ID NO: 110 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. Preferably both the leucines at position 117 and 118 in SEQ ID NO: 110 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 in SEQ ID NO: 130 and/or the leucine at position 165 in SEQ ID NO: 130 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130. Preferably both the leucines at position 164 and 165 in SEQ ID NO: 130 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 in SEQ ID NO: 140 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

AbDJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprises light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, (iii) comprises heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, (iii) comprises heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid

substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments, some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 in SEQ ID NO: 110 and/or the leucine at position 118 in SEQ ID NO: 110 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 117 and 118 in SEQ ID NO: 110 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 in SEQ ID NO: 130 and/or the leucine at position 165 in SEQ ID NO: 130 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 164 and 165 in SEQ ID NO: 130 are substituted by an amino acid that is not leucine, such as alanine. One or both Leucines may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 in SEQ ID NO: 140 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. The Leucine may be also substituted by other amino acids which are not Leucine, such as Glycine, Valine, or Isoleucine.

Brief description of Figures

Figure 1

Comparative systemic toxicity of site-specific ADCs, as described in Example 7.

Detailed description

Described herein are conjugates comprising a pyrrolobenzodiazepine (PBD) drug moiety with a labile C2 or N10 protecting group and an antibody which binds PSMA, wherein the antibody comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and wherein the drug moiety is conjugated to an interchain cysteine residue.


Also described herein are conjugates comprising the antibodies described herein conjugated to other (i.e. non-PBD) functional moieties. Examples of a functional moiety include a drug (PBD or non-PBD), a reporter, an organic moiety, and/or a binding moiety.

Also contemplated are conjugates comprising an antibody fragment as described herein, along with pharmaceutical compositions comprising the conjugates. Example antibodies or antibody fragment include scFv-Fc fusions and minibodies. Methods of preparing the conjugates and using the conjugates are disclosed, along with methods of using the conjugates to treat a number of diseases.

Pyrrolobenzodiazepines


In some embodiments, the conjugates described herein comprise a PBD drug moiety. Some pyrrolobenzodiazepines (PBDs) have the ability to recognise and bond to specific sequences of DNA; the preferred sequence is PuGPu. The first PBD antitumour antibiotic, anthramycin, was discovered in 1965 (Leimgruber, *et al.*, *J. Am. Chem. Soc.*, **87**, 5793-5795 (1965); Leimgruber, *et al.*, *J. Am. Chem. Soc.*, **87**, 5791-5793 (1965)). Since then, a number of naturally occurring PBDs have been reported, and over 10 synthetic routes have been developed to a variety of analogues (Thurston, *et al.*, *Chem. Rev.* **1994**, 433-465 (1994);

Antonow, D. and Thurston, D.E., *Chem. Rev.* **2011** 111 (4), 2815-2864). Family members include abbeymycin (Hochlowski, *et al.*, *J. Antibiotics*, **40**, 145-148 (1987)), chicamycin (Konishi, *et al.*, *J. Antibiotics*, **37**, 200-206 (1984)), DC-81 (Japanese Patent 58-180 487; Thurston, *et al.*, *Chem. Brit.*, **26**, 767-772 (1990); Bose, *et al.*, *Tetrahedron*, **48**, 751-758 (1992)), mazethramycin (Kuminoto, *et al.*, *J. Antibiotics*, **33**, 665-667 (1980)), neothramycins A and B (Takeuchi, *et al.*, *J. Antibiotics*, **29**, 93-96 (1976)), porothramycin (Tsunakawa, *et al.*, *J. Antibiotics*, **41**, 1366-1373 (1988)), prothracarcin (Shimizu, *et al.*, *J. Antibiotics*, **29**, 2492-2503 (1982); Langley and Thurston, *J. Org. Chem.*, **52**, 91-97 (1987)), sibanomicin (DC-102)(Hara, *et al.*, *J. Antibiotics*, **41**, 702-704 (1988); Itoh, *et al.*, *J. Antibiotics*, **41**, 1281-1284 (1988)), sibiromycin (Leber, *et al.*, *J. Am. Chem. Soc.*, **110**, 2992-2993 (1988)) and tomamycin (Arima, *et al.*, *J. Antibiotics*, **25**, 437-444 (1972)). PBDs are of the general structure:



They differ in the number, type and position of substituents, in both their aromatic A rings and pyrrolo C rings, and in the degree of saturation of the C ring. In the B-ring there is either an imine (N=C), a carbinolamine (NH-CH(OH)), or a carbinolamine methyl ether (NH-CH(OMe)) at the N10-C11 position which is the electrophilic centre responsible for alkylating DNA. All of the known natural products have an (*S*)-configuration at the chiral C11a position which provides them with a right-handed twist when viewed from the C ring towards the A ring. This gives them the appropriate three-dimensional shape for isohelicity with the minor groove of B-form DNA, leading to a snug fit at the binding site (Kohn, In *Antibiotics III*. Springer-Verlag, New York, pp. 3-11 (1975); Hurley and Needham-VanDevanter, *Acc. Chem. Res.*, **19**, 230-237 (1986)). Their ability to form an adduct in the minor groove, enables them to interfere with DNA processing, hence their use as antitumour agents.

One pyrrolobenzodiazepine compound is described by Gregson *et al.* (*Chem. Commun.* **1999**, 797-798) as compound **1**, and by Gregson *et al.* (*J. Med. Chem.* **2001**, *44*, 1161-1174) as compound **4a**. This compound, also known as SG2000, is shown below:



SG2000


WO 2007/085930 describes the preparation of dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody. The linker is present in the bridge linking the monomer PBD units of the dimer.

WO 2011/130613 and WO 2011/130616 describe dimer PBD compounds having linker groups for connection to a cell binding agent, such as an antibody. The linker in these compounds is attached to the PBD core via the C2 position, and are generally cleaved by action of an enzyme on the linker group. In WO 2011/130598, the linker in these compounds is attached to one of the available N10 positions on the PBD core, and are generally cleaved by action of an enzyme on the linker group.


Conjugates comprising PBD drug moieties

The present inventors have found that conjugates where the Drug unit (D^L) is conjugated to particular interchain cysteine residues have unexpected and advantageous properties including increased efficacy and stability, improved ease of manufacture, and reduced systemic toxicity.

Accordingly, in one aspect the disclosure provides a conjugate of formula L - $(DL)_p$, where DL is of formula I or II::



I



II

wherein:


L is an antibody (Ab) which binds PSMA;


when there is a double bond present between C2' and C3', R¹² is selected from the group consisting of:


(ia) C₅₋₁₀ aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene;

(ib) C₁₋₅ saturated aliphatic alkyl;


(ic) C₃₋₆ saturated cycloalkyl;

(id) , wherein each of R²¹, R²² and R²³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R¹² group is no more than 5;

(ie) , wherein one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

(if) , where R²⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;

when there is a single bond present between C2' and C3',

R¹² is , where R^{26a} and R^{26b} are independently selected from H, F, C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C₁₋₄ alkyl amido and C₁₋₄ alkyl ester; or, when one of R^{26a} and R^{26b} is H, the other is selected from nitrile and a C₁₋₄ alkyl ester;

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

where R and R' are independently selected from optionally substituted C₁₋₁₂ alkyl, C₃₋₂₀ heterocyclyl and C₅₋₂₀ aryl groups;

R⁷ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, NHRR', nitro, Me₃Sn and halo;

R" is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR^{N2} (where R^{N2} is H or C₁₋₄ alkyl), and/or aromatic rings, e.g. benzene or pyridine;

Y and Y' are selected from O, S, or NH;

R^{6'}, R^{7'}, R^{9'} are selected from the same groups as R⁶, R⁷ and R⁹ respectively;

[Formula I]

R^{L1'} is a linker for connection to the antibody (Ab);

R^{11a} is selected from OH, OR^A, where R^A is C₁₋₄ alkyl, and SO_zM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;

R²⁰ and R²¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R²⁰ is selected from H and R^C, where R^C is a capping group;


R²¹ is selected from OH, OR^A and SO_zM;


when there is a double bond present between C2 and C3, R² is selected from the group consisting of:


(ia) C₅₋₁₀ aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene;

(ib) C₁₋₅ saturated aliphatic alkyl;


(ic) C₃₋₆ saturated cycloalkyl;


(id)  , wherein each of R¹¹, R¹² and R¹³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R² group is no more than 5;

(ie)  , wherein one of R^{15a} and R^{15b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

(if)  , where R¹⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;


when there is a single bond present between C2 and C3,



R^2 is , where R^{16a} and R^{16b} are independently selected from H, F, C_{1-4} saturated alkyl, C_{2-3} alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C_{1-4} alkyl amido and C_{1-4} alkyl ester; or, when one of R^{16a} and R^{16b} is H, the other is selected from nitrile and a C_{1-4} alkyl ester;

[Formula II]


R^{22} is of formula IIIa, formula IIIb or formula IIIc:



where A is a C_{5-7} aryl group, and either


(i) Q^1 is a single bond, and Q^2 is selected from a single bond and $-Z-(CH_2)_n-$, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or

(ii) Q^1 is $-CH=CH-$, and Q^2 is a single bond;





where;

R^{C1} , R^{C2} and R^{C3} are independently selected from H and unsubstituted C_{1-2} alkyl;



where Q is selected from $O-R^{L2'}$, $S-R^{L2'}$ and $NR^N-R^{L2'}$, and R^N is selected from H, methyl and ethyl

X is selected from the group comprising: $O-R^{L2'}$, $S-R^{L2'}$, $CO_2-R^{L2'}$, $CO-R^{L2'}$, $NH-C(=O)-R^{L2'}$,

$NHNH-R^{L2'}$, $CONHNH-R^{L2'}$, , , $NR^N-R^{L2'}$, wherein R^N is

selected from the group comprising H and C_{1-4} alkyl;

$R^{L2'}$ is a linker for connection to the antibody (Ab);

R^{10} and R^{11} either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R^{10} is H and R^{11} is selected from OH, OR^A and SO_2M ;

R^{30} and R^{31} either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R^{30} is H and R^{31} is selected from OH, OR^A and SO_2M .


[Formula I and II]

wherein:

- (1) the antibody comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and the conjugation of the drug moiety to the antibody is at an interchain cysteine residue; and/or
- (2) the antibody comprises a heavy chain having a substitution of the amino acid at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

In some embodiments, it may be preferred that the conjugate is selected from a conjugate of formula ConjA, ConjB, ConjC, ConjD, ConjE, ConjF, ConjG and ConjH:


ConjA



ConjA

;


ConjB



ConjB

;


ConjC:



ConjC

;


ConjD :



ConjD

;


ConjE:



ConjE

;


ConjF:



ConjF

;


ConjG:



ConjG

ConjH:




A second aspect of the disclosure provides a method of making a conjugate according to the first aspect of the disclosure comprising conjugating a compound of formula I^L or II^L:



to the antibody (Ab) as defined below, wherein:


R^{L1} is a linker suitable for conjugation to the antibody (Ab);

R^{22L} is of formula IIIa^L, formula IIIb^L or formula IIIc^L:



where Q^L is selected from O-R^{L2}, S-R^{L2} and NR^N-R^{L2}, and R^N is selected from H, methyl and ethyl

X^L is selected from the group comprising: O-R^{L2}, S-R^{L2}, CO₂-R^{L2}, CO-R^{L2}, N=C=O-R^{L2},







selected from the group comprising H and C₁₋₄ alkyl;

R^{L2} is a linker suitable for conjugation to the antibody (Ab);


and all the remaining groups are as defined in the first aspect.

Thus it may be preferred in the second aspect, that the disclosure provides a method of making a conjugate selected from the group consisting of ConjA, ConjB, ConjC, ConjD,

ConjE, ConjF, ConjG and ConjH comprising conjugating a compound which is selected respectively from A:




E:




E ;

F:




;

G:



; or


H:



with an antibody as defined below.

Compounds A to E are disclosed in WO 2014/057073 and WO 2014/057074.

WO 2011/130613 discloses compound 51:



WO 2013/041606 discloses Compound F (see compound 13e in WO 2013/041606).

Compound F differs from compound 30 by only having a $(\text{CH}_2)_3$ tether between the PBD moieties, instead of a $(\text{CH}_2)_5$ tether, which reduces the lipophilicity of the released PBD dimer. The linking group in compounds F and G is attached to the C2-phenyl group in the para rather than meta position.

Compound H has a cleavable protecting group on the second imine group which avoids cross-reactions during its synthesis and in the final product avoids the formation of carbinolamine and carbinolamine methyl ethers. This protection also avoids the presence of an reactive imine group in the molecule.


Compounds A, B, C, D, E, F, G and H have two sp^2 centres in each C-ring, which may allow for stronger binding in the minor groove of DNA, than for compounds with only one sp^2 centre in each C-ring.

The drug linkers disclosed in WO 2010/043880, WO 2011/130613, WO 2011/130598, WO 2013/041606 and WO 2011/130616 may be used in the present disclosure, and are incorporated herein by reference. The drug linkers described herein may be synthesised as described in these disclosures.

Delivery of PBD compounds


The present disclosure is suitable for use in providing a PBD compound to a preferred site in a subject. The conjugate may allow the release of an active PBD compound that does not retain any part of the linker. In such as case there is no stub present that could affect the reactivity of the PBD compound.

ConjA would release the compound RelA:




RelA

ConjB and ConjF would release the compound RelB:




RelB

ConjC would release the compound RelC:




RelC

ConjD would release the compound RelD:




RelD

ConjE and ConjH would release the compound RelE:



RelE

and ConjG would release the compound RelG:



RelG

The specified link between the PBD dimer and the antibody, in the present disclosure is preferably stable extracellularly. Before transport or delivery into a cell, the antibody-drug conjugate (ADC) is preferably stable and remains intact, i.e. the antibody remains linked to the drug moiety. The linkers are stable outside the target cell and may be cleaved at some efficacious rate inside the cell. An effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow specific intracellular delivery of the conjugate or drug moiety; (iii) remain stable and intact, i.e. not cleaved, until the conjugate has been delivered or transported to its targeted site; and (iv) maintain a cytotoxic, cell-killing effect or a cytostatic effect of the PBD drug moiety. Stability of the ADC may be measured by standard analytical techniques such as *in vitro* cytotoxicity, mass spectroscopy, HPLC, and the separation/analysis technique LC/MS.

Delivery of the compounds of formulae RelA, RelB, RelC, RelD, RelE or RelG is achieved at the desired activation site of the conjugates of formulae ConjA, ConjB, ConjC, ConjD, ConjE, ConhF, ConjG or ConjH by the action of an enzyme, such as cathepsin, on the linking group, and in particular on the valine-alanine dipeptide moiety.

The Antibody: substitution of Interchain cysteine residues

In a first aspect, the antibody of the conjugates described herein comprise an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine.

Interchain cysteine residues

Naturally occurring antibodies generally include two larger heavy chains and two smaller light chains. In the case of native full-length antibodies, these chains join together to form a "Y-shaped" protein. Heavy chains and light chains include cysteine amino acids that can be joined to one another via disulphide linkages. Heavy chains are joined to one another in an

antibody by disulphide linkages between cysteine amino acids in each chain. Light chains are joined to heavy chains also by disulphide linkages between cysteine amino acids in the chains. Such disulphide linkages generally are formed between thiol side chain moieties of the free cysteine amino acids. The cysteine amino acids which typically take part in these interchain disulphide linkages in naturally occurring antibodies are described herein as "interchain cysteine residues" or "interchain cysteines". For example, three particular cysteine amino acids in each IgG1 isotype heavy chain ('HC' - 220, 226, and 229 in the EU index set forth in Kabat) and one particular cysteine in each light chain ('LC' – κ(kappa)214 or λ(lambda)213) are "interchain cysteines" as they generally participate in disulphide linkages between the antibody chains.

The interchain cysteine residues are located in the CL domain of the light chain, the CH₁ domain of the heavy chain, and in the hinge region. The number of interchain cysteine residues in an antibody depends on the antibody isotype.

Nature of substitutions

As noted above, the antibody of the conjugates described herein comprise an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine. The amino acid substituted for an interchain cysteine typically does not include a thiol moiety, and often is a valine, serine, threonine, alanine, glycine, leucine, isoleucine, other naturally occurring amino acid, or non-naturally occurring amino acid. In some preferred embodiments, the amino acid substitution is a valine for the interchain cysteine residue.

In some embodiments, one or more or all interchain cysteines are 'substituted' for no amino acid; that is, the one or more or all interchain cysteines is deleted and not replaced by another amino acid. Accordingly, in some embodiments the phrase "...a light chain comprising the amino acid sequence of SEQ ID NO. XXX wherein the cysteine at position YYY in SEQ ID NO: XXX, is substituted by an amino acid that is not cysteine." Has the same meaning as "...a light chain comprising the amino acid sequence of SEQ ID NO. XXX wherein the cysteine at position YYY in SEQ ID NO: XXX, is deleted."

For example, SEQ ID NO.153 as disclosed herein is an example of "a light chain comprising the amino acid sequence of SEQ ID NO. 150 wherein the cysteine at position 105 in SEQ ID NO: 150, is substituted by an amino acid that is not cysteine" wherein the cysteine is substituted for no amino acid i.e. deleted.

In embodiments comprising “a light chain comprising the amino acid sequence of SEQ ID NO. 160 wherein the cysteine at position 102 in SEQ ID NO: 160, is deleted” the serine at position 103 is also preferably deleted. See, for example, SEQ ID NO: 163.

Even when not explicitly stated, the terms “substituted” and “a substitution” as used herein in reference to amino acids is used to mean the replacement of an amino acid residue with a different – that is, *non-identical* – amino acid residue (or with no amino acid residue – that is, a deletion – as explained above). Thus, an amino acid residue nominally ‘replacement’ by an identical residue – for example replacing a cysteine residue with a cysteine residue – is not considered “substituted” or “a substitution”.

As used herein, “substitution of a leucine by an amino acid which is not leucine” means the replacement of the specified with any non-leucine amino acid. This can be - for example - Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, Cys, Gly, Ala, Val, Ile, Phe, Trp, Pro, or Met, but is preferably Gly, Ala, Val, or Ile, and most preferably Ala,

The statement in this “Nature of substitutions” section are applicable to all three aspects of the disclosure described herein.

Retention of unsubstituted interchain cysteines

The antibody of the conjugates described herein retains at least one unsubstituted interchain cysteine residue for conjugation of the drug moiety to the antibody. The number of retained interchain cysteine residues in the antibody is greater than zero but less than the total number of interchain cysteine residues in the parent (native) antibody. Thus, in some embodiments, the antibody has at least one, at least two, at least three, at least four, at least five, at least six or at least seven interchain cysteine residues. In typical embodiments, the antibody has an even integral number of interchain cysteine residues (e.g., at least two, four, six or eight). In some embodiments, the antibody has less than eight interchain cysteine residues.

In some embodiments, the antibody of the conjugates described herein retains the unsubstituted hinge region interchain cysteines. For example, in some embodiments the antibody retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein has an amino acid substitution of each of the hinge region interchain cysteines. For example, in some

embodiments the antibody has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein retains at least one unsubstituted hinge region interchain cysteine. For example, in some embodiments the antibody retains an unsubstituted HC226 according to the EU index as set forth in Kabat. In some embodiments the antibody retains an unsubstituted HC229 according to the EU index as set forth in Kabat. In some embodiments each heavy chain retains exactly one (i.e. not more than one) unsubstituted hinge region interchain cysteine.

In some embodiments, the antibody of the conjugates described herein has the amino acid substitution of valine for each of the hinge region interchain cysteines. For example, in some embodiments the antibody has the amino acid substitution of valine each of HC226 and HC229 according to the EU index as set forth in Kabat

Embodiments defined using the EU index of Kabat

In some embodiments, the antibody of the conjugates described herein comprise: (i) a light chain having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (ii) a heavy chain retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments, the antibody of the conjugates described herein comprise: (i) a light chain having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (ii) a heavy chain retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprise: (i) light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (ii) heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments, the antibody of the conjugates described herein comprise: (i) light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (ii) heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprise: (i) a light chain retaining the unsubstituted interchain cysteine located in the C_L domain, and (ii) a heavy chain having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments, the antibody of the conjugates described herein comprise: (i) a light chain retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (ii) a heavy chain having an amino acid substitution of the interchain cysteine residue HC220 according to the EU index as set forth in Kabat. In some embodiments the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments, the antibody of the conjugates described herein comprise: (i) light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (ii) heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments, the antibody of the conjugates described herein comprise: (i) light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (ii) heavy chains each having an amino acid substitution of the interchain cysteine residue HC220 according to the EU index as set forth in Kabat. In some embodiments the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

AbLJ

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise a light chain having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise a heavy chain retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise a light chain having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise a heavy chain retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

AbHJ

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise a light chain retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprise a heavy chain having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise a light chain retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise a heavy chain having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprise heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted

interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

AbBJ

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprise a light chain having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise a heavy chain retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise a light chain having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise a heavy chain retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of the hinge region interchain cysteines, (ii) comprises a light chain having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprises a heavy chain retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises a light chain

having an amino acid substitution of the interchain cysteine residue κ LC214 or λ LC213 according to the EU index as set forth in Kabat, and (iii) comprises a heavy chain retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of the hinge region interchain cysteines, (ii) comprises light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, and (iii) comprises heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each having an amino acid substitution of the interchain cysteine residue κ LC214 or λ LC213 according to the EU index as set forth in Kabat, and (iii) comprises heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

AbDJ

In some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of the hinge region interchain cysteines, (ii) comprises a light chain retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprises a heavy chain having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises a light chain retaining the unsubstituted interchain cysteine κ LC214 or λ LC213 according to the EU index as set forth in Kabat, and (iii) comprises a heavy chain having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κ LC214 or λ LC213 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprises light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprises

heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprises heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprises a light chain retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprises a heavy chain having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises a light chain retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprises a heavy chain having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

In some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of the hinge region interchain cysteines, (ii) comprises light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, and (iii) comprises heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain. For example, in some embodiments the antibody of the conjugates described herein: (i) has the amino acid substitution of valine for each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, and (iii) comprises heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

Correspondence between the Kabat system and the disclosed sequences

The following Table 1 illustrates positions of interchain cysteines in the heavy chain constant region and light chain constant region of particular antibody isotypes according to the EU index as set forth in Kabat and with reference to the sequences disclosed herein. Each of the interchain cysteine positions present in an antibody or antibody fragment may be substituted with an amino acid that is not a cysteine.

Antibody Isotype	Kabat EU / SEQ ID NO	Position of Cysteine					
		131	220	n/a	n/a	226	229
HC	Kabat EU position	131	220	n/a	n/a	226	229
IgG1	Corresponding position in SEQ ID NO: 110	n/a	103	n/a	n/a	109	112
IgG2	Corresponding position in SEQ ID NO: 120	14	103	n/a	n/a	106	109
IgG3	Corresponding position in SEQ ID NO: 130	14	n/a	n/a	n/a	111	114
IgG4	Corresponding position in SEQ ID NO: 140	14	n/a	n/a	n/a	106	109
LC							
κ	Kabat EU position	214					
	Corresponding position in SEQ ID NO: 150	105					
λ	Kabat EU position	213					
	Corresponding position in SEQ ID NO: 160	102					

Table 1

Heavy chain and Light Chain embodiments defined using disclosed sequences*AbLJ Heavy Chain*

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110 or fragment thereof, SEQ ID NO.120 or fragment thereof, SEQ ID NO.130 or fragment thereof, or SEQ ID NO.140 or fragment thereof. Preferably the drug moiety is conjugated to the cysteine at position 103 of

SEQ ID NO.110, the cysteine at position 14 of SEQ ID NO.120, the cysteine at position 14 of SEQ ID NO.130, or the cysteine at position 14 of SEQ ID NO.140.

AbHJ Heavy Chain

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein the cysteine at position 103 of SEQ ID NO.110, if present, is substituted by an amino acid that is not cysteine. For example, SEQ ID NO. 111 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110 wherein the cysteine at position 103 of SEQ ID NO.110 is substituted by a serine residue. SEQ ID NO. 112 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110 wherein the cysteine at position 103 of SEQ ID NO.110 is substituted by a valine residue.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein the cysteine at positions 14 of SEQ ID NO.120, if present, is substituted by an amino acid that is not cysteine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.

AbBJ Heavy Chain

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine. For example, SEQ ID NO: 113 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110 wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by a serine residue. SEQ ID NO: 114 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by a valine residue. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. In some embodiments, the cysteine at position 109 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 112 in SEQ ID NO: 110, if present, is unsubstituted. In some embodiments, the cysteine at position 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 109 in SEQ ID NO: 110, if present, is unsubstituted.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine. In some embodiments, the cysteine at position 102 in SEQ ID NO: 120, if present, is also substituted by an amino acid that is not cysteine. In some embodiments, all but one of the cysteines at positions 103, 106, 109, and 102 in SEQ ID NO: 120, if present, are substituted by an amino acid that is not cysteine. For example, in some embodiments, the cysteine at position 103, 106, 109, or 102 in SEQ ID NO: 120, if present, is unsubstituted. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.120.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine. In some embodiments, all but one of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, are substituted by an amino acid that is not cysteine. For example, in some embodiments, the cysteine at position 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, or 159 in SEQ ID NO: 130, if present, is unsubstituted. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine. In some embodiments, the cysteine at position 106 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 109 in SEQ ID NO: 140, if present, is unsubstituted. In some embodiments, the cysteine at position 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 106 in SEQ ID NO: 140, if

present, is unsubstituted. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbDJ Heavy Chain

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine. For example, SEQ ID NO: 115 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110 wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by a serine residue. SEQ ID NO: 116 discloses a heavy chain comprising the amino acid sequence of SEQ ID NO.110 wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by a valine residue. In some embodiments, the cysteine at position 109 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 112 in SEQ ID NO: 110, if present, is unsubstituted. In some embodiments, the cysteine at position 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 109 in SEQ ID NO: 110, if present, is unsubstituted.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14, 103, 106 and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine. In some embodiments, all but one of the cysteines at positions 103, 106, 109, and 102 in SEQ ID NO: 120, if present, are substituted by an amino acid that is not cysteine. For example, in some embodiments, the cysteine at position 103, 106, 109, or 102 in SEQ ID NO: 120, if present, is unsubstituted.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine. In some embodiments, all but one of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, are substituted by an amino acid that is not cysteine. For example, in some embodiments, the cysteine at position 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, or 159 in SEQ ID NO: 130, if present, is unsubstituted.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine. In some embodiments, the cysteine at position 106 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 109 in SEQ ID NO: 140, if present, is unsubstituted. In some embodiments, the cysteine at position 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine, and the cysteine at position 106 in SEQ ID NO: 140, if present, is unsubstituted.

Light Chains

In some embodiments, the antibody of the conjugates described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, or SEQ ID NO. 160 or fragment thereof. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

In some embodiments, the antibody of the conjugates described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, wherein the cysteine at position 105, if present, is substituted by an amino acid that is not cysteine. For example, SEQ ID NO. 151 discloses a light chain comprising the amino acid sequence of SEQ ID NO. 150 wherein the cysteine at position 105 is substituted by a serine residue. SEQ ID NO. 152 discloses a light chain comprising the amino acid sequence of SEQ ID NO. 150 wherein the cysteine at position 105 is substituted by a valine residue. SEQ ID NO. 153 discloses a light chain having the amino acid sequence of SEQ ID NO. 150, wherein the cysteine at position 105 has been deleted.

In some embodiments, the antibody of the conjugates described herein comprises a light chain comprising the amino acid sequence of SEQ ID NO. 160, or fragment thereof, wherein the cysteine at position 102, if present, is substituted by an amino acid that is not cysteine. For example, SEQ ID NO. 161 discloses a light chain comprising the amino acid sequence of SEQ ID NO. 160 wherein the cysteine at position 102 is substituted by a serine residue. SEQ ID NO. 162 discloses a light chain comprising the amino acid sequence of SEQ ID NO. 160 wherein the cysteine at position 102 is substituted by a valine residue. SEQ ID NO. 163 discloses a light chain having the amino acid sequence of SEQ ID NO. 160, wherein the cysteine at position 102 and the serine at position 103 have been deleted.

Immunoglobulin embodiments defined using disclosed sequences*AbLJ IgG1*

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

AbLJ IgG2

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.120.

AbLJ IgG3

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130.

AbLJ IgG4

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbHJ IgG1

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbHJ IgG2

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14 and 103 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbHJ IgG3

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbHJ IgG4

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbBJ IgG1

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

In some embodiments the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted for valine. In some embodiments the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160 is substituted by serine.

AbBJ IgG2A

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

In some embodiments, the cysteine at position 102 in SEQ ID NO: 120 is also substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.120.

In some embodiments the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120 are substituted for valine. In some embodiments the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by serine.

AbBJ IgG2B

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

In some embodiments, the cysteine at position 102 in SEQ ID NO: 120 is also substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.120.

In some embodiments the cysteines at positions 14, 106, and 109 in SEQ ID NO: 120 are substituted for valine. In some embodiments the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by serine.

AbBJ IgG3

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130.

In some embodiments each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 for valine.

In some embodiments the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by serine.

AbBJ IgG4

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

In some embodiments each of the cysteines at positions 106 and 109 in SEQ ID NO: 140 are substituted for valine. In some embodiments the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by serine.

AbDJ IgG1

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbDJ IgG2

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.120, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 103, 106 and 109 in SEQ ID NO: 120 is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbDJ IgG3

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbDJ IgG4

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

The Antibody: substitution of Kabat EU residues 234 and/or 235

In a second aspect, the antibody of the conjugates described herein comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat. It has been unexpectedly found that ADCs in which the antibody bears one, or preferably both, of these substitutions have improved tolerability and increased serum half-lives as compared to otherwise identical ADCs comprising antibodies which lack the specific mutations.

Substitution at Kabat EU 234 / 235

Hazareh, M. et al., Journal of Virology, Vol.75, No.24, pp.12161 – 12168 (2001) discloses an IgG1 antibody mutant comprising a heavy chain in which the leucine residue at Kabat EU 234 and the leucine residue at Kabat EU 235 are both substituted for alanine; the antibody is described in that reference as “IgG1 b12 (L234A, L235A)”. Hazareh et al. does not disclose the IgG1 b12 (L234A, L235A) as part of an ADC.

Hazareh et al. report that introduction of the L234A/L235A double mutation resulted in complete loss of antibody binding by the Fc(gamma)R and C1q proteins, with consequent abolition of both antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Wines, B. D., et al., Journal of Immunology, Vol.164, pp.5313-5318 (2000) shares authors with Hazareh et al. and also describes an L234A / L235A double mutant. There the authors report that the L234A / L235A double mutant slightly reduces (<25%) antibody binding to the FcRn receptor. The FcRn receptor is known to have an important role in antibody recycling, with increased antibody / FcRn affinity reported to extend antibody half-life *in vivo* and improve anti-tumour activity (see Zalevsky, J., Nature Biotechnology 28, 157–159 (2010) [doi:10.1038/nbt.1601]). However, in view of the size of the decrease in FcRn affinity, the

authors of Hazareh et al. conclude that the L234A / L235A double mutation is not expected to significantly reduce the antibody's serum half-life.

Contrary to the expectation following from the above disclosures, it has been found that the ADCs disclosed herein which comprise a heavy chain having substitutions of the residues at positions 234 and 235 in the EU index set forth in Kabat actually have *increased* serum half-lives as compared to otherwise identical ADCs comprising antibodies which lack the mutations. Furthermore, the ADCs comprising a heavy chain having substitutions of the residues at positions 234 and 235 in the EU index set forth also exhibit improved tolerability / reduced toxicity as compared to otherwise identical ADCs comprising antibodies which lack the mutations.

Embodiments defined using the EU index of Kabat

Accordingly, in a second aspect the antibody of the conjugates described herein comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted by any other amino acid.

In some embodiments the antibody is an IgG1 isotype and the leucine at position 234 in the EU index set forth in Kabat and/or the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine.

In some embodiments the antibody is an IgG3 isotype and the leucine at position 234 in the EU index set forth in Kabat and/or the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine.

In some embodiments the antibody is an IgG4 isotype and the leucine at position 235 in the EU index set forth in Kabat is substituted by an amino acid that is not leucine, such as alanine.

Correspondence between the Kabat system and the disclosed sequences.

The following Table 2 illustrates positions of corresponding residues in the heavy chain constant region of particular antibody isotypes according to the EU index as set forth in Kabat and with reference to the sequences disclosed herein.

Antibody Isotype	Kabat EU / SEQ ID NO	Position of Residue	
HC	Kabat EU position	234	235
IgG1	Corresponding position in SEQ ID NO: 110	117	118
IgG2	Corresponding position in SEQ ID NO: 120	-	-
IgG3	Corresponding position in SEQ ID NO: 130	164	165
IgG4	Corresponding position in SEQ ID NO: 140	-	115

Table 2

Immunoglobulin embodiments defined using disclosed sequences

In some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine.

The Antibody: substitution of Interchain cysteine residues combined with substitution of Kabat EU residues 234 and/or 235

The modifications described in the first aspect can be advantageously combined in the same antibody with the modifications described in the second aspect. Accordingly, in a third aspect the antibody of the conjugates described herein:

- (1) comprises one or more substitution of an interchain cysteine residue by an amino acid that is not cysteine and retains at least one unsubstituted interchain cysteine residue for conjugation of the drug moiety to the antibody; and
- (2) comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid (that is, an amino acid that is not identical to that found in the 'wild-type' sequence).

Embodiments defined using the Kabat EU numbering

AbLJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κLC214 or λLC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

AbHJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) retain the unsubstituted hinge region interchain cysteines, (ii) comprise light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, (iii) comprise heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the

residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, In some embodiments the antibody of the conjugates described herein: (i) retains unsubstituted HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each retaining the unsubstituted interchain cysteine κ LC214 or λ LC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κ LC214 or λ LC213 according to the EU index as set forth in Kabat.

AbBJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue located in the C_L domain, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprise light chains each having an amino acid substitution of the interchain cysteine residue κ LC214 or λ LC213 according to the EU index as set forth in Kabat, (iii) comprise heavy chains each retaining the unsubstituted interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the CH₁ domain, for example to HC220 according to the EU index as set forth in Kabat.

AbDJ(LALA)

In some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of the hinge region interchain cysteines, (ii) comprises light chains each retaining the unsubstituted interchain cysteine located in the C_L domain, (iii) comprises heavy chains each having an amino acid substitution of the interchain cysteine residue located in the CH₁ domain, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

For example, in some embodiments the antibody of the conjugates described herein: (i) has an amino acid substitution of each of HC226 and HC229 according to the EU index as set forth in Kabat, (ii) comprises light chains each retaining the unsubstituted interchain cysteine κLC214 or λLC213 according to the EU index as set forth in Kabat, (iii) comprises heavy chains each having an amino acid substitution of interchain cysteine HC220 according to the EU index as set forth in Kabat, and (iv) comprise heavy chains each having an amino acid substitution of the the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat by any other amino acid. Preferably both the residues at position 234 and 235 in the EU index set forth in Kabat are substituted. Preferably the drug moiety is conjugated to the unsubstituted interchain cysteine located in the C_L domain, for example to κLC214 or λLC213 according to the EU index as set forth in Kabat.

Embodiments defined using disclosed sequences*AbLJ(LALA)*

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.130. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbHJ(LALA)

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein the cysteine at position 14 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

AbBJ(LALA)

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety

is conjugated to the cysteine at position 14 of SEQ ID NO.130. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 14 of SEQ ID NO.140.

AbDJ(LALA)

In some embodiments, some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 117 and 118 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160. Preferably both the leucines at position 164 and 165 are substituted by an amino acid that is not leucine, such as alanine.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160;

wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 115 is substituted by an amino acid that is not leucine, such as alanine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

Conjugate / Antibody properties

Maximum Tolerated Dose (MTD)

The conjugates described herein have been found to be well-tolerated in *in vivo* disease models, allowing for reduced side-effects in subjects receiving the conjugates. Accordingly, in some embodiments the conjugates described herein have a higher MTD than an otherwise identical conjugate where the drug moieties are to the antibody at non-site specifically. MTD is typically tested in animals such as mouse (for example, *Mus musculus*), rat (for example, *Rattus norvegicus*), or monkey (for example, *Macaca fascicularis*). In some embodiments, the conjugates described herein have an MTD in rat of at least 1 mg/kg delivered as a single-dose, for example at least 1.2 mg/kg, at least 1.4 mg/kg, at least 1.6 mg/kg, at least 1.8 mg/kg, at least 2.0 mg/kg, at least 2.2 mg/kg, at least 2.4 mg/kg, at least 2.6 mg/kg, at least 2.8 mg/kg, at least 3.0 mg/kg, at least 4.0 mg/kg, or at least 5.0 mg/kg delivered as a single-dose.

Therapeutic index

In some embodiments the site-specific conjugates described herein have an improved therapeutic index as compared to an otherwise identical non site-specific conjugate. In some embodiments the therapeutic index for a site specific conjugate described herein is at least 2% higher than an otherwise identical non site-specific conjugate. That is, if the non site-specific conjugate has a therapeutic index of 100:1, the site specific conjugate has a therapeutic index of at least 102:1. In some embodiments the therapeutic index for a site specific conjugate described herein is at least 5% higher than an otherwise identical non site-specific conjugate, for example at least 5% higher, at least 7% higher, at least 10% higher, at least 12% higher, at least 15% higher, at least 20% higher, at least 25% higher, at least 30% higher, at least 40% higher, at least 50% higher, at least 70% higher, at least 100% higher, at least 150% higher, or at least 200% higher than an otherwise identical non site-specific conjugate.

Systemic toxicity

Strop et al., Chemistry & Biology 20, 161-167, February 21, 2013 reported that the conjugation site of the drug moiety on the antibody can influence the stability and pharmacokinetics of an ADC.

The relative systemic toxicity of a site-specific ADC newly described herein was compared to that of a known type of site-specific ADC – see Example 7 and Figure 1. The site-specific ADC newly described herein was not observed to induce significant systemic toxicity, in contrast to the known site-specific ADC.

Antibody affinity

In some embodiments, the site-specific conjugate has the same affinity for the cognate antigen as compared to an otherwise identical non site-specific conjugate. In some embodiments, the site-specific conjugate has a greater affinity for the cognate antigen as compared to an otherwise identical non site-specific conjugate. In some embodiments the site-specific conjugate binds the cognate antigen with a dissociation constant (Kd) of at least 10^{-6} M, such as at least 5×10^{-7} M, at least 10^{-7} M, at least 5×10^{-8} M, at least 10^{-9} M, such as at least 5×10^{-10} M, at least 10^{-10} M, at least 5×10^{-11} M, at least 10^{-11} M, at least 5×10^{-12} M, at least 10^{-12} M, at least 5×10^{-13} M, at least 10^{-13} M, at least 5×10^{-14} M, at least 10^{-14} M, at least 5×10^{-15} M, or at least 10^{-15} M. In one embodiment the site-specific conjugate competitively inhibits the *in vivo* and/or *in vitro* binding to the cognate antigen of an otherwise identical non site-specific conjugate.

As used herein, “binds [antigen X]” is used to mean the antibody binds [antigen X] with a higher affinity than a non-specific partner such as Bovine Serum Albumin (BSA, Genbank accession no. CAA76847, version no. CAA76847.1 GI:3336842, record update date: Jan 7, 2011 02:30 PM). In some embodiments the antibody binds [antigen X] with an association constant (Ka) at least 2, 3, 4, 5, 10, 20, 50, 100, 200, 500, 1000, 2000, 5000, 10^4 , 10^5 or 10^6 -fold higher than the antibody's association constant for BSA, when measured at physiological conditions. The antibodies of the disclosure can typically bind [antigen X] with a high affinity. For example, in some embodiments the antibody can bind [antigen X] with a KD equal to or less than about 10^{-6} M, such as 1×10^{-6} , 10^{-7} , 10^{-8} , 10^{-9} , 10^{-10} , 10^{-11} , 10^{-12} , 10^{-13} or 10^{-14} M.

Effective dose

In some embodiments the site-specific conjugate has an EC₅₀ of less than 35 ng/ml, such as less than 30 ng/ml, less than 25 ng/ml, less than 20 ng/ml, or less than 15 ng/ml. In some embodiments the EC₅₀ of the site-specific conjugate is no higher than an otherwise identical non site-specific conjugate. In some embodiments the EC₅₀ of the site-specific conjugate is at least 2 ng/ml lower than an otherwise identical non site-specific conjugate, for example at least 5 ng/ml lower, at least 10 ng/ml lower, at least 15 ng/ml lower, at least 20 ng/ml lower, at least 25 ng/ml lower, or at least 30 ng/ml lower.

Ease of manufacture

Embodiments of the site-specific ADCs newly described herein allow for simplification of the ADC manufacture procedure.

For example, in a cysteine engineered IgG version such as those described in Junutula et al., Nature Biotechnology, vol.26, no.8, pp.925-932, additional cysteines are engineered into the IgG1 to allow for site-specific conjugation on the engineered cysteines. When such cysteine engineered IgG are recombinantly expressed in mammalian cells, the engineered cysteines are typically capped with other sulphhydryl containing molecules such as GSH, cysteine etc. In order to release the engineered cysteines for conjugation, the molecule must be reduced. This typically will also reduce the interchain disulphide bond between the heavy and light chains, as well as those in the hinge region. This reduction of native interchain cysteines is undesirable, since drug conjugation can also occur on these native cysteines. Thus, the antibody molecule must be re-oxidized to re-establish these native interchain disulphide bonds before the cysteines engineered into the antibody can be conjugated to the drug.

In contrast, the present disclosure specifically contemplates embodiments where the antibody comprises only two interchain cysteines suitable for conjugation (for example, one on each heavy chain) with the other interchain cysteine residues present in a native antibody having been substituted for an amino acid which is not cysteine. This format allows the complex –reduction- reoxidation procedure described above to be dispensed with. Instead a straight forward reduction-conjugation procedure can be followed. This is possible because the site-specific antibody formats described herein typically do not contain interchain cysteines that are not ultimately intended to be conjugated to drug moieties. For example, in preferred embodiments the site-specific antibody contains only two interchain cysteines suitable for conjugation (for example, one on each heavy chain). It is therefore not necessary to reoxidize the antibody molecule after the initial reduction step. Instead the molecule is reduced with a reductant such as TCEP which reduces the (two) remaining interchain

cysteines (with the other interchain cysteines having been substituted for amino acids which are not cysteine). The reduced cysteine sulphhydryl moieties can then be conjugated to the drug-linker.

In the preferred embodiments where there are only two interchain cysteines, it is not possible to generate IgG species with DAR 3 or higher. This can be advantageous, since higher DAR species can contribute to ADC toxicity - see Jununtula et al., (Nature Biotech 26_925-932 (2008)).

The newly described site-specific ADCs also avoid other potential manufacturing problems. For example, during the analysis of cysteine engineered IgGs secreted by stably transfected Chinese Hamster Ovary (CHO) cells, the existence of Triple Light Chain antibodies (3LC) has been observed; the 3LC species appears to be the product of a disulfide bond formed between an extra light chain and an additional cysteine engineered into an IgG (Gomez et al., Biotechnol. Bioeng. 105(4)_748-60 (2010); Gomez et al., Biotechnol. Prog. 26(5)_1438-1445 (2010)). The newly described site-specific ADCs do not have inserted cysteines in the light chain, so have no potential to form contamination 3LC species.

Terminal half-life

In some embodiments, conjugates in which the antibody comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat have improved terminal half-life as compared to another otherwise identical conjugate lacking the 234/235 substitution(s). The terminal-half life may be measured as described herein in Example 6. Accordingly, in some embodiments conjugates in which the antibody comprises a heavy chain having a substitution of the residue at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat have a half-life which is at least 110% of the half-life of an otherwise identical conjugate lacking the 234/235 substitution(s); for example at least 115% of the half-life, at least 120% of the half-life, at least 125% of the half-life, at least 130% of the half-life, at least 135% of the half-life, at least 140% of the half-life, at least 145% of the half-life, at least 150% of the half-life, at least 160% of the half-life, at least 170% of the half-life, at least 180% of the half-life, at least 190% of the half-life, or at least 200% of the half-life of an otherwise identical conjugate lacking the 234/235 substitution(s).

Antigen binding

The antibody of the conjugates described herein is an antibody (Ab) which binds PSMA. That is, the conjugates described herein are conjugates comprising antibodies which specifically bind to PSMA.

As used herein, PSMA refers to Prostate-Specific Membrane Antigen. In one embodiment, PSMA polypeptide corresponds to Genbank accession no. AAA60209, version no. AAA60209.1 GI:190664, record update date: Jun 23, 2010 08:48 AM. In one embodiment, the nucleic acid encoding PSMA polypeptide corresponds to Genbank accession no. M99487, version no. M99487.1 GI:190663, record update date: Jun 23, 2010 08:48 AM.

In one aspect the antibody is in one aspect the antibody is an antibody that binds to PSMA, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, 10, 21, 22, 23, 24, 25, 26, or 27.

The antibody may further comprise a VL domain. In some embodiments the antibody further comprises a VL domain having the sequence according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, 18, 31, 32, 33, 34, 35, 36, or 37.

In some embodiments the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences selected from the group consisting of:

SEQ ID NO. 1 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 3 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 5 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 7 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 8 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 9 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;

or

SEQ ID NO. 10 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.

For example SEQ ID NO. 1 paired with SEQ ID NO. 2, SEQ ID NO. 3 paired with SEQ ID NO. 4, SEQ ID NO. 5 paired with SEQ ID NO. 6, SEQ ID NO. 7 paired with SEQ ID NO. 11, SEQ ID NO. 7 paired with SEQ ID NO. 12, SEQ ID NO. 7 paired with SEQ ID NO. 13, SEQ ID NO. 7 paired with SEQ ID NO. 14, SEQ ID NO. 7 paired with SEQ ID NO. 15, SEQ ID NO. 7 paired with SEQ ID NO. 16, SEQ ID NO. 7 paired with SEQ ID NO. 17, SEQ ID NO. 7 paired with SEQ ID NO. 18, SEQ ID NO. 8 paired with SEQ ID NO. 11, SEQ ID NO. 8 paired with SEQ ID NO. 12, SEQ ID NO. 8 paired with SEQ ID NO. 13, SEQ ID NO. 8 paired with SEQ ID NO. 14, SEQ ID NO. 8 paired with SEQ ID NO. 15, SEQ ID NO. 8 paired with SEQ

ID NO. 16, SEQ ID NO. 8 paired with SEQ ID NO. 17, SEQ ID NO. 8 paired with SEQ ID NO. 18, SEQ ID NO. 9 paired with SEQ ID NO. 11, SEQ ID NO. 9 paired with SEQ ID NO. 12, SEQ ID NO. 9 paired with SEQ ID NO. 13, SEQ ID NO. 9 paired with SEQ ID NO. 14, SEQ ID NO. 9 paired with SEQ ID NO. 15, SEQ ID NO. 9 paired with SEQ ID NO. 16, SEQ ID NO. 9 paired with SEQ ID NO. 17, SEQ ID NO. 9 paired with SEQ ID NO. 18, SEQ ID NO. 10 paired with SEQ ID NO. 11, SEQ ID NO. 10 paired with SEQ ID NO. 12, SEQ ID NO. 10 paired with SEQ ID NO. 13, SEQ ID NO. 10 paired with SEQ ID NO. 14, SEQ ID NO. 10 paired with SEQ ID NO. 15, SEQ ID NO. 10 paired with SEQ ID NO. 16, SEQ ID NO. 10 paired with SEQ ID NO. 17, or SEQ ID NO. 10 paired with SEQ ID NO. 18.

In some embodiments the antibody comprises a VH domain paired with a VL domain, the VH and VL domains having sequences selected from the group consisting of:

SEQ ID NO. 21 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 22 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 23 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 24 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 25 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 26 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37; and
SEQ ID NO. 27 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37. For example SEQ ID NO. 21 paired with SEQ ID NO. 31, SEQ ID NO. 21 paired with SEQ ID NO. 32, SEQ ID NO. 21 paired with SEQ ID NO. 33, SEQ ID NO. 21 paired with SEQ ID NO. 34, SEQ ID NO. 21 paired with SEQ ID NO. 35, SEQ ID NO. 21 paired with SEQ ID NO. 36, SEQ ID NO. 21 paired with SEQ ID NO. 37, SEQ ID NO. 22 paired with SEQ ID NO. 31, SEQ ID NO. 22 paired with SEQ ID NO. 32, SEQ ID NO. 22 paired with SEQ ID NO. 33, SEQ ID NO. 22 paired with SEQ ID NO. 34, SEQ ID NO. 22 paired with SEQ ID NO. 35, SEQ ID NO. 22 paired with SEQ ID NO. 36, SEQ ID NO. 22 paired with SEQ ID NO. 37, SEQ ID NO. 23 paired with SEQ ID NO. 31, SEQ ID NO. 23 paired with SEQ ID NO. 32, SEQ ID NO. 23 paired with SEQ ID NO. 33, SEQ ID NO. 23 paired with SEQ ID NO. 34, SEQ ID NO. 23 paired with SEQ ID NO. 35, SEQ ID NO. 23 paired with SEQ ID NO. 36, SEQ ID NO. 23 paired with SEQ ID NO. 37, SEQ ID NO. 24 paired with SEQ ID NO. 31, SEQ ID NO. 24 paired with SEQ ID NO. 32, SEQ ID NO. 24 paired with SEQ ID NO. 33, SEQ ID NO. 24 paired with SEQ ID NO. 34, SEQ ID NO. 24 paired with SEQ ID NO. 35, SEQ ID NO. 24 paired with SEQ ID NO. 36, SEQ ID NO. 24 paired with SEQ ID NO. 37, SEQ ID NO. 25 paired with SEQ ID NO. 31, SEQ ID NO. 25 paired with SEQ ID NO. 32, SEQ ID NO. 25 paired with SEQ ID NO. 33, SEQ ID NO. 25 paired with SEQ ID NO. 34, SEQ ID NO. 25 paired with SEQ ID NO. 35, SEQ ID NO. 25 paired with SEQ ID NO. 36, SEQ ID NO. 25 paired with SEQ ID NO. 37, SEQ ID NO. 26 paired with SEQ ID NO. 31,

SEQ ID NO. 26 paired with SEQ ID NO. 32, SEQ ID NO. 26 paired with SEQ ID NO. 33, SEQ ID NO. 26 paired with SEQ ID NO. 34, SEQ ID NO. 26 paired with SEQ ID NO. 35, SEQ ID NO. 26 paired with SEQ ID NO. 36, SEQ ID NO. 26 paired with SEQ ID NO. 37, SEQ ID NO. 27 paired with SEQ ID NO. 31, SEQ ID NO. 27 paired with SEQ ID NO. 32, SEQ ID NO. 27 paired with SEQ ID NO. 33, SEQ ID NO. 27 paired with SEQ ID NO. 34, SEQ ID NO. 27 paired with SEQ ID NO. 35, SEQ ID NO. 27 paired with SEQ ID NO. 36, or SEQ ID NO. 27 paired with SEQ ID NO. 37.

The VH and VL domain(s) may pair so as to form an antibody antigen binding site that binds PSMA.

In some embodiments the antibody is an intact antibody comprising a VH domain paired with a VL domain, the VH and VL domains having sequences selected from the group consisting of:

SEQ ID NO. 1 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 3 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 5 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 7 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 8 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;
 SEQ ID NO. 9 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18;

or

SEQ ID NO. 10 paired with any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, or 18.
 For example SEQ ID NO. 1 paired with SEQ ID NO. 2, SEQ ID NO. 3 paired with SEQ ID NO. 4, SEQ ID NO. 5 paired with SEQ ID NO. 6, SEQ ID NO. 7 paired with SEQ ID NO. 11, SEQ ID NO. 7 paired with SEQ ID NO. 12, SEQ ID NO. 7 paired with SEQ ID NO. 13, SEQ ID NO. 7 paired with SEQ ID NO. 14, SEQ ID NO. 7 paired with SEQ ID NO. 15, SEQ ID NO. 7 paired with SEQ ID NO. 16, SEQ ID NO. 7 paired with SEQ ID NO. 17, SEQ ID NO. 7 paired with SEQ ID NO. 18, SEQ ID NO. 8 paired with SEQ ID NO. 11, SEQ ID NO. 8 paired with SEQ ID NO. 12, SEQ ID NO. 8 paired with SEQ ID NO. 13, SEQ ID NO. 8 paired with SEQ ID NO. 14, SEQ ID NO. 8 paired with SEQ ID NO. 15, SEQ ID NO. 8 paired with SEQ ID NO. 16, SEQ ID NO. 8 paired with SEQ ID NO. 17, SEQ ID NO. 8 paired with SEQ ID NO. 18, SEQ ID NO. 9 paired with SEQ ID NO. 11, SEQ ID NO. 9 paired with SEQ ID NO. 12, SEQ ID NO. 9 paired with SEQ ID NO. 13, SEQ ID NO. 9 paired with SEQ ID NO. 14, SEQ ID NO. 9 paired with SEQ ID NO. 15, SEQ ID NO. 9 paired with SEQ ID NO. 16, SEQ ID NO. 9 paired with SEQ ID NO. 17, SEQ ID NO. 9 paired with SEQ ID NO. 18, SEQ ID NO. 10 paired with SEQ ID NO. 11, SEQ ID NO. 10 paired with SEQ ID NO. 12, SEQ ID NO. 10 paired with SEQ ID NO. 13, SEQ ID NO. 10 paired with SEQ ID NO. 14, SEQ ID NO. 10

paired with SEQ ID NO. 15, SEQ ID NO. 10 paired with SEQ ID NO. 16, SEQ ID NO. 10 paired with SEQ ID NO. 17, or SEQ ID NO. 10 paired with SEQ ID NO. 18.

In some embodiments the antibody is an intact antibody comprising a VH domain paired with a VL domain, the VH and VL domains having sequences selected from the group consisting of:

SEQ ID NO. 21 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 22 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 23 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 24 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 25 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37;
SEQ ID NO. 26 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37; and
SEQ ID NO. 27 paired with any one of SEQ ID NOs. 31, 32, 33, 34, 35, 36, or 37. For example SEQ ID NO. 21 paired with SEQ ID NO. 31, SEQ ID NO. 21 paired with SEQ ID NO. 32, SEQ ID NO. 21 paired with SEQ ID NO. 33, SEQ ID NO. 21 paired with SEQ ID NO. 34, SEQ ID NO. 21 paired with SEQ ID NO. 35, SEQ ID NO. 21 paired with SEQ ID NO. 36, SEQ ID NO. 21 paired with SEQ ID NO. 37, SEQ ID NO. 22 paired with SEQ ID NO. 31, SEQ ID NO. 22 paired with SEQ ID NO. 32, SEQ ID NO. 22 paired with SEQ ID NO. 33, SEQ ID NO. 22 paired with SEQ ID NO. 34, SEQ ID NO. 22 paired with SEQ ID NO. 35, SEQ ID NO. 22 paired with SEQ ID NO. 36, SEQ ID NO. 22 paired with SEQ ID NO. 37, SEQ ID NO. 23 paired with SEQ ID NO. 31, SEQ ID NO. 23 paired with SEQ ID NO. 32, SEQ ID NO. 23 paired with SEQ ID NO. 33, SEQ ID NO. 23 paired with SEQ ID NO. 34, SEQ ID NO. 23 paired with SEQ ID NO. 35, SEQ ID NO. 23 paired with SEQ ID NO. 36, SEQ ID NO. 23 paired with SEQ ID NO. 37, SEQ ID NO. 24 paired with SEQ ID NO. 31, SEQ ID NO. 24 paired with SEQ ID NO. 32, SEQ ID NO. 24 paired with SEQ ID NO. 33, SEQ ID NO. 24 paired with SEQ ID NO. 34, SEQ ID NO. 24 paired with SEQ ID NO. 35, SEQ ID NO. 24 paired with SEQ ID NO. 36, SEQ ID NO. 24 paired with SEQ ID NO. 37, SEQ ID NO. 25 paired with SEQ ID NO. 31, SEQ ID NO. 25 paired with SEQ ID NO. 32, SEQ ID NO. 25 paired with SEQ ID NO. 33, SEQ ID NO. 25 paired with SEQ ID NO. 34, SEQ ID NO. 25 paired with SEQ ID NO. 35, SEQ ID NO. 25 paired with SEQ ID NO. 36, SEQ ID NO. 25 paired with SEQ ID NO. 37, SEQ ID NO. 26 paired with SEQ ID NO. 31, SEQ ID NO. 26 paired with SEQ ID NO. 32, SEQ ID NO. 26 paired with SEQ ID NO. 33, SEQ ID NO. 26 paired with SEQ ID NO. 34, SEQ ID NO. 26 paired with SEQ ID NO. 35, SEQ ID NO. 26 paired with SEQ ID NO. 36, SEQ ID NO. 26 paired with SEQ ID NO. 37, SEQ ID NO. 27 paired with SEQ ID NO. 31, SEQ ID NO. 27 paired with SEQ ID NO. 32, SEQ ID NO. 27 paired with SEQ ID NO. 33, SEQ ID NO. 27 paired with SEQ ID NO. 34,

SEQ ID NO. 27 paired with SEQ ID NO. 35, SEQ ID NO. 27 paired with SEQ ID NO. 36, or SEQ ID NO. 27 paired with SEQ ID NO. 37.

In some embodiments, the antibody competes with the antibody secreted by hybridoma ATCC accession No. HB-12126 for binding to PSMA. In another aspect, the antibody competes with the antibody secreted by hybridoma ATCC accession No. HB-12109 for binding to PSMA. In one embodiment the antibody binds PSMA with an association constant (K_a) no less than 2, 5 or 10-fold less than the antibody secreted by the hybridoma.

In one aspect the antibody is the antibody secreted by a hybridoma. In one embodiment the hybridoma is ATCC accession No. HB-12126.

In aspect the antibody is an antibody as described herein which has been modified (or further modified) as described below. In some embodiments the antibody is a humanised, deimmunised or resurfaced version of an antibody disclosed herein.

SOME EMBODIMENTS

Listed below are some specifically contemplated embodiments.

Substitution of Interchain cysteine residues

AbLJ-PSMA IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.151;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.152;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.153;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.161;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.162;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.163;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

AbHJ-PSMA IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.111;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.112;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

AbBJ-PSMA IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

Preferably the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by valine.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.151;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.152;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.153;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.161;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.162;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
a light chain comprising the amino acid sequence of SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.151;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.152;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.153;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.161;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.162;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114;
a light chain comprising the amino acid sequence of SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at positions 109 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine and the cysteine at positions 112 in SEQ ID NO: 110 is unsubstituted;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moieties are conjugated to the cysteines at positions 103 and 112 of SEQ ID NO.110. Preferably the cysteine at position 109 in SEQ ID NO: 110 is substituted by valine.

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at positions 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine and the cysteine at positions 109 in SEQ ID NO: 110 is unsubstituted;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine.

Preferably the drug moieties are conjugated to the cysteines at positions 103 and 109 of SEQ ID NO.110. Preferably the cysteine at position 112 in SEQ ID NO: 110 is substituted by valine.

AbDJ-PSMA IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160. Preferably the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by valine.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.115;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.116;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by an amino acid that is not cysteine and the cysteine at positions 103 in SEQ ID NO: 110 is unsubstituted. Preferably the drug moieties are conjugated to: (i) the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160; and (ii) the cysteine at position 103 of SEQ ID NO.110. Preferably the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by valine.

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 103 and 112 in SEQ ID NO: 110 are substituted by an amino acid that is not cysteine and the cysteine at position 109 in SEQ ID NO: 110 is unsubstituted. Preferably the drug moieties are conjugated to: (i) the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160; and (ii) the cysteine at position 109 of SEQ ID NO.110. Preferably the cysteine at position 112 in SEQ ID NO: 110 is substituted by valine.

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 103 and 109 in SEQ ID NO: 110 are substituted by an amino acid that is not cysteine and the cysteine at position 112 in SEQ ID NO: 110 is unsubstituted. Preferably the drug moieties are conjugated to: (i) the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160; and (ii) the cysteine at position 112 of SEQ ID NO.110. Preferably the cysteine at position 109 in SEQ ID NO: 110 is substituted by valine.

Substitution of Kabat EU residues 234 and/or 235

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the leucine at position 117 of SEQ ID NO.110 and/or the leucine at position 118 of SEQ ID NO.110 is substituted by an amino acid that is not leucine.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1101;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1102;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1104;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1105;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1106;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.130, a light chain, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the leucine at position 164 of SEQ ID NO.130 and/or the leucine at position 165 of SEQ ID NO.130 is substituted by an amino acid that is not leucine.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.131;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.132;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.133;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.134;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.135;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.136;
a light chain;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.140, a light chain, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the leucine at position 115 of SEQ ID NO.140 is substituted by an amino acid that is not leucine.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.141;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.142;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.143;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.144;
- a light chain;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

Substitution of Interchain cysteine residues combined with substitution of Kabat EU residues 234 and/or 235

AbLJ(LALA) IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence

of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 of SEQ ID NO.110 and/or the leucine at position 118 of SEQ ID NO.110 is substituted by an amino acid that is not leucine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1101, SEQ ID NO.1102, SEQ ID NO.1103, SEQ ID NO.1104, SEQ ID NO.1105, SEQ ID NO.1106;

a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;

a light chain comprising the amino acid sequence of SEQ ID NO.151;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;

a light chain comprising the amino acid sequence of SEQ ID NO.152;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;

a light chain comprising the amino acid sequence of SEQ ID NO.153;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;

a light chain comprising the amino acid sequence of SEQ ID NO.161;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;
a light chain comprising the amino acid sequence of SEQ ID NO.162;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;
a light chain comprising the amino acid sequence of SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

AbHJ(LALA) IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein the cysteine at position 103 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 of SEQ ID NO.110 and/or the leucine at position 118 of SEQ ID NO.110 is substituted by an amino acid that is not leucine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1111;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1112;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1113;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1114;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1115;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1116;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1121;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1122;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID
NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1123;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID
NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1124;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID
NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1125;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID
NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1126;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID
NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

AbBJ(LALA) IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 4;

wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the cysteine at position 105 in SEQ ID NO: 150 or the cysteine at position 102 in SEQ ID NO: 160, is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 of SEQ ID NO.110 and/or the leucine at position 118 of SEQ ID NO.110 is substituted by an amino acid that is not leucine. Preferably the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110. Preferably the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by valine.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1131, SEQ ID NO.1132, SEQ ID NO.1133, SEQ ID NO.1134, SEQ ID NO.1135, SEQ ID NO.1136;

a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;

a light chain comprising the amino acid sequence of SEQ ID NO.151;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;

a light chain comprising the amino acid sequence of SEQ ID NO.152;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;

a light chain comprising the amino acid sequence of SEQ ID NO.153;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;
a light chain comprising the amino acid sequence of SEQ ID NO.161;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;
a light chain comprising the amino acid sequence of SEQ ID NO.162;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1133;
a light chain comprising the amino acid sequence of SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1141, SEQ ID NO.1142, SEQ ID NO.1143, SEQ ID NO.1144, SEQ ID NO.1145, SEQ ID NO.1146;
a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.151;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.152;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.153;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.161;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.162;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1143;
a light chain comprising the amino acid sequence of SEQ ID NO.163;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

AbDJ591 IgG1

An antibody of the conjugates described herein comprising a heavy chain comprising the amino acid sequence of SEQ ID NO.110, a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160, a VH domain having the sequence SEQ ID NO. 3, and a VL domain having the sequence SEQ ID NO. 3;

wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110 is substituted by an amino acid that is not cysteine;

and wherein the leucine at position 117 of SEQ ID NO.110 and/or the leucine at position 118 of SEQ ID NO.110 is substituted by an amino acid that is not leucine. Preferably the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160. Preferably the cysteines at positions 109 and 112 in SEQ ID NO: 110 are substituted by valine.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1151;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1152;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1153;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1154;
- a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;
- a VH domain having the sequence SEQ ID NO. 3; and
- a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1155;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1156;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO. 116;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1161;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1162;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and

a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1163;

a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160;

a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1164;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or
SEQ ID NO.160;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1165;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or
SEQ ID NO.160;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

An antibody of the conjugates described herein comprising:

a heavy chain comprising the amino acid sequence of SEQ ID NO.1166;
a light chain comprising the amino acid sequence of SEQ ID NO.150 or
SEQ ID NO.160;
a VH domain having the sequence SEQ ID NO. 3; and
a VL domain having the sequence SEQ ID NO. 4.

Definitions

Numbering of amino acid positions in Immunoglobulin (Ig) molecules

The numbering of the amino acids used herein is according to the numbering system of the EU index as set forth in Kabat et al. (1991, NIH Publication 91-3242, National Technical Information Service, Springfield, VA, hereinafter "Kabat"). The "EU index as set forth in Kabat" refers to the residue numbering of the human IgG 1 EU antibody as described in Kabat et al. supra.

In the case of substitutions in, for example, IgG2, IgG3, and IgG4 (or of IgA1, IgA2, IgD, IgE, IgM etc.) the skilled person can readily use sequence alignment programs such as NCBI BLAST® (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) to align the sequences with IgG1 to determine which residues of the desired isoform correspond to the Kabat positions described herein.

Antibody

The term "antibody" as used encompasses any molecule comprising an antibody antigen-binding site (as, for example, formed by a paired VH domain and a VL domain). Thus, for example, the term "antibody" encompasses monoclonal antibodies (including intact monoclonal antibodies), polyclonal antibodies, multispecific antibodies formed from at least two different epitope binding fragments (e.g., bispecific antibodies), human antibodies, humanized antibodies, camelised antibodies, chimeric antibodies, single-chain antibodies (such as scFv fusions with CH3), antibody fragments that exhibit the desired biological activity (e.g. the antigen binding portion; for example minibodies), and anti-idiotypic (anti-Id) antibodies, intrabodies, and epitope-binding fragments of any of the above, so long as they exhibit the desired biological activity, for example, the ability to bind the cognate antigen. Antibodies may be murine, human, humanized, chimeric, or derived from other species. In one embodiment the antibody is a single-chain Fv antibody fused to a CH3 domain (scFv-CH3). In one embodiment the antibody is a single-chain Fv antibody fused to a Fc region (scFv-Fc). In one embodiment the antibody is a minibody.

An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C., Travers, P., Walport, M., Shlomchik (2001) *Immuno Biology*, 5th Ed., Garland Publishing, New York). A target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody. An antibody includes an intact immunoglobulin molecule or an immunologically active portion of a intact immunoglobulin molecule, i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease.

In particular, antibodies include immunoglobulin molecules and immunologically active fragments of immunoglobulin molecules, i.e., molecules that contain at least one antigen binding site. The antibody can be of any isotype (e.g. IgG, IgE, IgM, IgD, and IgA), class (e.g. IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass, or allotype (e.g. human G1m1, G1m2, G1m3, non-G1m1 [that, is any allotype other than G1m1], G1m17, G2m23, G3m21, G3m28, G3m11, G3m5, G3m13, G3m14, G3m10, G3m15, G3m16, G3m6, G3m24, G3m26, G3m27, A2m1, A2m2, Km1, Km2 and Km3) of antibody molecule. The immunoglobulins can be derived from any species, including human, murine, or rabbit origin.

An "intact antibody" herein is one comprising VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CH1, CH2 and CH3. The constant domains may be native sequence constant domains (e.g. human native sequence constant domains) or amino acid sequence variant thereof. The intact antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include C1q binding; complement dependent cytotoxicity; Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; and down regulation of cell surface receptors such as B cell receptor and BCR.

Antibody heavy chain constant region, or a portion thereof

The terms "antibody heavy chain constant region", "Fc region", "Fc domain" and "Fc", as used herein refer to the portion of an antibody molecule that correlates to a crystallizable fragment obtained by papain digestion of an IgG molecule.

As used herein, the terms "Fc region", "Fc domain" and "Fc" relate to the constant region of an antibody excluding the first constant region immunoglobulin domain and further relates to portions of that region. Thus, Fc refers to the last two constant region immunoglobulin domains of IgA, IgD, and IgG, and the last three constant region immunoglobulin domains of IgE and IgM, and the flexible hinge N-terminal to these domains, or portions thereof. For IgA and IgM, Fc may include the J chain.

For IgG, Fc comprises immunoglobulin domains Cy2 and Cy3 (C gamma 2 and C gamma 3) and the hinge between Cy1 (C gamma 1) and Cy2 (C gamma 2). Although the boundaries of the Fc region may vary, the human IgG heavy chain Fc region is usually defined to comprise residues C226 or P230 to its carboxyl-terminus, as numbered according to the numbering system of the EU index as set forth in Kabat et al. *supra*. Typically, the Fc domain comprises from about amino acid residue 236 to about 447 of the human IgG1 constant domain.

Fc polypeptide may refer to this region in isolation, or this region in the context of an antibody, or an antigen-binding portion thereof, or Fc fusion protein.

The "intact heavy chain constant region" comprises the Fc region and further comprises the CH1 domain and hinge as well as the CH2 and CH3 (and, optionally, CH4 of IgA and IgE) domains of the IgG heavy chain.

"Hinge region" as used herein, is generally defined as stretching from Glu216 to Pro230 of human IgG1 (Burton, 1985, *Malec. Immunol.* 22: 161-206), and refers to the portion of an IgG molecule comprising the C-terminal portion of the CH1 domain and the N-terminal portion of the CH2 domain. Exemplary hinge regions for human IgG1, IgG2, IgG2 and IgG4 and mouse IgG1 and IgG2A are provided in US Patent No. 6,165,476, at the Table shown at column 4, line 54 to column 5, line 15, and also illustrated, for example, in Janeway et al., 1999, *Immunology: The Immune System in Health and Disease*, 4th ed. (Elsevier Science Ltd.); Bloom et al., 1997, *Protein Science* 6:407-415; Humphreys et al., 1997, *J. Immunol. Methods* 209:193-202. Hinge regions of other IgG isotypes may be aligned with the IgG 1 sequence by placing the first and last cysteine residues forming inter-heavy chain S-S bonds in the same positions.

The "lower hinge region" of an Fc region is normally defined as the stretch of residues immediately C-terminal to the hinge region, i.e. residues 233 to 239 of the Fe region. The term "IgG hinge-Fc region" or "hinge-Fc fragment" as used herein refers to a hinge region (approximately residues 216-230) and an Fc region (residues 231-447) C-terminal thereto.

The term "fragment" is used herein to describe a portion of sequence that is shorter than the full-length sequence disclosed herein. Preferably antibodies comprising "fragments" as disclosed herein retain the ability to bind the target antigen, most preferably with a specific binding activity of about 70% or more compared to of an otherwise identical antibody comprising the full-length sequence disclosed herein (for example, about 10% or more, 50% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more of the binding activity). In certain embodiments, the specific binding activity is *in vitro*. The specific binding activity sometimes is quantified by an *in vitro* homogeneous assay or an *in vitro* heterogeneous assay. In some embodiments the specific binding activity is *in vivo*, and sometimes, the specific binding activity is determined *in situ*. In some embodiments a "fragment" is at least 50 amino acids long, such as at least 75, at least 100, at least 150, at least 200, at least 250, or at least 300 amino acids long.

Sequence modifications

The sequences of the antibody heavy chain variable regions and/or the light chain variable regions disclosed herein may be modified by substitution, insertion or deletion. Amino acid sequences that are substantially the same as the sequences described herein include sequences comprising conservative amino acid substitutions, as well as amino acid

deletions and/or insertions. A conservative amino acid substitution refers to the replacement of a first amino acid by a second amino acid that has chemical and/or physical properties (e.g., charge, structure, polarity, hydrophobicity/hydrophilicity) that are similar to those of the first amino acid. Preferred conservative substitutions are those wherein one amino acid is substituted for another within the groups of amino acids indicated herein below:

- Amino acids having polar side chains (Asp, Glu, Lys, Arg, His, Asn, Gln, Ser, Thr, Tyr, and Cys)
- Amino acids having non-polar side chains (Gly, Ala, Val, Leu, Ile, Phe, Trp, Pro, and Met)
- Amino acids having aliphatic side chains (Gly, Ala, Val, Leu, Ile)
- Amino acids having cyclic side chains (Phe, Tyr, Trp, His, Pro)
- Amino acids having aromatic side chains (Phe, Tyr, Trp)
- Amino acids having acidic side chains (Asp, Glu)
- Amino acids having basic side chains (Lys, Arg, His)
- Amino acids having amide side chains (Asn, Gln)
- Amino acids having hydroxy side chains (Ser, Thr)
- Amino acids having sulphur-containing side chains (Cys, Met),
- Neutral, weakly hydrophobic amino acids (Pro, Ala, Gly, Ser, Thr)
- Hydrophilic, acidic amino acids (Gln, Asn, Glu, Asp), and
- Hydrophobic amino acids (Leu, Ile, Val)

Particular preferred conservative amino acids substitution groups are: Val-Leu-Ile, Phe-Tyr, Lys-Arg, Ala-Val, and Asn-Gln.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain having an amino acid sequence with 80% or more amino acid sequence identity (for example, about 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more sequence identity) to a heavy chain described herein. In some embodiments, the antibody of the conjugates described herein comprises a light chain having an amino acid sequence with 80% or more amino acid sequence identity (for example, about 85% or more, 86% or more, 87% or more, 88% or more, 89% or more, 90% or more, 91% or more, 92% or more, 93% or more, 94% or more, 95% or more, 96% or more, 97% or more, 98% or more, 99% or more sequence identity) to a light chain described herein.

In some embodiments, the antibody of the conjugates described herein comprises a heavy chain having an amino acid sequence identical to the amino acid sequence of a heavy chain described herein, except that it includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications (e.g., substitutions, insertions and/or deletions) relative to the amino acid sequence of the heavy chain described herein. In some embodiments, the antibody of the conjugates described herein comprises a light chain having an amino acid sequence identical to the amino acid sequence of a light chain described herein, except that it includes 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid modifications (e.g., substitutions, insertions and/or deletions) relative to the amino acid sequence of the light chain described herein.

Reduction of Immunogenicity

The antibodies disclosed herein may be modified. For example, to make them less immunogenic to a human subject. This may be achieved using any of a number of techniques familiar to the person skilled in the art. Some of these techniques are described in more detail below.

Humanisation

Techniques to reduce the *in vivo* immunogenicity of a non-human antibody or antibody fragment include those termed "humanisation".

A "humanized antibody" refers to a polypeptide comprising at least a portion of a modified variable region of a human antibody wherein a portion of the variable region, preferably a portion substantially less than the intact human variable domain, has been substituted by the corresponding sequence from a non-human species and wherein the modified variable region is linked to at least another part of another protein, preferably the constant region of a human antibody. The expression "humanized antibodies" includes human antibodies in which one or more complementarity determining region ("CDR") amino acid residues and/or one or more framework region ("FW" or "FR") amino acid residues are substituted by amino acid residues from analogous sites in rodent or other non-human antibodies. The expression "humanized antibody" also includes an immunoglobulin amino acid sequence variant or fragment thereof that comprises an FR having substantially the amino acid sequence of a human immunoglobulin and a CDR having substantially the amino acid sequence of a non-human immunoglobulin.

"Humanized" forms of non-human (e.g., murine) antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulin. Or, looked at another way, a humanized antibody is a human antibody that also contains selected sequences from

non-human (e.g. murine) antibodies in place of the human sequences. A humanized antibody can include conservative amino acid substitutions or non-natural residues from the same or different species that do not significantly alter its binding and/or biologic activity. Such antibodies are chimeric antibodies that contain minimal sequence derived from non-human immunoglobulins.

There are a range of humanisation techniques, including 'CDR grafting', 'guided selection', 'deimmunization', 'resurfacing' (also known as 'veneering'), 'composite antibodies', 'Human String Content Optimisation' and framework shuffling.

CDR grafting

In this technique, the humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary-determining region (CDR) of the recipient antibody are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, camel, bovine, goat, or rabbit having the desired properties (in effect, the non-human CDRs are 'grafted' onto the human framework). In some instances, framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues (this may happen when, for example, a particular FR residue has significant effect on antigen binding).

Furthermore, humanized antibodies can comprise residues that are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and maximize antibody performance. Thus, in general, a humanized antibody will comprise all of at least one, and in one aspect two, variable domains, in which all or all of the hypervariable loops correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence. The humanized antibody optionally also will comprise at least a portion of an immunoglobulin constant region (Fc), or that of a human immunoglobulin.

Guided selection

The method consists of combining the V_H or V_L domain of a given non-human antibody specific for a particular epitope with a human V_H or V_L library and specific human V domains are selected against the antigen of interest. This selected human V_H is then combined with a V_L library to generate a completely human V_HxV_L combination. The method is described in Nature Biotechnology (N.Y.) 12, (1994) 899-903.

Composite antibodies

In this method, two or more segments of amino acid sequence from a human antibody are combined within the final antibody molecule. They are constructed by combining multiple human VH and VL sequence segments in combinations which limit or avoid human T cell epitopes in the final composite antibody V regions. Where required, T cell epitopes are limited or avoided by, exchanging V region segments contributing to or encoding a T cell epitope with alternative segments which avoid T cell epitopes. This method is described in US 2008/0206239 A1.

Deimmunization

This method involves the removal of human (or other second species) T-cell epitopes from the V regions of the therapeutic antibody (or other molecule). The therapeutic antibodies V-region sequence is analysed for the presence of MHC class II- binding motifs by, for example, comparison with databases of MHC-binding motifs (such as the "motifs" database hosted at www.wehi.edu.au). Alternatively, MHC class II- binding motifs may be identified using computational threading methods such as those devised by Altuvia et al. (J. Mol. Biol. 249 244-250 (1995)); in these methods, consecutive overlapping peptides from the V-region sequences are testing for their binding energies to MHC class II proteins. This data can then be combined with information on other sequence features which relate to successfully presented peptides, such as amphipathicity, Rothbard motifs, and cleavage sites for cathepsin B and other processing enzymes.

Once potential second species (e.g. human) T-cell epitopes have been identified, they are eliminated by the alteration of one or more amino acids. The modified amino acids are usually within the T-cell epitope itself, but may also be adjacent to the epitope in terms of the primary or secondary structure of the protein (and therefore, may not be adjacent in the primary structure). Most typically, the alteration is by way of substitution but, in some circumstances amino acid addition or deletion will be more appropriate.

All alterations can be accomplished by recombinant DNA technology, so that the final molecule may be prepared by expression from a recombinant host using well established methods such as Site Directed Mutagenesis. However, the use of protein chemistry or any other means of molecular alteration is also possible.

Resurfacing

This method involves:

(a) determining the conformational structure of the variable region of the non-human (e.g. rodent) antibody (or fragment thereof) by constructing a three-dimensional model of the non-human antibody variable region;

(b) generating sequence alignments using relative accessibility distributions from x-ray crystallographic structures of a sufficient number of non-human and human antibody variable region heavy and light chains to give a set of heavy and light chain framework positions wherein the alignment positions are identical in 98% of the sufficient number of non-human antibody heavy and light chains;

(c) defining for the non-human antibody to be humanized, a set of heavy and light chain surface exposed amino acid residues using the set of framework positions generated in step (b);

(d) identifying from human antibody amino acid sequences a set of heavy and light chain surface exposed amino acid residues that is most closely identical to the set of surface exposed amino acid residues defined in step (c), wherein the heavy and light chain from the human antibody are or are not naturally paired;

(e) substituting, in the amino acid sequence of the non-human antibody to be humanized, the set of heavy and light chain surface exposed amino acid residues defined in step (c) with the set of heavy and light chain surface exposed amino acid residues identified in step (d);

(f) constructing a three-dimensional model of the variable region of the non-human antibody resulting from the substituting specified in step (e);

(g) identifying, by comparing the three-dimensional models constructed in steps (a) and (f), any amino acid residues from the sets identified in steps (c) or (d), that are within 5 Angstroms of any atom of any residue of the complementarity determining regions of the non-human antibody to be humanized; and

(h) changing any residues identified in step (g) from the human to the original non-human amino acid residue to thereby define a non-human antibody humanizing set of surface exposed amino acid residues; with the proviso that step (a) need not be conducted first, but must be conducted prior to step (g).

Superhumanization

The method compares the non-human sequence with the functional human germline gene repertoire. Those human genes encoding canonical structures identical or closely related to the non-human sequences are selected. Those selected human genes with highest homology within the CDRs are chosen as FR donors. Finally, the non-human CDRs are grafted onto these human FRs. This method is described in patent WO 2005/079479 A2.

Human String Content Optimization

This method compares the non-human (e.g. mouse) sequence with the repertoire of human germline genes and the differences are scored as Human String Content (HSC) that quantifies a sequence at the level of potential MHC/T-cell epitopes. The target sequence is then humanized by maximizing its HSC rather than using a global identity measure to generate multiple diverse humanized variants (described in *Molecular Immunology*, 44, (2007) 1986–1998).

Framework Shuffling

The CDRs of the non-human antibody are fused in-frame to cDNA pools encompassing all known heavy and light chain human germline gene frameworks. Humanised antibodies are then selected by e.g. panning of the phage displayed antibody library. This is described in *Methods* **36**, 43-60 (2005).

Epitope binding domain

As used herein, the term epitope binding domain refers to a domain which is able to specifically recognize and bind an antigenic epitope. The classic example of an epitope binding domain would be an antibody paratope comprising a V_H domain and a V_L domain forming an antigen binding site.

The sequences of the antibody heavy chain variable regions and/or the light chain variable regions disclosed herein may be modified by, for example, insertions, substitutions and/or deletions to the extent that the epitope binding domain maintains the ability to bind to the cognate antigen. The skilled person can ascertain the maintenance of this activity by performing the functional assays described herein, or known in the art. Accordingly, in some embodiments the heavy chain variable region comprises no more than 20 insertions, substitutions and/or deletions, such as no more than 15, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 insertion, substitution and/or deletion. In some embodiments the light chain variable region comprises no more than 20 insertions, substitutions and/or deletions, such as no more than 15, no more than 10, no more than 9, no more than 8, no more than 7, no more than 6, no more than 5, no more than 4, no more than 3, no more than 2, or no more than 1 insertion, substitution and/or deletion. In some embodiments the antibodies of the disclosure include comprising V_H and V_L domains with amino acid sequences that are identical to the sequences described herein.

Therapeutic index

As used herein, the term “therapeutic index is used as a comparison of the amount of a therapeutic agent that causes the therapeutic effect to the amount that causes death (in animal studies) or toxicity (in human studies).

Therapeutic index = LD_{50}/ED_{50} (animal studies), or = TD_{50}/ED_{50} (human studies),

where LD = lethal dose for 50% of the population, TD = toxic dose for 50% of the population, and ED = minimum effective dose for 50% of the population. The levels of “effective” and “toxic” doses can be readily determined by a medical practitioner or person skilled in the art. When comparing the therapeutic indexes of the site-specific and non-site-specific conjugates, the levels of “effective” and “toxic” are determined in an identical manner

Otherwise identical

The term “otherwise identical non site-specific conjugate” as used herein refers to a conjugate which is identical to the defined or claimed site-specific conjugate in all respects apart from the position(s) at which the Drug units (D^L) are conjugated to antibody heavy chain constant region, or a portion thereof. Specifically, in the defined or claimed site-specific conjugate Drug units (D^L) are uniformly and consistently conjugated to the specified residue(s), whereas in an otherwise identical non site-specific the degree and position of conjugation of Drug unit (D^L) to the antibody is variable from batch to batch.

For example, in one embodiment of a site specific antibody-drug conjugate of the disclosure there are two Drug units (D^L), one conjugated to each of the position 442 residues (kabat numbering) of the two antibody heavy chain constant regions, or a portions thereof. The ‘otherwise identical non site-specific conjugate’ for this example would be an antibody with identical amino acid sequence and polypeptide structure, also with two conjugated Drug unit (D^L); however, the Drug unit (D^L) would not uniformly and consistently conjugated to each 442 position, but rather conjugated to a selection of different positions the precise combination of which varies from conjugate to conjugate within a population (for example, conjugation may be via lysine side chains or by reduced interchain disulfide bonds).

As described herein, properties such as affinity, therapeutic index and stability are bulk properties measured at a population level, as opposed to being measured at a molecular level. Thus, the comparisons made herein between the properties of a site-specific conjugate and an “otherwise identical non site-specific conjugate” are comparisons of properties exhibited by populations of those molecules.

Functional moieties

The humanised antibody of the disclosure may be conjugated to a functional moiety. Examples of functional moieties include an amino acid, a peptide, a protein, a polysaccharide, a nucleoside, a nucleotide, an oligonucleotide, a nucleic acid, a drug, a hormone, a lipid, a lipid assembly, a synthetic polymer, a polymeric microparticle, a biological cell, a virus, a reporter (such as a fluorophore, a chromophore, or a dye), a toxin, a hapten, an enzyme, a binding member (such as an antibody, or an antibody fragment), a radioisotope, solid matrixes, semisolid matrixes and combinations thereof, or an organic moiety.

Examples of a drug include a cytotoxic agent, a chemotherapeutic agent, a peptide, a peptidomimetic, a protein scaffold, DNA, RNA, siRNA, microRNA, and a peptidonucleic acid. In preferred embodiments the functional moiety is a PBD drug moiety. In other embodiments the humanised antibody is conjugated to a therapeutic agent or drug moiety that modifies a given biological response. Therapeutic agents or drug moieties are not to be construed as limited to classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, cholera toxin, or diphtheria toxin; a protein such as tumor necrosis factor, α -interferon, β -interferon, nerve growth factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- α , TNF- β , AIM I (see, International Publication No. WO 97/33899), AIM II (see, International Publication No. WO 97/34911), Fas Ligand (Takahashi et al., 1994, J Immunol., 6: 1567), and VEGf (see, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., angiostatin or endostatin; or, a biological response modifier such as, for example, a lymphokine (e.g., interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-4 ("IL-4"), interleukin-6 ("IL-6"), interleukin-7 ("IL-7"), interleukin-9 ("IL-9"), interleukin-15 ("IL-15"), interleukin-12 ("IL-12"), granulocyte macrophage colony stimulating factor ("GM-CSF"), and granulocyte colony stimulating factor ("G-CSF")), or a growth factor (e.g., growth hormone ("GH")).

Examples of a reporter include a fluorophore, a chromophore, a radionuclide, and an enzyme. Such antibody-reporter conjugates can be useful for monitoring or prognosing the development or progression of a disorder (such as, but not limited to cancer) as part of a clinical testing procedure, such as determining the efficacy of a particular therapy. Such diagnosis and detection can be accomplished by fusing or conjugating the antibody to detectable substances including, but not limited to various enzymes, such as but not limited to horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or

acetylcholinesterase; prosthetic groups, such as but not limited to streptavidin/biotin and avidin/biotin; fluorescent materials, such as but not limited to, umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; luminescent materials, such as but not limited to, bioluminescent materials, such as but not limited to, luciferase, luciferin, and aequorin; radioactive materials, such as but not limited to, bismuth (^{213}Bi), carbon (^{14}C), chromium (^{51}Cr), cobalt (^{57}Co), fluorine (^{18}F), gadolinium (^{153}Gd , ^{159}Gd), gallium (^{68}Ga , ^{67}Ga), germanium (^{68}Ge), holmium (^{166}Ho), indium (^{115}In , ^{113}In , ^{112}In , ^{111}In), iodine (^{131}I , ^{125}I , ^{123}I , ^{121}I), lanthanum (^{140}La), lutetium (^{177}Lu), manganese (^{54}Mn), molybdenum (^{99}Mo), palladium (^{103}Pd), phosphorous (^{32}P), praseodymium (^{142}Pr), promethium (^{149}Pm), rhenium (^{186}Re , ^{188}Re), rhodium (^{105}Rh), ruthenium (^{97}Ru), samarium (^{153}Sm), scandium (^{47}Sc), selenium (^{75}Se), strontium (^{85}Sr), sulfur (^{35}S), technetium (^{99}Tc), thallium (^{201}Tl), tin (^{113}Sn , ^{117}Sn), tritium (^3H), xenon (^{133}Xe), ytterbium (^{169}Yb , ^{175}Yb), yttrium (^{90}Y), zinc (^{65}Zn); positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions.

Examples of a binding member include an antibody or antibody fragment, and biotin and/or streptavidin.

A toxin, cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples of toxins include radioisotopes such as ^{131}I , a ribosome inactivating protein such as pseudomonas exotoxin (PE38 fragment), plant or bacterial toxins such as ricin, the α -chain of ricin, saporin, pokeweed antiviral protein, diphtheria toxin, or *Pseudomonas* exotoxin A (Kreitman and Pastan (1998) Adv. Drug Delivery Rev. 31:53.). Other toxins and cytotoxins include, e.g., a cytostatic or cytotoxic agent, or a radioactive metal ion, e.g., alpha-emitters. Examples include paclitaxel, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, teniposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, puromycin, epirubicin, and cyclophosphamide and analogs or homologs thereof, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BCNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine). Chemical toxins can also be taken from the group chosen from duocarmycin (U.S. Patent Nos.

5,703,080; 4,923,990), methotrexate, doxorubicin, melphalan, chlorambucil, ARA-C, vindesine, mitomycin C, cisplatin, etoposide, bleomycin and 5-fluorouracil. Examples of chemotherapeutic agents also include Adriamycin, Doxorubicin, 5-Fluorouracil, Cytosine arabinoside (Ara-C), Cyclophosphamide, Thiotepa, Taxotere (docetaxel), Busulfan, Cytosin, Taxol, Methotrexate, In one embodiment, the cytotoxic agent is chosen from an enediyne, a lexitropsin, a duocarmycin, a taxane, a puromycin, a dolastatin, a maytansinoid, and a vinca alkaloid. In other embodiments, the cytotoxic agent is paclitaxel, docetaxel, CC-I 065, SN-38, topotecan, morpholino-doxorubicin, rhizoxin, cyanomorpholino-doxorubicin, dolastatin-10, echinomycin, combretastatin, calicheamicin, maytansine, DM-1, an auristatin or other dolastatin derivatives, such as auristatin E or auristatin F, AEB, AEVB, AEF, MMAE (monomethylauristatin E), MMAF (monomethylauristatin F), e1eutherobin or netropsin. In certain embodiments, the cytotoxic agent is Maytansine or Maytansinoids, and derivatives thereof, wherein antibodies (full length or fragments) of the disclosure are conjugated to one or more maytansinoid molecules. Maytansinoids are mitototic inhibitors which act by inhibiting tubulin polymerization. In other embodiments the toxin is a small molecule or protein toxins, such as, but not limited to abrin, brucine, cicutoxin, diphtheria toxin, batrachotoxin, botulism toxin, shiga toxin, endotoxin, Pseudomonas exotoxin, Pseudomonas endotoxin, tetanus toxin, pertussis toxin, anthrax toxin, cholera toxin, falcarinol, fumonisin B1, fumonisin B2, aflatoxin, maurotoxin, agitoxin, charybdoxin, margatoxin, slotoxin, scyllatoxin, hefutoxin, calciseptine, taicatoxin, calciclude, geldanamycin, gelonin, lotaustralin, ocratoxin A, patulin, ricin, strychnine, trichothecene, zearalenone, and tetradotoxin. Enzymatically active toxins and fragments thereof which can be used include diphtheria A chain, non-binding active fragments of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, Aleurites fordii proteins, dianthin proteins, Phytolaca americana proteins (PAPI, P APII, and PAP-S), Momordica charantia inhibitor, curcin, croton, Saponaria officinalis inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin and the trichothecenes.

The humanized antibody may be modified by conjugation to an organic moiety. Such modification can produce an antibody or antigen-binding fragment with improved pharmacokinetic properties (e.g., increased in vivo serum half-life). The organic moiety can be a linear or branched hydrophilic polymeric group, fatty acid group, or fatty acid ester group. In particular embodiments, the hydrophilic polymeric group can have a molecular weight of about 800 to about 120,000 Daltons and can be a polyalkane glycol (e.g., polyethylene glycol (PEG), polypropylene glycol (PPG)), carbohydrate polymer, amino acid polymer or polyvinyl pyrrolidone, and the fatty acid or fatty acid ester group can comprise from about eight to about forty carbon atoms. In certain embodiments, the cytotoxic or

cytostatic agent is a dolastatin. In more specific embodiments, the dolastatin is of the auristatin class. In a specific embodiment of the disclosure, the cytotoxic or cytostatic agent is MMAE. In another specific embodiment of the disclosure, the cytotoxic or cytostatic agent is AEFP. In another specific embodiment of the disclosure, the cytotoxic or cytostatic agent is MMAF.

The humanized antibody and antigen-binding fragments can comprise one or more organic moieties that are covalently bonded, directly or indirectly, to the antibody. Each organic moiety that is bonded to an antibody or antigen-binding fragment described herein can independently be a hydrophilic polymeric group, a fatty acid group or a fatty acid ester group. As used herein, the term "fatty acid" encompasses mono-carboxylic acids and di-carboxylic acids. A "hydrophilic polymeric group," as the term is used herein, refers to an organic polymer that is more soluble in water than in octane. For example, polylysine is more soluble in water than in octane. Thus, an antibody modified by the covalent attachment of polylysine is encompassed by the present disclosure. Hydrophilic polymers suitable for modifying antibodies described herein can be linear or branched and include, for example, polyalkane glycols (e.g., PEG, monomethoxy-polyethylene glycol (mPEG), PPG and the like), carbohydrates (e.g., dextran, cellulose, oligosaccharides, polysaccharides and the like), polymers of hydrophilic amino acids (e.g., polylysine, polyarginine, polyaspartate and the like), polyalkane oxides (e.g., polyethylene oxide, polypropylene oxide and the like) and polyvinyl pyrrolidone. Preferably, the hydrophilic polymer that modifies the antibody described herein has a molecular weight of about 800 to about 150,000 Daltons as a separate molecular entity. For example PEG5000 and PEG20,000, wherein the numerical component of the name is the average molecular weight of the polymer in Daltons, can be used. The hydrophilic polymeric group can be substituted with one to about six alkyl, fatty acid or fatty acid ester groups. Hydrophilic polymers that are substituted with a fatty acid or fatty acid ester group can be prepared by employing suitable methods. For example, a polymer comprising an amine group can be coupled to a carboxylate of the fatty acid or fatty acid ester, and an activated carboxylate (e.g., activated with N,N-carbonyl diimidazole) on a fatty acid or fatty acid ester can be coupled to a hydroxyl group on a polymer.

Fatty acids and fatty acid esters suitable for modifying antibodies described herein can be saturated or can contain one or more units of unsaturation. Fatty acids that are suitable for modifying antibodies described herein include, for example, n-dodecanoate (C12, laurate), n-tetradecanoate (C14, myristate), n-octadecanoate (C18, stearate), n-eicosanoate (C20, arachidate), n-docosanoate (C22, behenate), n-triacontanoate (C30), n-tetracontanoate (C40), cis- δ 9-octadecanoate (C18, oleate), all cis- δ 5,8,11,14-eicosatetraenoate (C20,

arachidonate), octanedioic acid, tetradecanedioic acid, octadecanedioic acid, docosanedioic acid, and similar fatty acids. Suitable fatty acid esters include mono-esters of dicarboxylic acids that comprise a linear or branched lower alkyl group. The lower alkyl group can comprise from one to about twelve, preferably one to about six, carbon atoms.

The above conjugates can be prepared using suitable methods, such as by reaction with one or more modifying agents: a "modifying agent" as the term is used herein, refers to a suitable organic group (e.g., hydrophilic polymer, a fatty acid, a fatty acid ester) that comprises an activating group; an "activating group" is a chemical moiety or functional group that can, under appropriate conditions, react with a second chemical group thereby forming a covalent bond between the modifying agent and the second chemical group.

For example, amine-reactive activating groups include electrophilic groups such as tosylate, mesylate, halo (chloro, bromo, fluoro, iodo), N-hydroxysuccinimidyl esters (NHS), and the like. Activating groups that can react with thiols include, for example, maleimide, iodoacetyl, acryloyl, pyridyl disulfides, 5-thiol-2-nitrobenzoic acid thiol (TNB-thiol), and the like. An aldehyde functional group can be coupled to amine- or hydrazide-containing molecules, and an azide group can react with a trivalent phosphorous group to form phosphoramidate or phosphorimide linkages. Suitable methods to introduce activating groups into molecules are known in the art (see for example, Hernanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, Calif. (1996)). An activating group can be bonded directly to the organic group (e.g., hydrophilic polymer, fatty acid, fatty acid ester), or through a linker moiety, for example a divalent C1-C12 group wherein one or more carbon atoms can be replaced by a heteroatom such as oxygen, nitrogen or sulfur. Suitable linker moieties include, for example, tetraethylene glycol, --(CH₂)₃--, --NH--(CH₂)₆--NH--, --(CH₂)₂--NH-- and --CH₂--O--CH₂--CH₂--O--CH₂--CH₂--O--CH₂--NH--. Modifying agents that comprise a linker moiety can be produced, for example, by reacting a mono-Boc-alkyldiamine (e.g., mono-Boc-ethylenediamine, mono-Boc-diaminohexane) with a fatty acid in the presence of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) to form an amide bond between the free amine and the fatty acid carboxylate. The Boc protecting group can be removed from the product by treatment with trifluoroacetic acid (TFA) to expose a primary amine that can be coupled to another carboxylate as described, or can be reacted with maleic anhydride and the resulting product cyclized to produce an activated maleimido derivative of the fatty acid. (See, for example, Thompson, et al., WO 92/16221 the entire teachings of which are incorporated herein by reference.)

The above conjugates can be produced by reacting a human antibody or antigen-binding fragment with a modifying agent. For example, the organic moieties can be bonded to the antibody in a non-site-specific manner by employing an amine-reactive modifying agent, for example, an NHS ester of PEG. Modified human antibodies or antigen-binding fragments can also be prepared by reducing disulfide bonds (e.g., inter-chain disulfide bonds) of an antibody or antigen-binding fragment. The reduced antibody or antigen-binding fragment can then be reacted with a thiol-reactive modifying agent to produce the modified antibody described herein. Modified human antibodies and antigen-binding fragments comprising an organic moiety that is bonded to specific sites of an antibody described herein can be prepared using suitable methods, such as reverse proteolysis (Fisch et al., *Bioconjugate Chem.*, 3:147-153 (1992); Werlen et al., *Bioconjugate Chem.*, 5:411-417 (1994); Kumaran et al., *Protein Sci.* 6(10):2233-2241 (1997); Itoh et al., *Bioorg. Chem.*, 24(1): 59-68 (1996); Capellas et al., *Biotechnol. Bioeng.*, 56(4):456-463 (1997)), and the methods described in Hermanson, G. T., *Bioconjugate Techniques*, Academic Press: San Diego, Calif. (1996).

Pharmaceutically acceptable cations

Examples of pharmaceutically acceptable monovalent and divalent cations are discussed in Berge, *et al.*, *J. Pharm. Sci.*, **66**, 1-19 (1977), which is incorporated herein by reference.

The pharmaceutically acceptable cation may be inorganic or organic.

Examples of pharmaceutically acceptable monovalent inorganic cations include, but are not limited to, alkali metal ions such as Na^+ and K^+ . Examples of pharmaceutically acceptable divalent inorganic cations include, but are not limited to, alkaline earth cations such as Ca^{2+} and Mg^{2+} . Examples of pharmaceutically acceptable organic cations include, but are not limited to, ammonium ion (i.e. NH_4^+) and substituted ammonium ions (e.g. NH_3R^+ , NH_2R_2^+ , NHR_3^+ , NR_4^+). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is $\text{N}(\text{CH}_3)_4^+$.

Substituents

The phrase "optionally substituted" as used herein, pertains to a parent group which may be unsubstituted or which may be substituted.

Unless otherwise specified, the term “substituted” as used herein, pertains to a parent group which bears one or more substituents. The term “substituent” is used herein in the conventional sense and refers to a chemical moiety which is covalently attached to, or if appropriate, fused to, a parent group. A wide variety of substituents are well known, and methods for their formation and introduction into a variety of parent groups are also well known.

Examples of substituents are described in more detail below.

C₁₋₁₂ alkyl: The term “C₁₋₁₂ alkyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 12 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). The term “C₁₋₄ alkyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a carbon atom of a hydrocarbon compound having from 1 to 4 carbon atoms, which may be aliphatic or alicyclic, and which may be saturated or unsaturated (e.g. partially unsaturated, fully unsaturated). Thus, the term “alkyl” includes the sub-classes alkenyl, alkynyl, cycloalkyl, etc., discussed below.

Examples of saturated alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), propyl (C₃), butyl (C₄), pentyl (C₅), hexyl (C₆) and heptyl (C₇).

Examples of saturated linear alkyl groups include, but are not limited to, methyl (C₁), ethyl (C₂), n-propyl (C₃), n-butyl (C₄), n-pentyl (amyl) (C₅), n-hexyl (C₆) and n-heptyl (C₇).

Examples of saturated branched alkyl groups include iso-propyl (C₃), iso-butyl (C₄), sec-butyl (C₄), tert-butyl (C₄), iso-pentyl (C₅), and neo-pentyl (C₅).

C₂₋₁₂ Alkenyl: The term “C₂₋₁₂ alkenyl” as used herein, pertains to an alkyl group having one or more carbon-carbon double bonds.

Examples of unsaturated alkenyl groups include, but are not limited to, ethenyl (vinyl, -CH=CH₂), 1-propenyl (-CH=CH-CH₃), 2-propenyl (allyl, -CH-CH=CH₂), isopropenyl (1-methylvinyl, -C(CH₃)=CH₂), butenyl (C₄), pentenyl (C₅), and hexenyl (C₆).

C₂₋₁₂ alkynyl: The term “C₂₋₁₂ alkynyl” as used herein, pertains to an alkyl group having one or more carbon-carbon triple bonds.

Examples of unsaturated alkynyl groups include, but are not limited to, ethynyl ($-\text{C}\equiv\text{CH}$) and 2-propynyl (propargyl, $-\text{CH}_2-\text{C}\equiv\text{CH}$).

C₃₋₁₂ cycloalkyl: The term “C₃₋₁₂ cycloalkyl” as used herein, pertains to an alkyl group which is also a cyclyl group; that is, a monovalent moiety obtained by removing a hydrogen atom from an alicyclic ring atom of a cyclic hydrocarbon (carbocyclic) compound, which moiety has from 3 to 7 carbon atoms, including from 3 to 7 ring atoms.

Examples of cycloalkyl groups include, but are not limited to, those derived from:

saturated monocyclic hydrocarbon compounds:

cyclopropane (C₃), cyclobutane (C₄), cyclopentane (C₅), cyclohexane (C₆), cycloheptane (C₇), methylcyclopropane (C₄), dimethylcyclopropane (C₅), methylcyclobutane (C₅), dimethylcyclobutane (C₆), methylcyclopentane (C₆), dimethylcyclopentane (C₇) and methylcyclohexane (C₇);

unsaturated monocyclic hydrocarbon compounds:

cyclopropene (C₃), cyclobutene (C₄), cyclopentene (C₅), cyclohexene (C₆), methylcyclopropene (C₄), dimethylcyclopropene (C₅), methylcyclobutene (C₅), dimethylcyclobutene (C₆), methylcyclopentene (C₆), dimethylcyclopentene (C₇) and methylcyclohexene (C₇); and

saturated polycyclic hydrocarbon compounds:

norcarane (C₇), norpinane (C₇), norbornane (C₇).

C₃₋₂₀ heterocyclyl: The term “C₃₋₂₀ heterocyclyl” as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from a ring atom of a heterocyclic compound, which moiety has from 3 to 20 ring atoms, of which from 1 to 10 are ring heteroatoms. Preferably, each ring has from 3 to 7 ring atoms, of which from 1 to 4 are ring heteroatoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₃₋₇, C₅₋₆, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term “C₅₋₆heterocyclyl”, as used herein, pertains to a heterocyclyl group having 5 or 6 ring atoms.

Examples of monocyclic heterocyclyl groups include, but are not limited to, those derived from:

N₁: aziridine (C₃), azetidene (C₄), pyrrolidine (tetrahydropyrrole) (C₅), pyrroline (e.g., 3-pyrroline, 2,5-dihydropyrrole) (C₅), 2H-pyrrole or 3H-pyrrole (isopyrrole, isoazole) (C₅), piperidine (C₆), dihydropyridine (C₆), tetrahydropyridine (C₆), azepine (C₇);

O₁: oxirane (C₃), oxetane (C₄), oxolane (tetrahydrofuran) (C₅), oxole (dihydrofuran) (C₅), oxane (tetrahydropyran) (C₆), dihydropyran (C₆), pyran (C₆), oxepin (C₇);

S₁: thiirane (C₃), thietane (C₄), thiolane (tetrahydrothiophene) (C₅), thiane (tetrahydrothiopyran) (C₆), thiepane (C₇);

O₂: dioxolane (C₅), dioxane (C₆), and dioxepane (C₇);

O₃: trioxane (C₆);

N₂: imidazolidine (C₅), pyrazolidine (diazolidine) (C₅), imidazoline (C₅), pyrazoline (dihydropyrazole) (C₅), piperazine (C₆);

N₁O₁: tetrahydrooxazole (C₅), dihydrooxazole (C₅), tetrahydroisoxazole (C₅), dihydroisoxazole (C₅), morpholine (C₆), tetrahydrooxazine (C₆), dihydrooxazine (C₆), oxazine (C₆);

N₁S₁: thiazoline (C₅), thiazolidine (C₅), thiomorpholine (C₆);

N₂O₁: oxadiazine (C₆);

O₁S₁: oxathiole (C₅) and oxathiane (thioxane) (C₆); and,

N₁O₁S₁: oxathiazine (C₆).

Examples of substituted monocyclic heterocyclyl groups include those derived from saccharides, in cyclic form, for example, furanoses (C₅), such as arabinofuranose, lyxofuranose, ribofuranose, and xylofuranose, and pyranoses (C₆), such as allopyranose, altropyranose, glucopyranose, mannopyranose, gulopyranose, idopyranose, galactopyranose, and talopyranose.

C₅₋₂₀ aryl: The term "C₅₋₂₀ aryl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 3 to 20 ring atoms. The term "C₅₋₇ aryl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 5 to 7 ring atoms and the term "C₅₋₁₀ aryl", as used herein, pertains to a monovalent moiety obtained by removing a hydrogen atom from an aromatic ring atom of an aromatic compound, which moiety has from 5 to 10 ring atoms. Preferably, each ring has from 5 to 7 ring atoms.

In this context, the prefixes (e.g. C₃₋₂₀, C₅₋₇, C₅₋₆, C₅₋₁₀, etc.) denote the number of ring atoms, or range of number of ring atoms, whether carbon atoms or heteroatoms. For example, the term "C₅₋₆ aryl" as used herein, pertains to an aryl group having 5 or 6 ring atoms.

The ring atoms may be all carbon atoms, as in “carboaryl groups”.

Examples of carboaryl groups include, but are not limited to, those derived from benzene (i.e. phenyl) (C₆), naphthalene (C₁₀), azulene (C₁₀), anthracene (C₁₄), phenanthrene (C₁₄), naphthacene (C₁₈), and pyrene (C₁₆).

Examples of aryl groups which comprise fused rings, at least one of which is an aromatic ring, include, but are not limited to, groups derived from indane (e.g. 2,3-dihydro-1H-indene) (C₉), indene (C₉), isoindene (C₉), tetraline (1,2,3,4-tetrahydronaphthalene (C₁₀), acenaphthene (C₁₂), fluorene (C₁₃), phenalene (C₁₃), acephenanthrene (C₁₅), and aceanthrene (C₁₆).

Alternatively, the ring atoms may include one or more heteroatoms, as in “heteroaryl groups”. Examples of monocyclic heteroaryl groups include, but are not limited to, those derived from:

N₁: pyrrole (azole) (C₅), pyridine (azine) (C₆);

O₁: furan (oxole) (C₅);

S₁: thiophene (thiole) (C₅);

N₁O₁: oxazole (C₅), isoxazole (C₅), isoxazine (C₆);

N₂O₁: oxadiazole (furazan) (C₅);

N₃O₁: oxatriazole (C₅);

N₁S₁: thiazole (C₅), isothiazole (C₅);

N₂: imidazole (1,3-diazole) (C₅), pyrazole (1,2-diazole) (C₅), pyridazine (1,2-diazine) (C₆), pyrimidine (1,3-diazine) (C₆) (e.g., cytosine, thymine, uracil), pyrazine (1,4-diazine) (C₆);

N₃: triazole (C₅), triazine (C₆); and,

N₄: tetrazole (C₅).

Examples of heteroaryl which comprise fused rings, include, but are not limited to:

C₉ (with 2 fused rings) derived from benzofuran (O₁), isobenzofuran (O₁), indole (N₁), isoindole (N₁), indolizine (N₁), indoline (N₁), isoindoline (N₁), purine (N₄) (e.g., adenine, guanine), benzimidazole (N₂), indazole (N₂), benzoxazole (N₁O₁), benzisoxazole (N₁O₁), benzodioxole (O₂), benzofurazan (N₂O₁), benzotriazole (N₃), benzothiofuran (S₁), benzothiazole (N₁S₁), benzothiadiazole (N₂S);

C₁₀ (with 2 fused rings) derived from chromene (O₁), isochromene (O₁), chroman (O₁), isochroman (O₁), benzodioxan (O₂), quinoline (N₁), isoquinoline (N₁), quinolizine (N₁), benzoxazine (N₁O₁), benzodiazine (N₂), pyridopyridine (N₂), quinoxaline (N₂), quinazoline (N₂), cinnoline (N₂), phthalazine (N₂), naphthyridine (N₂), pteridine (N₄);

C₁₁ (with 2 fused rings) derived from benzodiazepine (N₂);

C₁₃ (with 3 fused rings) derived from carbazole (N₁), dibenzofuran (O₁), dibenzothiophene (S₁), carboline (N₂), perimidine (N₂), pyridoindole (N₂); and,

C₁₄ (with 3 fused rings) derived from acridine (N₁), xanthene (O₁), thioxanthene (S₁), oxanthrene (O₂), phenoxathiin (O₁S₁), phenazine (N₂), phenoxazine (N₁O₁), phenothiazine (N₁S₁), thianthrene (S₂), phenanthridine (N₁), phenanthroline (N₂), phenazine (N₂).

The above groups, whether alone or part of another substituent, may themselves optionally be substituted with one or more groups selected from themselves and the additional substituents listed below.

Halo: -F, -Cl, -Br, and -I.

Hydroxy: -OH.

Ether: -OR, wherein R is an ether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇ alkoxy group, discussed below), a C₃₋₂₀ heterocyclyl group (also referred to as a C₃₋₂₀ heterocycloxy group), or a C₅₋₂₀ aryl group (also referred to as a C₅₋₂₀ aryloxy group), preferably a C₁₋₇alkyl group.

Alkoxy: -OR, wherein R is an alkyl group, for example, a C₁₋₇ alkyl group. Examples of C₁₋₇ alkoxy groups include, but are not limited to, -OMe (methoxy), -OEt (ethoxy), -O(nPr) (n-propoxy), -O(iPr) (isopropoxy), -O(nBu) (n-butoxy), -O(sBu) (sec-butoxy), -O(iBu) (isobutoxy), and -O(tBu) (tert-butoxy).

Acetal: -CH(OR¹)(OR²), wherein R¹ and R² are independently acetal substituents, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group, or, in the case of a "cyclic" acetal group, R¹ and R², taken together with the two oxygen atoms to which they are attached, and the carbon atoms to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Examples of acetal groups include, but are not limited to, -CH(OMe)₂, -CH(OEt)₂, and -CH(OMe)(OEt).

Hemiacetal: -CH(OH)(OR¹), wherein R¹ is a hemiacetal substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of hemiacetal groups include, but are not limited to, -CH(OH)(OMe) and -CH(OH)(OEt).

Ketal: $-\text{CR}(\text{OR}^1)(\text{OR}^2)$, where R^1 and R^2 are as defined for acetals, and R is a ketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples ketal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OMe})_2$, $-\text{C}(\text{Me})(\text{OEt})_2$, $-\text{C}(\text{Me})(\text{OMe})(\text{OEt})$, $-\text{C}(\text{Et})(\text{OMe})_2$, $-\text{C}(\text{Et})(\text{OEt})_2$, and $-\text{C}(\text{Et})(\text{OMe})(\text{OEt})$.

Hemiketal: $-\text{CR}(\text{OH})(\text{OR}^1)$, where R^1 is as defined for hemiacetals, and R is a hemiketal substituent other than hydrogen, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of hemiacetal groups include, but are not limited to, $-\text{C}(\text{Me})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Et})(\text{OH})(\text{OMe})$, $-\text{C}(\text{Me})(\text{OH})(\text{OEt})$, and $-\text{C}(\text{Et})(\text{OH})(\text{OEt})$.

Oxo (keto, -one): $=\text{O}$.

Thione (thioketone): $=\text{S}$.

Imino (imine): $=\text{NR}$, wherein R is an imino substituent, for example, hydrogen, C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $=\text{NH}$, $=\text{NMe}$, $=\text{NEt}$, and $=\text{NPh}$.

Formyl (carbaldehyde, carboxaldehyde): $-\text{C}(=\text{O})\text{H}$.

Acyl (keto): $-\text{C}(=\text{O})\text{R}$, wherein R is an acyl substituent, for example, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylacyl or C_{1-7} alkanoyl), a C_{3-20} heterocyclyl group (also referred to as C_{3-20} heterocyclylacyl), or a C_{5-20} aryl group (also referred to as C_{5-20} arylacyl), preferably a C_{1-7} alkyl group. Examples of acyl groups include, but are not limited to, $-\text{C}(=\text{O})\text{CH}_3$ (acetyl), $-\text{C}(=\text{O})\text{CH}_2\text{CH}_3$ (propionyl), $-\text{C}(=\text{O})\text{C}(\text{CH}_3)_3$ (t-butyryl), and $-\text{C}(=\text{O})\text{Ph}$ (benzoyl, phenone).

Carboxy (carboxylic acid): $-\text{C}(=\text{O})\text{OH}$.

Thiocarboxy (thiocarboxylic acid): $-\text{C}(=\text{S})\text{SH}$.

Thiolocarboxy (thiolocarboxylic acid): $-\text{C}(=\text{O})\text{SH}$.

Thionocarboxy (thionocarboxylic acid): $-\text{C}(=\text{S})\text{OH}$.

Imidic acid: $-C(=NH)OH$.

Hydroxamic acid: $-C(=NOH)OH$.

Ester (carboxylate, carboxylic acid ester, oxycarbonyl): $-C(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $-C(=O)OCH_3$, $-C(=O)OCH_2CH_3$, $-C(=O)OC(CH_3)_3$, and $-C(=O)OPh$.

Acyloxy (reverse ester): $-OC(=O)R$, wherein R is an acyloxy substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of acyloxy groups include, but are not limited to, $-OC(=O)CH_3$ (acetoxyl), $-OC(=O)CH_2CH_3$, $-OC(=O)C(CH_3)_3$, $-OC(=O)Ph$, and $-OC(=O)CH_2Ph$.


Oxycarboxyloxy: $-OC(=O)OR$, wherein R is an ester substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of ester groups include, but are not limited to, $-OC(=O)OCH_3$, $-OC(=O)OCH_2CH_3$, $-OC(=O)OC(CH_3)_3$, and $-OC(=O)OPh$.

Amino: $-NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, for example, hydrogen, a C_{1-7} alkyl group (also referred to as C_{1-7} alkylamino or di- C_{1-7} alkylamino), a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably H or a C_{1-7} alkyl group, or, in the case of a "cyclic" amino group, R^1 and R^2 , taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 4 to 8 ring atoms. Amino groups may be primary ($-NH_2$), secondary ($-NHR^1$), or tertiary ($-NHR^1R^2$), and in cationic form, may be quaternary ($-^+NR^1R^2R^3$). Examples of amino groups include, but are not limited to, $-NH_2$, $-NHCH_3$, $-NHC(CH_3)_2$, $-N(CH_3)_2$, $-N(CH_2CH_3)_2$, and $-NHPh$. Examples of cyclic amino groups include, but are not limited to, aziridino, azetidino, pyrrolidino, piperidino, piperazino, morpholino, and thiomorpholino.

Amido (carbamoyl, carbamyl, aminocarbonyl, carboxamide): $-C(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=O)NH_2$, $-C(=O)NHCH_3$, $-C(=O)N(CH_3)_2$, $-C(=O)NHCH_2CH_3$, and $-C(=O)N(CH_2CH_3)_2$, as well as amido groups in which R^1 and R^2 , together with the nitrogen atom to which they are attached, form a heterocyclic structure as in, for example, piperidinocarbonyl, morpholinocarbonyl, thiomorpholinocarbonyl, and piperazinocarbonyl.

Thioamido (thiocarbamyl): $-C(=S)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of amido groups include, but are not limited to, $-C(=S)NH_2$, $-C(=S)NHCH_3$, $-C(=S)N(CH_3)_2$, and $-C(=S)NHCH_2CH_3$.

Acylamido (acylamino): $-NR^1C(=O)R^2$, wherein R^1 is an amide substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group, and R^2 is an acyl substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of acylamide groups include, but are not limited to, $-NHC(=O)CH_3$, $-NHC(=O)CH_2CH_3$, and $-NHC(=O)Ph$. R^1 and R^2 may together form a cyclic structure, as in, for example, succinimidyl, maleimidyl, and phthalimidyl:




Aminocarbonyloxy: $-OC(=O)NR^1R^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of aminocarbonyloxy groups include, but are not limited to, $-OC(=O)NH_2$, $-OC(=O)NHMe$, $-OC(=O)NMe_2$, and $-OC(=O)NEt_2$.

Ureido: $-N(R^1)CONR^2R^3$ wherein R^2 and R^3 are independently amino substituents, as defined for amino groups, and R^1 is a ureido substituent, for example, hydrogen, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably hydrogen or a C_{1-7} alkyl group. Examples of ureido groups include, but are not limited to, $-NHCONH_2$, $-NHCONHMe$, $-NHCONHEt$, $-NHCONMe_2$, $-NHCONEt_2$, $-NMeCONH_2$, $-NMeCONHMe$, $-NMeCONHEt$, $-NMeCONMe_2$, and $-NMeCONEt_2$.

Guanidino: $-NH-C(=NH)NH_2$.

Tetrazolyl: a five membered aromatic ring having four nitrogen atoms and one carbon atom,



Imino: =NR, wherein R is an imino substituent, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇alkyl group. Examples of imino groups include, but are not limited to, =NH, =NMe, and =NEt.

Amidine (amidino): -C(=NR)NR₂, wherein each R is an amidine substituent, for example, hydrogen, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably H or a C₁₋₇ alkyl group. Examples of amidine groups include, but are not limited to, -C(=NH)NH₂, -C(=NH)NMe₂, and -C(=NMe)NMe₂.

Nitro: -NO₂.

Nitroso: -NO.

Azido: -N₃.

Cyano (nitrile, carbonitrile): -CN.

Isocyano: -NC.

Cyanato: -OCN.

Isocyanato: -NCO.

Thiocyano (thiocyanato): -SCN.

Isothiocyano (isothiocyanato): -NCS.

Sulfhydryl (thiol, mercapto): -SH.

Thioether (sulfide): -SR, wherein R is a thioether substituent, for example, a C₁₋₇ alkyl group (also referred to as a C₁₋₇alkylthio group), a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of C₁₋₇ alkylthio groups include, but are not limited to, -SCH₃ and -SCH₂CH₃.

Disulfide: -SS-R, wherein R is a disulfide substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group (also referred to herein

as C₁₋₇ alkyl disulfide). Examples of C₁₋₇ alkyl disulfide groups include, but are not limited to, -SSCH₃ and -SSCH₂CH₃.

Sulfine (sulfinyl, sulfoxide): -S(=O)R, wherein R is a sulfine substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfine groups include, but are not limited to, -S(=O)CH₃ and -S(=O)CH₂CH₃.

Sulfone (sulfonyl): -S(=O)₂R, wherein R is a sulfone substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group, including, for example, a fluorinated or perfluorinated C₁₋₇ alkyl group. Examples of sulfone groups include, but are not limited to, -S(=O)₂CH₃ (methanesulfonyl, mesyl), -S(=O)₂CF₃ (triflyl), -S(=O)₂CH₂CH₃ (esyl), -S(=O)₂C₄F₉ (nonafllyl), -S(=O)₂CH₂CF₃ (tresyl), -S(=O)₂CH₂CH₂NH₂ (tauryl), -S(=O)₂Ph (phenylsulfonyl, besyl), 4-methylphenylsulfonyl (tosyl), 4-chlorophenylsulfonyl (closyl), 4-bromophenylsulfonyl (brosyl), 4-nitrophenyl (nosyl), 2-naphthalenesulfonate (napsyl), and 5-dimethylamino-naphthalen-1-ylsulfonate (dansyl).

Sulfinic acid (sulfino): -S(=O)OH, -SO₂H.

Sulfonic acid (sulfo): -S(=O)₂OH, -SO₃H.

Sulfinate (sulfinic acid ester): -S(=O)OR; wherein R is a sulfinate substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfinate groups include, but are not limited to, -S(=O)OCH₃ (methoxysulfinyl; methyl sulfinate) and -S(=O)OCH₂CH₃ (ethoxysulfinyl; ethyl sulfinate).

Sulfonate (sulfonic acid ester): -S(=O)₂OR, wherein R is a sulfonate substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfonate groups include, but are not limited to, -S(=O)₂OCH₃ (methoxysulfonyl; methyl sulfonate) and -S(=O)₂OCH₂CH₃ (ethoxysulfonyl; ethyl sulfonate).

Sulfinyloxy: -OS(=O)R, wherein R is a sulfinyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group. Examples of sulfinyloxy groups include, but are not limited to, -OS(=O)CH₃ and -OS(=O)CH₂CH₃.

Sulfonyloxy: -OS(=O)₂R, wherein R is a sulfonyloxy substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group.

Examples of sulfonyloxy groups include, but are not limited to, $-\text{OS}(=\text{O})_2\text{CH}_3$ (mesylate) and $-\text{OS}(=\text{O})_2\text{CH}_2\text{CH}_3$ (esylate).

Sulfate: $-\text{OS}(=\text{O})_2\text{OR}$; wherein R is a sulfate substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfate groups include, but are not limited to, $-\text{OS}(=\text{O})_2\text{OCH}_3$ and $-\text{SO}(=\text{O})_2\text{OCH}_2\text{CH}_3$.

Sulfamyl (sulfamoyl; sulfinic acid amide; sulfinamide): $-\text{S}(=\text{O})\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfamyl groups include, but are not limited to, $-\text{S}(=\text{O})\text{NH}_2$, $-\text{S}(=\text{O})\text{NH}(\text{CH}_3)$, $-\text{S}(=\text{O})\text{N}(\text{CH}_3)_2$, $-\text{S}(=\text{O})\text{NH}(\text{CH}_2\text{CH}_3)$, $-\text{S}(=\text{O})\text{N}(\text{CH}_2\text{CH}_3)_2$, and $-\text{S}(=\text{O})\text{NHPh}$.

Sulfonamido (sulfinamoyl; sulfonic acid amide; sulfonamide): $-\text{S}(=\text{O})_2\text{NR}^1\text{R}^2$, wherein R^1 and R^2 are independently amino substituents, as defined for amino groups. Examples of sulfonamido groups include, but are not limited to, $-\text{S}(=\text{O})_2\text{NH}_2$, $-\text{S}(=\text{O})_2\text{NH}(\text{CH}_3)$, $-\text{S}(=\text{O})_2\text{N}(\text{CH}_3)_2$, $-\text{S}(=\text{O})_2\text{NH}(\text{CH}_2\text{CH}_3)$, $-\text{S}(=\text{O})_2\text{N}(\text{CH}_2\text{CH}_3)_2$, and $-\text{S}(=\text{O})_2\text{NHPh}$.

Sulfamino: $-\text{NR}^1\text{S}(=\text{O})_2\text{OH}$, wherein R^1 is an amino substituent, as defined for amino groups. Examples of sulfamino groups include, but are not limited to, $-\text{NHS}(=\text{O})_2\text{OH}$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})_2\text{OH}$.

Sulfonamino: $-\text{NR}^1\text{S}(=\text{O})_2\text{R}$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfonamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfonamino groups include, but are not limited to, $-\text{NHS}(=\text{O})_2\text{CH}_3$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})_2\text{C}_6\text{H}_5$.

Sulfinamino: $-\text{NR}^1\text{S}(=\text{O})\text{R}$, wherein R^1 is an amino substituent, as defined for amino groups, and R is a sulfinamino substituent, for example, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably a C_{1-7} alkyl group. Examples of sulfinamino groups include, but are not limited to, $-\text{NHS}(=\text{O})\text{CH}_3$ and $-\text{N}(\text{CH}_3)\text{S}(=\text{O})\text{C}_6\text{H}_5$.

Phosphino (phosphine): $-\text{PR}_2$, wherein R is a phosphino substituent, for example, -H, a C_{1-7} alkyl group, a C_{3-20} heterocyclyl group, or a C_{5-20} aryl group, preferably -H, a C_{1-7} alkyl group, or a C_{5-20} aryl group. Examples of phosphino groups include, but are not limited to, $-\text{PH}_2$, $-\text{P}(\text{CH}_3)_2$, $-\text{P}(\text{CH}_2\text{CH}_3)_2$, $-\text{P}(\text{t-Bu})_2$, and $-\text{P}(\text{Ph})_2$.

Phospho: $-\text{P}(=\text{O})_2$.

Phosphinyl (phosphine oxide): $-P(=O)R_2$, wherein R is a phosphinyl substituent, for example, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably a C₁₋₇ alkyl group or a C₅₋₂₀ aryl group. Examples of phosphinyl groups include, but are not limited to, $-P(=O)(CH_3)_2$, $-P(=O)(CH_2CH_3)_2$, $-P(=O)(t-Bu)_2$, and $-P(=O)(Ph)_2$.

Phosphonic acid (phosphono): $-P(=O)(OH)_2$.

Phosphonate (phosphono ester): $-P(=O)(OR)_2$, where R is a phosphonate substituent, for example, -H, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphonate groups include, but are not limited to, $-P(=O)(OCH_3)_2$, $-P(=O)(OCH_2CH_3)_2$, $-P(=O)(O-t-Bu)_2$, and $-P(=O)(OPh)_2$.

Phosphoric acid (phosphonooxy): $-OP(=O)(OH)_2$.

Phosphate (phosphonooxy ester): $-OP(=O)(OR)_2$, where R is a phosphate substituent, for example, -H, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphate groups include, but are not limited to, $-OP(=O)(OCH_3)_2$, $-OP(=O)(OCH_2CH_3)_2$, $-OP(=O)(O-t-Bu)_2$, and $-OP(=O)(OPh)_2$.

Phosphorous acid: $-OP(OH)_2$.

Phosphite: $-OP(OR)_2$, where R is a phosphite substituent, for example, -H, a C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphite groups include, but are not limited to, $-OP(OCH_3)_2$, $-OP(OCH_2CH_3)_2$, $-OP(O-t-Bu)_2$, and $-OP(OPh)_2$.

Phosphoramidite: $-OP(OR^1)NR^2_2$, where R¹ and R² are phosphoramidite substituents, for example, -H, a (optionally substituted) C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of phosphoramidite groups include, but are not limited to, $-OP(OCH_2CH_3)N(CH_3)_2$, $-OP(OCH_2CH_3)N(i-Pr)_2$, and $-OP(OCH_2CH_2CN)N(i-Pr)_2$.

Phosphoramidate: $-OP(=O)(OR^1)NR^2_2$, where R¹ and R² are phosphoramidate substituents, for example, -H, a (optionally substituted) C₁₋₇ alkyl group, a C₃₋₂₀ heterocyclyl group, or a C₅₋₂₀ aryl group, preferably -H, a C₁₋₇ alkyl group, or a C₅₋₂₀ aryl group. Examples of

phosphoramidate groups include, but are not limited to, $-\text{OP}(=\text{O})(\text{OCH}_2\text{CH}_3)-\text{N}(\text{CH}_3)_2$, $-\text{OP}(=\text{O})(\text{OCH}_2\text{CH}_3)-\text{N}(\text{i-Pr})_2$, and $-\text{OP}(=\text{O})(\text{OCH}_2\text{CH}_2\text{CN})-\text{N}(\text{i-Pr})_2$.

Alkylene

C_{3-12} alkylene: The term “ C_{3-12} alkylene”, as used herein, pertains to a bidentate moiety obtained by removing two hydrogen atoms, either both from the same carbon atom, or one from each of two different carbon atoms, of a hydrocarbon compound having from 3 to 12 carbon atoms (unless otherwise specified), which may be aliphatic or alicyclic, and which may be saturated, partially unsaturated, or fully unsaturated. Thus, the term “alkylene” includes the sub-classes alkenylene, alkynylene, cycloalkylene, etc., discussed below.

Examples of linear saturated C_{3-12} alkylene groups include, but are not limited to, $-(\text{CH}_2)_n-$ where n is an integer from 3 to 12, for example, $-\text{CH}_2\text{CH}_2\text{CH}_2-$ (propylene), $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ (butylene), $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ (pentylene) and $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2-$ (heptylene).

Examples of branched saturated C_{3-12} alkylene groups include, but are not limited to, $-\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2-$, $-\text{CH}_2\text{CH}(\text{CH}_3)\text{CH}_2\text{CH}_2-$, $-\text{CH}(\text{CH}_2\text{CH}_3)-$, $-\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2-$, and $-\text{CH}_2\text{CH}(\text{CH}_2\text{CH}_3)\text{CH}_2-$.

Examples of linear partially unsaturated C_{3-12} alkylene groups (C_{3-12} alkenylene, and alkynylene groups) include, but are not limited to, $-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}_2-\text{CH}=\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}=\text{CH}-$, $-\text{CH}=\text{CH}-\text{CH}_2-\text{CH}_2-\text{CH}=\text{CH}-$, and $-\text{CH}_2-\text{C}\equiv\text{C}-\text{CH}_2-$.


Examples of branched partially unsaturated C_{3-12} alkylene groups (C_{3-12} alkenylene and alkynylene groups) include, but are not limited to, $-\text{C}(\text{CH}_3)=\text{CH}-$, $-\text{C}(\text{CH}_3)=\text{CH}-\text{CH}_2-$, $-\text{CH}=\text{CH}-\text{CH}(\text{CH}_3)-$ and $-\text{C}\equiv\text{C}-\text{CH}(\text{CH}_3)-$.

Examples of alicyclic saturated C_{3-12} alkylene groups (C_{3-12} cycloalkylenes) include, but are not limited to, cyclopentylene (e.g. cyclopent-1,3-ylene), and cyclohexylene (e.g. cyclohex-1,4-ylene).

Examples of alicyclic partially unsaturated C_{3-12} alkylene groups (C_{3-12} cycloalkylenes) include, but are not limited to, cyclopentenylene (e.g. 4-cyclopenten-1,3-ylene),


cyclohexenylene (e.g. 2-cyclohexen-1,4-ylene; 3-cyclohexen-1,2-ylene; 2,5-cyclohexadien-1,4-ylene).

Carbamate nitrogen protecting group: the term “carbamate nitrogen protecting group” pertains to a moiety which masks the nitrogen in the imine bond, and these are well known in the art. These groups have the following structure:



wherein R¹⁰ is R as defined above. A large number of suitable groups are described on pages 503 to 549 of Greene, T.W. and Wuts, G.M., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by reference.

Hemi-aminal nitrogen protecting group: the term “hemi-aminal nitrogen protecting group” pertains to a group having the following structure:




wherein R¹⁰ is R as defined above. A large number of suitable groups are described on pages 633 to 647 as amide protecting groups of Greene, T.W. and Wuts, G.M., Protective Groups in Organic Synthesis, 3rd Edition, John Wiley & Sons, Inc., 1999, which is incorporated herein by reference.

The groups Carbamate nitrogen protecting group and Hemi-aminal nitrogen protecting group may be jointly termed a “nitrogen protecting group for synthesis”.

Conjugates

The present disclosure provides a conjugate comprising a PBD compound connected to the antibody via a Linker Unit.

In one embodiment, the conjugate comprises the antibody connected to a spacer connecting group, the spacer connected to a trigger, the trigger connected to a self-immolative linker, and the self-immolative linker connected to the N10 position of the PBD compound. Such a conjugate is illustrated below:



where Ab is the antibody as defined above and PBD is a pyrrolobenzodiazepine compound (D), as described herein. The illustration shows the portions that correspond to R^L , A, L^1 and L^2 in certain embodiments of the disclosure. R^L may be either R^{L1} or R^{L2} . D is D^L with R^{L1} or R^{L2} removed.

The present disclosure is suitable for use in providing a PBD compound to a preferred site in a subject. In the preferred embodiments, the conjugate allows the release of an active PBD compound that does not retain any part of the linker. There is no stub present that could affect the reactivity of the PBD compound.

The linker attaches the antibody to the PBD drug moiety D through covalent bond(s). The linker is a bifunctional or multifunctional moiety which can be used to link one or more drug moiety (D) and an antibody unit (Ab) to form antibody-drug conjugates (ADC). The linker (R^L) may be stable outside a cell, i.e. extracellular, or it may be cleavable by enzymatic activity, hydrolysis, or other metabolic conditions. Antibody-drug conjugates (ADC) can be conveniently prepared using a linker having reactive functionality for binding to the drug moiety and to the antibody. A cysteine thiol, or an amine, e.g. N-terminus or amino acid side chain such as lysine, of the antibody (Ab) can form a bond with a functional group of a linker or spacer reagent, PBD drug moiety (D) or drug-linker reagent (D^L , $D-R^L$), where R^L can be R^{L1} or R^{L2} .

The linkers of the ADC preferably prevent aggregation of ADC molecules and keep the ADC freely soluble in aqueous media and in a monomeric state.


The linkers of the ADC are preferably stable extracellularly. Before transport or delivery into a cell, the antibody-drug conjugate (ADC) is preferably stable and remains intact, i.e. the antibody remains linked to the drug moiety. The linkers are stable outside the target cell and may be cleaved at some efficacious rate inside the cell. An effective linker will: (i) maintain the specific binding properties of the antibody; (ii) allow intracellular delivery of the conjugate

or drug moiety; (iii) remain stable and intact, i.e. not cleaved, until the conjugate has been delivered or transported to its targetted site; and (iv) maintain a cytotoxic, cell-killing effect or a cytostatic effect of the PBD drug moiety. Stability of the ADC may be measured by standard analytical techniques such as mass spectroscopy, HPLC, and the separation/analysis technique LC/MS.

Covalent attachment of the antibody and the drug moiety requires the linker to have two reactive functional groups, i.e. bivalency in a reactive sense. Bivalent linker reagents which are useful to attach two or more functional or biologically active moieties, such as peptides, nucleic acids, drugs, toxins, antibodies, haptens, and reporter groups are known, and methods have been described their resulting conjugates (Hermanson, G.T. (1996) *Bioconjugate Techniques*; Academic Press: New York, p 234-242).

In another embodiment, the linker may be substituted with groups which modulate aggregation, solubility or reactivity. For example, a sulfonate substituent may increase water solubility of the reagent and facilitate the coupling reaction of the linker reagent with the antibody or the drug moiety, or facilitate the coupling reaction of Ab-L with D^L, or D^L-L with Ab, depending on the synthetic route employed to prepare the ADC.

In one embodiment, L-R^L is a group:



where the asterisk indicates the point of attachment to the Drug Unit (D), Ab is the antibody (L), L¹ is a linker, A is a connecting group connecting L¹ to the antibody, L² is a covalent bond or together with -OC(=O)- forms a self-immolative linker, and L¹ or L² is a cleavable linker.

L¹ is preferably the cleavable linker, and may be referred to as a trigger for activation of the linker for cleavage.

The nature of L¹ and L², where present, can vary widely. These groups are chosen on the basis of their cleavage characteristics, which may be dictated by the conditions at the site to which the conjugate is delivered. Those linkers that are cleaved by the action of enzymes are preferred, although linkers that are cleavable by changes in pH (e.g. acid or base labile),

temperature or upon irradiation (e.g. photolabile) may also be used. Linkers that are cleavable under reducing or oxidising conditions may also find use in the present disclosure.

L¹ may comprise a contiguous sequence of amino acids. The amino acid sequence may be the target substrate for enzymatic cleavage, thereby allowing release of L-R^L from the N10 position.

In one embodiment, L¹ is cleavable by the action of an enzyme. In one embodiment, the enzyme is an esterase or a peptidase.

In one embodiment, L² is present and together with -C(=O)O- forms a self-immolative linker. In one embodiment, L² is a substrate for enzymatic activity, thereby allowing release of L-R^L from the N10 position.

In one embodiment, where L¹ is cleavable by the action of an enzyme and L² is present, the enzyme cleaves the bond between L¹ and L².

L¹ and L², where present, may be connected by a bond selected from:

-C(=O)NH-,
-C(=O)O-,
-NHC(=O)-,
-OC(=O)-,
-OC(=O)O-,
-NHC(=O)O-,
-OC(=O)NH-, and
-NHC(=O)NH-.


An amino group of L¹ that connects to L² may be the N-terminus of an amino acid or may be derived from an amino group of an amino acid side chain, for example a lysine amino acid side chain.

A carboxyl group of L¹ that connects to L² may be the C-terminus of an amino acid or may be derived from a carboxyl group of an amino acid side chain, for example a glutamic acid amino acid side chain.

A hydroxyl group of L¹ that connects to L² may be derived from a hydroxyl group of an amino acid side chain, for example a serine amino acid side chain.

The term “amino acid side chain” includes those groups found in: (i) naturally occurring amino acids such as alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine; (ii) minor amino acids such as ornithine and citrulline; (iii) unnatural amino acids, beta-amino acids, synthetic analogs and derivatives of naturally occurring amino acids; and (iv) all enantiomers, diastereomers, isomerically enriched, isotopically labelled (e.g. ^2H , ^3H , ^{14}C , ^{15}N), protected forms, and racemic mixtures thereof.

In one embodiment, $-\text{C}(=\text{O})\text{O}-$ and L^2 together form the group:




where the asterisk indicates the point of attachment to the N10 position, the wavy line indicates the point of attachment to the linker L^1 , Y is $-\text{N}(\text{H})-$, $-\text{O}-$, $-\text{C}(=\text{O})\text{N}(\text{H})-$ or $-\text{C}(=\text{O})\text{O}-$, and n is 0 to 3. The phenylene ring is optionally substituted with one, two or three substituents as described herein. In one embodiment, the phenylene group is optionally substituted with halo, NO_2 , R or OR.

In one embodiment, Y is NH.

In one embodiment, n is 0 or 1. Preferably, n is 0.

Where Y is NH and n is 0, the self-immolative linker may be referred to as a p-aminobenzylcarbonyl linker (PABC).


The self-immolative linker will allow for release of the protected compound when a remote site is activated, proceeding along the lines shown below (for n=0):



where L^* is the activated form of the remaining portion of the linker. These groups have the advantage of separating the site of activation from the compound being protected. As described above, the phenylene group may be optionally substituted.


In one embodiment described herein, the group L^* is a linker L^1 as described herein, which may include a dipeptide group.

In another embodiment, $-C(=O)O-$ and L^2 together form a group selected from:



where the asterisk, the wavy line, Y, and n are as defined above. Each phenylene ring is optionally substituted with one, two or three substituents as described herein. In one embodiment, the phenylene ring having the Y substituent is optionally substituted and the phenylene ring not having the Y substituent is unsubstituted. In one embodiment, the phenylene ring having the Y substituent is unsubstituted and the phenylene ring not having the Y substituent is optionally substituted.

In another embodiment, $-C(=O)O-$ and L^2 together form a group selected from:



where the asterisk, the wavy line, Y, and n are as defined above, E is O, S or NR, D is N, CH, or CR, and F is N, CH, or CR.

In one embodiment, D is N.

In one embodiment, D is CH.

In one embodiment, E is O or S.

In one embodiment, F is CH.

In a preferred embodiment, the linker is a cathepsin labile linker.

In one embodiment, L¹ comprises a dipeptide. The dipeptide may be represented as -NH-X₁-X₂-CO-, where -NH- and -CO- represent the N- and C-terminals of the amino acid groups X₁ and X₂ respectively. The amino acids in the dipeptide may be any combination of natural amino acids. Where the linker is a cathepsin labile linker, the dipeptide may be the site of action for cathepsin-mediated cleavage.

Additionally, for those amino acids groups having carboxyl or amino side chain functionality, for example Glu and Lys respectively, CO and NH may represent that side chain functionality.

In one embodiment, the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

- Phe-Lys-,
- Val-Ala-,
- Val-Lys-,
- Ala-Lys-,
- Val-Cit-,
- Phe-Cit-,
- Leu-Cit-,
- Ile-Cit-,
- Phe-Arg-,
- Trp-Cit-

where Cit is citrulline.

Preferably, the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

- Phe-Lys-,
- Val-Ala-,
- Val-Lys-,
- Ala-Lys-,
- Val-Cit-

Most preferably, the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is -Phe-Lys- or -Val-Ala-.

Other dipeptide combinations may be used, including those described by Dubowchik *et al.*, *Bioconjugate Chemistry*, 2002, 13,855-869, which is incorporated herein by reference.

In one embodiment, the amino acid side chain is derivatised, where appropriate. For example, an amino group or carboxy group of an amino acid side chain may be derivatised.

In one embodiment, an amino group NH₂ of a side chain amino acid, such as lysine, is a derivatised form selected from the group consisting of NHR and NRR'.

In one embodiment, a carboxy group COOH of a side chain amino acid, such as aspartic acid, is a derivatised form selected from the group consisting of COOR, CONH₂, CONHR and CONRR'.

In one embodiment, the amino acid side chain is chemically protected, where appropriate. The side chain protecting group may be a group as discussed below in relation to the group R^L. The present inventors have established that protected amino acid sequences are cleavable by enzymes. For example, it has been established that a dipeptide sequence comprising a Boc side chain-protected Lys residue is cleavable by cathepsin.

Protecting groups for the side chains of amino acids are well known in the art and are described in the Novabiochem Catalog. Additional protecting group strategies are set out in *Protective Groups in Organic Synthesis*, Greene and Wuts.

Possible side chain protecting groups are shown below for those amino acids having reactive side chain functionality:

Arg: Z, Mtr, Tos;
Asn: Trt, Xan;
Asp: Bzl, t-Bu;
Cys: Acn, Bzl, Bzl-OMe, Bzl-Me, Trt;
Glu: Bzl, t-Bu;
Gln: Trt, Xan;
His: Boc, Dnp, Tos, Trt;
Lys: Boc, Z-Cl, Fmoc, Z, Alloc;
Ser: Bzl, TBDMS, TBDPS;
Thr: Bz;
Trp: Boc;
Tyr: Bzl, Z, Z-Br.

In one embodiment, the side chain protection is selected to be orthogonal to a group provided as, or as part of, a capping group, where present. Thus, the removal of the side chain protecting group does not remove the capping group, or any protecting group functionality that is part of the capping group.


In other embodiments of the disclosure, the amino acids selected are those having no reactive side chain functionality. For example, the amino acids may be selected from: Ala, Gly, Ile, Leu, Met, Phe, Pro, and Val.

In one embodiment, the dipeptide is used in combination with a self-immolative linker. The self-immolative linker may be connected to $-X_2-$.

Where a self-immolative linker is present, $-X_2-$ is connected directly to the self-immolative linker. Preferably the group $-X_2-CO-$ is connected to Y, where Y is NH, thereby forming the group $-X_2-CO-NH-$.


$-NH-X_1-$ is connected directly to A. A may comprise the functionality $-CO-$ thereby to form an amide link with $-X_1-$.

In one embodiment, L^1 and L^2 together with $-OC(=O)-$ comprise the group $NH-X_1-X_2-CO-PABC-$. The PABC group is connected directly to the N10 position. Preferably, the self-immolative linker and the dipeptide together form the group $-NH-Phe-Lys-CO-NH-PABC-$, which is illustrated below:




where the asterisk indicates the point of attachment to the N10 position, and the wavy line indicates the point of attachment to the remaining portion of the linker L^1 or the point of attachment to A. Preferably, the wavy line indicates the point of attachment to A. The side chain of the Lys amino acid may be protected, for example, with Boc, Fmoc, or Alloc, as described above.

Alternatively, the self-immolative linker and the dipeptide together form the group -NH-Val-Ala-CO-NH-PABC-, which is illustrated below:



where the asterisk and the wavy line are as defined above.

Alternatively, the self-immolative linker and the dipeptide together form the group -NH-Val-Cit-CO-NH-PABC-, which is illustrated below:



where the asterisk and the wavy line are as defined above.

In one embodiment, A is a covalent bond. Thus, L¹ and the antibody are directly connected. For example, where L¹ comprises a contiguous amino acid sequence, the N-terminus of the sequence may connect directly to the antibody.

Thus, where A is a covalent bond, the connection between the antibody and L¹ may be selected from:

- C(=O)NH-,
- C(=O)O-,
- NHC(=O)-,
- OC(=O)-,
- OC(=O)O-,
- NHC(=O)O-,
- OC(=O)NH-,
- NHC(=O)NH-,
- C(=O)NHC(=O)-,
- S-,
- S-S-,

-CH₂C(=O)-, and
=N-NH-.

An amino group of L¹ that connects to the antibody may be the N-terminus of an amino acid or may be derived from an amino group of an amino acid side chain, for example a lysine amino acid side chain.


An carboxyl group of L¹ that connects to the antibody may be the C-terminus of an amino acid or may be derived from a carboxyl group of an amino acid side chain, for example a glutamic acid amino acid side chain.

A hydroxyl group of L¹ that connects to the antibody may be derived from a hydroxyl group of an amino acid side chain, for example a serine amino acid side chain.

A thiol group of L¹ that connects to the antibody may be derived from a thiol group of an amino acid side chain, for example a serine amino acid side chain.

The comments above in relation to the amino, carboxyl, hydroxyl and thiol groups of L¹ also apply to the antibody.


In one embodiment, L² together with -OC(=O)- represents:



where the asterisk indicates the point of attachment to the N10 position, the wavy line indicates the point of attachment to L¹, n is 0 to 3, Y is a covalent bond or a functional group, and E is an activatable group, for example by enzymatic action or light, thereby to generate a self-immolative unit. The phenylene ring is optionally further substituted with one, two or three substituents as described herein. In one embodiment, the phenylene group is optionally further substituted with halo, NO₂, R or OR. Preferably n is 0 or 1, most preferably 0.

E is selected such that the group is susceptible to activation, e.g. by light or by the action of an enzyme. E may be -NO₂ or glucuronic acid. The former may be susceptible to the action of a nitroreductase, the latter to the action of a β-glucuronidase.

In this embodiment, the self-immolative linker will allow for release of the protected compound when E is activated, proceeding along the lines shown below (for n=0):



where the asterisk indicates the point of attachment to the N10 position, E^+ is the activated form of E, and Y is as described above. These groups have the advantage of separating the site of activation from the compound being protected. As described above, the phenylene group may be optionally further substituted.

The group Y may be a covalent bond to L^1 .

The group Y may be a functional group selected from:

- C(=O)-
- NH-
- O-
- C(=O)NH-
- C(=O)O-
- NHC(=O)-
- OC(=O)-
- OC(=O)O-
- NHC(=O)O-
- OC(=O)NH-
- NHC(=O)NH-
- NHC(=O)NH
- C(=O)NHC(=O)-, and
- S-


Where L^1 is a dipeptide, it is preferred that Y is -NH- or -C(=O)-, thereby to form an amide bond between L^1 and Y. In this embodiment, the dipeptide sequence need not be a substrate for an enzymatic activity.

In another embodiment, A is a spacer group. Thus, L^1 and the antibody are indirectly connected.

L^1 and A may be connected by a bond selected from:


-C(=O)NH-,
 -C(=O)O-,
 -NHC(=O)-,
 -OC(=O)-,
 -OC(=O)O-,
 -NHC(=O)O-,
 -OC(=O)NH-, and
 -NHC(=O)NH-.

In one embodiment, the group A is:




where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the group A is:




where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the group A is:



where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, and most preferably 4 or 8. In another embodiment, m is 10 to 30, and preferably 20 to 30. Alternatively, m is 0 to 50. In this embodiment, m is preferably 10-40 and n is 1.


In one embodiment, the group A is:



where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, and most preferably 4 or 8. In another embodiment, m is 10 to 30, and preferably 20 to 30. Alternatively, m is 0 to 50. In this embodiment, m is preferably 10-40 and n is 1.


In one embodiment, the connection between the antibody and A is through a thiol residue of the antibody and a maleimide group of A.

In one embodiment, the connection between the antibody and A is:




where the asterisk indicates the point of attachment to the remaining portion of A and the wavy line indicates the point of attachment to the remaining portion of the antibody. In this embodiment, the S atom is typically derived from the antibody.

In each of the embodiments above, an alternative functionality may be used in place of the maleimide-derived group shown below:



where the wavy line indicates the point of attachment to the antibody as before, and the asterisk indicates the bond to the remaining portion of the A group.

In one embodiment, the maleimide-derived group is replaced with the group:




where the wavy line indicates point of attachment to the antibody, and the asterisk indicates the bond to the remaining portion of the A group.

In one embodiment, the maleimide-derived group is replaced with a group, which optionally together with the antibody, is selected from:

- C(=O)NH-,
- C(=O)O-,
- NHC(=O)-,
- OC(=O)-,
- OC(=O)O-,
- NHC(=O)O-,
- OC(=O)NH-,
- NHC(=O)NH-,
- NHC(=O)NH,
- C(=O)NHC(=O)-,
- S-,
- S-S-,
- CH₂C(=O)-
- C(=O)CH₂-,
- =N-NH-, and
- NH-N=.

In one embodiment, the maleimide-derived group is replaced with a group, which optionally together with the antibody, is selected from:



where the wavy line indicates either the point of attachment to the antibody or the bond to the remaining portion of the A group, and the asterisk indicates the other of the point of attachment to the antibody or the bond to the remaining portion of the A group.

Other groups suitable for connecting L¹ to the antibody are described in WO 2005/082023.

In one embodiment, the Connecting Group A is present, the Trigger L¹ is present and Self-Immolative Linker L² is absent. Thus, L¹ and the Drug unit are directly connected via a bond.

Equivalently in this embodiment, L² is a bond. This may be particularly relevant when D^L is of Formula II.

L¹ and D may be connected by a bond selected from:

-C(=O)N<,
 -C(=O)O-,
 -NHC(=O)-,
 -OC(=O)-,
 -OC(=O)O-,
 -NHC(=O)O-,
 -OC(=O)N<, and
 -NHC(=O)N<,

where N< or O- are part of D.

In one embodiment, L¹ and D are preferably connected by a bond selected from:


-C(=O)N<, and
 -NHC(=O)-.

In one embodiment, L¹ comprises a dipeptide and one end of the dipeptide is linked to D. As described above, the amino acids in the dipeptide may be any combination of natural amino acids and non-natural amino acids. In some embodiments, the dipeptide comprises natural amino acids. Where the linker is a cathepsin labile linker, the dipeptide is the site of action for cathepsin-mediated cleavage. The dipeptide then is a recognition site for cathepsin.

In one embodiment, the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

-Phe-Lys-,
 -Val-Ala-,
 -Val-Lys-,
 -Ala-Lys-,
 -Val-Cit-,
 -Phe-Cit-,
 -Leu-Cit-,
 -Ile-Cit-,
 -Phe-Arg-, and
 -Trp-Cit-;


where Cit is citrulline. In such a dipeptide, -NH- is the amino group of X₁, and CO is the carbonyl group of X₂.



where the asterisks, -N< and the wavy line are as defined above.


In one embodiment, the dipeptide is valine-citrulline.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 7, preferably 3 to 7, most preferably 3 or 7.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A-L¹ are:




where the asterisk indicates the point of attachment to L^2 or D, the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A- L^1 is:




where the asterisk indicates the point of attachment to L^2 or D, the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A- L^1 are:




where the asterisk indicates the point of attachment to L^2 or D, S is a sulfur group of the Ligand unit, the wavy line indicates the point of attachment to the rest of the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the group A-L¹ are:




where the asterisk indicates the point of attachment to L² or D, S is a sulfur group of the Ligand unit, the wavy line indicates the point of attachment to the remainder of the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A¹-L¹ are:




where the asterisk indicates the point of attachment to L² or D, S is a sulfur group of the Ligand unit, the wavy line indicates the point of attachment to the remainder of the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A¹-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 7, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A¹-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the remainder of the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A¹-L¹ are:




where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the remainder of the Ligand unit, and n is 0 to 6. In one embodiment, n is 5.

In one embodiment, the groups A¹-L¹ are:



where the asterisk indicates the point of attachment to L² or D, the wavy line indicates the point of attachment to the remainder of the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

In one embodiment, the groups A¹-L¹ are:



where the asterisk indicates the point of attachment to L^2 or D, the wavy line indicates the point of attachment to the remainder of the Ligand unit, n is 0 or 1, and m is 0 to 30. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 8, preferably 4 to 8, most preferably 4 or 8.

The group $R^{L'}$ is derivable from the group R^L . The group R^L may be converted to a group $R^{L'}$ by connection of an antibody to a functional group of R^L . Other steps may be taken to convert R^L to $R^{L'}$. These steps may include the removal of protecting groups, where present, or the installation of an appropriate functional group.


R^L

Linkers can include protease-cleavable peptidic moieties comprising one or more amino acid units. Peptide linker reagents may be prepared by solid phase or liquid phase synthesis methods (E. Schröder and K. Lübke, *The Peptides*, volume 1, pp 76-136 (1965) Academic Press) that are well known in the field of peptide chemistry, including t-BOC chemistry (Geiser et al "Automation of solid-phase peptide synthesis" in *Macromolecular Sequencing and Synthesis*, Alan R. Liss, Inc., 1988, pp. 199-218) and Fmoc/HBTU chemistry (Fields, G. and Noble, R. (1990) "Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids", *Int. J. Peptide Protein Res.* 35:161-214), on an automated synthesizer such as the Rainin Symphony Peptide Synthesizer (Protein Technologies, Inc., Tucson, AZ), or Model 433 (Applied Biosystems, Foster City, CA).

Exemplary amino acid linkers include a dipeptide, a tripeptide, a tetrapeptide or a pentapeptide. Exemplary dipeptides include: valine-citrulline (vc or val-cit), alanine-phenylalanine (af or ala-phe). Exemplary tripeptides include: glycine-valine-citrulline (gly-val-cit) and glycine-glycine-glycine (gly-gly-gly). Amino acid residues which comprise an amino acid linker component include those occurring naturally, as well as minor amino acids and non-naturally occurring amino acid analogs, such as citrulline. Amino acid linker components can be designed and optimized in their selectivity for enzymatic cleavage by a

particular enzymes, for example, a tumor-associated protease, cathepsin B, C and D, or a plasmin protease.


Amino acid side chains include those occurring naturally, as well as minor amino acids and non-naturally occurring amino acid analogs, such as citrulline. Amino acid side chains include hydrogen, methyl, isopropyl, isobutyl, sec-butyl, benzyl, p-hydroxybenzyl, -CH₂OH, -CH(OH)CH₃, -CH₂CH₂SCH₃, -CH₂CONH₂, -CH₂COOH, -CH₂CH₂CONH₂, -CH₂CH₂COOH, -(CH₂)₃NHC(=NH)NH₂, -(CH₂)₃NH₂, -(CH₂)₃NHCOCH₃, -(CH₂)₃NHCHO, -(CH₂)₄NHC(=NH)NH₂, -(CH₂)₄NH₂, -(CH₂)₄NHCOCH₃, -(CH₂)₄NHCHO, -(CH₂)₃NHCONH₂, -(CH₂)₄NHCONH₂, -CH₂CH₂CH(OH)CH₂NH₂, 2-pyridylmethyl-, 3-pyridylmethyl-, 4-pyridylmethyl-, phenyl, cyclohexyl, as well as the following structures:



When the amino acid side chains include other than hydrogen (glycine), the carbon atom to which the amino acid side chain is attached is chiral. Each carbon atom to which the amino acid side chain is attached is independently in the (*S*) or (*R*) configuration, or a racemic mixture. Drug-linker reagents may thus be enantiomerically pure, racemic, or diastereomeric.


In exemplary embodiments, amino acid side chains are selected from those of natural and non-natural amino acids, including alanine, 2-amino-2-cyclohexylacetic acid, 2-amino-2-phenylacetic acid, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, γ -aminobutyric acid, α,α -dimethyl γ -aminobutyric acid, β,β -dimethyl γ -aminobutyric acid, ornithine, and citrulline (Cit).

An exemplary valine-citrulline (val-cit or vc) dipeptide linker reagent useful for constructing a linker-PBD drug moiety intermediate for conjugation to an antibody, having a para-aminobenzylcarbamoyl (PAB) self-immolative spacer has the structure:



where Q is C_1-C_8 alkyl, $-O-(C_1-C_8)$ alkyl, -halogen, $-NO_2$ or $-CN$; and m is an integer ranging from 0-4.

An exemplary phe-lys(Mtr) dipeptide linker reagent having a p-aminobenzyl group can be prepared according to Dubowchik, et al. (1997) Tetrahedron Letters, 38:5257-60, and has the structure:




where Mtr is mono-4-methoxytrityl, Q is C_1-C_8 alkyl, $-O-(C_1-C_8)$ alkyl, -halogen, $-NO_2$ or $-CN$; and m is an integer ranging from 0-4.



The "self-immolative linker" PAB (para-aminobenzylloxycarbonyl), attaches the drug moiety to the antibody in the antibody drug conjugate (Carl et al (1981) J. Med. Chem. 24:479-480; Chakravarty et al (1983) J. Med. Chem. 26:638-644; US 6214345; US20030130189; US20030096743; US6759509; US20040052793; US6218519; US6835807; US6268488; US20040018194; WO98/13059; US20040052793; US6677435; US5621002; US20040121940; WO2004/032828). Other examples of self-immolative spacers besides PAB include, but are not limited to: (i) aromatic compounds that are electronically similar to the PAB group such as 2-aminoimidazol-5-methanol derivatives (Hay et al. (1999) Bioorg. Med. Chem. Lett. 9:2237), thiazoles (US 7375078), multiple, elongated PAB units (de Groot et al (2001) J. Org. Chem. 66:8815-8830); and ortho or para-aminobenzylacetals; and (ii) homologated styryl PAB analogs (US 7223837). Spacers can be used that undergo cyclization upon amide bond hydrolysis, such as substituted and unsubstituted 4-

aminobutyric acid amides (Rodrigues et al (1995) *Chemistry Biology* 2:223), appropriately substituted bicyclo[2.2.1] and bicyclo[2.2.2] ring systems (Storm et al (1972) *J. Amer. Chem. Soc.* 94:5815) and 2-aminophenylpropionic acid amides (Amsberry, et al (1990) *J. Org. Chem.* 55:5867). Elimination of amine-containing drugs that are substituted at glycine (Kingsbury et al (1984) *J. Med. Chem.* 27:1447) are also examples of self-immolative spacers useful in ADC.

In one embodiment, a valine-citrulline dipeptide PAB analog reagent has a 2,6 dimethyl phenyl group and has the structure:



Linker reagents useful for the antibody drug conjugates of the disclosure include, but are not limited to: BMPEO, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate), and bis-maleimide reagents: DTME, BMB, BMDB, BMH, BMOE, 1,8-bis-maleimidodiethyleneglycol (BM(PEO)₂), and 1,11-bis-maleimidotriethyleneglycol (BM(PEO)₃), which are commercially available from Pierce Biotechnology, Inc., ThermoScientific, Rockford, IL, and other reagent suppliers. Bis-maleimide reagents allow the attachment of a free thiol group of a cysteine residue of an antibody to a thiol-containing drug moiety, label, or linker intermediate, in a sequential or concurrent fashion. Other functional groups besides maleimide, which are reactive with a thiol group of an antibody, PBD drug moiety, or linker intermediate include iodoacetamide, bromoacetamide, vinyl pyridine, disulfide, pyridyl disulfide, isocyanate, and isothiocyanate.


BM(PEO)₂BM(PEO)₃

Other embodiments of linker reagents are: N-succinimidyl-4-(2-pyridylthio)pentanoate (SPP), N-succinimidyl-3-(2-pyridylthio) propionate (SPDP, Carlsson et al (1978) *Biochem. J.* 173:723-737), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC),

iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). Useful linker reagents can also be obtained via other commercial sources, such as Molecular Biosciences Inc.(Boulder, CO), or synthesized in accordance with procedures described in Toki et al (2002) J. Org. Chem. 67:1866-1872; US 6214345; WO 02/088172; US 2003130189; US2003096743; WO 03/026577; WO 03/043583; and WO 04/032828.

The Linker may be a dendritic type linker for covalent attachment of more than one drug moiety through a branching, multifunctional linker moiety to an antibody (US 2006/116422; US 2005/271615; de Groot et al (2003) Angew. Chem. Int. Ed. 42:4490-4494; Amir et al (2003) Angew. Chem. Int. Ed. 42:4494-4499; Shamis et al (2004) J. Am. Chem. Soc. 126:1726-1731; Sun et al (2002) Bioorganic & Medicinal Chemistry Letters 12:2213-2215; Sun et al (2003) Bioorganic & Medicinal Chemistry 11:1761-1768; King et al (2002) Tetrahedron Letters 43:1987-1990). Dendritic linkers can increase the molar ratio of drug to antibody, i.e. loading, which is related to the potency of the ADC. Thus, where an antibody bears only one reactive cysteine thiol group, a multitude of drug moieties may be attached through a dendritic or branched linker.

One exemplary embodiment of a dendritic type linker has the structure:



where the asterisk indicate the point of attachment to the N10 position of a PBD moiety.

R^c, Capping Group

The conjugate of the first aspect of the disclosure may have a capping group R^c at the N10 position.

The group R^c is removable from the N10 position of the PBD moiety to leave an N10-C11 imine bond, a carbinolamine, a substituted carbinolamine, where QR¹¹ is OSO₃M, a bisulfite adduct, a thiocarbinolamine, a substituted thiocarbinolamine, or a substituted carbinolamine.

In one embodiment, R^c, may be a protecting group that is removable to leave an N10-C11 imine bond, a carbinolamine, a substituted cabinolamine, or, where QR¹¹ is OSO₃M, a bisulfite adduct. In one embodiment, R^c is a protecting group that is removable to leave an N10-C11 imine bond.

The group R^c is intended to be removable under the same conditions as those required for the removal of the group R¹⁰, for example to yield an N10-C11 imine bond, a carbinolamine and so on. The capping group acts as a protecting group for the intended functionality at the N10 position. The capping group is intended not to be reactive towards an antibody. For example, R^c is not the same as R^L.

Compounds having a capping group may be used as intermediates in the synthesis of dimers having an imine monomer. Alternatively, compounds having a capping group may be used as conjugates, where the capping group is removed at the target location to yield an imine, a carbinolamine, a substituted cabinolamine and so on. Thus, in this embodiment, the capping group may be referred to as a therapeutically removable nitrogen protecting group, as defined in the inventors' earlier application WO 00/12507.

In one embodiment, the group R^c is removable under the conditions that cleave the linker R^L of the group R¹⁰. Thus, in one embodiment, the capping group is cleavable by the action of an enzyme.

In an alternative embodiment, the capping group is removable prior to the connection of the linker R^L to the antibody. In this embodiment, the capping group is removable under conditions that do not cleave the linker R^L.

Where a compound includes a functional group G¹ to form a connection to the antibody, the capping group is removable prior to the addition or unmasking of G¹.

The capping group may be used as part of a protecting group strategy to ensure that only one of the monomer units in a dimer is connected to an antibody.

The capping group may be used as a mask for a N10-C11 imine bond. The capping group may be removed at such time as the imine functionality is required in the compound. The capping group is also a mask for a carbinolamine, a substituted carbinolamine, and a bisulfite adduct, as described above.

R^C may be an N10 protecting group, such as those groups described in the inventors' earlier application, WO 00/12507. In one embodiment, R^C is a therapeutically removable nitrogen protecting group, as defined in the inventors' earlier application, WO 00/12507.

In one embodiment, R^C is a carbamate protecting group.

In one embodiment, the carbamate protecting group is selected from:


Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.

Optionally, the carbamate protecting group is further selected from Moc.

In one embodiment, R^C is a linker group R^L lacking the functional group for connection to the antibody.

This application is particularly concerned with those R^C groups which are carbamates.

In one embodiment, R^C is a group:



where the asterisk indicates the point of attachment to the N10 position, G² is a terminating group, L³ is a covalent bond or a cleavable linker L¹, L² is a covalent bond or together with OC(=O) forms a self-immolative linker.

Where L³ and L² are both covalent bonds, G² and OC(=O) together form a carbamate protecting group as defined above.

L¹ is as defined above in relation to R¹⁰.

L² is as defined above in relation to R¹⁰.

Various terminating groups are described below, including those based on well known protecting groups.

In one embodiment L^3 is a cleavable linker L^1 , and L^2 , together with $OC(=O)$, forms a self-immolative linker. In this embodiment, G^2 is Ac (acetyl) or Moc, or a carbamate protecting group selected from:

Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.


Optionally, the carbamate protecting group is further selected from Moc.

In another embodiment, G^2 is an acyl group $-C(=O)G^3$, where G^3 is selected from alkyl (including cycloalkyl, alkenyl and alkynyl), heteroalkyl, heterocyclyl and aryl (including heteroaryl and carboaryl). These groups may be optionally substituted. The acyl group together with an amino group of L^3 or L^2 , where appropriate, may form an amide bond. The acyl group together with a hydroxy group of L^3 or L^2 , where appropriate, may form an ester bond.

In one embodiment, G^3 is heteroalkyl. The heteroalkyl group may comprise polyethylene glycol. The heteroalkyl group may have a heteroatom, such as O or N, adjacent to the acyl group, thereby forming a carbamate or carbonate group, where appropriate, with a heteroatom present in the group L^3 or L^2 , where appropriate.


In one embodiment, G^3 is selected from NH_2 , NHR and NRR' . Preferably, G^3 is NRR' .

In one embodiment G^2 is the group:




where the asterisk indicates the point of attachment to L^3 , n is 0 to 6 and G^4 is selected from OH, OR, SH, SR, COOR, $CONH_2$, CONHR, $CONRR'$, NH_2 , NHR, NRR' , NO_2 , and halo. The groups OH, SH, NH_2 and NHR are protected. In one embodiment, n is 1 to 6, and preferably n is 5. In one embodiment, G^4 is OR, SR, COOR, $CONH_2$, CONHR, $CONRR'$, and NRR' . In one embodiment, G^4 is OR, SR, and NRR' . Preferably G^4 is selected from OR and NRR' , most preferably G^4 is OR. Most preferably G^4 is OMe.

In one embodiment, the group G^2 is:




where the asterisk indicates the point of attachment to L³, and n and G⁴ are as defined above.

In one embodiment, the group G² is:




where the asterisk indicates the point of attachment to L³, n is 0 or 1, m is 0 to 50, and G⁴ is selected from OH, OR, SH, SR, COOR, CONH₂, CONHR, CONRR', NH₂, NHR, NRR', NO₂, and halo. In a preferred embodiment, n is 1 and m is 0 to 10, 1 to 2, preferably 4 to 8, and most preferably 4 or 8. In another embodiment, n is 1 and m is 10 to 50, preferably 20 to 40. The groups OH, SH, NH₂ and NHR are protected. In one embodiment, G⁴ is OR, SR, COOR, CONH₂, CONHR, CONRR', and NRR'. In one embodiment, G⁴ is OR, SR, and NRR'. Preferably G⁴ is selected from OR and NRR', most preferably G⁴ is OR. Preferably G⁴ is OMe.

In one embodiment, the group G² is:



where the asterisk indicates the point of attachment to L³, and n, m and G⁴ are as defined above.


In one embodiment, the group G² is:



where n is 1-20, m is 0-6, and G⁴ is selected from OH, OR, SH, SR, COOR, CONH₂, CONHR, CONRR', NH₂, NHR, NRR', NO₂, and halo. In one embodiment, n is 1-10. In another embodiment, n is 10 to 50, preferably 20 to 40. In one embodiment, n is 1. In one embodiment, m is 1. The groups OH, SH, NH₂ and NHR are protected. In one embodiment, G⁴ is OR, SR, COOR, CONH₂, CONHR, CONRR', and NRR'. In one embodiment, G⁴ is OR,

SR, and NRR'. Preferably G^4 is selected from OR and NRR', most preferably G^4 is OR. Preferably G^4 is OMe.

In one embodiment, the group G^2 is:



where the asterisk indicates the point of attachment to L^3 , and n , m and G^4 are as defined above.

In each of the embodiments above G^4 may be OH, SH, NH_2 and NHR. These groups are preferably protected.

In one embodiment, OH is protected with Bzl, TBDMS, or TBDPS.

In one embodiment, SH is protected with Acm, Bzl, Bzl-OMe, Bzl-Me, or Trt.

In one embodiment, NH_2 or NHR are protected with Boc, Moc, Z-Cl, Fmoc, Z, or Alloc.

In one embodiment, the group G^2 is present in combination with a group L^3 , which group is a dipeptide.

The capping group is not intended for connection to the antibody. Thus, the other monomer present in the dimer serves as the point of connection to the antibody via a linker.

Accordingly, it is preferred that the functionality present in the capping group is not available for reaction with an antibody. Thus, reactive functional groups such as OH, SH, NH_2 , COOH are preferably avoided. However, such functionality may be present in the capping group if protected, as described above.

Embodiments

Embodiments of the present disclosure include ConjA wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjB wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjC wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjD wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjE wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjF wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjG wherein the antibody is as defined above.

Embodiments of the present disclosure include ConjH wherein the antibody is as defined above.

Drug loading

The drug loading is the average number of PBD drugs per antibody, e.g. antibody. Where the compounds of the disclosure are bound to native cysteines, drug loading may range from 1 to 8 drugs (D^L) per antibody, i.e. where 1, 2, 3, 4, 5, 6, 7, and 8 drug moieties are covalently attached to the antibody. Compositions of conjugates include collections of antibodies, conjugated with a range of drugs, from 1 to 8. Where the compounds of the disclosure are bound to lysines, drug loading may range from 1 to 80 drugs (D^L) per antibody, although an upper limit of 40, 20, 10 or 8 may be preferred. Compositions of conjugates include collections of antibodies, conjugated with a range of drugs, from 1 to 80, 1 to 40, 1 to 20, 1 to 10 or 1 to 8.

The average number of drugs per antibody in preparations of ADC from conjugation reactions may be characterized by conventional means such as UV, reverse phase HPLC, HIC, mass spectroscopy, ELISA assay, and electrophoresis. The quantitative distribution of ADC in terms of p may also be determined. By ELISA, the averaged value of p in a particular preparation of ADC may be determined (Hamblett et al (2004) Clin. Cancer Res. 10:7063-7070; Sanderson et al (2005) Clin. Cancer Res. 11:843-852). However, the distribution of p (drug) values is not discernible by the antibody-antigen binding and detection limitation of ELISA. Also, ELISA assay for detection of antibody-drug conjugates does not determine where the drug moieties are attached to the antibody, such as the heavy chain or light chain fragments, or the particular amino acid residues. In some instances, separation, purification, and characterization of homogeneous ADC where p is a certain

value from ADC with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis. Such techniques are also applicable to other types of conjugates.

For some antibody-drug conjugates, p may be limited by the number of attachment sites on the antibody. For example, an antibody may have only one or several cysteine thiol groups, or may have only one or several sufficiently reactive thiol groups through which a linker may be attached. Higher drug loading, e.g. $p > 5$, may cause aggregation, insolubility, toxicity, or loss of cellular permeability of certain antibody-drug conjugates.

Typically, fewer than the theoretical maximum of drug moieties are conjugated to an antibody during a conjugation reaction. An antibody may contain, for example, many lysine residues that do not react with the drug-linker intermediate (D-L) or linker reagent. Only the most reactive lysine groups may react with an amine-reactive linker reagent. Also, only the most reactive cysteine thiol groups may react with a thiol-reactive linker reagent. Generally, antibodies do not contain many, if any, free and reactive cysteine thiol groups which may be linked to a drug moiety. Most cysteine thiol residues in the antibodies of the compounds exist as disulfide bridges and must be reduced with a reducing agent such as dithiothreitol (DTT) or TCEP, under partial or total reducing conditions. The loading (drug/antibody ratio) of an ADC may be controlled in several different manners, including: (i) limiting the molar excess of drug-linker intermediate (D-L) or linker reagent relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.

Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (dithiothreitol). Each cysteine bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Traut's reagent) resulting in conversion of an amine into a thiol. Reactive thiol groups may be introduced into the antibody (or fragment thereof) by engineering one, two, three, four, or more cysteine residues (e.g., preparing mutant antibodies comprising one or more non-native cysteine amino acid residues). US 7521541 teaches engineering antibodies by introduction of reactive cysteine amino acids.

Cysteine amino acids may be engineered at reactive sites in an antibody and which do not form intrachain or intermolecular disulfide linkages (Junutula, et al., 2008b Nature Biotech., 26(8):925-932; Dornan et al (2009) Blood 114(13):2721-2729; US 7521541; US 7723485; WO2009/052249). The engineered cysteine thiols may react with linker reagents or the

drug-linker reagents of the present disclosure which have thiol-reactive, electrophilic groups such as maleimide or alpha-halo amides to form ADC with cysteine engineered antibodies and the PBD drug moieties. The location of the drug moiety can thus be designed, controlled, and known. The drug loading can be controlled since the engineered cysteine thiol groups typically react with thiol-reactive linker reagents or drug-linker reagents in high yield. Engineering an IgG antibody to introduce a cysteine amino acid by substitution at a single site on the heavy or light chain gives two new cysteines on the symmetrical antibody. A drug loading near 2 can be achieved with near homogeneity of the conjugation product ADC.

Alternatively, site-specific conjugation can be achieved by engineering antibodies to contain unnatural amino acids in their heavy and/or light chains as described by Axup et al. ((2012), Proc Natl Acad Sci U S A. 109(40):16101-16116). The unnatural amino acids provide the additional advantage that orthogonal chemistry can be designed to attach the linker reagent and drug.

Where more than one nucleophilic or electrophilic group of the antibody reacts with a drug-linker intermediate, or linker reagent followed by drug moiety reagent, then the resulting product is a mixture of ADC compounds with a distribution of drug moieties attached to an antibody, e.g. 1, 2, 3, etc. Liquid chromatography methods such as polymeric reverse phase (PLRP) and hydrophobic interaction (HIC) may separate compounds in the mixture by drug loading value. Preparations of ADC with a single drug loading value (p) may be isolated, however, these single loading value ADCs may still be heterogeneous mixtures because the drug moieties may be attached, via the linker, at different sites on the antibody.

Thus the antibody-drug conjugate compositions of the disclosure include mixtures of antibody-drug conjugate compounds where the antibody has one or more PBD drug moieties and where the drug moieties may be attached to the antibody at various amino acid residues.

In one embodiment, the average number of dimer pyrrolobenzodiazepine groups per antibody is in the range 1 to 20. In some embodiments the range is selected from 1 to 8, 2 to 8, 2 to 6, 2 to 4, and 4 to 8.

In some embodiments, there is one dimer pyrrolobenzodiazepine group per antibody.

Includes Other Forms

Unless otherwise specified, included in the above are the well known ionic, salt, solvate, and protected forms of these substituents. For example, a reference to carboxylic acid (-COOH) also includes the anionic (carboxylate) form (-COO⁻), a salt or solvate thereof, as well as conventional protected forms. Similarly, a reference to an amino group includes the protonated form (-N⁺HR¹R²), a salt or solvate of the amino group, for example, a hydrochloride salt, as well as conventional protected forms of an amino group. Similarly, a reference to a hydroxyl group also includes the anionic form (-O⁻), a salt or solvate thereof, as well as conventional protected forms.

Salts

It may be convenient or desirable to prepare, purify, and/or handle a corresponding salt of the active compound, for example, a pharmaceutically-acceptable salt. Examples of pharmaceutically acceptable salts are discussed in Berge, *et al.*, *J. Pharm. Sci.*, **66**, 1-19 (1977).

For example, if the compound is anionic, or has a functional group which may be anionic (e.g. -COOH may be -COO⁻), then a salt may be formed with a suitable cation. Examples of suitable inorganic cations include, but are not limited to, alkali metal ions such as Na⁺ and K⁺, alkaline earth cations such as Ca²⁺ and Mg²⁺, and other cations such as Al³⁺. Examples of suitable organic cations include, but are not limited to, ammonium ion (i.e. NH₄⁺) and substituted ammonium ions (e.g. NH₃R⁺, NH₂R₂⁺, NHR₃⁺, NR₄⁺). Examples of some suitable substituted ammonium ions are those derived from: ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine, ethylenediamine, ethanolamine, diethanolamine, piperazine, benzylamine, phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids, such as lysine and arginine. An example of a common quaternary ammonium ion is N(CH₃)₄⁺.

If the compound is cationic, or has a functional group which may be cationic (e.g. -NH₂ may be -NH₃⁺), then a salt may be formed with a suitable anion. Examples of suitable inorganic anions include, but are not limited to, those derived from the following inorganic acids: hydrochloric, hydrobromic, hydroiodic, sulfuric, sulfurous, nitric, nitrous, phosphoric, and phosphorous.


Examples of suitable organic anions include, but are not limited to, those derived from the following organic acids: 2-acetoxybenzoic, acetic, ascorbic, aspartic, benzoic, camphorsulfonic, cinnamic, citric, edetic, ethanedisulfonic, ethanesulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxymaleic, hydroxynaphthalene carboxylic, isethionic, lactic, lactobionic, lauric, maleic, malic, methanesulfonic, mucic, oleic, oxalic, palmitic, pantoic, pantothenic, phenylacetic, phenylsulfonic, propionic, pyruvic, salicylic, stearic, succinic, sulfanilic, tartaric, toluenesulfonic, trifluoroacetic acid and valeric.

Examples of suitable polymeric organic anions include, but are not limited to, those derived from the following polymeric acids: tannic acid, carboxymethyl cellulose.

Solvates

It may be convenient or desirable to prepare, purify, and/or handle a corresponding solvate of the active compound. The term "solvate" is used herein in the conventional sense to refer to a complex of solute (e.g. active compound, salt of active compound) and solvent. If the solvent is water, the solvate may be conveniently referred to as a hydrate, for example, a mono-hydrate, a di-hydrate, a tri-hydrate, etc.

The disclosure includes compounds where a solvent adds across the imine bond of the PBD moiety, which is illustrated below where the solvent is water or an alcohol ($R^A\text{OH}$, where R^A is C_{1-4} alkyl):



These forms can be called the carbinolamine and carbinolamine ether forms of the PBD (as described in the section relating to R^{10} above). The balance of these equilibria depend on the conditions in which the compounds are found, as well as the nature of the moiety itself.

These particular compounds may be isolated in solid form, for example, by lyophilisation.

Isomers

Certain compounds of the disclosure may exist in one or more particular geometric, optical, enantiomeric, diastereomeric, epimeric, atropic, stereoisomeric, tautomeric, conformational, or anomeric forms, including but not limited to, cis- and trans-forms; E- and Z-forms; c-, t-, and r-forms; endo- and exo-forms; R-, S-, and meso-forms; D- and L-forms; d- and l-forms; (+) and (-) forms; keto-, enol-, and enolate-forms; syn- and anti-forms; synclinal- and anticlinal-forms; α - and β -forms; axial and equatorial forms; boat-, chair-, twist-, envelope-,

and halfchair-forms; and combinations thereof, hereinafter collectively referred to as "isomers" (or "isomeric forms").

The term "chiral" refers to molecules which have the property of non-superimposability of the mirror image partner, while the term "achiral" refers to molecules which are superimposable on their mirror image partner.

The term "stereoisomers" refers to compounds which have identical chemical constitution, but differ with regard to the arrangement of the atoms or groups in space.

"Diastereomer" refers to a stereoisomer with two or more centers of chirality and whose molecules are not mirror images of one another. Diastereomers have different physical properties, e.g. melting points, boiling points, spectral properties, and reactivities. Mixtures of diastereomers may separate under high resolution analytical procedures such as electrophoresis and chromatography.


"Enantiomers" refer to two stereoisomers of a compound which are non-superimposable mirror images of one another.

Stereochemical definitions and conventions used herein generally follow S. P. Parker, Ed., *McGraw-Hill Dictionary of Chemical Terms* (1984) McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., "Stereochemistry of Organic Compounds", John Wiley & Sons, Inc., New York, 1994. The compounds of the disclosure may contain asymmetric or chiral centers, and therefore exist in different stereoisomeric forms. It is intended that all stereoisomeric forms of the compounds of the disclosure, including but not limited to, diastereomers, enantiomers and atropisomers, as well as mixtures thereof such as racemic mixtures, form part of the present disclosure. Many organic compounds exist in optically active forms, i.e., they have the ability to rotate the plane of plane-polarized light. In describing an optically active compound, the prefixes D and L, or *R* and *S*, are used to denote the absolute configuration of the molecule about its chiral center(s). The prefixes d and l or (+) and (-) are employed to designate the sign of rotation of plane-polarized light by the compound, with (-) or l meaning that the compound is levorotatory. A compound prefixed with (+) or d is dextrorotatory. For a given chemical structure, these stereoisomers are identical except that they are mirror images of one another. A specific stereoisomer may also be referred to as an enantiomer, and a mixture of such isomers is often called an enantiomeric mixture. A 50:50 mixture of enantiomers is referred to as a racemic mixture or a racemate, which may occur where there has been no stereoselection or stereospecificity in

a chemical reaction or process. The terms “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomeric species, devoid of optical activity.

Note that, except as discussed below for tautomeric forms, specifically excluded from the term “isomers”, as used herein, are structural (or constitutional) isomers (i.e. isomers which differ in the connections between atoms rather than merely by the position of atoms in space). For example, a reference to a methoxy group, -OCH₃, is not to be construed as a reference to its structural isomer, a hydroxymethyl group, -CH₂OH. Similarly, a reference to ortho-chlorophenyl is not to be construed as a reference to its structural isomer, meta-chlorophenyl. However, a reference to a class of structures may well include structurally isomeric forms falling within that class (e.g. C₁₋₇ alkyl includes n-propyl and iso-propyl; butyl includes n-, iso-, sec-, and tert-butyl; methoxyphenyl includes ortho-, meta-, and para-methoxyphenyl).

The above exclusion does not pertain to tautomeric forms, for example, keto-, enol-, and enolate-forms, as in, for example, the following tautomeric pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol, amidine/amidone, nitroso/oxime, thioketone/enethiol, N-nitroso/hydroxyazo, and nitro/aci-nitro.



The term “tautomer” or “tautomeric form” refers to structural isomers of different energies which are interconvertible via a low energy barrier. For example, proton tautomers (also known as prototropic tautomers) include interconversions via migration of a proton, such as keto-enol and imine-enamine isomerizations. Valence tautomers include interconversions by reorganization of some of the bonding electrons.

Note that specifically included in the term “isomer” are compounds with one or more isotopic substitutions. For example, H may be in any isotopic form, including ¹H, ²H (D), and ³H (T); C may be in any isotopic form, including ¹²C, ¹³C, and ¹⁴C; O may be in any isotopic form, including ¹⁶O and ¹⁸O; and the like.

Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such

as, but not limited to ^2H (deuterium, D), ^3H (tritium), ^{11}C , ^{13}C , ^{14}C , ^{15}N , ^{18}F , ^{31}P , ^{32}P , ^{35}S , ^{36}Cl , and ^{125}I . Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ^3H , ^{13}C , and ^{14}C are incorporated. Such isotopically labelled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients. Deuterium labelled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism, and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements. An ^{18}F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. Further, substitution with heavier isotopes, particularly deuterium (i.e., ^2H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index. It is understood that deuterium in this context is regarded as a substituent. The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.

Unless otherwise specified, a reference to a particular compound includes all such isomeric forms, including (wholly or partially) racemic and other mixtures thereof. Methods for the preparation (e.g. asymmetric synthesis) and separation (e.g. fractional crystallisation and chromatographic means) of such isomeric forms are either known in the art or are readily obtained by adapting the methods taught herein, or known methods, in a known manner.

Biological Activity

In vitro cell proliferation assays

Generally, the cytotoxic or cytostatic activity of an antibody-drug conjugate (ADC) is measured by: exposing mammalian cells having receptor proteins to the antibody of the ADC in a cell culture medium; culturing the cells for a period from about 6 hours to about 5 to 7 days; and measuring cell viability. Cell-based *in vitro* assays are used to measure viability

(proliferation), cytotoxicity, and induction of apoptosis (caspase activation) of an ADC of the disclosure.

The *in vitro* potency of antibody-drug conjugates can be measured by a cell proliferation assay. The CellTiter-Glo® Luminescent Cell Viability Assay is a commercially available (Promega Corp., Madison, WI), homogeneous assay method based on the recombinant expression of *Coleoptera* luciferase (US Patent Nos. 5583024; 5674713 and 5700670). This cell proliferation assay determines the number of viable cells in culture based on quantitation of the ATP present, an indicator of metabolically active cells (Crouch *et al* (1993) *J. Immunol. Meth.* 160:81-88; US 6602677). The CellTiter-Glo® Assay is conducted in 96 well format, making it amenable to automated high-throughput screening (HTS) (Cree *et al* (1995) *AntiCancer Drugs* 6:398-404). The homogeneous assay procedure involves adding the single reagent (CellTiter-Glo® Reagent) directly to cells cultured in serum-supplemented medium. Cell washing, removal of medium and multiple pipetting steps are not required. The system detects as few as 15 cells/well in a 384-well format in 10 minutes after adding reagent and mixing. The cells may be treated continuously with ADC, or they may be treated and separated from ADC. Generally, cells treated briefly, i.e. 3 hours, showed the same potency effects as continuously treated cells.

The homogeneous “add-mix-measure” format results in cell lysis and generation of a luminescent signal proportional to the amount of ATP present. The amount of ATP is directly proportional to the number of cells present in culture. The CellTiter-Glo® Assay generates a “glow-type” luminescent signal, produced by the luciferase reaction, which has a half-life generally greater than five hours, depending on cell type and medium used. Viable cells are reflected in relative luminescence units (RLU). The substrate, Beetle Luciferin, is oxidatively decarboxylated by recombinant firefly luciferase with concomitant conversion of ATP to AMP and generation of photons.

The *in vitro* potency of antibody-drug conjugates can also be measured by a cytotoxicity assay. Cultured adherent cells are washed with PBS, detached with trypsin, diluted in complete medium, containing 10% FCS, centrifuged, re-suspended in fresh medium and counted with a haemocytometer. Suspension cultures are counted directly. Monodisperse cell suspensions suitable for counting may require agitation of the suspension by repeated aspiration to break up cell clumps.

The cell suspension is diluted to the desired seeding density and dispensed (100 µl per well) into black 96 well plates. Plates of adherent cell lines are incubated overnight to allow adherence. Suspension cell cultures can be used on the day of seeding.

A stock solution (1 ml) of ADC (20 µg/ml) is made in the appropriate cell culture medium. Serial 10-fold dilutions of stock ADC are made in 15 ml centrifuge tubes by serially transferring 100µl to 900µl of cell culture medium.

Four replicate wells of each ADC dilution (100 µl) are dispensed in 96-well black plates, previously plated with cell suspension (100 µl), resulting in a final volume of 200 µl. Control wells receive cell culture medium (100 µl).

If the doubling time of the cell line is greater than 30 hours, ADC incubation is for 5 days, otherwise a four day incubation is done.

At the end of the incubation period, cell viability is assessed with the Alamar blue assay. AlamarBlue (Invitrogen) is dispensed over the whole plate (20 µl per well) and incubated for 4 hours. Alamar blue fluorescence is measured at excitation 570nm, emission 585nm on the Varioskan flash plate reader. Percentage cell survival is calculated from the mean fluorescence in the ADC treated wells compared to the mean fluorescence in the control wells.

Use

The conjugates of the disclosure may be used to provide a PBD compound at a target location.

The target location is preferably a proliferative cell population, such as a population of proliferative cancer cells. Other targets locations include a quiescent cell population, such as a population of quiescent cancer cells, or a population of cancer stem cells. The antibody is an antibody for an antigen present on a proliferative cell population.

In one embodiment the antigen is absent or present at a reduced level in a non-proliferative cell population compared to the amount of antigen present in the proliferative cell population, for example a tumour cell population.

At the target location the linker may be cleaved so as to release a compound RelA, RelB, RelC, RelD, RelE or RelG. Thus, the conjugate may be used to selectively provide a compound RelA, RelB, RelC, RelD, RelE or RelG to the target location.

The linker may be cleaved by an enzyme present at the target location.

The target location may be *in vitro*, *in vivo* or *ex vivo*.

The antibody-drug conjugate (ADC) compounds of the disclosure include those with utility for anticancer activity. In particular, the compounds include an antibody conjugated, i.e. covalently attached by a linker, to a PBD drug moiety, i.e. toxin. When the drug is not conjugated to an antibody, the PBD drug has a cytotoxic effect. The biological activity of the PBD drug moiety is thus modulated by conjugation to an antibody. The antibody-drug conjugates (ADC) of the disclosure selectively deliver an effective dose of a cytotoxic agent to tumor tissue whereby greater selectivity, i.e. a lower efficacious dose, may be achieved.

Thus, in one aspect, the present disclosure provides a conjugate compound as described herein for use in therapy.

In a further aspect there is also provides a conjugate compound as described herein for use in the treatment of a proliferative disease. A second aspect of the present disclosure provides the use of a conjugate compound in the manufacture of a medicament for treating a proliferative disease.

One of ordinary skill in the art is readily able to determine whether or not a candidate conjugate treats a proliferative condition for any particular cell type. For example, assays which may conveniently be used to assess the activity offered by a particular compound are described in the examples below.

The term "proliferative disease" pertains to an unwanted or uncontrolled cellular proliferation of excessive or abnormal cells which is undesired, such as, neoplastic or hyperplastic growth, whether *in vitro* or *in vivo*.

Examples of proliferative conditions include, but are not limited to, benign, pre-malignant, and malignant cellular proliferation, including but not limited to, neoplasms and tumours (e.g. histocytoma, glioma, astrocyoma, osteoma), cancers (e.g. lung cancer, small cell lung cancer, gastrointestinal cancer, bowel cancer, colon cancer, breast carcinoma, ovarian carcinoma, prostate cancer, testicular cancer, liver cancer, kidney cancer, bladder cancer, pancreas cancer, brain cancer, sarcoma, osteosarcoma, Kaposi's sarcoma, melanoma), lymphomas, leukemias, psoriasis, bone diseases, fibroproliferative disorders (e.g. of connective tissues), and atherosclerosis. Cancers of particular interest include, but are not limited to prostate cancers, leukemias and ovarian cancers.

Any type of cell may be treated, including but not limited to, lung, gastrointestinal (including, e.g. bowel, colon), breast (mammary), ovarian, prostate, liver (hepatic), kidney (renal), bladder, pancreas, brain, and skin.

For methods of treatment employing a conjugate comprising an antibody that specifically binds PSMA, cancers of particular interest include, but are not limited to, prostate cancers. PSMA has also shown to be widely expressed in the neovasculature of non-prostate solid tumors including carcinomas of the colon, breast, bladder, pancreas, kidney and melanoma, but not normal vasculature. Thus, a PSMA specific ADC can be used for the treatment of non-prostate tumors with PSMA positive neovasculature

It is contemplated that the antibody-drug conjugates (ADC) of the present disclosure may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen. Exemplary conditions or hyperproliferative disorders include benign or malignant tumors; leukemia, haematological, and lymphoid malignancies. Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune, disorders.

Generally, the disease or disorder to be treated is a hyperproliferative disease such as cancer. Examples of cancer to be treated herein include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g. epithelial squamous cell cancer), lung cancer including small-cell lung cancer, non-small cell lung cancer, adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.

Autoimmune diseases for which the ADC compounds may be used in treatment include rheumatologic disorders (such as, for example, rheumatoid arthritis, Sjögren's syndrome, scleroderma, lupus such as SLE and lupus nephritis, polymyositis/dermatomyositis, cryoglobulinemia, anti-phospholipid antibody syndrome, and psoriatic arthritis), osteoarthritis, autoimmune gastrointestinal and liver disorders (such as, for example, inflammatory bowel diseases (e.g. ulcerative colitis and Crohn's disease), autoimmune gastritis and pernicious

anemia, autoimmune hepatitis, primary biliary cirrhosis, primary sclerosing cholangitis, and celiac disease), vasculitis (such as, for example, ANCA-associated vasculitis, including Churg-Strauss vasculitis, Wegener's granulomatosis, and polyarteritis), autoimmune neurological disorders (such as, for example, multiple sclerosis, opsoclonus myoclonus syndrome, myasthenia gravis, neuromyelitis optica, Parkinson's disease, Alzheimer's disease, and autoimmune polyneuropathies), renal disorders (such as, for example, glomerulonephritis, Goodpasture's syndrome, and Berger's disease), autoimmune dermatologic disorders (such as, for example, psoriasis, urticaria, hives, pemphigus vulgaris, bullous pemphigoid, and cutaneous lupus erythematosus), hematologic disorders (such as, for example, thrombocytopenic purpura, thrombotic thrombocytopenic purpura, post-transfusion purpura, and autoimmune hemolytic anemia), atherosclerosis, uveitis, autoimmune hearing diseases (such as, for example, inner ear disease and hearing loss), Behcet's disease, Raynaud's syndrome, organ transplant, and autoimmune endocrine disorders (such as, for example, diabetic-related autoimmune diseases such as insulin-dependent diabetes mellitus (IDDM), Addison's disease, and autoimmune thyroid disease (e.g. Graves' disease and thyroiditis)). More preferred such diseases include, for example, rheumatoid arthritis, ulcerative colitis, ANCA-associated vasculitis, lupus, multiple sclerosis, Sjögren's syndrome, Graves' disease, IDDM, pernicious anemia, thyroiditis, and glomerulonephritis.

Methods of Treatment

The conjugates of the present disclosure may be used in a method of therapy. Also provided is a method of treatment, comprising administering to a subject in need of treatment a therapeutically-effective amount of a conjugate compound of the disclosure. The term "therapeutically effective amount" is an amount sufficient to show benefit to a patient. Such benefit may be at least amelioration of at least one symptom. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage, is within the responsibility of general practitioners and other medical doctors.

A compound of the disclosure may be administered alone or in combination with other treatments, either simultaneously or sequentially dependent upon the condition to be treated. Examples of treatments and therapies include, but are not limited to, chemotherapy (the administration of active agents, including, e.g. drugs, such as chemotherapeutics); surgery; and radiation therapy.

A “chemotherapeutic agent” is a chemical compound useful in the treatment of cancer, regardless of mechanism of action. Classes of chemotherapeutic agents include, but are not limited to: alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic/antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors. Chemotherapeutic agents include compounds used in “targeted therapy” and conventional chemotherapy.

Examples of chemotherapeutic agents include: erlotinib (TARCEVA®, Genentech/OSI Pharm.), docetaxel (TAXOTERE®, Sanofi-Aventis), 5-FU (fluorouracil, 5-fluorouracil, CAS No. 51-21-8), gemcitabine (GEMZAR®, Lilly), PD-0325901 (CAS No. 391210-10-9, Pfizer), cisplatin (cis-diamine, dichloroplatinum(II), CAS No. 15663-27-1), carboplatin (CAS No. 41575-94-4), paclitaxel (TAXOL®, Bristol-Myers Squibb Oncology, Princeton, N.J.), trastuzumab (HERCEPTIN®, Genentech), temozolomide (4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo [4.3.0] nona-2,7,9-triene-9-carboxamide, CAS No. 85622-93-1, TEMODAR®, TEMODAL®, Schering Plough), tamoxifen ((Z)-2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine, NOLVADEX®, ISTUBAL®, VALODEX®), and doxorubicin (ADRIAMYCIN®), Akti-1/2, HPPD, and rapamycin.

More examples of chemotherapeutic agents include: oxaliplatin (ELOXATIN®, Sanofi), bortezomib (VELCADE®, Millennium Pharm.), sunitinib (SUNITINIB®, SU11248, Pfizer), letrozole (FEMARA®, Novartis), imatinib mesylate (GLEEVEC®, Novartis), XL-518 (Mek inhibitor, Exelixis, WO 2007/044515), ARRY-886 (Mek inhibitor, AZD6244, Array BioPharma, AstraZeneca), SF-1126 (PI3K inhibitor, Semafore Pharmaceuticals), BEZ-235 (PI3K inhibitor, Novartis), XL-147 (PI3K inhibitor, Exelixis), PTK787/ZK 222584 (Novartis), fulvestrant (FASLODEX®, AstraZeneca), leucovorin (folinic acid), rapamycin (sirolimus, RAPAMUNE®, Wyeth), lapatinib (TYKERB®, GSK572016, Glaxo Smith Kline), lonafarnib (SARASAR™, SCH 66336, Schering Plough), sorafenib (NEXAVAR®, BAY43-9006, Bayer Labs), gefitinib (IRESSA®, AstraZeneca), irinotecan (CAMPTOSAR®, CPT-11, Pfizer), tipifarnib (ZARNESTRA™, Johnson & Johnson), ABRAXANE™ (Cremophor-free), albumin-engineered nanoparticle formulations of paclitaxel (American Pharmaceutical Partners, Schaumburg, IL), vandetanib (rINN, ZD6474, ZACTIMA®, AstraZeneca), chlorambucil, AG1478, AG1571 (SU 5271; Sugen), temsirolimus (TORISEL®, Wyeth), pazopanib (GlaxoSmithKline), canfosfamide (TELCYTA®, Telik), thiotepa and cyclophosphamide (CYTOXAN®, NEOSAR®); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, triethylenephosphoramidate, triethylenethiophosphoramidate and trimethylmelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including the synthetic analog topotecan); bryostatin;

callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogs); cryptophycins (particularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogs, KW-2189 and CB1-TM1); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, chlorophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, and ranimustine; antibiotics such as the enediyne antibiotics (e.g. calicheamicin, calicheamicin gamma1I, calicheamicin omegal1 (*Angew Chem. Intl. Ed. Engl.* (1994) 33:183-186); dynemicin, dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabycin, carminomycin, carzinophilin, chromomycinis, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, nemorubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, porfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogs such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiothane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elfornithine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidainine; maytansinoids such as maytansine and ansamitocins; mitoguazone; mitoxantrone; mopidanmol; nitraerine; pentostatin; phenamet; pirarubicin; losoxantrone; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK® polysaccharide complex (JHS Natural Products, Eugene, OR); razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiotepa; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; etoposide (VP-16); ifosfamide; mitoxantrone; vincristine; vinorelbine

(NAVELBINE®); novantrone; teniposide; edatrexate; daunomycin; aminopterin; capecitabine (XELODA®, Roche); ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; and pharmaceutically acceptable salts, acids and derivatives of any of the above.

Also included in the definition of “chemotherapeutic agent” are: (i) anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including NOLVADEX®; tamoxifen citrate), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and FARESTON® (toremifine citrate); (ii) aromatase inhibitors that inhibit the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, MEGASE® (megestrol acetate), AROMASIN® (exemestane; Pfizer), formestanie, fadrozole, RIVISOR® (vorozole), FEMARA® (letrozole; Novartis), and ARIMIDEX® (anastrozole; AstraZeneca); (iii) anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; as well as troxacitabine (a 1,3-dioxolane nucleoside cytosine analog); (iv) protein kinase inhibitors such as MEK inhibitors (WO 2007/044515); (v) lipid kinase inhibitors; (vi) antisense oligonucleotides, particularly those which inhibit expression of genes in signaling pathways implicated in aberrant cell proliferation, for example, PKC-alpha, Raf and H-Ras, such as oblimersen (GENASENSE®, Genta Inc.); (vii) ribozymes such as VEGF expression inhibitors (e.g., ANGIOZYME®); (viii) vaccines such as gene therapy vaccines, for example, ALLOVECTIN®, LEUVECTIN®, and VAXID®; PROLEUKIN® rIL-2; topoisomerase 1 inhibitors such as LURTOTECAN®; ABARELIX® rmRH; (ix) anti-angiogenic agents such as bevacizumab (AVASTIN®, Genentech); and pharmaceutically acceptable salts, acids and derivatives of any of the above.

Also included in the definition of “chemotherapeutic agent” are therapeutic antibodies such as alemtuzumab (Campath), bevacizumab (AVASTIN®, Genentech); cetuximab (ERBITUX®, Imclone); panitumumab (VECTIBIX®, Amgen), rituximab (RITUXAN®, Genentech/Biogen Idec), ofatumumab (ARZERRA®, GSK), pertuzumab (PERJETA™, OMNITARG™, 2C4, Genentech), trastuzumab (HERCEPTIN®, Genentech), tositumomab (Bexxar, Corixia), and the antibody drug conjugate, gemtuzumab ozogamicin (MYLOTARG®, Wyeth).

Humanized monoclonal antibodies with therapeutic potential as chemotherapeutic agents in combination with the conjugates of the disclosure include: alemtuzumab, apolizumab, aselizumab, atlizumab, bapineuzumab, bevacizumab, bivatumumab mertansine, cantuzumab

mertansine, cedelizumab, certolizumab pegol, cidfusituzumab, cidtuzumab, daclizumab, eculizumab, efalizumab, epratuzumab, erlizumab, felvizumab, fontolizumab, gemtuzumab, ozogamicin, inotuzumab, ozogamicin, ipilimumab, labetuzumab, lintuzumab, matuzumab, mepolizumab, motavizumab, motovizumab, natalizumab, nimotuzumab, nolovizumab, numavizumab, ocrelizumab, omalizumab, palivizumab, pascolizumab, pecfusituzumab, pectuzumab, pertuzumab, pexelizumab, ralivizumab, ranibizumab, reslivizumab, reslizumab, resyvizumab, rovelizumab, ruplizumab, sibrotuzumab, siplizumab, sontuzumab, tacatuzumab, tetraxetan, tadocizumab, talizumab, tefibazumab, tocilizumab, toralizumab, trastuzumab, tucotuzumab, celmoleukin, tucosituzumab, umavizumab, urtoxazumab, and visilizumab.

Pharmaceutical compositions according to the present disclosure, and for use in accordance with the present disclosure, may comprise, in addition to the active ingredient, i.e. a conjugate compound, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous, or intravenous.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may comprise a solid carrier or an adjuvant. Liquid pharmaceutical compositions generally comprise a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included. A capsule may comprise a solid carrier such as a gelatin.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Formulations

While it is possible for the conjugate compound to be used (e.g., administered) alone, it is often preferable to present it as a composition or formulation.

In one embodiment, the composition is a pharmaceutical composition (e.g., formulation, preparation, medicament) comprising a conjugate compound, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient.

In one embodiment, the composition is a pharmaceutical composition comprising at least one conjugate compound, as described herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including, but not limited to, pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, anti-oxidants, lubricants, stabilisers, solubilisers, surfactants (e.g., wetting agents), masking agents, colouring agents, flavouring agents, and sweetening agents.

In one embodiment, the composition further comprises other active agents, for example, other therapeutic or prophylactic agents.

Suitable carriers, diluents, excipients, etc. can be found in standard pharmaceutical texts. See, for example, Handbook of Pharmaceutical Additives, 2nd Edition (eds. M. Ash and I. Ash), 2001 (Synapse Information Resources, Inc., Endicott, New York, USA), Remington's Pharmaceutical Sciences, 20th edition, pub. Lippincott, Williams & Wilkins, 2000; and Handbook of Pharmaceutical Excipients, 2nd edition, 1994.

Another aspect of the present disclosure pertains to methods of making a pharmaceutical composition comprising admixing at least one [¹¹C]-radiolabelled conjugate or conjugate-like compound, as defined herein, together with one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, e.g., carriers, diluents, excipients, etc. If formulated as discrete units (e.g., tablets, etc.), each unit contains a predetermined amount (dosage) of the active compound.

The term “pharmaceutically acceptable,” as used herein, pertains to compounds, ingredients, materials, compositions, dosage forms, etc., which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of the subject in question (e.g., human) without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio. Each carrier, diluent, excipient, etc. must also be “acceptable” in the sense of being compatible with the other ingredients of the formulation.

The formulations may be prepared by any methods well known in the art of pharmacy. Such methods include the step of bringing into association the active compound with a carrier which constitutes one or more accessory ingredients. In general, the formulations are prepared by uniformly and intimately bringing into association the active compound with carriers (e.g., liquid carriers, finely divided solid carrier, etc.), and then shaping the product, if necessary.

The formulation may be prepared to provide for rapid or slow release; immediate, delayed, timed, or sustained release; or a combination thereof.

Formulations suitable for parenteral administration (e.g., by injection), include aqueous or non-aqueous, isotonic, pyrogen-free, sterile liquids (e.g., solutions, suspensions), in which the active ingredient is dissolved, suspended, or otherwise provided (e.g., in a liposome or other microparticulate). Such liquids may additionally contain other pharmaceutically acceptable ingredients, such as anti-oxidants, buffers, preservatives, stabilisers, bacteriostats, suspending agents, thickening agents, and solutes which render the formulation isotonic with the blood (or other relevant bodily fluid) of the intended recipient. Examples of excipients include, for example, water, alcohols, polyols, glycerol, vegetable oils, and the like. Examples of suitable isotonic carriers for use in such formulations include Sodium Chloride Injection, Ringer's Solution, or Lactated Ringer's Injection. Typically, the concentration of the active ingredient in the liquid is from about 1 ng/ml to about 10 µg/ml, for example from about 10 ng/ml to about 1 µg/ml. The formulations may be presented in unit-dose or multi-dose sealed containers, for example, ampoules and vials, and may be stored in a freeze-dried (lyophilised) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules, and tablets.

Dosage

It will be appreciated by one of skill in the art that appropriate dosages of the conjugate compound, and compositions comprising the conjugate compound, can vary from patient to patient. Determining the optimal dosage will generally involve the balancing of the level of therapeutic benefit against any risk or deleterious side effects. The selected dosage level will depend on a variety of factors including, but not limited to, the activity of the particular compound, the route of administration, the time of administration, the rate of excretion of the compound, the duration of the treatment, other drugs, compounds, and/or materials used in combination, the severity of the condition, and the species, sex, age, weight, condition, general health, and prior medical history of the patient. The amount of compound and route

of administration will ultimately be at the discretion of the physician, veterinarian, or clinician, although generally the dosage will be selected to achieve local concentrations at the site of action which achieve the desired effect without causing substantial harmful or deleterious side-effects.

Administration can be effected in one dose, continuously or intermittently (e.g., in divided doses at appropriate intervals) throughout the course of treatment. Methods of determining the most effective means and dosage of administration are well known to those of skill in the art and will vary with the formulation used for therapy, the purpose of the therapy, the target cell(s) being treated, and the subject being treated. Single or multiple administrations can be carried out with the dose level and pattern being selected by the treating physician, veterinarian, or clinician.

In general, a suitable dose of the active compound is in the range of about 100 ng to about 25 mg (more typically about 1 μ g to about 10 mg) per kilogram body weight of the subject per day. Where the active compound is a salt, an ester, an amide, a prodrug, or the like, the amount administered is calculated on the basis of the parent compound and so the actual weight to be used is increased proportionately.

In one embodiment, the active compound is administered to a human patient according to the following dosage regime: about 100 mg, 3 times daily.

In one embodiment, the active compound is administered to a human patient according to the following dosage regime: about 150 mg, 2 times daily.

In one embodiment, the active compound is administered to a human patient according to the following dosage regime: about 200 mg, 2 times daily.

However in one embodiment, the conjugate compound is administered to a human patient according to the following dosage regime: about 50 or about 75 mg, 3 or 4 times daily.

In one embodiment, the conjugate compound is administered to a human patient according to the following dosage regime: about 100 or about 125 mg, 2 times daily.

The dosage amounts described above may apply to the conjugate (including the PBD moiety and the linker to the antibody) or to the effective amount of PBD compound provided, for example the amount of compound that is releasable after cleavage of the linker.

For the prevention or treatment of disease, the appropriate dosage of an ADC of the disclosure will depend on the type of disease to be treated, as defined above, the severity and course of the disease, whether the molecule is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The molecule is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 $\mu\text{g}/\text{kg}$ to 15 mg/kg (e.g. 0.1-20 mg/kg) of molecule is an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. A typical daily dosage might range from about 1 $\mu\text{g}/\text{kg}$ to 100 mg/kg or more, depending on the factors mentioned above. An exemplary dosage of ADC to be administered to a patient is in the range of about 0.1 to about 10 mg/kg of patient weight. For repeated administrations over several days or longer, depending on the condition, the treatment is sustained until a desired suppression of disease symptoms occurs. An exemplary dosing regimen comprises a course of administering an initial loading dose of about 4 mg/kg , followed by additional doses every week, two weeks, or three weeks of an ADC. Other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

Treatment

The term "treatment," as used herein in the context of treating a condition, pertains generally to treatment and therapy, whether of a human or an animal (e.g., in veterinary applications), in which some desired therapeutic effect is achieved, for example, the inhibition of the progress of the condition, and includes a reduction in the rate of progress, a halt in the rate of progress, regression of the condition, amelioration of the condition, and cure of the condition. Treatment as a prophylactic measure (i.e., prophylaxis, prevention) is also included.

The term "therapeutically-effective amount," as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an active compound, which is effective for producing some desired therapeutic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.

Similarly, the term "prophylactically-effective amount," as used herein, pertains to that amount of an active compound, or a material, composition or dosage from comprising an

active compound, which is effective for producing some desired prophylactic effect, commensurate with a reasonable benefit/risk ratio, when administered in accordance with a desired treatment regimen.

Preparation of Drug conjugates

Antibody drug conjugates may be prepared by several routes, employing organic chemistry reactions, conditions, and reagents known to those skilled in the art, including reaction of a nucleophilic group of an antibody with a drug-linker reagent. This method may be employed to prepare the antibody-drug conjugates of the disclosure.

Nucleophilic groups on antibodies include, but are not limited to side chain thiol groups, e.g. cysteine. Thiol groups are nucleophilic and capable of reacting to form covalent bonds with electrophilic groups on linker moieties such as those of the present disclosure. Certain antibodies have reducible interchain disulfides, i.e. cysteine bridges. Antibodies may be made reactive for conjugation with linker reagents by treatment with a reducing agent such as DTT (Cleland's reagent, dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine hydrochloride; Getz et al (1999) Anal. Biochem. Vol 273:73-80; Soltec Ventures, Beverly, MA). Each cysteine disulfide bridge will thus form, theoretically, two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies through the reaction of lysines with 2-iminothiolane (Traut's reagent) resulting in conversion of an amine into a thiol.

The Subject/Patient

The subject/patient may be an animal, mammal, a placental mammal, a marsupial (e.g., kangaroo, wombat), a monotreme (e.g., duckbilled platypus), a rodent (e.g., a guinea pig, a hamster, a rat, a mouse), murine (e.g., a mouse), a lagomorph (e.g., a rabbit), avian (e.g., a bird), canine (e.g., a dog), feline (e.g., a cat), equine (e.g., a horse), porcine (e.g., a pig), ovine (e.g., a sheep), bovine (e.g., a cow), a primate, simian (e.g., a monkey or ape), a monkey (e.g., marmoset, baboon), an ape (e.g., gorilla, chimpanzee, orangutang, gibbon), or a human.

Furthermore, the subject/patient may be any of its forms of development, for example, a foetus. In one preferred embodiment, the subject/patient is a human.

Further Preferences

The following preferences may apply to all aspects of the disclosure as described above, or may relate to a single aspect. The preferences may be combined together in any combination.

In some embodiments, $R^{6'}$, $R^{7'}$, $R^{9'}$, and Y' are preferably the same as R^6 , R^7 , R^9 , and Y respectively.

Dimer link

Y and Y' are preferably O.

R'' is preferably a C_{3-7} alkylene group with no substituents. More preferably R'' is a C_3 , C_5 or C_7 alkylene. Most preferably, R'' is a C_3 or C_5 alkylene.

R^6 to R^9

R^9 is preferably H.

R^6 is preferably selected from H, OH, OR, SH, NH_2 , nitro and halo, and is more preferably H or halo, and most preferably is H.


R^7 is preferably selected from H, OH, OR, SH, SR, NH_2 , NHR, NRR' , and halo, and more preferably independently selected from H, OH and OR, where R is preferably selected from optionally substituted C_{1-7} alkyl, C_{3-10} heterocyclyl and C_{5-10} aryl groups. R may be more preferably a C_{1-4} alkyl group, which may or may not be substituted. A substituent of interest is a C_{5-6} aryl group (e.g. phenyl). Particularly preferred substituents at the 7- positions are OMe and OCH_2Ph . Other substituents of particular interest are dimethylamino (i.e. $-NMe_2$); $-(OC_2H_4)_qOMe$, where q is from 0 to 2; nitrogen-containing C_6 heterocyclyls, including morpholino, piperidiny and N-methyl-piperazinyl.

These preferences apply to $R^{9'}$, $R^{6'}$ and $R^{7'}$ respectively.


R^{12}

When there is a double bond present between $C2'$ and $C3'$, R^{12} is selected from:


- (a) C_{5-10} aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, C_{1-7} alkyl, C_{3-7} heterocyclyl and bis-oxy- C_{1-3} alkylene;
- (b) C_{1-5} saturated aliphatic alkyl;
- (c) C_{3-6} saturated cycloalkyl;



(d) , wherein each of R^{21} , R^{22} and R^{23} are independently selected from H, C_{1-3} saturated alkyl, C_{2-3} alkenyl, C_{2-3} alkynyl and cyclopropyl, where the total number of carbon atoms in the R^{12} group is no more than 5;



(e) , wherein one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo methyl, methoxy; pyridyl; and thiophenyl; and



(f) , where R^{24} is selected from: H; C_{1-3} saturated alkyl; C_{2-3} alkenyl; C_{2-3} alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo methyl, methoxy; pyridyl; and thiophenyl.

When R^{12} is a C_{5-10} aryl group, it may be a C_{5-7} aryl group. A C_{5-7} aryl group may be a phenyl group or a C_{5-7} heteroaryl group, for example furanyl, thiophenyl and pyridyl. In some embodiments, R^{12} is preferably phenyl. In other embodiments, R^{12} is preferably thiophenyl, for example, thiophen-2-yl and thiophen-3-yl.

When R^{12} is a C_{5-10} aryl group, it may be a C_{8-10} aryl, for example a quinolinyl or isoquinolinyl group. The quinolinyl or isoquinolinyl group may be bound to the PBD core through any available ring position. For example, the quinolinyl may be quinolin-2-yl, quinolin-3-yl, quinolin-4yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl and quinolin-8-yl. Of these quinolin-3-yl and quinolin-6-yl may be preferred. The isoquinolinyl may be isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl and isoquinolin-8-yl. Of these isoquinolin-3-yl and isoquinolin-6-yl may be preferred.

When R^{12} is a C_{5-10} aryl group, it may bear any number of substituent groups. It preferably bears from 1 to 3 substituent groups, with 1 and 2 being more preferred, and singly substituted groups being most preferred. The substituents may be any position.

Where R^{12} is C_{5-7} aryl group, a single substituent is preferably on a ring atom that is not adjacent the bond to the remainder of the compound, i.e. it is preferably β or γ to the bond to the remainder of the compound. Therefore, where the C_{5-7} aryl group is phenyl, the

substituent is preferably in the meta- or para- positions, and more preferably is in the para-position.

Where R^{12} is a C_{8-10} aryl group, for example quinolinyl or isoquinolinyl, it may bear any number of substituents at any position of the quinoline or isoquinoline rings. In some embodiments, it bears one, two or three substituents, and these may be on either the proximal and distal rings or both (if more than one substituent).

R^{12} substituents, when R^{12} is a C_{5-10} aryl group

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is halo, it is preferably F or Cl, more preferably Cl.

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is ether, it may in some embodiments be an alkoxy group, for example, a C_{1-7} alkoxy group (e.g. methoxy, ethoxy) or it may in some embodiments be a C_{5-7} aryloxy group (e.g. phenoxy, pyridyloxy, furanyloxy). The alkoxy group may itself be further substituted, for example by an amino group (e.g. dimethylamino).

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is C_{1-7} alkyl, it may preferably be a C_{1-4} alkyl group (e.g. methyl, ethyl, propyl, butyl).

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is C_{3-7} heterocyclyl, it may in some embodiments be C_6 nitrogen containing heterocyclyl group, e.g. morpholino, thiomorpholino, piperidinyl, piperazinyl. These groups may be bound to the rest of the PBD moiety via the nitrogen atom. These groups may be further substituted, for example, by C_{1-4} alkyl groups. If the C_6 nitrogen containing heterocyclyl group is piperazinyl, the said further substituent may be on the second nitrogen ring atom.

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is bis-oxy- C_{1-3} alkylene, this is preferably bis-oxy-methylene or bis-oxy-ethylene.

If a substituent on R^{12} when R^{12} is a C_{5-10} aryl group is ester, this is preferably methyl ester or ethyl ester.


Particularly preferred substituents when R^{12} is a C_{5-10} aryl group include methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-


thiophenyl. Other particularly preferred substituent for R¹² are dimethylaminopropoxy and carboxy.

Particularly preferred substituted R¹² groups when R¹² is a C₅₋₁₀ aryl group include, but are not limited to, 4-methoxy-phenyl, 3-methoxyphenyl, 4-ethoxy-phenyl, 3-ethoxy-phenyl, 4-fluoro-phenyl, 4-chloro-phenyl, 3,4-bisoxymethylene-phenyl, 4-methylthiophenyl, 4-cyanophenyl, 4-phenoxyphenyl, quinolin-3-yl and quinolin-6-yl, isoquinolin-3-yl and isoquinolin-6-yl, 2-thienyl, 2-furanyl, methoxynaphthyl, and naphthyl. Another possible substituted R¹² group is 4-nitrophenyl. R¹² groups of particular interest include 4-(4-methylpiperazin-1-yl)phenyl and 3,4-bisoxymethylene-phenyl.

When R¹² is C₁₋₅ saturated aliphatic alkyl, it may be methyl, ethyl, propyl, butyl or pentyl. In some embodiments, it may be methyl, ethyl or propyl (n-pentyl or isopropyl). In some of these embodiments, it may be methyl. In other embodiments, it may be butyl or pentyl, which may be linear or branched.

When R¹² is C₃₋₆ saturated cycloalkyl, it may be cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl. In some embodiments, it may be cyclopropyl.



When R¹² is , each of R²¹, R²² and R²³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R¹² group is no more than 5. In some embodiments, the total number of carbon atoms in the R¹² group is no more than 4 or no more than 3.

In some embodiments, one of R²¹, R²² and R²³ is H, with the other two groups being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.

In other embodiments, two of R²¹, R²² and R²³ are H, with the other group being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.

In some embodiments, the groups that are not H are selected from methyl and ethyl. In some of these embodiments, the groups that are not H are methyl.

In some embodiments, R²¹ is H.


In some embodiments, R²² is H.


In some embodiments, R²³ is H.


In some embodiments, R²¹ and R²² are H.

In some embodiments, R²¹ and R²³ are H.

In some embodiments, R²² and R²³ are H.


An R¹² group of particular interest is: 

When R¹² is , one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl. In some embodiments, the group which is not H is optionally substituted phenyl. If the phenyl optional substituent is halo, it is preferably fluoro. In some embodiment, the phenyl group is unsubstituted.

When R¹² is , R²⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo methyl, methoxy; pyridyl; and thiophenyl. If the phenyl optional substituent is halo, it is preferably fluoro. In some embodiment, the phenyl group is unsubstituted.

In some embodiments, R²⁴ is selected from H, methyl, ethyl, ethenyl and ethynyl. In some of these embodiments, R²⁴ is selected from H and methyl.

When there is a single bond present between C2' and C3',

R¹² is , where R^{26a} and R^{26b} are independently selected from H, F, C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C₁₋₄ alkyl amido and C₁₋₄ alkyl ester; or, when one of R^{26a} and R^{26b} is H, the other is selected from nitrile and a C₁₋₄ alkyl ester.

In some embodiments, it is preferred that R^{26a} and R^{26b} are both H.

In other embodiments, it is preferred that R^{26a} and R^{26b} are both methyl.

In further embodiments, it is preferred that one of R^{26a} and R^{26b} is H, and the other is selected from C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted. In these further embodiment, it may be further preferred that the group which is not H is selected from methyl and ethyl.

*R*²

The above preferences for R¹² apply equally to R².

*R*²²

In some embodiments, R²² is of formula IIa.

A in R²² when it is of formula IIa may be phenyl group or a C₅₋₇ heteroaryl group, for example furanyl, thiophenyl and pyridyl. In some embodiments, A is preferably phenyl.

Q²-X may be on any of the available ring atoms of the C₅₋₇ aryl group, but is preferably on a ring atom that is not adjacent the bond to the remainder of the compound, i.e. it is preferably β or γ to the bond to the remainder of the compound. Therefore, where the C₅₋₇ aryl group (A) is phenyl, the substituent (Q²-X) is preferably in the meta- or para- positions, and more preferably is in the para- position.



In some embodiments, Q¹ is a single bond. In these embodiments, Q² is selected from a single bond and -Z-(CH₂)_n-, where Z is selected from a single bond, O, S and NH and is from 1 to 3. In some of these embodiments, Q² is a single bond. In other embodiments, Q² is -Z-(CH₂)_n-. In these embodiments, Z may be O or S and n may be 1 or n may be 2. In other of these embodiments, Z may be a single bond and n may be 1.

In other embodiments, Q¹ is -CH=CH-.

In other embodiments, R²² is of formula IIb. In these embodiments, R^{C1}, R^{C2} and R^{C3} are independently selected from H and unsubstituted C₁₋₂ alkyl. In some preferred embodiments, R^{C1}, R^{C2} and R^{C3} are all H. In other embodiments, R^{C1}, R^{C2} and R^{C3} are all

methyl. In certain embodiments, R^{C1} , R^{C2} and R^{C3} are independently selected from H and methyl.

X is a group selected from the list comprising: $O-R^{L2'}$, $S-R^{L2'}$, $CO_2-R^{L2'}$, $CO-R^{L2'}$, $NH-C(=O)-$

$R^{L2'}$, $NHNH-R^{L2'}$, $CONHNH-R^{L2'}$, , , $NR^N R^{L2'}$, wherein R^N is selected from the group comprising H and C_{1-4} alkyl. X may preferably be: OH, SH, CO_2H , $-N=C=O$ or NHR^N , and may more preferably be: $O-R^{L2'}$, $S-R^{L2'}$, $CO_2-R^{L2'}$, $-NH-C(=O)-R^{L2'}$ or $NH-R^{L2'}$. Particularly preferred groups include: $O-R^{L2'}$, $S-R^{L2'}$ and $NH-R^{L2'}$, with $NH-R^{L2'}$ being the most preferred group.

In some embodiments R^{22} is of formula IIc. In these embodiments, it is preferred that Q is $NR^N R^{L2'}$. In other embodiments, Q is $O-R^{L2'}$. In further embodiments, Q is $S-R^{L2'}$. R^N is preferably selected from H and methyl. In some embodiment, R^N is H. In other embodiments, R^N is methyl.

In some embodiments, R^{22} may be $-A-CH_2-X$ and $-A-X$. In these embodiments, X may be $O-R^{L2'}$, $S-R^{L2'}$, $CO_2-R^{L2'}$, $CO-R^{L2'}$ and $NH-R^{L2'}$. In particularly preferred embodiments, X may be $NH-R^{L2'}$.

R^{10} , R^{11}

In some embodiments, R^{10} and R^{11} together form a double bond between the nitrogen and carbon atoms to which they are bound.

In some embodiments, R^{11} is OH.

In some embodiments, R^{11} is OMe.

In some embodiments, R^{11} is $SO_z M$, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation.

R^{11a}

In some embodiments, R^{11a} is OH.

In some embodiments, R^{11a} is OMe.

In some embodiments, R^{11a} is SO_zM , where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation.

R^{20}, R^{21}

In some embodiments, R^{20} and R^{21} together form a double bond between the nitrogen and carbon atoms to which they are bound.

In some embodiments R^{20} is H.

In some embodiments, R^{20} is R^C .

In some embodiments, R^{21} is OH.

In some embodiments, R^{21} is OMe.

In some embodiments, R^{21} is SO_zM , where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation.

R^{30}, R^{31}

In some embodiments, R^{30} and R^{31} together form a double bond between the nitrogen and carbon atoms to which they are bound.

In some embodiments, R^{31} is OH.

In some embodiments, R^{31} is OMe.


In some embodiments, R^{31} is SO_zM , where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation.

M and z

It is preferred that M is a monovalent pharmaceutically acceptable cation, and is more preferably Na^+ .

z is preferably 3.

Preferred conjugates of the first aspect of the present disclosure may have a D^I of formula Ia:



la








where

R^{L1'}, R²⁰ and R²¹ are as defined above;

n is 1 or 3;


R^{1a} is methyl or phenyl; and

R^{2a} is selected from:



Preferred conjugates of the first aspect of the present disclosure may have a D^L of formula

lb:



lb


where

R^{L1'}, R²⁰ and R²¹ are as defined above;

n is 1 or 3; and

R^{1a} is methyl or phenyl.

Preferred conjugates of the first aspect of the present disclosure may have a D^L of formula










Ic:

where R^{L2'}, R¹⁰, R¹¹, R³⁰ and R³¹ are as defined above


n is 1 or 3;

R^{12a} is selected from:



the amino group is at either the meta or para positions of the phenyl group.

Preferred conjugates of the first aspect of the present disclosure may have a D^L of formula










Id:

where R^{L2'}, R¹⁰, R¹¹, R³⁰ and R³¹ are as defined above

n is 1 or 3;


R^{1a} is methyl or phenyl;

R^{12a} is selected from:



Preferred conjugates of the first aspect of the present disclosure may have a D^L of formula

le:










where $R^{L2'}$, R^{10} , R^{11} , R^{30} and R^{31} are as defined above

n is 1 or 3;

R^{1a} is methyl or phenyl;

R^{12a} is selected from:



Examples

General Experimental Methods

Optical rotations were measured on an ADP 220 polarimeter (Bellingham Stanley Ltd.) and concentrations (c) are given in g/100mL. Melting points were measured using a digital melting point apparatus (Electrothermal). IR spectra were recorded on a Perkin-Elmer Spectrum 1000 FT IR Spectrometer. ^1H and ^{13}C NMR spectra were acquired at 300 K using a Bruker Avance NMR spectrometer at 400 and 100 MHz, respectively. Chemical shifts are reported relative to TMS ($\delta = 0.0$ ppm), and signals are designated as s (singlet), d

(doublet), t (triplet), dt (double triplet), dd (doublet of doublets), ddd (double doublet of doublets) or m (multiplet), with coupling constants given in Hertz (Hz). Mass spectroscopy (MS) data were collected using a Waters Micromass ZQ instrument coupled to a Waters 2695 HPLC with a Waters 2996 PDA. Waters Micromass ZQ parameters used were: Capillary (kV), 3.38; Cone (V), 35; Extractor (V), 3.0; Source temperature (°C), 100; Desolvation Temperature (°C), 200; Cone flow rate (L/h), 50; De-solvation flow rate (L/h), 250. High-resolution mass spectroscopy (HRMS) data were recorded on a Waters Micromass QTOF Global in positive W-mode using metal-coated borosilicate glass tips to introduce the samples into the instrument. Thin Layer Chromatography (TLC) was performed on silica gel aluminium plates (Merck 60, F₂₅₄), and flash chromatography utilised silica gel (Merck 60, 230-400 mesh ASTM). Except for the HOBt (NovaBiochem) and solid-supported reagents (Argonaut), all other chemicals and solvents were purchased from Sigma-Aldrich and were used as supplied without further purification. Anhydrous solvents were prepared by distillation under a dry nitrogen atmosphere in the presence of an appropriate drying agent, and were stored over 4Å molecular sieves or sodium wire. Petroleum ether refers to the fraction boiling at 40-60°C.

General LC/MS conditions:

The HPLC (Waters Alliance 2695) was run using a mobile phase of water (A) (formic acid 0.1%) and acetonitrile (B) (formic acid 0.1%). Gradient: initial composition 5% B held over 1.0 min, then increase from 5% B to 95% B over a 3 min period. The composition was held for 0.1 min at 95% B, then returned to 5% B in 0.03 minutes and hold there for 0.87 min. Total gradient run time equals 5 minutes.

Flow rate 3.0 mL/min, 400µL was split *via* a zero dead volume tee piece which passes into the mass spectrometer. Wavelength detection range: 220 to 400 nm. Function type: diode array (535 scans). Column: Phenomenex Onyx Monolithic C18 50 x 4.60 mm.

The reverse phase flash purification conditions were as follows: The Flash purification system (Varian 971-Fp) was run using a mobile phase of water (A) and acetonitrile (B). Gradient: initial composition 5% B over 20 C.V. (Column Volume) then 5% B to 70% B within 60 C.V. The composition was held for 15 C.V. at 95% B, and then returned to 5% B in 5 C.V. and held at 5%B for 10 C.V. Total gradient run time equals 120 C.V. Flow rate 6.0 mL/min. Wavelength detection range: 254 nm. Column: Agilent AX1372-1 SF10-5.5gC8.

Preparative HPLC: Reverse-phase ultra-high-performance liquid chromatography (UPLC) was carried out on Phenomenex Gemini NX 5µ C-18 columns of the following dimensions:

150 x 4.6 mm for analysis, and 150 x 21.20 mm for preparative work. All UPLC experiments were performed with gradient conditions. Eluents used were solvent A (H₂O with 0.1% Formic acid) and solvent B (CH₃CN with 0.1% Formic acid). Flow rates used were 1.0 ml/min for analytical, and 20.0 ml/min for preparative HPLC. Detection was at 254 and 280 nm.

Example 1: Formation of conjugates*Conjugation of AbHJ591, AbDJ591, AbBJ591*

Antibodies AbHJ591, AbDJ591, AbBJ591 were prepared for reduction in a buffer containing 1 mM EDTA in PBS pH 7.4 at an antibody concentration of 1-10 mg/mL. TCEP reductant was added to the batch as a 50-fold molar excess with respect to the antibody and the reduction mixture was heated at +37°C for 3 hours in an incubator with slow orbital shaking. After confirming by RP-HPLC that reduction was complete, the antibody was cooled down to room temperature and buffer exchanged into PBS buffer containing 1 mM EDTA to remove excess TCEP. Reduced antibody was reoxidised by the addition of 50 mM dehydroascorbic acid (DHAA) as a 50 fold molar excess with respect to antibody, and the reoxidation mixture is allowed to proceed for a total of 2 hours with HPLC monitoring, then sterile filtered to remove DHAA. Conjugation was initiated by the addition of 10 mM drug linker stock diluted into DMSO (to a final 10% v/v concentration) and 10 fold excess relative to the antibody. The conjugation reaction was incubated for 16 hours at room temperature. Post conjugation the reaction was quenched with a 10 fold molar excess of *N*-acetyl cysteine and incubated for an additional 30 mins. The final product was exchanged into formulation buffer (30 mM Histidine, 200 mM sorbitol, 0.02% Tween-20) and analysed by SEC, HIC, RP-HPLC.

Conjugation of AbLJ591

Initial attempts to conjugate AbLJ591 directly or following complete reduction/re-oxidation results in a complete lack of conjugation confirming that the unpaired heavy chain Cys were disulphide bridged together and would re-oxidise at the same rate as the heavy-heavy disulphide bonds. A site specific reduction process based on literature precedent (mAbs 1:6, 563-571; November/December, 2009) was attempted both in solution and on a resin. Both approaches were successful but the solid phase approach had certain practical advantages:

- Avoided the need for process optimization to increase protein concentration during reduction – to maintain concentration during subsequent steps
- Results in concentration not dilution of the reduced antibody
- Ensures excellent toxin linker removal which can require multiple passes down G25 or TFF for a solution based process

It is expected that many resins will be capable of supporting this process with the requirement for the resin being:

- Ability to capture the educed antibody from the reduction process
- Lack of affinity / binding of Cys
- No blocking of the target free thiol

An example of a resin likely to work for this is Protein A.

Solid phase

AbLJ591 (25.5mg, 5.1mg/mL in PBS) was conjugated with Compound E in a multi-step process. In the first step the AbLJ591 antibody was buffer exchanged into 20mM HEPES pH 8.0 via G25 column chromatography (NAP25, GE Healthcare) and diluted to 1mg/mL. Cysteine was then added to 5mM final concentration from a freshly prepared stock of 500mM in deionised water. The site specific reduction process was allowed to proceed for 90 minutes at 37°C. The reduced AbLJ591 was then captured on a 2mL column of protein L mimetic resin to achieve fast and complete removal of the reductant (FabSorbent F1P HF, Prometic biosciences Ltd). The column was immediately washed with 20 column volumes of phosphate buffered saline (PBS) and then with PBS containing 5% v/v of dimethylacetamide (DMA). The resin was suspended in 10mL of PBS, 5% v/v DMA containing Compound E at 5 fold molar excess over antibody and allowed to conjugate for 60 minutes at room temperature. The column was then washed with 20 column volumes of PBS containing 5% v/v of dimethylacetamide (DMA) and then 20 column volumes of phosphate buffered saline (PBS). The purified conjugate was then eluted from the resin with 0.1M Glycine pH 3.0 and immediately buffer exchanged into 30mM Histidine, 200mM sorbitol pH 6 via G25 column chromatography (HiTrap G25, GE Healthcare). Polysorbate 20 was then added to 0.01% w/v from a freshly prepared stock of 1% w/v Polysorbate 20 in deionised water. The formulated conjugate was then subjected to a sterilizing grade filtration via a 0.22 µm, polyethersulfone membrane (Steriflip, EMD Millipore).

The AbLJ591-ConjE ADC was analysed by hydrophobic interaction chromatography (HIC) to determine the amount of DAR2 relative to unwanted DAR<2 and DAR>2 species. The percentage of on-target heavy-chain conjugation was determined by RP-HPLC and monomer content by size exclusion chromatography.

Solution phase

AbLJ591 (25.5mg, 5.1mg/mL in PBS) was conjugated with Compound E in a multi-step process. In the first step the AbLJ591 antibody was buffer exchanged into 20mM HEPES pH

8.0 via G25 column chromatography (NAP25, GE Healthcare) and diluted to 1mg/mL. Cysteine was then added to 5mM final concentration from a freshly prepared stock of 500mM in deionised water. The site specific reduction process was allowed to proceed for 90 minutes at 37°C. The reduced AbLJ591 was then buffer exchanged into PBS, 5% v/v DMA via G25 column chromatography (NAP25, GE Healthcare) and Compound E added at a 5 fold molar excess over antibody and allowed to conjugate for 60 minutes at room temperature. The conjugate was then buffer exchanged into 30mM Histidine, 200mM sorbitol pH 6 via G25 column chromatography (HiTrap G25, GE Healthcare). Polysorbate 20 was then added to 0.01% w/v from a freshly prepared stock of 1% w/v Polysorbate 20 in deionised water. The formulated conjugate was then subjected to a sterilizing grade filtration via a 0.22 µm, polyethersulfone membrane (Steriflip, EMD Millipore).

The AbLJ591-ConjE ADC was analysed by hydrophobic interaction chromatography (HIC) to determine the amount of DAR2 relative to unwanted DAR<2 and DAR>2 species. The percentage of on-target heavy-chain conjugation was determined by RP-HPLC and monomer content by size exclusion chromatography.

Conjugation #2 of AbLJ

AbLJ-ConjE

4mL (approx. 5mg/mL) AbLJ in PBS is buffer exchanged into 20mM Tris/Cl, 1M Lysine, 5mM EDTA pH 8.0 using a G25 fine desalting column (GE Healthcare HiPrep 26/10).

The antibody was diluted to 1 mg/mL (approx. 20 mL volume) based on UV absorbance and reduction initiated by the addition of N-acetyl cysteine (500mM NAC in water, Sigma A7250) to 5mM final concentration. The reduction process was allowed to proceed for 75 minutes. The reduction process is stopped by removal of the NAC by binding the reduced protein in batch mode to a protein A mimetic resin.

2mL Fabsorbent™ F1P HF (Prometics Biosciences) was pre-equilibrated with phosphate buffered saline, filtered to remove the PBS and then suspended in the reduced antibody solution and mixed gently on a roller for 15 minutes. The resin is washed 5 times with 10 mL of 20mM Tris/Cl, 5mM EDTA. The washed resin was then suspended in 10 mL volumes of 20mM Tris/Cl, 5mM EDTA, 5% v/v Dimethylacetamide (DMA). Compound E was added to 5 equivalents relative to total antibody from a 10mM stock solution in DMA. This conjugation reaction was mixed gently on a roller for 60 minutes. The resin bound conjugate was then washed sequentially with 3 x 10mL of PBS/5% v/v DMA followed by 3 x 10 mL of PBS.

The conjugate was released from the resin by suspending the resin in 10 mL of 0.1M Glycine pH 3.0 for 5 minutes and the conjugate containing supernatant collected by filtering off the resin. The elution process was repeated and the two elution fractions combined and immediately formulated by buffer exchange into 30M Histidine/Cl, 200mM sorbitol pH 6.0 using a G25 fine desalting column (GE Healthcare PD10 or HiPrep 26/10). Polysorbate 20 was then added to 0.02% w/v from a 10% w/v stock solution in water.

The final formulated conjugate was 0.2um filtered (Steriflip-GP PES filtration unit, Merck Millipore).

Site-specific conjugation to the heavy chain and average DAR are determined by RP-HPLC (PLRP) and monomer content by size exclusion chromatography as described above. The final conjugate had an average DAR of 1.8 and a monomer / HMW content of 95.2 and 1.6% respectively.

Conjugation of AbLJ(LALA)

AbLJ(LALA)-ConjE

The AbLJ(LALA) antibody was conjugated to Compound E exactly as described above for Conjugation #2 of AbLJ.

The final conjugate had an average DAR of 1.8 and a monomer / HMW content of 95% and 1.8% respectively.

DAR Determination

Antibody or ADC (ca. 35 µg in 35 µL) was reduced by addition of 10 µL borate buffer (100 mM, pH 8.4) and 5 µL DTT (0.5 M in water), and heated at 37°C for 15 minutes. The sample was diluted with 1 volume of acetonitrile: water: formic acid (49%: 49%: 2% v/v), and injected onto a Widespore 3.6µ XB-C18 150 x 2.1 mm (P/N 00F-4482-AN) column (Phenomenex Aeris) at 80°C, in a UPLC system (Shimadzu Nexera) with a flow rate of 1 ml/min equilibrated in 75% Buffer A (Water, Trifluoroacetic acid (0.1% v/v) (TFA), 25% buffer B (Acetonitrile: water: TFA 90%: 10%: 0.1% v/v). Bound material was eluted using a gradient from 25% to 55% buffer B in 10 min. Peaks of UV absorption at 214 nm were integrated. The following peaks were identified for each ADC or antibody: native antibody light chain (L0), native antibody heavy chain (H0), and each of these chains with added drug-linkers (labelled L1 for light chain with one drug and H1, H2, H3 for heavy chain with 1, 2 or 3 attached drug-

linkers). The UV chromatogram at 330 nm was used for identification of fragments containing drug-linkers (i.e., L1, H1, H2, H3).

A PBD/protein molar ratio was calculated for both light chains and heavy chains:

$$\frac{\text{Drug}}{\text{Protein}} \text{ ratio on light chain} = \frac{\% \text{Area at 214nm for L1}}{\% \text{Area at 214 nm for L0 and L1}}$$

$$\frac{\text{Drug}}{\text{Protein}} \text{ ratio on heavy chain} = \frac{\sum_{n=0}^9 n \times (\% \text{area at 214 for Hn})}{\sum_{n=0}^9 \% \text{area at 214 for Hn}}$$

Final DAR is calculated as:

$$\text{DAR} = 2 \times \left(\frac{\text{Drug}}{\text{Protein}} \text{ ratio on light chain} + \frac{\text{Drug}}{\text{Protein}} \text{ ratio on heavy chain} \right)$$

DAR measurement is carried out at 214 nm because it minimises interference from drug-linker absorbance.

Test	AbHJ591-ConjE	AbDJ591-ConjE	AbBJ591-ConjE	AbLJ591-ConjE
Visual	Clear, colourless, particulate free	Clear, colourless, particulate free	Clear, colourless, particulate free	0.63
C (by A280/330 nm) in mg/ml*	0.77*	1.0*	Nd*	Nd
C (SEC 214 nm) in mg/mL*	0.88*	Nd*	1.18*	1.8
DAR by HIC	1.5	1.9	1.7	1.8
DAR by PLRP	1.5	1.9	1.8	100%
SEC (% monomer)	99.4%	98.1%	95.6%	Nd
Free drug-linker	< LOD	< LOD	<LOD	Nd
DMA	DMA not used	DMA not used	DMA not used	0.63

*Two concentration methods were used: SEC (214 nm) vs known concentration reference sample or A280/A330 as described in patent. When data was available concentration was recalculated using this formula.

Example 2: *In vitro* cytotoxicity of anti-PSMA conjugates

Cytotoxicity assay

The concentration and viability of cultures of suspended cells (at up to 1×10^6 /ml) were determined by mixing 1:1 with Trypan blue and counting clear (live)/blue (dead) cells with a haemocytometer. The cell suspension was diluted to the required seeding density (generally 10^5 /ml) and dispensed into 96-well flat bottomed plates. For Alamar blue assay, 100 μ l/well was dispensed in black-well plates. For MTS assay, 50 μ l/well was dispensed in clear-well plates. A stock solution (1 ml) of ADC (20 μ g/ml) was made by dilution of filter-sterile ADC into cell culture medium. A set of 8 x 10-fold dilutions of stock ADC were made in a 24 well plate by serial transfer of 100 μ l onto 900 μ l of cell culture medium. Each ADC dilution (100 μ l/well for Alamar blue, 50 μ l/well for MTS) was dispensed into 4 replicate wells of the 96-well plate, containing cell suspension. Control wells received the same volume of culture medium only. After incubation for 4 days, cell viability was measured by either Alamar blue or MTS assay.

AlamarBlue® (Invitrogen, catalogue number DAL1025) was dispensed (20 μ l per well) into each well and incubated for 4 hours at 37°C in the CO₂-gassed incubator. Well fluorescence was measured at excitation 570 nm, emission 585 nm. Cell survival (%) was calculated from the ratio of mean fluorescence in the 4 ADC-treated wells compared to the mean fluorescence in the 4 control wells (100%).

MTS (Promega, catalogue number G5421) was dispensed (20 μ l per well) into each well and incubated for 4 hours at 37°C in the CO₂-gassed incubator. Absorbance was measured at 490 nm. Cell survival (%) was calculated from the mean absorbance in the 4 ADC-treated wells compared to the mean absorbance in the 4 control wells (100%). Dose response curves were generated from the mean data of 3 replicate experiments and the EC₅₀ was determined by fitting data to a sigmoidal dose-response curve with variable slope using Prism (GraphPad, San Diego, CA).

Results

In order to produce site-specific versions of the PSMA-targeted ADCs, engineered versions of the AbJ antibody was conjugated the PBD warhead linker ConjE. The engineered AbJ antibodies were transiently produced in CHO cells. The *in vitro* cytotoxic efficacy of the site-

specific ADCs were compared to wild-type AbJ-ADC conjugate (AbJ-ConjE) in the PSMA +ve cell line LNCaP.

AbJ591 →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
- a light chain comprising the amino acid sequence of SEQ ID NO.150;
- a VH domain having the sequence SEQ ID NO.3; and
- a VL domain having the sequence SEQ ID NO.4.

AbJ591-ConjE → AbJ stochastically conjugated to Compound E

AbHJ591-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.111;
 - a light chain comprising the amino acid sequence of SEQ ID NO.150;
 - a VH domain having the sequence SEQ ID NO. 3; and
 - a VL domain having the sequence SEQ ID NO. 4;
- conjugated to Compound E at C105 of SEQ ID NO.150.

AbDJ591-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.115;
 - a light chain comprising the amino acid sequence of SEQ ID NO.150;
 - a VH domain having the sequence SEQ ID NO. 3; and
 - a VL domain having the sequence SEQ ID NO. 4;
- conjugated to Compound E at C105 of SEQ ID NO.150.

AbBJ591-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.113;
 - a light chain comprising the amino acid sequence of SEQ ID NO.151;
 - a VH domain having the sequence SEQ ID NO. 3; and
 - a VL domain having the sequence SEQ ID NO. 4;
- conjugated to Compound E at C103 of SEQ ID NO.113.

AbLJ591-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.110;
 - a light chain comprising the amino acid sequence of SEQ ID NO.151;
 - a VH domain having the sequence SEQ ID NO. 3; and
 - a VL domain having the sequence SEQ ID NO. 4;
- conjugated to Compound E at C103 of SEQ ID NO.110.

ADC candidate	Binding EC50 (ng/ml)	Cytotoxicity IC50 (ng/ml)
AbJ591	59	-
AbJ591-ConjE	44	56
AbHJ591-ConjE	55	18
AbDJ591-ConjE	44	12
AbBJ591-ConjE	49	23

No significant differences were reported in the EC50 values when the site-specific AbJ conjugates were compared to the corresponding wild-type conjugates.

Example 3

In vivo efficacy of site-specific and non-site specific anti-PSMA conjugates

8 to 12 weeks old male CB.17 SCID mice were implanted with 1×10^7 CWR22Rv1 tumor cells in 50% Matrigel s.c. in flank. On Day 1 of the study, mice bearing established CWR22Rv1 xenografts (average size of 100 - 150 mm³) were sorted into treatment groups (n = 10), and dosing was initiated at either 0.33 mg/kg or 1.0 mg/kg. Tumors were measured twice per week until the study was ended.

Results

The various ADCs were tested in the CWR22Rv1 xenograft model. At 0.3 mg/kg qd x 1, AbHJ591-ConjE and AbBJ591-ConjE were equally efficacious providing tumor stasis for 30 days. AbDJ591-ConjE was slightly more efficacious providing tumor stasis for up to 35 days. At 1.0 mg/kg qd x 1, AbBJ591-ConjE, AbHJ591-ConjE and AbDJ591-ConjE provided tumor stasis for 55, 70 and > 95 days.

Example 4

Plasma/serum stability of site-specific and non-site specific conjugates:

Stochastically conjugated ADCs (AbJ) and site-specifically conjugated ADCs were spiked in cyno or human plasma or PBS at a concentration of 60 ug/ml and incubated at 37°C for 24 h, one and three weeks.

After one week samples were harvested and in vitro cytotoxicity of the ADCs was determined. ADC instability would result in a loss of potency on the cells due to release of warhead from the ADC.

GI₅₀ data were generated by least squares fitting OD₄₉₀ data derived from the CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS) to a sigmoidal, 4PL X is log(concentration) algorithm using Graph Pad Prism v6.03. Cells were cultured for 6 days with the ADC-plasma mix, before MTS assay as described in the application.

	GI ₅₀ (ng/ml) in cells				
	Human plasma stability				
	Unfrozen control	Days at 37°C before storage at -80°C until assay			
		0	1	7	21
AbJ591-ConjE	16.8	65.0	95.9	62.4	480.9
AbBJ591-ConjE	12.8	22.5	18.1	48.0	287.1
AbHJ591-ConjE	11.3	9.0	10.7	39.5	234.8
AbDJ591-ConjE	7.1	7.2	7.6	20.2	258.2
Cynomolgus monkey plasma stability					
AbJ591-ConjE	16.8	26.2	32.1	74.4	111.8
AbBJ591-ConjE	12.8	14.0	19.6	56.7	74.4
AbHJ591-ConjE	11.3	9.8	13.3	24.3	44.4
AbDJ591-ConjE	7.1	7.6	8.7	13.0	48.2

AbBJ591-ConjE, AbDJ591-ConjE and AbHJ591-ConjE showed improved stability when compared to the stochastic conjugate AbJ591-ConjE in human and cynomolgus plasma upon 1, 7 or 21 days incubation at 37°C.

Example 5

Tolerability of different site-specific conjugates.

The effect of the mutation of the residues at Kabat EU positions 234 and 235 on the tolerability of the ADCs to rats was investigated.

Single dose studies were performed in male sprague-dawley rats, with necropsy on day 21 following dosing. Bodyweights and food consumption were monitored frequently with in-life sampling for clinical pathology (blood on days 8 and 21) and repeated sampling for

pharmacokinetics. At necropsy, macroscopic observations were taken with selected organs weighed and retained for possible histopathology.

Results

AbLJ-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;
 - a light chain comprising the amino acid sequence of SEQ ID NO.151;
 - a VH domain; and
 - a VL domain;
- conjugated to Compound E at C103 of SEQ ID NO.1103.

AbLJ(LALA)-ConjE →

An antibody comprising:

- a heavy chain comprising the amino acid sequence of SEQ ID NO.1103;
 - a light chain comprising the amino acid sequence of SEQ ID NO.151;
 - a VH domain; and
 - a VL domain;
- conjugated to Compound E at C103 of SEQ ID NO.1103.

The VH and VL domains present in the AbLJ-ConjE conjugate were identical to those present in the AbLJ(LALA)-ConjE conjugate.

Rat toxicology study observations ¹		AbLJ-ConjE (2 mg/kg)	AbLJ(LALA)-ConjE (2 mg/kg)
Clinical observations		Moderate raised hair / hunched posture & pale extremities	Mild raised hair / hunched posture
Bodyweight gain ²		-78%	-45%
Haematology ³			
	Reticulocytes	-93%	-56%
	Platelets	-72%	-60%
	Neutrophils	-98%	-97%
	Anemia	Minimal	Minimal
Organ weights ⁴			
	Liver	-23%	-12%
	Lung	+16%	+16%
	Thymus	-81%	-73%
	Spleen	-41%	-33%
	Kidney	-27%	-17%
	Testis	-23%	-19%

¹ 21 day study, single dose on day 1 (male SD rats)

² associated with reduced food intake

³ nadir on day 8, trending towards recovery by day 21

⁴ absolute organ weights

The results indicate that mutation of the residues at Kabat EU positions 234 and 235 substantially improves ADC tolerability.

Example 6

Pharmacokinetics of different site-specific conjugates .

The effect of the mutation of the residues at Kabat EU positions 234 and 235 on the pharmacokinetics was investigated. AbLJ-ConjE and AbLJ(LALA)-ConjE as described above in Example 5 were used.

Rats were dosed with 2 mg/kg of ADC and serum samples were taken frequently until day 20. A fit-for-purpose ELISA was developed for measuring conjugated antibody. Calibration curve, QCs and study samples were diluted in a low adhesion plate and added to a plate coated with a mouse monoclonal antibody directed against anti-SG3249 . After incubation and washing, the plate was incubated with a mouse monoclonal antibody to human Fc-HRP conjugated.

As substrate, 3,3',5,5'-Tetramethylbenzidine (TMB) was used, the reaction stopped with 1M HCl and the plate read at 450 nm absorbance at a Versamax plate reader. The Lower Limit Of Quantification (LLOQ) was 750 ng/ml in rat serum. All samples were measured using the PBD-ADC specific assay and the measured terminal half-lives (mean of three animals) for AbLJ(LALA)-ConjE and AbLJ-ConjE were calculated using Phoenix 64 WinNonlin 6.4 (Pharsight) software.

Results

ADC	Terminal Half life (h)
AbLJ(LALA)-ConjE	306.3
AbLJ-ConjE	200.1

The results indicate that mutation of the residues at Kabat EU positions 234 and 235 substantially improves ADC terminal half-life.

Example 7**Reduced systemic toxicity**

AbCJ specific for human PSMA, was engineered to contain a cysteine instead of a serine at position 442 (designated as AbCJ591) and conjugated to drug-linkers ConjH and ConjE.


The toxicity of AbCJ591-ConjH and AbCJ591-ConjE in cynomolgus monkey was compared to that of AbBJ591-ConjE (as described above in Example 2).

The study used three cynomolgus monkeys per group (males or females), the monkeys being approximately 3 years old (4 kg) at dosing. All animals were dosed once on day 1, with data presented up to day 22 for surviving animals.

Results

Due to adverse clinical signs, including bleeding associated with marked platelet depletion, animals were either found dead or euthanised early with AbCJ591-ConjH (by day 13) and with AbCJ591-ConjE (by day 16); see Figure 1. AbBJ591-ConjE did not induce significant platelet depletion and monkeys received a second dose at day 21.

Example 7



(a) **(S)**-7-methoxy-8-(3-(((**S**)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl trifluoromethanesulfonate (**82**)

Pd(PPh₃)₄ (20.6 mg, 0.018 mmol) was added to a stirred mixture of the bis-enol triflate **12** (500 mg, 0.44 mmol) (Compound 8a in WO 2010/043880), N-methyl piperazine boronic ester (100 mg, 0.4 mmol), Na₂CO₃ (218 mg, 2.05 mmol), MeOH (2.5 mL), toluene (5 mL) and water (2.5 mL). The reaction mixture was allowed to stir at 30°C under a nitrogen

atmosphere for 24 hours after which time all the boronic ester has consumed. The reaction mixture was then evaporated to dryness before the residue was taken up in EtOAc (100 mL) and washed with H₂O (2 x 50 mL), brine (50 mL), dried (MgSO₄), filtered and evaporated under reduced pressure to provide the crude product. Purification by flash chromatography (gradient elution: 80:20 v/v Hexane/EtOAc to 60:40 v/v Hexane/EtOAc) afforded product **82** as a yellowish foam (122.6 mg, 25%).

LC/MS 3.15 min (ES+) *m/z* (relative intensity) 1144 ([*M* + H]⁺, 20%).

(b) (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-1-((4-((*S*)-7-methoxy-8-(3-(((*S*)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-8-yl)oxy)propoxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (**83**)

PBD-triflate **82** (359 mg, 0.314 mmol), boronic pinacol ester **20** (250 mg, 0.408 mmol) (Compound 20 in WO 2014/057073) and triethylamine (0.35 mL, 2.51 mmol) were dissolved in a mixture of toluene/MeOH/H₂O, 2:1:1 (3 mL). The microwave vessel was purged and filled with argon three times before *tetrakis*(triphenylphosphine)palladium(0) (21.7 mg, 0.018 mmol) was added and the reaction mixture placed in the microwave at 80°C for 10 minutes. Subsequently, CH₂Cl₂ (100 mL) was added and the organics were washed with water (2 x 50 mL) and brine (50 mL) before being dried with MgSO₄, filtered and the volatiles removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel chromatography column (CHCl₃/MeOH, 100% to 9:1) to afford pure **83** (200 mg, 43% yield). LC/MS 3.27 min (ES+) *m/z* (relative intensity) 1478 ([*M* + H]⁺, 100%).

(c) (9*H*-fluoren-9-yl)methyl ((*S*)-1-(((*S*)-1-((4-((*S*)-7-methoxy-8-(3-(((*S*)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5-oxo-5,11a-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-8-yl)oxy)propoxy)-5-oxo-5,11a-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (**84**)

A solution of Super-Hydride® (0.34 mL, 1M in THF) was added dropwise to a solution of SEM-dilactam **83** (200 mg, 0.135 mmol) in THF (5 mL) at -78°C under an argon atmosphere. The addition was completed over 5 minutes in order to maintain the internal temperature of the reaction mixture constant. After 20 minutes, an aliquot was quenched with water for LC/MS analysis, which revealed that the reaction was complete. Water (20 mL) was added to the reaction mixture and the cold bath was removed. The organic layer was extracted with EtOAc (3 x 30 mL) and the combined organics were washed with brine (50 mL), dried with MgSO₄, filtered and the solvent removed by rotary evaporation under reduced pressure. The crude product was dissolved in MeOH (6 mL), CH₂Cl₂ (3 mL), water (1 mL) and enough

silica gel to form a thick stirring suspension. After 5 days, the suspension was filtered through a sintered funnel and washed with CH₂Cl₂/MeOH (9:1) (100 mL) until the elution of the product was complete. The organic layer was washed with brine (2 x 50 mL), dried with MgSO₄, filtered and the solvent removed by rotary evaporation under reduced pressure. Purification by silica gel column chromatography (100% CHCl₃ to 96% CHCl₃/ 4% MeOH) afforded the product **84** as a yellow solid (100 mg, 63%). LC/MS 2.67 min (ES+) *m/z* (relative intensity) 1186 ([*M* + H]⁺, 5%).


(d) **(S)**-2-amino-N-((**S**)-1-((4-((**R**)-7-methoxy-8-(3-(((**R**)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5-oxo-5,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5-oxo-5,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)-3-methylbutanamide (**85**)

Excess piperidine was added (0.1 mL, 1 mmol) to a solution of PBD **84** (36.4 mg, 0.03 mmol) in DMF (0.9 mL). The mixture was allowed to stir at room temperature for 20 min, at which point the reaction had gone to completion (as monitored by LC/MS). The reaction mixture was diluted with CH₂Cl₂ (50 mL) and the organic phase was washed with H₂O (3 x 50 mL) until complete piperidine removal. The organic phase was dried over MgSO₄, filtered and excess solvent removed by rotary evaporation under reduced pressure to afford crude product **85** which was used as such in the next step. LC/MS 2.20 min (ES+) *m/z* (relative intensity) 964 ([*M* + H]⁺, 5%).

(e) 1-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)-N-((2S)-1-(((2S)-1-((4-(7-methoxy-8-(3-((7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)propoxy)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-amide (**86**)

EDCI hydrochloride (8 mg, 0.042 mmol) was added to a suspension of Maleimide-PEG₈-acid (25 mg, 0.042 mmol) in dry CH₂Cl₂ (4 mL) under argon atmosphere. PBD **85** (42 mg, crude) was added straight away and stirring was maintained until the reaction was complete (3 hours). The reaction was diluted with CH₂Cl₂ and the organic phase was washed with H₂O and brine before being dried over MgSO₄, filtered and excess solvent removed by rotary evaporation under reduced pressure by rotary evaporation under reduced pressure. The product was purified by careful silica gel chromatography (slow elution starting with 100% CHCl₃ up to 9:1 CHCl₃/MeOH) followed by reverse phase HPLC to remove unreacted maleimide-PEG₈-acid. The product **86** was isolated in 10% over two steps (6.6 mg). LC/MS 1.16 min (ES+) *m/z* (relative intensity) 770.20 ([*M* + 2H]⁺, 40%).


Example 8 – alternative synthesis of compound 83



(9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-(4-((S)-7-methoxy-8-(3-(((S)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)propoxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (**83**)

PBD-triflate **21** (469 mg, 0.323 mmol) (Compound 21 in WO 2014/057073), boronic pinacol ester (146.5 mg, 0.484 mmol) and Na₂CO₃ (157 mg, 1.48 mmol) were dissolved in a mixture of toluene/MeOH/H₂O, 2:1:1 (10 mL). The reaction flask was purged with argon three times before *tetrakis*(triphenylphosphine)palladium(0) (7.41 mg, 0.0064 mmol) was added and the reaction mixture heated to 30°C overnight. The solvents were removed under reduced pressure and the residue was taken up in H₂O (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organics were washed with brine (100 mL), dried with MgSO₄, filtered and the volatiles removed by rotary evaporation under reduced pressure. The crude product was purified by silica gel column chromatography (CHCl₃ 100% to CHCl₃/MeOH 95%:5%) to afford pure **83** in 33% yield (885 mg). LC/MS 3.27 min (ES+) *m/z* (relative intensity) 1478 ([M + H]⁺, 100%).

Example 9



(a) *(S)*-7-methoxy-8-(((*S*)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl trifluoromethanesulfonate (**88**)

Pd(PPh₃)₄ (30 mg, 26 μmol) was added to a stirred mixture of the bis-enol triflate **87** (1 g, 0.87 mmol)(Compound 8b in WO 2010/043880), 4-(4-methylpiperazin-1-yl)phenylboronic acid, pinacol ester (264 mg, 0.87 mmol), Na₂CO₃ (138 mg, 1.30 mmol), EtOH (5 mL), toluene (10 mL) and water (5 mL). The reaction mixture was allowed to stir under a nitrogen atmosphere overnight at room temperature after which time the complete consumption of starting material was observed by TLC (EtOAc) and LC/MS (1.52 min (ES+) *m/z* (relative intensity) 1171.40 ([*M* + H]⁺, 100)). The reaction mixture was diluted with EtOAc (400 mL) and washed with H₂O (2 x 300 mL), brine (200 mL), dried (MgSO₄), filtered and evaporated

under reduced pressure to provide the crude product. Purification by flash chromatography (gradient elution: 100:0 v/v EtOAc/MeOH to 85:15 v/v EtOAc/MeOH) afforded the asymmetrical triflate **88** (285 mg, 28%). ¹H NMR (400 MHz, CDCl₃) δ 7.39 (s, 1H), 7.37 – 7.29 (m, 4H), 7.23 (d, J = 2.8 Hz, 2H), 7.14 (t, J = 2.0 Hz, 1H), 6.89 (d, J = 9.0 Hz, 2H), 5.54 (d, J = 10.0 Hz, 2H), 4.71 (dd, J = 10.0, 2.6 Hz, 2H), 4.62 (td, J = 10.7, 3.5 Hz, 2H), 4.13 – 4.01 (m, 4H), 3.97 – 3.87 (m, 8H), 3.85 – 3.75 (m, 2H), 3.74 – 3.63 (m, 2H), 3.31 – 3.22 (m, 4H), 3.14 (tdd, J = 16.2, 10.8, 2.2 Hz, 2H), 2.73 – 2.56 (m, 4H), 2.38 (d, J = 2.4 Hz, 3H), 2.02 – 1.92 (m, 4H), 1.73 (dd, J = 9.4, 6.0 Hz, 2H), 1.04 – 0.90 (m, 4H), 0.05 – -0.00 (m, 18H). MS (ES⁺) *m/z* (relative intensity) 1171.40 ([M + H]⁺, 100).

(b) (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-((S)-7-methoxy-8-((5-(((S)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-5,11-dioxo-10-((2-(trimethylsilyl)ethoxy)methyl)-5,10,11,11a-tetrahydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (**89**)

Pd(PPh₃)₄ (8 mg, 7 μmol) was added to a stirred mixture of the asymmetrical triflate **88** (269 mg, 0.23 mmol), Fmoc-Val-Ala-4-aminophenylboronic acid, pinacol ester **20** (210 mg, 0.34 mmol), Na₂CO₃ (36.5 mg, 0.34 mmol), EtOH (5 mL), toluene (10 mL), THF (1 mL), and water (5 mL). The reaction mixture was allowed to stir under a nitrogen atmosphere at 35°C for 2 hours after which time the complete consumption of starting material was observed by TLC (80:20 v/v EtOAc/MeOH) and LC/MS (1.68 min (ES⁺) *m/z* (relative intensity) 1508.10 ([M + H]⁺, 100)). The reaction mixture was diluted with EtOAc (100 mL) and washed with H₂O (1 x 100 mL), brine (200 mL), dried (MgSO₄), filtered and evaporated under reduced pressure to provide the crude product. Purification by flash chromatography (gradient elution: 100:0 v/v EtOAc/MeOH to 80:20 v/v EtOAc/MeOH) afforded the SEM protected dimer **89** (240 mg, 69%). ¹H NMR (400 MHz, CDCl₃) δ 8.42 (s, 1H), 7.76 (d, J = 7.5 Hz, 2H), 7.63 – 7.49 (m, 4H), 7.45 – 7.28 (m, 9H), 7.25 (d, J = 2.9 Hz, 1H), 6.87 (t, J = 14.0 Hz, 2H), 6.41 (s, 1H), 5.63 – 5.49 (m, 2H), 5.25 (s, 1H), 4.71 (d, J = 10.1 Hz, 2H), 4.68 – 4.57 (m, 2H), 4.49 (d, J = 6.7 Hz, 2H), 4.20 (s, 1H), 4.16 – 4.02 (m, 4H), 4.00 – 3.87 (m, 7H), 3.86 – 3.61 (m, 7H), 3.30 – 3.21 (m, 4H), 3.19 – 3.05 (m, 2H), 2.69 – 2.54 (m, 4H), 2.37 (s, 3H), 2.04 – 1.92 (m, 4H), 1.91 – 1.79 (m, 4H), 1.72 (s, 2H), 1.46 (d, J = 6.9 Hz, 3H), 1.04 – 0.82 (m, 8H), 0.04 – -0.02 (m, 18H). MS (ES⁺) *m/z* (relative intensity) 1508.10 ([M + H]⁺, 100).

(c) (9H-fluoren-9-yl)methyl ((S)-1-(((S)-1-((4-((S)-7-methoxy-8-((5-(((S)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)carbamate (**90**)

Super hydride (0.358 mL, 0.358 mmol, 1.0 M in THF) was added dropwise to a stirred solution of the SEM-tetralactam **89** (216 mg, 0.143 mmol) in anhydrous THF (10 mL) at -78°C. The reaction mixture was allowed to stir for 3 hours after which time the complete conversion of starting material directly was observed by LC/MS (1.37 min (ES+) *m/z* (relative intensity) 608.15 ($([M + 2H]^{2+})/2$, 100)). The reaction mixture was carefully diluted with H₂O (100 mL) and extracted with DCM (100 mL). The organic layers was washed with brine (100 mL), dried over MgSO₄, filtered and evaporated under reduced pressure to provide the intermediate SEM-carbinolamine. The white solids were immediately dissolved in MeOH (100 mL), DCM (10 mL) and H₂O (20 mL) and treated with flash silica gel (50 g). The thick suspension was allowed to stir at room temperature for 4 days after which time the formation of a significant quantity of desired product was observed by TLC (90:10 v/v CHCl₃/MeOH). The reaction mixture was filtered through a porosity 3 sinter funnel and the pad rinsed slowly and thoroughly with 90:10 v/v CHCl₃/MeOH until no further product eluted (checked by TLC). The filtrate was washed with brine (100 mL), dried (MgSO₄), filtered and evaporated *in vacuo*, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 98:2 v/v CHCl₃/MeOH to 88:12 v/v CHCl₃/MeOH) gave **90** as a mixture of carbinolamine ethers and imine (80 mg, 46%).
¹H NMR (400 MHz, CDCl₃) δ 8.52 (s, 1H), 7.87 (d, J = 3.9 Hz, 2H), 7.75 (d, J = 7.5 Hz, 2H), 7.66 – 7.26 (m, 12H), 6.90 (d, J = 8.8 Hz, 2H), 6.81 (s, 1H), 6.64 (d, J = 6.0 Hz, 1H), 5.37 (d, J = 5.7 Hz, 1H), 4.74 – 4.58 (m, 2H), 4.54 – 4.31 (m, 4H), 4.26 – 3.98 (m, 6H), 3.94 (s, 2H), 3.86 (dd, J = 13.6, 6.6 Hz, 1H), 3.63 – 3.48 (m, 2H), 3.37 (dd, J = 16.5, 5.6 Hz, 2H), 3.31 – 3.17 (m, 4H), 2.66 – 2.51 (m, 4H), 2.36 (s, 3H), 2.16 (d, J = 5.1 Hz, 1H), 2.06 – 1.88 (m, 4H), 1.78 – 1.55 (m, 6H), 1.46 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.8 Hz, 6H). MS (ES⁺) *m/z* (relative intensity) 608.15 ($([M + 2H]^{2+})/2$, 100).


(d) 1-(3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)-N-((S)-1-(((S)-1-((4-((S)-7-methoxy-8-(((S)-7-methoxy-2-(4-(4-methylpiperazin-1-yl)phenyl)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)pentyl)oxy)-5-oxo-5,11a-dihydro-1H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-2-yl)phenyl)amino)-1-oxopropan-2-yl)amino)-3-methyl-1-oxobutan-2-yl)-3,6,9,12,15,18,21,24-octaoxaheptacosan-27-amide (**91**)

Piperidine (0.2 mL) was added to a solution of **90** (77 mg, 63.4 μmol) in DMF (1 mL). The reaction mixture was allowed to stir for 20 minutes. The reaction mixture was carefully diluted with DCM (50 mL) and washed with water (50 mL). The organic layers was washed with brine (100 mL), dried over MgSO₄, filtered and evaporated under reduced pressure to provide the unprotected valine intermediate. The crude residue was immediately redissolved in chloroform (5 mL). Mal(Peg)₈-acid (56 mg, 95 μmol) and EDCI (18 mg, 95 μmol) were added, followed by methanol (0.1 mL). The reaction was allowed to stir for 3

hours at room temperature at which point completion was observed by TLC and LC/MS (1.19 min (ES+) m/z (relative intensity) 784.25 ($([M + 2H]^{2+})/2$, 100)). The reaction mixture was diluted with chloroform (50 mL), washed with water (100 mL), dried ($MgSO_4$), filtered and evaporated *in vacuo*, followed by high vacuum drying, to provide the crude product. Purification by flash chromatography (gradient elution: HPLC grade 96:4 v/v $CHCl_3/MeOH$ to 90:10 v/v $CHCl_3/MeOH$) gave **91** as a yellow solid (43 mg, 43%). 1H NMR (400 MHz, $CDCl_3$) δ 8.73 (s, 1H), 7.88 (dd, $J = 7.6, 3.9$ Hz, 2H), 7.75 (d, $J = 8.6$ Hz, 2H), 7.52 (d, $J = 2.0$ Hz, 2H), 7.44 (s, 1H), 7.40 – 7.28 (m, 4H), 6.91 (d, $J = 8.8$ Hz, 2H), 6.81 (s, 2H), 6.69 (s, 2H), 6.48 (s, 1H), 4.72 – 4.63 (m, 1H), 4.46 – 4.34 (m, 2H), 4.25 – 4.03 (m, 6H), 3.95 (s, 4H), 3.84 (dd, $J = 17.2, 10.1$ Hz, 4H), 3.72 – 3.46 (m, 30H), 3.44 – 3.32 (m, 4H), 3.30 – 3.20 (m, 4H), 2.75 – 2.63 (m, 1H), 2.59 (s, 4H), 2.55 – 2.43 (m, 3H), 2.37 (s, 3H), 2.29 (dd, $J = 12.7, 6.7$ Hz, 1H), 2.03 – 1.89 (m, 4H), 1.72 (d, $J = 22.7$ Hz, 8H), 1.46 (d, $J = 7.2$ Hz, 3H), 1.01 (dd, $J = 11.5, 6.9$ Hz, 6H). MS (ES+) m/z (relative intensity) 784.25 ($([M + 2H]^{2+})/2$, 100).

Example 10

(i) *(S)*-((pentane-1,5-diylbis(oxy))bis(2-amino-5-methoxy-4,1-phenylene))bis(((*S*)-2-(((*tert*-butyldimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrol-1-yl)methanone) (**98**)



(a) *(S,R)*-((pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((2*S*,4*R*)-2-(((*tert*-butyldimethylsilyl)oxy)methyl)-4-hydroxypyrrolidin-1-yl)methanone) (**94**)

Anhydrous DMF (approx. 0.5 mL) was added dropwise to a stirred suspension of 4,4'-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitrobenzoic acid) (**92**) (36.64 g, 74.0 mmol) and oxalyl chloride (18.79 mL, 0.222 mol, 3.0 eq.) in anhydrous DCM (450 mL) until vigorous effervescence occurred and the reaction mixture was left to stir overnight. The reaction mixture was evaporated to dryness, and triturated with diethyl ether. The resulting yellow precipitate was filtered from solution, washed with diethyl ether (100 mL) and immediately added to a solution of (3*R*,5*S*)-5-((*tert*-butyldimethylsilyloxy)methyl) pyrrolidin-3-ol (**93**) (39.40 g, 0.170 mol, 2.3 eq.) and anhydrous triethylamine (82.63 mL, 0.592 mol, 8 eq.) in

anhydrous DCM (400 mL) at -40°C. The reaction mixture was allowed to slowly warm to room temperature (over 2.5 hours) after which, LCMS analysis indicated complete reaction. DCM (250 mL) was added and the mixture was transferred into a separating funnel. The organic layer was washed successively with 0.1M HCl (2 x 800 mL), saturated NaHCO₃ (500 mL) and brine (300 mL). After drying over MgSO₄ and filtration, evaporation of the solvent left the product as a yellow foam (62.8 g, 92%). LC/MS: RT 1.96 min; MS (ES+) *m/z* (relative intensity) 921.45 ([M+H]⁺, 100).

(b) (5S,5'S)-1,1'-(4,4'-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(5-(((tert-butyl)dimethylsilyl)oxy)methyl)pyrrolidin-3-one (95)

Trichloroisocyanuric acid (21.86 g, 94.07 mmol, 1.4 eq) was added in one portion to a solution of diol **94** (61.90 g, 67.20 mmol) and TEMPO (2.10 g, 13.44 mmol, 0.2 eq) in anhydrous DCM (500 mL) under an atmosphere of argon at 0°C. The reaction mixture was stirred at 0°C for 20 minutes after which, LCMS analysis of the reaction mixture showed complete reaction. The reaction mixture was diluted with DCM (400 mL) and washed with saturated sodium bicarbonate (500 mL), 0.2 M sodium thiosulfate solution (600 mL), brine (400 mL) and dried (MgSO₄). Evaporation of the solvent gave the crude product. Flash chromatography [gradient elution 80% n-hexane/20% ethyl acetate to 100% ethyl acetate] gave pure **95** as yellow solid (49.30 g, 80%). LC/MS: RT 2.03 min; MS (ES+) *m/z* (relative intensity) 917.55 ([M+H]⁺, 100).

(c) (5S,5'S)-1,1'-(4,4'-(pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitrobenzoyl))bis(5-(((tert-butyl)dimethylsilyl)oxy)methyl)-4,5-dihydro-1H-pyrrole-3,1-diyl) bis(trifluoromethanesulfonate), (96)

Triflic anhydride (24.19 mL, 0.144 mol, 6.0 eq) was added dropwise to a vigorously stirred solution of bis-ketone **95** (21.98 g, 23.96 mmol) in anhydrous DCM (400 mL) containing 2,6-lutidine (22.33 mL, 0.192 mol, 8.0 eq) at -40 °C. The reaction mixture was stirred at -40 °C for 30 min after which, LCMS analysis indicated complete reaction. Reaction mixture was rapidly diluted with DCM (500 mL) and washed with ice-cold water (600 mL), ice-cold saturated sodium bicarbonate (400 mL) and brine (500 mL), dried over MgSO₄, filtered and evaporated to leave a crude brown oil. Flash chromatography [gradient elution 80% n-hexane/20% ethyl acetate to 66% n-hexane/33% ethyl acetate] gave pure **96** as a brown foam (16.40 g, 58%). LC/MS: RT 2.28 min; MS (ES+) *m/z* (relative intensity) no data.


(d) (S)-((pentane-1,5-diylbis(oxy))bis(5-methoxy-2-nitro-4,1-phenylene))bis(((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrol-1-yl)methanone (97)

Triflate **96** (5.06 g, 4.29 mmol), methyl boronic acid (1.80 g, 30.00 mmol, 7 eq) and triphenylarsine (1.05 g, 3.43 mmol, 0.8 eq) were dissolved in anhydrous dioxane and stirred under argon. Pd (II) bisbenzotrile chloride was then added and the reaction mixture heated rapidly to 80 °C for 20 min. Reaction mixture cooled, filtered through Celite (washed through with ethyl acetate), filtrate washed with water (500 mL), brine (500 mL), dried over MgSO₄, filtered and evaporated. Flash chromatography [gradient elution 50% n-hexane/50% ethyl acetate] gave pure **97** as a brown foam (4.31 g, 59%). LC/MS: RT 2.23 min; MS (ES+) *m/z* (relative intensity) 913.50 ([M+H]⁺, 100).

(e) *(S)-((pentane-1,5-diylbis(oxy))bis(2-amino-5-methoxy-4,1-phenylene))bis(((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrol-1-yl)methanone* (**98**)

Zinc dust (26.48 g, 0.405 mol, 36.0 eq) was added in one portion to a solution of bis-nitro compound **97** (10.26 g, 11.24 mmol) in 5% formic acid / methanol (200 mL) keeping the temperature between 25-30°C with the aid of a cold water bath. The reaction was stirred at 30°C for 20 minutes after which, LCMS showed complete reaction. The reaction mixture was filtered through Celite to remove the excess zinc, which was washed with ethyl acetate (600 mL). The organic fractions were washed with water (500 mL), saturated sodium bicarbonate (500 mL) and brine (400 mL), dried over MgSO₄ and evaporated. Flash chromatography [gradient elution 100% chloroform to 99% chloroform/1% methanol] gave pure **98** as an orange foam (6.22 g, 65%). LC/MS: RT 2.20 min; MS (ES+) *m/z* (relative intensity) 853.50 ([M+H]⁺, 100).

(ii) 4-((R)-2-((R)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl 4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl ((S)-((pentane-1,5-diylbis(oxy))bis(2-((S)-2-(hydroxymethyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxy-5,1-phenylene))dicarbamate (**103**)



(a) Allyl (5-((5-(5-amino-4-((S)-2-(((tert-butylidimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-2-methoxyphenoxy)pentyl)oxy)-2-((S)-2-(((tert-butylidimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxyphenyl)carbamate (**99**)

Pyridine (1.156 mL, 14.30 mmol, 1.5 eq) was added to a solution of the bis-aniline **98** (8.14 g, 9.54 mmol) in anhydrous DCM (350 mL) at -78°C under an atmosphere of argon. After 5 minutes, allyl chloroformate (0.911 mL, 8.58 mmol, 0.9 eq) was added and the reaction mixture allowed to warm to room temperature. The reaction mixture was diluted with DCM (250 mL), washed with saturated CuSO_4 solution (400 mL), saturated sodium bicarbonate (400 mL) and brine (400 mL), dried over MgSO_4 . Flash chromatography [gradient elution 66% n-hexane/33% ethyl acetate to 33% n-hexane/66% ethyl acetate] gave pure **99** as an

orange foam (3.88 g, 43%). LC/MS: RT 2.27 min; MS (ES+) *m/z* (relative intensity) 937.55 ([M+H]⁺, 100).

(b) *Allyl 4-((10S,13S)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl ((S)-(pentane-1,5-diylbis(oxy))bis(2-((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxy-5,1-phenylene))dicarbamate (100)*

Triethylamine (0.854 mL, 6.14 mmol, 2.2 eq) was added to a stirred solution of the aniline **99** (2.62 g, 2.79 mmol) and triphosgene (0.30 g, 1.00 mmol, 0.36 eq) in anhydrous THF (50 mL) under argon 0°C. The reaction mixture was stirred at room temperature for 5 minutes. LCMS analysis of an aliquot quenched with methanol, showed formation of the isocyanate. A solution of mPEG₂-Val-Ala-PAB-OH (1.54 g, 3.63 mmol, 1.3 eq) and triethylamine (0.583 mL, 4.19 mmol, 1.5 eq) in dry THF (50 mL) was added in one portion and the resulting mixture was stirred overnight at 40°C. The solvent of the reaction mixture was evaporated leaving a crude product. Flash chromatography [gradient elution 100% chloroform to 98% chloroform/2% methanol] gave pure **100** as a light orange solid (2.38 g, 62%). LC/MS: RT 2.29 min; MS (ES+) *m/z* (relative intensity) no data.

(c) *4-((10S,13S)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl (5-((5-(5-amino-4-((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-2-methoxyphenoxy)pentyl)oxy)-2-((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxyphenyl)carbamate (101)*

Tetrakis(triphenylphosphine)palladium (39 mg, 0.034 mmol, 0.02 eq) was added to a stirred solution of **100** (2.35 g, 1.69 mmol) and pyrrolidine (0.35 mL, 4.24 mmol, 2.5 eq) in anhydrous DCM (25 mL) under argon at room temperature. Reaction mixture allowed to stir for 45 min then diluted with DCM (100 mL), washed with saturated ammonium chloride solution (100mL), brine (100mL), dried over MgSO₄, filtered and evaporated. Flash chromatography [gradient elution 100% chloroform to 95% chloroform/5% methanol] gave pure **101** as a yellow solid (1.81 g, 82%). LC/MS: RT 2.21 min; MS (ES+) *m/z* (relative intensity) 1303.65 ([M+H]⁺, 100).


(d) *4-((R)-2-((R)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl 4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl ((S)-(pentane-1,5-diylbis(oxy))bis(2-((S)-2-(((tert-butyl)dimethylsilyl)oxy)methyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxy-5,1-phenylene))dicarbamate (102)*

Triethylamine (0.419 mL, 3.01 mmol, 2.2 eq) was added to a stirred solution of the aniline **101** (1.78 g, 1.37 mmol) and triphosgene (0.15 g, 0.49 mmol, 0.36 eq) in anhydrous THF (50 mL) under argon 0 °C. The reaction mixture was stirred at room temperature for 5 min. LCMS analysis of an aliquot quenched with methanol, showed formation of the isocyanate. A solution of Alloc-Val-Ala-PAB-OH (0.67 g, 1.78 mmol, 1.3 eq) and triethylamine (0.29 mL, 2.05 mmol, 1.5 eq) in dry THF (45 mL) was added in one portion and the resulting mixture was stirred overnight at 40 °C. The solvent of the reaction mixture was evaporated leaving a crude product. Flash chromatography [gradient elution 100% ethyl acetate to 97% ethyl acetate/3% methanol] gave pure **102** as a pale yellow solid (1.33 g, 57%). LC/MS: RT 2.21 min; MS (ES+) *m/z* (relative intensity) no data.

(e) 4-((R)-2-((R)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl 4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl ((S)-(pentane-1,5-diylbis(oxy))bis(2-((S)-2-(hydroxymethyl)-4-methyl-2,3-dihydro-1H-pyrrole-1-carbonyl)-4-methoxy-5,1-phenylene))dicarbamate (103)

Tetra-*n*-butylammonium fluoride (1 M, 1.52 mL, 1.52 mmol, 2.0 eq) was added to a solution of the TBS protected compound **102** (1.30 g, 0.76 mmol) in anhydrous THF (15 mL). The reaction mixture was stirred at room temperature for 4 hours. The reaction mixture was diluted with chloroform (100 mL) and washed sequentially with water (40 mL) and brine (40 mL). The organic phase was dried over MgSO₄ and evaporated to leave a yellow solid. Flash chromatography [gradient elution 95% ethyl acetate/5% methanol to 90% ethyl acetate/10% methanol] gave pure **103** as a pale yellow solid (1.00 g, 89%). LC/MS: RT 1.60 min; MS (ES+) *m/z* (relative intensity) 1478.45 (100).

(iii) (11S,11aS)-4-((2R,5R)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl 11-hydroxy-8-((5-(((11S,11aS)-11-hydroxy-10-(((4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl)oxy)carbonyl)-7-methoxy-2-methyl-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)pentyl)oxy)-7-methoxy-2-methyl-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (106)



(a) (11*S*,11*aS*)-4-((*R*)-2-((*R*)-2-(((allyloxy)carbonyl)amino)-3-methylbutanamido)propanamido)benzyl 11-hydroxy-8-((5-(((11*S*,11*aS*)-11-hydroxy-10-(((4-((10*R*,13*R*)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl)oxy)carbonyl)-7-methoxy-2-methyl-5-oxo-5,10,11,11*a*-tetrahydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepin-8-yl)oxy)pentyl)oxy)-7-methoxy-2-methyl-5-oxo-11,11*a*-dihydro-1*H*-pyrrolo[2,1-*c*][1,4]benzodiazepine-10(5*H*)-carboxylate (**104**)

Dess-Martin periodinane (0.59 g, 1.38 mmol, 2.1 eq) was added to a stirred solution of **103** (0.97 g, 0.66 mmol) in anhydrous DCM under argon at room temperature. The reaction mixture was allowed to stir for 4 hours. Reaction mixture diluted with DCM (100 mL), washed with saturated sodium bicarbonate solution (3 x 100 mL), water (100 mL), brine (100 mL), dried over MgSO₄, filtered and evaporated. Flash chromatography [gradient elution 100% chloroform to 95% chloroform/5% methanol] gave pure **104** as a pale yellow solid (0.88 g, 90%). LC/MS: RT 1.57 min; MS (ES⁺) *m/z* (relative intensity) 1473.35 (100).

(b) (11S,11aS)-4-((R)-2-((R)-2-amino-3-methylbutanamido)propanamido)benzyl 11-hydroxy-8-((5-(((11S,11aS)-11-hydroxy-10-(((4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl)oxy)carbonyl)-7-methoxy-2-methyl-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)pentyl)oxy)-7-methoxy-2-methyl-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (**105**)

Tetrakis(triphenylphosphine)palladium (5 mg, 0.004 mmol, 0.06 eq) was added to a solution of **104** (105 mg, 0.071 mmol) and pyrrolidine (7 μ L, 0.086 mmol, 1.2 eq) in anhydrous DCM (5 mL). The reaction mixture was stirred 15 minutes then diluted with chloroform (50 mL) and washed sequentially with saturated aqueous ammonium chloride (30 mL) and brine (30 mL). The organic phase was dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% chloroform to 90% chloroform/10% methanol] gave pure **105** as a pale yellow solid (54 mg, 55%). LC/MS: RT 1.21 min; MS (ES+) *m/z* (relative intensity) 1389.50 (100).

(c) (11S,11aS)-4-((2R,5R)-37-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)-5-isopropyl-2-methyl-4,7,35-trioxo-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontanamido)benzyl 11-hydroxy-8-((5-(((11S,11aS)-11-hydroxy-10-(((4-((10R,13R)-10-isopropyl-13-methyl-8,11-dioxo-2,5-dioxa-9,12-diazatetradecanamido)benzyl)oxy)carbonyl)-7-methoxy-2-methyl-5-oxo-5,10,11,11a-tetrahydro-1H-pyrrolo[2,1-c][1,4]benzodiazepin-8-yl)oxy)pentyl)oxy)-7-methoxy-2-methyl-5-oxo-11,11a-dihydro-1H-pyrrolo[2,1-c][1,4]benzodiazepine-10(5H)-carboxylate (**106**)

N-(3-Dimethylaminopropyl)-N'-ethylcarbodiimide (28 mg, 0.146 mmol, 1 eq) was added to a solution of **105** (203 mg, 0.146 mmol) and maleimide-PEG₈ acid (87 mg, 0.146 mmol) in chloroform (5 mL). The reaction was stirred for 1.5 h then diluted with chloroform (50 mL), washed with water (50 mL), brine (30 mL), dried over magnesium sulphate, filtered and evaporated. Flash chromatography [gradient elution 100% DCM to 90% DCM/10% methanol] gave **106** as a pale yellow solid (205 mg, 72%). LC/MS: RT 5.75 min; MS (ES+) *m/z* (relative intensity) 982.90 (100), 1963.70 (5).

Example 11: Activity of released compoundsK562 assay



K562 human chronic myeloid leukaemia cells were maintained in RPM1 1640 medium supplemented with 10% fetal calf serum and 2 mM glutamine at 37°C in a humidified atmosphere containing 5% CO₂ and were incubated with a specified dose of drug for 1 hour or 96 hours at 37°C in the dark. The incubation was terminated by centrifugation (5 min, 300 g) and the cells were washed once with drug-free medium. Following the appropriate drug treatment, the cells were transferred to 96-well microtiter plates (10⁴ cells per well, 8 wells per sample). Plates were then kept in the dark at 37°C in a humidified atmosphere containing 5% CO₂. The assay is based on the ability of viable cells to reduce a yellow soluble tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2*H*-tetrazolium bromide (MTT, Aldrich-Sigma), to an insoluble purple formazan precipitate. Following incubation of the plates for 4 days (to allow control cells to increase in number by approximately 10 fold), 20 µL of MTT solution (5 mg/mL in phosphate-buffered saline) was added to each well and the plates further incubated for 5 h. The plates were then centrifuged for 5 min at 300 g and the bulk of the medium pipetted from the cell pellet leaving 10–20 µL per well. DMSO (200 µL) was added to each well and the samples agitated to ensure complete mixing. The optical density was then read at a wavelength of 550 nm on a Titertek Multiscan ELISA plate reader, and a dose-response curve was constructed. For each curve, an IC₅₀ value was read as the dose required to reduce the final optical density to 50% of the control value.

Abbreviations

Ac	acetyl
Acm	acetamidomethyl
Alloc	allyloxycarbonyl
Boc	di- <i>tert</i> -butyl dicarbonate
t-Bu	tert-butyl
Bzl	benzyl, where Bzl-OMe is methoxybenzyl and Bzl-Me is methylbenzene
Cbz or Z	benzyloxy-carbonyl, where Z-Cl and Z-Br are chloro- and bromobenzyloxy carbonyl respectively
DMF	<i>N,N</i> -dimethylformamide
Dnp	dinitrophenyl
DTT	dithiothreitol
Fmoc	9 <i>H</i> -fluoren-9-ylmethoxycarbonyl
imp	<i>N</i> -10 imine protecting group: 3-(2-methoxyethoxy)propanoate-Val-Ala-PAB
MC-OSu	maleimidocaproyl- <i>O</i> - <i>N</i> -succinimide
Moc	methoxycarbonyl
MP	maleimidopropanamide
Mtr	4-methoxy-2,3,6-trimethylbenzenesulfonyl
PAB	para-aminobenzyloxycarbonyl
PEG	ethyleneoxy
PNZ	<i>p</i> -nitrobenzyl carbamate
Psec	2-(phenylsulfonyl)ethoxycarbonyl
TBDMS	tert-butyldimethylsilyl
TBDPS	tert-butyldiphenylsilyl
Teoc	2-(trimethylsilyl)ethoxycarbonyl
Tos	tosyl
Troc	2,2,2-trichloroethoxycarbonyl chloride
Trt	trityl
Xan	xanthyl

Statements of Invention

1. A conjugate of formula L - (DL)_p, where DL is of formula I or II:





wherein:


L is an antibody (Ab) which binds PSMA;

when there is a double bond present between C2' and C3', R¹² is selected from the group consisting of:


- (ia) C₅₋₁₀ aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene;
- (ib) C₁₋₅ saturated aliphatic alkyl;
- (ic) C₃₋₆ saturated cycloalkyl;

- (id) , wherein each of R²¹, R²² and R²³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R¹² group is no more than 5;

- (ie) , wherein one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

(if) , where R²⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;

when there is a single bond present between C2' and C3',

R¹² is , where R^{26a} and R^{26b} are independently selected from H, F, C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C₁₋₄ alkyl amido and C₁₋₄ alkyl ester; or, when one of R^{26a} and R^{26b} is H, the other is selected from nitrile and a C₁₋₄ alkyl ester;

R⁶ and R⁹ are independently selected from H, R, OH, OR, SH, SR, NH₂, NHR, NRR', nitro, Me₃Sn and halo;

where R and R' are independently selected from optionally substituted C₁₋₁₂ alkyl, C₃₋₂₀ heterocyclyl and C₅₋₂₀ aryl groups;

R⁷ is selected from H, R, OH, OR, SH, SR, NH₂, NHR, NHRR', nitro, Me₃Sn and halo;

Rⁿ is a C₃₋₁₂ alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR^{N2} (where R^{N2} is H or C₁₋₄ alkyl), and/or aromatic rings, e.g. benzene or pyridine;

Y and Y' are selected from O, S, or NH;

R^{6'}, R^{7'}, R^{9'} are selected from the same groups as R⁶, R⁷ and R⁹ respectively;

[Formula I]

R^{L1'} is a linker for connection to the antibody (Ab);

R^{11a} is selected from OH, OR^A, where R^A is C₁₋₄ alkyl, and SO_zM, where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;

R²⁰ and R²¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R²⁰ is selected from H and R^C, where R^C is a capping group;


R²¹ is selected from OH, OR^A and SO_zM;


when there is a double bond present between C2 and C3, R² is selected from the group consisting of:


(ia) C₅₋₁₀ aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene;


(ib) C₁₋₅ saturated aliphatic alkyl;

(ic) C₃₋₆ saturated cycloalkyl;

- (id)  , wherein each of R¹¹, R¹² and R¹³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R² group is no more than 5;


- (ie)  , wherein one of R^{15a} and R^{15b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

- (if)  , where R¹⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; when there is a single bond present between C2 and C3,

- R² is  , where R^{16a} and R^{16b} are independently selected from H, F, C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C₁₋₄ alkyl amido and C₁₋₄ alkyl ester; or, when one of R^{16a} and R^{16b} is H, the other is selected from nitrile and a C₁₋₄ alkyl ester;


[Formula II]

R²² is of formula IIIa, formula IIIb or formula IIIc:




where A is a C₅₋₇ aryl group, and either

- (i) Q¹ is a single bond, and Q² is selected from a single bond and -Z-(CH₂)_n-, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
 (ii) Q¹ is -CH=CH-, and Q² is a single bond;



where;



R^{C1}, R^{C2} and R^{C3} are independently selected from H and unsubstituted C₁₋₂ alkyl;



(c)

where Q is selected from O-R^{L2'}, S-R^{L2'} and NR^N-R^{L2'}, and R^N is selected from H, methyl and ethyl

X is selected from the group comprising: O-R^{L2'}, S-R^{L2'}, CO₂-R^{L2'}, CO-R^{L2'}, NH-C(=O)-R^{L2'},

NHNH-R^{L2'}, CONHNH-R^{L2'}, , , NR^NR^{L2'}, wherein R^N is

selected from the group comprising H and C₁₋₄ alkyl;

R^{L2'} is a linker for connection to the antibody (Ab);

R¹⁰ and R¹¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;


R¹⁰ is H and R¹¹ is selected from OH, OR^A and SO₂M;

R³⁰ and R³¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R³⁰ is H and R³¹ is selected from OH, OR^A and SO₂M.

2. The conjugate according to statement 1, wherein the conjugate is not:


ConjA



ConjA

;


ConjB




ConjB

;


ConjC:



ConjD




ConjE:



3. The conjugate according to either statement 1 or statement 2, wherein R^7 is selected from H, OH and OR.
4. The conjugate according to statement 3, wherein R^7 is a C_{1-4} alkyloxy group.
5. The conjugate according to any one of statements 1 to 4, wherein Y is O.

6. The conjugate according to any one of the preceding statements, wherein R¹¹ is C₃₋₇ alkylene.
7. The conjugate according to any one of statements 1 to 6, wherein R⁹ is H.
8. The conjugate according to any one of statements 1 to 7, wherein R⁶ is selected from H and halo.
9. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₅₋₇ aryl group.
10. The conjugate according to statement 9, wherein R¹² is phenyl.
11. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₈₋₁₀ aryl group.
12. The conjugate according to any one of statements 9 to 11, wherein R¹² bears one to three substituent groups.
13. The conjugate according to any one of statements 9 to 12, wherein the substituents are selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl.
14. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₁₋₅ saturated aliphatic alkyl group.
15. A compound according to statement 14, wherein R¹² is methyl, ethyl or propyl.
16. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₃₋₆ saturated cycloalkyl group.
17. The conjugate according to statement 16, wherein R¹² is cyclopropyl.
18. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:




19. The conjugate according to statement 18, wherein the total number of carbon atoms in the R¹² group is no more than 4.

20. The conjugate according to statement 19, wherein the total number of carbon atoms in the R¹² group is no more than 3.


21. The conjugate according to any one of statements 18 to 20, wherein one of R²¹, R²² and R²³ is H, with the other two groups being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.

22. The conjugate according to any one of statements 18 to 20, wherein two of R²¹, R²² and R²³ are H, with the other group being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.


23. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:



24. The conjugate according to statement 23, wherein R¹² is the group:




25. The conjugate according to any one of statements 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:




26. The conjugate according to statement 25, wherein R²⁴ is selected from H, methyl, ethyl, ethenyl and ethynyl.

27. The conjugate according to statement 26, wherein R²⁴ is selected from H and methyl.


28. The conjugate according to any one of statements 1 to 8, wherein there is a single

bond between C2' and C3', R¹² is  and R^{26a} and R^{26b} are both H.

29. The conjugate according to any one of statements 1 to 8, wherein there is a single

bond between C2' and C3', R¹² is , and R^{26a} and R^{26b} are both methyl.

30. The conjugate according to any one of statements 1 to 8, wherein there is a single

bond between C2' and C3', R¹² is , one of R^{26a} and R^{26b} is H, and the other is selected from C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted.

[Formula I]

31. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a C₅₋₇ aryl group.

32. The conjugate according to statement 31, wherein R² is phenyl.


33. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R¹ is a C₈₋₁₀ aryl group.

34. A compound according to any one of statements 31 to 33, wherein R² bears one to three substituent groups.


35. The conjugate according to any one of statements 31 to 34, wherein the substituents are selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl.

36. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a C₁₋₅ saturated aliphatic alkyl group.


37. The conjugate according to statement 36, wherein R² is methyl, ethyl or propyl.
38. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a C₃₋₆ saturated cycloalkyl group.
39. The conjugate according to statement 38, wherein R² is cyclopropyl.
40. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:




41. The conjugate according to statement 40, wherein the total number of carbon atoms in the R² group is no more than 4.
42. The conjugate according to statement 41, wherein the total number of carbon atoms in the R² group is no more than 3.
43. The conjugate according to any one of statements 40 to 42, wherein one of R¹¹, R¹² and R¹³ is H, with the other two groups being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
44. The conjugate according to any one of statements 40 to 42, wherein two of R¹¹, R¹² and R¹³ are H, with the other group being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
45. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:



46. The conjugate according to statement 45, wherein R² is the group:




47. The conjugate according to any one of statements 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:




48. The conjugate according to statement 47, wherein R¹⁴ is selected from H, methyl, ethyl, ethenyl and ethynyl.

49. The conjugate according to statement 47, wherein R¹⁴ is selected from H and methyl.


50. The conjugate according to any one of statements 1 to 30, wherein there is a single

bond between C2 and C3, R² is  and R^{16a} and R^{16b} are both H.

51. The conjugate according to any one of statements 1 to 30, wherein there is a single

bond between C2 and C3, R² is , and R^{16a} and R^{16b} are both methyl.

52. The conjugate according to any one of statements 1 to 30, wherein there is a single

bond between C2 and C3, R² is , one of R^{16a} and R^{16b} is H, and the other is selected from C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted.


53. The conjugate according to any one of statements 1 to 52, wherein R^{11a} is OH.

54. The conjugate according to any one of statements 1 to 53, wherein R²¹ is OH.

55. The conjugate according to any one of statements 1 to 53, wherein R²¹ is OMe.

56. The conjugate according to any one of statements 1 to 55, wherein R²⁰ is H.
57. The conjugate according to any one of statements 1 to 55, wherein R²⁰ is R^C.
58. The conjugate according to statement 57, wherein R^C is selected from the group consisting of: Alloc, Fmoc, Boc, and Troc.
56. The conjugate according to statement 57, wherein R^C is selected from the group consisting of: Teoc, Psec, Cbz and PNZ.

60. The conjugate according to statement 57, wherein R^C is a group:



where the asterisk indicates the point of attachment to the N10 position, G² is a terminating group, L³ is a covalent bond or a cleavable linker L¹, L² is a covalent bond or together with OC(=O) forms a self-immolative linker.


61. The conjugate according to statement 60, wherein G² is Ac or Moc or is selected from the group consisting of: Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.
62. The conjugate according to any one of statements 1 to 53, wherein R²⁰ and R²¹ together form a double bond between the nitrogen and carbon atoms to which they are bound.

[Formula II]

63. The conjugate according to any one of statements 1 to 30, wherein R²² is of formula IIIa, and A is phenyl.
64. The conjugate according to any one of statements 1 to 30 and statement 63, wherein R²² is of formula IIa, and Q¹ is a single bond.
65. The conjugate according to statement 63, wherein Q² is a single bond.
66. The conjugate according to statement 63, wherein Q² is -Z-(CH₂)_n-, Z is O or S and n is 1 or 2.

67. The conjugate according any one of statements 1 to 30 and statement 63, wherein R^{22} is of formula IIIa, and Q^1 is $-\text{CH}=\text{CH}-$.
68. The conjugate according to any one of statements 1 to 30, wherein R^{22} is of formula IIIb,
and R^{C1} , R^{C2} and R^{C3} are independently selected from H and methyl.
69. The conjugate according to statement 68, wherein R^{C1} , R^{C2} and R^{C3} are all H.
70. The conjugate according to statement 68, wherein R^{C1} , R^{C2} and R^{C3} are all methyl.
71. The conjugate according to any one of statements 1 to 30 and statements 63 to 70, wherein R^{22} is of formula IIIa or formula IIIb and X is selected from $\text{O}-R^{L2'}$, $\text{S}-R^{L2'}$, $\text{CO}_2-R^{L2'}$, $-\text{N}-\text{C}(=\text{O})-R^{L2'}$ and $\text{NH}-R^{L2'}$.
72. The conjugate according to statement 71, wherein X is $\text{NH}-R^{L2'}$.
73. The conjugate according to any one of statements 1 to 30, wherein R^{22} is of formula IIIc, and Q is $\text{NR}^N-R^{L2'}$.
74. The conjugate according to statement 73, wherein R^N is H or methyl.
75. The conjugate according to any one of statements 1 to 30, wherein R^{22} is of formula IIIc, and Q is $\text{O}-R^{L2'}$ or $\text{S}-R^{L2'}$.
76. The conjugate according to any one of statements 1 to 30 and statements 63 to 75, wherein R^{11} is OH.
77. The conjugate according to any one of statements 1 to 30 and statements 63 to 75, wherein R^{11} is OMe.
78. The conjugate according to any one of statements 1 to 30 and statements 63 to 77, wherein R^{10} is H.

79. The conjugate according to any one of statements 1 to 30 and statements 63 to 75, wherein R¹⁰ and R¹¹ together form a double bond between the nitrogen and carbon atoms to which they are bound.
80. The conjugate according to any one of statements 1 to 30 and statements 63 to 79, wherein R³¹ is OH.
81. The conjugate according to any one of statements 1 to 30 and statements 63 to 79, wherein R³¹ is OMe.
82. The conjugate according to any one of statements 1 to 30 and statements 63 to 81, wherein R³⁰ is H.
83. The conjugate according to any one of statements 1 to 30 and statements 63 to 79, wherein R³⁰ and R³¹ together form a double bond between the nitrogen and carbon atoms to which they are bound.
84. The conjugate according to any one of statements 1 to 83, wherein R⁶, R⁷, R⁹, and Y' are the same as R⁶, R⁷, R⁹, and Y.
85. The conjugate according to any one of statements 1 to 84 wherein, wherein L-R^{L1'} or L-R^{L2'} is a group:



where the asterisk indicates the point of attachment to the PBD, Ab is the antibody, L¹ is a cleavable linker, A is a connecting group connecting L¹ to the antibody, L² is a covalent bond or together with -OC(=O)- forms a self-immolative linker.

86. The conjugate of statement 85, wherein L¹ is enzyme cleavable.
87. The conjugate of statement 85 or statement 86, wherein L¹ comprises a contiguous sequence of amino acids.
88. The conjugate of statement 87, wherein L¹ comprises a dipeptide and the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

-Phe-Lys-,
 -Val-Ala-,
 -Val-Lys-,
 -Ala-Lys-,
 -Val-Cit-,
 -Phe-Cit-,
 -Leu-Cit-,
 -Ile-Cit-,
 -Phe-Arg-,
 -Trp-Cit-.

89. The conjugate according to statement 88, wherein the group $-X_1-X_2-$ in dipeptide, $-NH-X_1-X_2-CO-$, is selected from:

-Phe-Lys-,
 -Val-Ala-,
 -Val-Lys-,
 -Ala-Lys-,
 -Val-Cit-.


90. The conjugate according to statement 89, wherein the group $-X_1-X_2-$ in dipeptide, $-NH-X_1-X_2-CO-$, is -Phe-Lys-, -Val-Ala- or -Val-Cit-.

91. The conjugate according to any one of statements 88 to 90, wherein the group X_2-CO- is connected to L^2 .

92. The conjugate according to any one of statements 88 to 91, wherein the group $NH-X_1-$ is connected to A.

93. The conjugate according to any one of statements 88 to 92, wherein L^2 together with $OC(=O)$ forms a self-immolative linker.

94. The conjugate according to statement 93, wherein $C(=O)O$ and L^2 together form the group:




where the asterisk indicates the point of attachment to the PBD, the wavy line indicates the point of attachment to the linker L¹, Y is NH, O, C(=O)NH or C(=O)O, and n is 0 to 3.


95. The conjugate according to statement 94, wherein Y is NH.

96. The conjugate according to statement 94 or statement 95, wherein n is 0.

97. The conjugate according to statement 95, wherein L¹ and L² together with -OC(=O)- comprise a group selected from:



or




where the asterisk indicates the point of attachment to the PBD, and the wavy line indicates the point of attachment to the remaining portion of the linker L¹ or the point of attachment to A.

98. The conjugate according to statement 97, wherein the wavy line indicates the point of attachment to A.


99. The conjugate according to any one of statements 85 to 98, wherein A is:

(i)




where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, and n is 0 to 6; or

(ii)




where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, n is 0 or 1, and m is 0 to 30.

100. A conjugate according to statement 1 of formula ConjA:




ConjA

ConjB:




ConjB

ConjC:




ConjC

ConjD:



ConjD


ConjE:



ConjE

;


ConjF:



ConjF

;


ConjG:



ConjG

; or

ConjH:



101. The conjugate according to any one of statements 1 to 100 wherein the antibody comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine and the conjugation of the drug moiety to the antibody is at an interchain cysteine residue.

102. The conjugate according to statement 101 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110 or fragment thereof, SEQ ID NO.120 or fragment thereof, SEQ ID NO.130 or fragment thereof, or SEQ ID NO.140 or fragment thereof.

103. The conjugate according to statement 102 wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110, the cysteine at position 14 of SEQ ID NO.120, the cysteine at position 103 of SEQ ID NO.120, the cysteine at position 14 of SEQ ID NO.130, or the cysteine at position 14 of SEQ ID NO.140.

104. The conjugate according to either one of statements 102 or 103 wherein the antibody comprises:

a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, wherein the cysteine at position 105, if present, is substituted by an amino acid that is not cysteine; or

a light chain comprising the amino acid sequence of SEQ ID NO. 160, or fragment thereof, wherein the cysteine at position 102, if present, is substituted by an amino acid that is not cysteine.

105. The conjugate according to statement 101 wherein the antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO.110 and light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;
optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.
106. The conjugate according to statement 101 to 100 wherein the antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein the cysteine at position 103 of SEQ ID NO.110, if present, is substituted by an amino acid that is not cysteine;
a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14 and 103 of SEQ ID NO.120, if present, is substituted by an amino acid that is not cysteine;
a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or
a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.
107. The conjugate according to statement 106 wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.
108. The conjugate according to statement 101 wherein the antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO.111 and a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160.
109. The conjugate according to statement 101 wherein the antibody comprises:
a heavy chain comprising the amino acid sequence of SEQ ID NO.112 and a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160.
110. The conjugate according to any one of statements 107 to 109 wherein the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160.

111. The conjugate according to statement 101 wherein the antibody comprises:
- a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine;
 - a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;
 - a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14, 106, and 112 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;
 - a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or
 - a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.
112. The conjugate according to statement 111 the cysteine at position 102 in SEQ ID NO: 120, if present, is also substituted by an amino acid that is not cysteine.
113. The conjugate according to either one of statements 111 or 112 wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110, the cysteine at position 14 of SEQ ID NO.120, the cysteine at position 103 of SEQ ID NO.120, the cysteine at position 14 of SEQ ID NO.130, or the cysteine at position 14 of SEQ ID NO.140.
114. The conjugate according to any one of statements 111 to 113 wherein the antibody comprises:
- a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, wherein the cysteine at position 105, if present, is substituted by an amino acid that is not cysteine; or
 - a light chain comprising the amino acid sequence of SEQ ID NO. 160, or fragment thereof, wherein the cysteine at position 102, if present, is substituted by an amino acid that is not cysteine.
115. The conjugate according to statement 101 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113 and a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.113.

116. The conjugate according to statement 101 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114 and a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.114.

117. The conjugate according to statement 101 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14, 103, 106 and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or

a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.

118. The conjugate according to statement 117 wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

119. The conjugate according to statement 101 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.115 and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

120. The conjugate according to statement 101 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.116 and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

121. The conjugate according to statement 118 wherein the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160

122. The conjugate according to any one of statements 1 to 100 wherein the antibody comprises a heavy chain having a substitution of the amino acid at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

123. The conjugate according to statement 122 wherein the antibody comprises a heavy chain having a substitution of the amino acid at position 234 in the EU index set forth in Kabat and a substitution of the residue at position 235 in the EU index set forth in Kabat.

124. The conjugate according to statement 122 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine.

125. The conjugate according to statement 124 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and wherein the leucine at position 117 and the leucine at position 118 are substituted by an amino acid that is not leucine.

126. The conjugate according to statement 122 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine.

127. The conjugate according to statement 126 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and wherein the leucine at position 164 and the leucine at position 165 are substituted by an amino acid that is not leucine.

128. The conjugate according to statement 122 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and wherein the leucine at position 115 is substituted by an amino acid that is not leucine.
129. The conjugate according to any one of statements 102 to 121 wherein:
the leucine at position 117 in SEQ ID NO: 110 and/or the leucine at position 118 in SEQ ID NO: 110 is substituted by an amino acid that is not leucine;
the leucine at position 164 in SEQ ID NO: 130 and/or the leucine at position 165 in SEQ ID NO: 130 is substituted by an amino acid that is not leucine; or
the leucine at position 115 in SEQ ID NO: 140 is substituted by an amino acid that is not leucine.
130. The conjugate according to statement 129 wherein:
the leucine at position 117 in SEQ ID NO: 110 and the leucine at position 118 in SEQ ID NO: 110 are substituted by an amino acid that is not leucine; or
the leucine at position 164 in SEQ ID NO: 130 and the leucine at position 165 in SEQ ID NO: 130 are substituted by an amino acid that is not leucine.
131. The conjugate according to any one of statements 122 to 130 wherein the substituted amino acids are replaced by alanine, glycine, valine, or isoleucine.
132. The conjugate according to any one of statements 122 to 131 wherein the substituted amino acids are replaced by alanine.
133. The conjugate according to any one of statements 1 to 132 wherein the antibody comprises a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, 10, 21, 22, 23, 24, 25, 26, or 27.
134. The conjugate according to statement 133 wherein the antibody further comprises a VL domain having the sequence according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, 18, 31, 32, 33, 34, 35, 36, or 37.
135. The conjugate according to any one of the preceding statements wherein the antibody comprises a VH domain having a sequence SEQ ID NO. 3;
and, optionally, further comprises a VL domain having a sequence SEQ ID NO. 4.

136. The conjugate according to any one of the preceding statements wherein the antibody comprises a VH domain having a sequence SEQ ID NO. 1;
and, optionally, further comprises a VL domain having a sequence SEQ ID NO. 2.
137. The conjugate according to any one of the preceding statements wherein the antibody is in an intact antibody.
138. The conjugate according to any one of the preceding statements wherein the antibody is humanised, deimmunised or resurfaced.
139. The conjugate according to any one of the preceding statements wherein the conjugate has a maximum tolerated dose in rat at least 2.0 mg/kg delivered as a single-dose.
140. The conjugate according to any one of the preceding statements wherein the drug loading (p) of drugs (D) to antibody (Ab) is 2 or 4.
141. The conjugate according to any one of statements 1 to 140, for use in therapy.
142. The conjugate according to any one of statements 1 to 140, for use in the treatment of a proliferative disease in a subject.
143. The conjugate according to statement 142, wherein the disease is cancer.
144. A pharmaceutical composition comprising the conjugate of any one of statements 1 to 140 and a pharmaceutically acceptable diluent, carrier or excipient.
145. The pharmaceutical composition of statement 144 further comprising a therapeutically effective amount of a chemotherapeutic agent.
146. Use of a conjugate according to any one of statements 1 to 140 in the preparation of a medicament for use in the treatment of a proliferative disease in a subject.
147. A method of treating cancer comprising administering to a patient the pharmaceutical composition of statement 144.

148. The method of statement 147 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

SEQUENCES

SEQ ID NO. 1 (J591 VH):

EVQLQQSGPELKKPGTTSVRISCKTSGYTFTEYTIHWVKQSHGKSLEWIGNINPNNGGTTYN
QKFEDKATLTVDKSSSTAYMELRSLTSEDSAVYYCAAGWNFDYWGQGTTTLTVSS

SEQ ID NO. 2 (J591 VL):

DIVMTQSHKFMSTSVGDRVSIICKASQDVGTAVDWYQQKPGQSPKLLIYWASTRHTGVPD
RFTGSGSGTDFTLTITNVQSEDLADYFCQQYNSYPLTFGAGTMLDLK

SEQ ID NO. 3 (J591 VH Delm):

EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYN
QKFEDKATLTVDKSTDTAYMELSSLRSEDYAVYYCAAGWNFDYWGQGTTLLTVSS

SEQ ID NO. 4 (J591 VK Delm):

DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGPSPKLLIYWASTRHTGIPSR
FSGSGSGTDFTLTISLQPEDFADYYCQQYNSYPLTFGPGTKVDIK

SEQ ID NO. 5 (J415 VH):

EVKLEESGGGLVQPGGSMKLSVASGFTFSNYWMNWVRQSPEKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKSSVYLQMNNLRAEDTGIYYCTRRWNNFWGQGTTTLTVSS

SEQ ID NO. 6 (J415 VL):

NIVMTQFPKSMISVGERVTLTCKASENVGTYVSWYQQKPEQSPKMLIYGASNRFTGVPDR
FTGSGSATDFILTISVQTEDLVDDYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 7 (J415-2 VH Delm):

EVKLEESGGGLVQPGGSMKISCVASGFTFSNYWMNWVRQTPEKGLEWVALIRSQSNNFA
THYAESVKGRVIISRDDSKSSVYLQMNSLRAEDYAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 8 (J415-3 VH Delm):

EVKLEESGGGLVQPGGSMKISCVASGFTFSNYWMNWVRQTPEKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKSSVYLQMNSLRAEDYAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 9 (J415 VH Delm consensus):

EVKLEESGGGLVQPGGSMKISCVASGFTFSNYWMNWVRQTPEKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKSSVYLQMNSLRAEDYAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 10 (J415 VH-MuVH consensus):

EVKLEESGGGLVQPGGSMKLSVCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRLQSDNFA
THYAESVKGRVIISRDDSKSSVYLQMNNLRAEDTGIYYCTTGGYGGRRSWNAFWGQGLV
TVSS

SEQ ID NO. 11 (J415-2 VL Delm):

NIVMTQSPKMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTASSVQAEDPVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 12 (J415-3 VL Delm):

NIVMTQSPKMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTASSVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 13 (J415-4 VL Delm):

NIVMTQSPKMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTISVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 14 (J415-6 VL Delm):

NIVMTQFPKMSASAGERMTLTCKASENVGTYVSWYQQKPEQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTISVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 15 (J415-7 VL Delm):

NIVMTQFPKMSASAGERVTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTISVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 16 (J415-8 VL Delm):

NIVMTQFPKMSASAGERMTLTCKASENSGTYVSWYQQKPEQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTISVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 17 (J415 VL consensus):

NIVMTQFPKMSASAGERMTLTCKASENVGTYVSWYQQKPTQSPKMLIYGASNRFTGVPD
RFSGSGSGTDFILTISVQAEDLVDYYCGQSYTFPYTFGGGKLEMK

SEQ ID NO. 18 (J415 VL-MuVL1 consensus):

DIVMTQSPSSLAVSAGEKVTLSCKASELLNVGNQKTYVAWYQQKPGQSPKLLIYGASTRE
SGVPDRFTGSGSGTDFILTISVQAEDLAVYYCGNSYSFPLTFGGGKLELK

SEQ ID NO. 19 (J591 Delm heavy chain):

EVQLVQSGPEVKKPGATVKISCKTSGYTFTEYTIHWVKQAPGKGLEWIGNINPNNGGTTYN
QKFEDKATLTVDKSTDTAYMELSSLRSEDTAVYYCAAGWNFDYWGGTLLTVSSASTKGP
SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSVHTFPAVLQSSGLYSLSS
VVTVPSSSLGTQTYICNVNHKPSNTKVDKKEPKSCDKTHTCPPCPAPELLGGPSVFLFPP
KPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSV
LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTC
LVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNVFSCSV
MHEALHNHYTQKSLSLSPGK

SEQ ID NO. 20 (J591 Delm light chain):

DIQMTQSPSSLSTSVGDRVTLTCKASQDVGTAVDWYQQKPGSPKLLIYWASTRHTGIPSR
FSGSGSGTDFTLTISLQPEDFADYYCQQYNSYPLTFGPGTKVDIKRTVAAPSVFIFPPSDE
QLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSK
ADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO. 21 (J415RHA):

EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSQSNNFA
THYAESVKGRFTISRDDSKNTAYLQMNSLKTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 22 (J415RHB):

EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 23 (J415RHC):

EVQLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 24 (J415RHD):

EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSQSNNFA
THYAESVKGRVIISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 25 (J415RHE):

EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVGEIRSQSNNFA
THYAESVKGRFTISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 26 (J415RHF):

EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAEIRSQSNNFA
THYAESVKGRFTISRDDSKNTVYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 27 (J415RHG):

EVKLVESGGGLVQPGGSLKLSCAASGFTFSNYWMNWVRQASGKGLEWVAEIRSQSNNFA
THYAESVKGRVIISRDDSKNTAYLQMNSLRTEDTAVYYCTRRWNNFWGQGTTVTVSS

SEQ ID NO. 31 (J415RKA):

DIQMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKLLIYGASNRFTGVPSR
FSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 32 (J415RKB):

DIQMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGVPS
RFSGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 33 (J415RKC):

NIVMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGV
PDRFTGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 34 (J415RKD):

DIQMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGV
PDRFTGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 35 (J415RKE):

NIVMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKLLIYGASNRFTGV
PDRFTGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 36 (J415RKF):

NIVMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGV
PSRFSGSGSATDFILTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 37 (J415RKG):

NIVMTQSPSSVSASVGDRVITITCKASENVGTYVSWYQQKPGTAPKMLIYGASNRFTGV
PDRFTGSGSATDFTLTINNLQPEDFATYYCGQSYTFPYTFGQGGTKVEIK

SEQ ID NO. 110 (IgG1 HC constant region)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1101 (IgG1 HC constant region, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEALGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1102 (IgG1 HC constant region, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1103 (IgG1 HC constant region, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEAAAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1104 (IgG1 HC constant region, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEGGGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1105 (IgG1 HC constant region, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEV**V**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1106 (IgG1 HC constant region, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPEI**I**GGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 111 (IgG1 HC constant region, HJ C→S)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS**S**DKTHTCPPCPAPE**L**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1111 (IgG1 HC constant region, HJ C→S, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS**S**DKTHTCPPCPAPE**A**LGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1112 (IgG1 HC constant region, HJ C→S, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKS**S**DKTHTCPPCPAPE**L**AGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY

RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1113 (IgG1 HC constant region, HJ C→S, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTCPPCPAPE**AA**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1114 (IgG1 HC constant region, HJ C→S, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTCPPCPAPE**GG**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1115 (IgG1 HC constant region, HJ C→S, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTCPPCPAPE**VV**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1116 (IgG1 HC constant region, HJ C→S, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTCPPCPAPE**II**GGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 112 (IgG1 HC constant region, HJ C→V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPELLGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1121 (IgG1 HC constant region, HJ C→V, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPEALGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1122 (IgG1 HC constant region, HJ C→V, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPELAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1123 (IgG1 HC constant region, HJ C→V, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPEAAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1124 (IgG1 HC constant region, HJ C→V, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPEGGGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1125 (IgG1 HC constant region, HJ C→V, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPEV**V**GGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1126 (IgG1 HC constant region, HJ C→V, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTCPPCPAPEI**I**GGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 113 (IgG1 HC constant region, BJ C→S)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSP**APPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1131 (IgG1 HC constant region, BJ C→S, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSP**AP**A**LGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1132 (IgG1 HC constant region, BJ C→S, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSPAPELAGG**PS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1133 (IgG1 HC constant region, BJ C→S, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSPAPEAA**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1134 (IgG1 HC constant region, BJ C→S, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSPAPEGG**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1135 (IgG1 HC constant region, BJ C→S, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSPAPEVV**GGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1136 (IgG1 HC constant region, BJ C→S, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHT**SPPSPAPEII**GGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ

VSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 114 (IgG1 HC constant region, BJ C→V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPELLGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1141 (IgG1 HC constant region, BJ C→V, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPEALGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1142 (IgG1 HC constant region, BJ C→V, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPELAGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1143 (IgG1 HC constant region, BJ C→V, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPEAAAGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1144 (IgG1 HC constant region, BJ C→V, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPEGGGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1145 (IgG1 HC constant region, BJ C→V, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPEVVGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGDSFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1146 (IgG1 HC constant region, BJ C→V, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTVPPVPAPEIIGGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 115 (IgG1 HC constant region, DJ C→S)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTSPPSPAPELLGGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1151 (IgG1 HC constant region, DJ C→S, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTSPPSPAPEALGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1152 (IgG1 HC constant region, DJ C→S, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHT**SPPSPAPELAGG**PS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1153 (IgG1 HC constant region, DJ C→S, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHT**SPPSPAPEAA**GGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1154 (IgG1 HC constant region, DJ C→S, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHT**SPPSPAPEG**GGGGS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1155 (IgG1 HC constant region, DJ C→S, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHT**SPPSPAPEV**VGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1156 (IgG1 HC constant region, DJ C→S, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSSDKTHTSPSPAPEIIGGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFIYPSDIAVEWESNGQPENNYKTTPVLDSGFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 116 (IgG1 HC constant region, DJ C→V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPPELLGGPSV
 FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
 VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
 VSLTCLVKGFIYPSDIAVEWESNGQPENNYKTTPVLDSGFFLYSKLTVDKSRWQQGNV
 FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1161 (IgG1 HC constant region, DJ C→V, L117A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPPEALGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFIYPSDIAVEWESNGQPENNYKTTPVLDSGFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1162 (IgG1 HC constant region, DJ C→V, L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPPELAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
 QVSLTCLVKGFIYPSDIAVEWESNGQPENNYKTTPVLDSGFFLYSKLTVDKSRWQQGN
 VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1163 (IgG1 HC constant region, DJ C→V, L117A & L118A)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVVTPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPPEAAGGPS
 VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
 RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN

QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1164 (IgG1 HC constant region, DJ C→V, L117G & L118G)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPEGGGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1165 (IgG1 HC constant region, DJ C→V, L117V & L118V)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPEVWGGPS
VFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTY
RVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKN
QVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGN
VFSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 1166 (IgG1 HC constant region, DJ C→V, L117I & L118I)

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSVDKTHTVPPVPAPEIIGGPSV
FLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYR
VVS LTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQ
VSLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNV
FSCSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 120 (IgG2 HC constant region)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSKVHTFPFAVLQSSG
LYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTKVERKCCVECPPCPAPPVAGPSVFLF
PPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVV
SVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVS
LTCLVKGFYPSDIAVEWESNGQPENNYKTTTPMLDSGDSFFLYSKLTVDKSRWQQGNVFS
CSVMHEALHNHYTQKSLSLSPGK

SEQ ID NO. 130 (IgG3 HC constant region)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 131 (IgG3 HC constant region, L164A)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPEALGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 132 (IgG3 HC constant region, L165A)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELAGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 133 (IgG3 HC constant region, L164A & L165A)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPEAAAGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 134 (IgG3 HC constant region, L164G & L165G)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPEGGGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 135 (IgG3 HC constant region, L164V & L165V)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPEVVGGGPSVFLFPPKPKDTL
 MISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQ
 DWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGF
 YPSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEAL
 HNHFTQKSLSLSPGK

SEQ ID NO. 136 (IgG3 HC constant region, L164I & L165I)

ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSS
 GLYSLSSVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTHHTCPRCPEPKSCD
 TPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPEIIGGPSVFLFPPKPKDTLMI
 SRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQD
 WLNKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFY
 PSDIAVEWESSGQPENNYKTTTPVLDSGDSFFLYSKLTVDKSRWQQGNIFSCSVMHEALH
 NHFTQKSLSLSPGK

SEQ ID NO. 140 (IgG4 HC constant region)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVTVPSSSLGKTYTCNVNKHPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFL
 FPPKPKDTLMISRTPEVTCVVVDVSDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
 VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSREEMTKNQV
 SLTCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSGDSFFLYSRLTVDKSRWQEGNVF
 SCSVMHEALHNHYTQKSLSLSLGK

SEQ ID NO. 141 (IgG4 HC constant region, L115A)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVTVPSSSLGKTYTCNVNKHPSNTKVDKRVESKYGPPCPSCPAPEFAGGPSVFL

FPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
 VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQQEEMTKNQV
 SLTCLVKGFIYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVF
 SCSVMHEALHNHYTQKSLSLGLGK

SEQ ID NO. 142 (IgG4 HC constant region, L115G)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQKTYTCNVDPKPSNTKVDKRVESKYGPPCPSCPAPEF**GG**GPSVFL
 FPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
 VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQQEEMTKNQV
 SLTCLVKGFIYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVF
 SCSVMHEALHNHYTQKSLSLGLGK

SEQ ID NO. 143 (IgG4 HC constant region, L115V)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQKTYTCNVDPKPSNTKVDKRVESKYGPPCPSCPAPEF**VGG**GPSVFL
 FPPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRV
 VSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQQEEMTKNQV
 SLTCLVKGFIYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVF
 SCSVMHEALHNHYTQKSLSLGLGK

SEQ ID NO. 144 (IgG4 HC constant region, L115I)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSG
 LYSLSVVTVPSSSLGTQKTYTCNVDPKPSNTKVDKRVESKYGPPCPSCPAPEF**IGG**GPSVFLF
 PPKPKDTLMISRTPEVTCVVVDVSDQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVV
 SVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQQEEMTKNQVS
 LTCLVKGFIYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSRLTVDKSRWQEGNVFS
 CSVMHEALHNHYTQKSLSLGLGK

SEQ ID NO. 150 (κLC constant region)

VAAPSVFIFPPSDEQLKSGTASVCLLNNFYPRFAKVKVQWVDNALQSGNSQESVTEQDSK
 DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC

SEQ ID NO. 151 (κLC constant region, C105S)

VAAPSVFIFPPSDEQLKSGTASVCLLNNFYPRFAKVKVQWVDNALQSGNSQESVTEQDSK
 DSTYLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNR**GES**

SEQ ID NO. 152 (κ LC constant region, C105V)

VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGEV

SEQ ID NO. 153 (κ LC constant region, C105del)

VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK
DSTYLSLSSTLTLSKADYEEKHKVYACEVTHQGLSSPVTKSFNRGE

SEQ ID NO. 160 (λ LC constant region)

KAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSSPVKAGVETTTPSKQSN
NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTECS

SEQ ID NO. 161 (λ LC constant region, C102S)

KAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSSPVKAGVETTTPSKQSN
NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTESS

SEQ ID NO. 162 (λ LC constant region, C102V)



KAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSSPVKAGVETTTPSKQSN
NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTEVS

SEQ ID NO. 163 (λ LC constant region, C102&S103del)

KAAPSVTLFPPSSEELQANKATLVCLISDFYPGAVTVAWKADSSSPVKAGVETTTPSKQSN
NKYAASSYLSLTPEQWKSHRSYSCQVTHEGSTVEKTVAPTE

Claims

1. A conjugate of formula L - (DL)_p, where DL is of formula I or II:




wherein:

L is an antibody (Ab) which binds PSMA, and which comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine;


when there is a double bond present between C2' and C3', R¹² is selected from the group consisting of:

- (ia) C₅₋₁₀ aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C₁₋₇ alkyl, C₃₋₇ heterocyclyl and bis-oxy-C₁₋₃ alkylene;
- (ib) C₁₋₅ saturated aliphatic alkyl;
- (ic) C₃₋₆ saturated cycloalkyl;




- (id) , wherein each of R²¹, R²² and R²³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R¹² group is no more than 5;

- (ie) , wherein one of R^{25a} and R^{25b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

(if)  R^{24} , where R^{24} is selected from: H; C_{1-3} saturated alkyl; C_{2-3} alkenyl; C_{2-3} alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl;

when there is a single bond present between $C2'$ and $C3'$,

R^{12} is , where R^{26a} and R^{26b} are independently selected from H, F, C_{1-4} saturated alkyl, C_{2-3} alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C_{1-4} alkyl amido and C_{1-4} alkyl ester; or, when one of R^{26a} and R^{26b} is H, the other is selected from nitrile and a C_{1-4} alkyl ester;

R^6 and R^9 are independently selected from H, R, OH, OR, SH, SR, NH_2 , NHR, NRR' , nitro, Me_3Sn and halo;

where R and R' are independently selected from optionally substituted C_{1-12} alkyl, C_{3-20} heterocyclyl and C_{5-20} aryl groups;

R^7 is selected from H, R, OH, OR, SH, SR, NH_2 , NHR, $NHRR'$, nitro, Me_3Sn and halo;

R'' is a C_{3-12} alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NR^{N2} (where R^{N2} is H or C_{1-4} alkyl), and/or aromatic rings, e.g. benzene or pyridine;

Y and Y' are selected from O, S, or NH;

R^6 , R^7 , R^9 are selected from the same groups as R^6 , R^7 and R^9 respectively;

[Formula I]

$R^{L1'}$ is a linker for connection to the antibody (Ab);

R^{11a} is selected from OH, OR^A , where R^A is C_{1-4} alkyl, and SO_zM , where z is 2 or 3 and M is a monovalent pharmaceutically acceptable cation;

R^{20} and R^{21} either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R^{20} is selected from H and R^C , where R^C is a capping group;


R^{21} is selected from OH, OR^A and SO_zM ;


when there is a double bond present between C2 and C3, R^2 is selected from the group consisting of:


(ia) C_{5-10} aryl group, optionally substituted by one or more substituents selected from the group comprising: halo, nitro, cyano, ether, carboxy, ester, C_{1-7} alkyl, C_{3-7} heterocyclyl and bis-oxy- C_{1-3} alkylene;


(ib) C_{1-5} saturated aliphatic alkyl;

(ic) C_{3-6} saturated cycloalkyl;

- (id)  , wherein each of R¹¹, R¹² and R¹³ are independently selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl, where the total number of carbon atoms in the R² group is no more than 5;


- (ie)  , wherein one of R^{15a} and R^{15b} is H and the other is selected from: phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; and

- (if)  , where R¹⁴ is selected from: H; C₁₋₃ saturated alkyl; C₂₋₃ alkenyl; C₂₋₃ alkynyl; cyclopropyl; phenyl, which phenyl is optionally substituted by a group selected from halo, methyl, methoxy; pyridyl; and thiophenyl; when there is a single bond present between C2 and C3,

- R² is  , where R^{16a} and R^{16b} are independently selected from H, F, C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C₁₋₄ alkyl amido and C₁₋₄ alkyl ester; or, when one of R^{16a} and R^{16b} is H, the other is selected from nitrile and a C₁₋₄ alkyl ester;


[Formula II]

R²² is of formula IIIa, formula IIIb or formula IIIc:




where A is a C₅₋₇ aryl group, and either

- (i) Q¹ is a single bond, and Q² is selected from a single bond and -Z-(CH₂)_n-, where Z is selected from a single bond, O, S and NH and n is from 1 to 3; or
 (ii) Q¹ is -CH=CH-, and Q² is a single bond;





where;

R^{C1}, R^{C2} and R^{C3} are independently selected from H and unsubstituted C₁₋₂ alkyl;



where Q is selected from O-R^{L2'}, S-R^{L2'} and NR^N-R^{L2'}, and R^N is selected from H, methyl and ethyl

X is selected from the group comprising: O-R^{L2'}, S-R^{L2'}, CO₂-R^{L2'}, CO-R^{L2'}, NH-C(=O)-R^{L2'},

NHNH-R^{L2'}, CONHNH-R^{L2'}, , , NR^NR^{L2'}, wherein R^N is selected from the group comprising H and C₁₋₄ alkyl;

R^{L2'} is a linker for connection to the antibody (Ab);

R¹⁰ and R¹¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;

R¹⁰ is H and R¹¹ is selected from OH, OR^A and SO₂M;

R³⁰ and R³¹ either together form a double bond between the nitrogen and carbon atoms to which they are bound or;


R³⁰ is H and R³¹ is selected from OH, OR^A and SO₂M;

[Formula I and II]

wherein the conjugation of the drug moiety to the antibody is at an interchain cysteine residue.

2. The conjugate according to claim 1, wherein the conjugate is not:


ConjA



ConjA

;


ConjB




ConjB

;


ConjC:



ConjD




ConjE:




3. The conjugate according to either claim 1 or claim 2, wherein R⁷ is selected from H, OH and OR.
4. The conjugate according to claim 3, wherein R⁷ is a C₁₋₄ alkyloxy group.
5. The conjugate according to any one of claims 1 to 4, wherein Y is O.


6. The conjugate according to any one of the preceding claims, wherein R⁷ is C₃₋₇ alkylene.
7. The conjugate according to any one of claims 1 to 6, wherein R⁹ is H.
8. The conjugate according to any one of claims 1 to 7, wherein R⁶ is selected from H and halo.
9. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₅₋₇ aryl group.
10. The conjugate according to claim 9, wherein R¹² is phenyl.
11. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₈₋₁₀ aryl group.
12. The conjugate according to any one of claims 9 to 11, wherein R¹² bears one to three substituent groups.
13. The conjugate according to any one of claims 9 to 12, wherein the substituents are selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl.
14. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₁₋₅ saturated aliphatic alkyl group.
15. A compound according to claim 14, wherein R¹² is methyl, ethyl or propyl.
16. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a C₃₋₆ saturated cycloalkyl group.
17. The conjugate according to claim 16, wherein R¹² is cyclopropyl.
18. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:




19. The conjugate according to claim 18, wherein the total number of carbon atoms in the R¹² group is no more than 4.
20. The conjugate according to claim 19, wherein the total number of carbon atoms in the R¹² group is no more than 3.
21. The conjugate according to any one of claims 18 to 20, wherein one of R²¹, R²² and R²³ is H, with the other two groups being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
22. The conjugate according to any one of claims 18 to 20, wherein two of R²¹, R²² and R²³ are H, with the other group being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
23. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:



24. The conjugate according to claim 23, wherein R¹² is the group:




25. The conjugate according to any one of claims 1 to 8, wherein there is a double bond between C2' and C3', and R¹² is a group of formula:




26. The conjugate according to claim 25, wherein R²⁴ is selected from H, methyl, ethyl, ethenyl and ethynyl.

27. The conjugate according to claim 26, wherein R^{24} is selected from H and methyl.


28. The conjugate according to any one of claims 1 to 8, wherein there is a single bond

between C2' and C3', R^{12} is  and R^{26a} and R^{26b} are both H.

29. The conjugate according to any one of claims 1 to 8, wherein there is a single bond

between C2' and C3', R^{12} is , and R^{26a} and R^{26b} are both methyl.

30. The conjugate according to any one of claims 1 to 8, wherein there is a single bond

between C2' and C3', R^{12} is , one of R^{26a} and R^{26b} is H, and the other is selected from C_{1-4} saturated alkyl, C_{2-3} alkenyl, which alkyl and alkenyl groups are optionally substituted.

[Formula I]

31. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R^2 is a C_{5-7} aryl group.

32. The conjugate according to claim 31, wherein R^2 is phenyl.


33. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R^1 is a C_{8-10} aryl group.

34. A compound according to any one of claims 31 to 33, wherein R^2 bears one to three substituent groups.


35. The conjugate according to any one of claims 31 to 34, wherein the substituents are selected from methoxy, ethoxy, fluoro, chloro, cyano, bis-oxy-methylene, methyl-piperazinyl, morpholino and methyl-thiophenyl.

36. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R^2 is a C_{1-5} saturated aliphatic alkyl group.


37. The conjugate according to claim 36, wherein R² is methyl, ethyl or propyl.
38. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R² is a C₃₋₆ saturated cycloalkyl group.
39. The conjugate according to claim 38, wherein R² is cyclopropyl.
40. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:




41. The conjugate according to claim 40, wherein the total number of carbon atoms in the R² group is no more than 4.
42. The conjugate according to claim 41, wherein the total number of carbon atoms in the R² group is no more than 3.
43. The conjugate according to any one of claims 40 to 42, wherein one of R¹¹, R¹² and R¹³ is H, with the other two groups being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
44. The conjugate according to any one of claims 40 to 42, wherein two of R¹¹, R¹² and R¹³ are H, with the other group being selected from H, C₁₋₃ saturated alkyl, C₂₋₃ alkenyl, C₂₋₃ alkynyl and cyclopropyl.
45. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:



46. The conjugate according to claim 45, wherein R² is the group:




47. The conjugate according to any one of claims 1 to 30, wherein there is a double bond between C2 and C3, and R² is a group of formula:



48. The conjugate according to claim 47, wherein R¹⁴ is selected from H, methyl, ethyl, ethenyl and ethynyl.


49. The conjugate according to claim 47, wherein R¹⁴ is selected from H and methyl.

50. The conjugate according to any one of claims 1 to 30, wherein there is a single bond

between C2 and C3, R² is  and R^{16a} and R^{16b} are both H.


The structure shows a double bond between two carbons. The left carbon has a wavy line, and the right carbon is bonded to R^{16a} and R^{16b}.

51. The conjugate according to any one of claims 1 to 30, wherein there is a single bond

between C2 and C3, R² is , and R^{16a} and R^{16b} are both methyl.

The structure shows a double bond between two carbons. The left carbon has a wavy line, and the right carbon is bonded to R^{16a} and R^{16b}.

52. The conjugate according to any one of claims 1 to 30, wherein there is a single bond

between C2 and C3, R² is , one of R^{16a} and R^{16b} is H, and the other is selected from C₁₋₄ saturated alkyl, C₂₋₃ alkenyl, which alkyl and alkenyl groups are optionally substituted.

The structure shows a double bond between two carbons. The left carbon has a wavy line, and the right carbon is bonded to R^{16a} and R^{16b}.


53. The conjugate according to any one of claims 1 to 52, wherein R^{11a} is OH.

54. The conjugate according to any one of claims 1 to 53, wherein R²¹ is OH.

55. The conjugate according to any one of claims 1 to 53, wherein R²¹ is OMe.

56. The conjugate according to any one of claims 1 to 55, wherein R²⁰ is H.
57. The conjugate according to any one of claims 1 to 55, wherein R²⁰ is R^C.
58. The conjugate according to claim 57, wherein R^C is selected from the group consisting of: Alloc, Fmoc, Boc, and Troc.
59. The conjugate according to claim 57, wherein R^C is selected from the group consisting of: Teoc, Psec, Cbz and PNZ.

60. The conjugate according to claim 57, wherein R^C is a group:



where the asterisk indicates the point of attachment to the N10 position, G² is a terminating group, L³ is a covalent bond or a cleavable linker L¹, L² is a covalent bond or together with OC(=O) forms a self-immolative linker.

61. The conjugate according to claim 60, wherein G² is Ac or Moc or is selected from the group consisting of: Alloc, Fmoc, Boc, Troc, Teoc, Psec, Cbz and PNZ.
62. The conjugate according to any one of claims 1 to 53, wherein R²⁰ and R²¹ together form a double bond between the nitrogen and carbon atoms to which they are bound.

[Formula II]

63. The conjugate according to any one of claims 1 to 30, wherein R²² is of formula IIIa, and A is phenyl.
64. The conjugate according to any one of claims 1 to 30 and claim 63, wherein R²² is of formula IIa, and Q¹ is a single bond.
65. The conjugate according to claim 63, wherein Q² is a single bond.
66. The conjugate according to claim 63, wherein Q² is -Z-(CH₂)_n-, Z is O or S and n is 1 or 2.

67. The conjugate according any one of claims 1 to 30 and claim 63, wherein R^{22} is of formula IIIa, and Q^1 is $-\text{CH}=\text{CH}-$.
68. The conjugate according to any one of claims 1 to 30, wherein R^{22} is of formula IIIb, and R^{C1} , R^{C2} and R^{C3} are independently selected from H and methyl.
69. The conjugate according to claim 68, wherein R^{C1} , R^{C2} and R^{C3} are all H.
70. The conjugate according to claim 68, wherein R^{C1} , R^{C2} and R^{C3} are all methyl.
71. The conjugate according to any one of claims 1 to 30 and claims 63 to 70, wherein R^{22} is of formula IIIa or formula IIIb and X is selected from $\text{O}-R^{L2'}$, $\text{S}-R^{L2'}$, $\text{CO}_2-R^{L2'}$, $-\text{N}-\text{C}(=\text{O})-R^{L2'}$ and $\text{NH}-R^{L2'}$.
72. The conjugate according to claim 71, wherein X is $\text{NH}-R^{L2'}$.
73. The conjugate according to any one of claims 1 to 30, wherein R^{22} is of formula IIIc, and Q is $\text{NR}^N-R^{L2'}$.
74. The conjugate according to claim 73, wherein R^N is H or methyl.
75. The conjugate according to any one of claims 1 to 30, wherein R^{22} is of formula IIIc, and Q is $\text{O}-R^{L2'}$ or $\text{S}-R^{L2'}$.
76. The conjugate according to any one of claims 1 to 30 and claims 63 to 75, wherein R^{11} is OH.
77. The conjugate according to any one of claims 1 to 30 and claims 63 to 75, wherein R^{11} is OMe.
78. The conjugate according to any one of claims 1 to 30 and claims 63 to 77, wherein R^{10} is H.
79. The conjugate according to any one of claims 1 to 30 and claims 63 to 75, wherein R^{10} and R^{11} together form a double bond between the nitrogen and carbon atoms to which they are bound.

80. The conjugate according to any one of claims 1 to 30 and claims 63 to 79, wherein R³¹ is OH.


81. The conjugate according to any one of claims 1 to 30 and claims 63 to 79, wherein R³¹ is OMe.

82. The conjugate according to any one of claims 1 to 30 and claims 63 to 81, wherein R³⁰ is H.

83. The conjugate according to any one of claims 1 to 30 and claims 63 to 79, wherein R³⁰ and R³¹ together form a double bond between the nitrogen and carbon atoms to which they are bound.

84. The conjugate according to any one of claims 1 to 83, wherein R⁶, R⁷, R⁹, and Y' are the same as R⁶, R⁷, R⁹, and Y.

85. The conjugate according to any one of claims 1 to 84 wherein, wherein L-R^{L1'} or L-R^{L2'} is a group:



where the asterisk indicates the point of attachment to the PBD, Ab is the antibody, L¹ is a cleavable linker, A is a connecting group connecting L¹ to the antibody, L² is a covalent bond or together with -OC(=O)- forms a self-immolative linker.

86. The conjugate of claim 85, wherein L¹ is enzyme cleavable.

87. The conjugate of claim 85 or claim 86, wherein L¹ comprises a contiguous sequence of amino acids.

88. The conjugate of claim 87, wherein L¹ comprises a dipeptide and the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

- Phe-Lys-,
- Val-Ala-,
- Val-Lys-,
- Ala-Lys-,

-Val-Cit-,
 -Phe-Cit-,
 -Leu-Cit-,
 -Ile-Cit-,
 -Phe-Arg-,
 -Trp-Cit-.

89. The conjugate according to claim 88, wherein the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is selected from:

-Phe-Lys-,
 -Val-Ala-,
 -Val-Lys-,
 -Ala-Lys-,
 -Val-Cit-.


90. The conjugate according to claim 89, wherein the group -X₁-X₂- in dipeptide, -NH-X₁-X₂-CO-, is -Phe-Lys-, -Val-Ala- or -Val-Cit-.

91. The conjugate according to any one of claims 88 to 90, wherein the group X₂-CO- is connected to L².

92. The conjugate according to any one of claims 88 to 91, wherein the group NH-X₁- is connected to A.


93. The conjugate according to any one of claims 88 to 92, wherein L² together with OC(=O) forms a self-immolative linker.

94. The conjugate according to claim 93, wherein C(=O)O and L² together form the group:




where the asterisk indicates the point of attachment to the PBD, the wavy line indicates the point of attachment to the linker L¹, Y is NH, O, C(=O)NH or C(=O)O, and n is 0 to 3.

95. The conjugate according to claim 94, wherein Y is NH.
96. The conjugate according to claim 94 or claim 95, wherein n is 0.
97. The conjugate according to claim 95, wherein L¹ and L² together with -OC(=O)- comprise a group selected from:




or



where the asterisk indicates the point of attachment to the PBD, and the wavy line indicates the point of attachment to the remaining portion of the linker L¹ or the point of attachment to A.


98. The conjugate according to claim 97, wherein the wavy line indicates the point of attachment to A.
99. The conjugate according to any one of claims 85 to 98, wherein A is:

(i)




where the asterisk indicates the point of attachment to L¹, the wavy line indicates the point of attachment to the antibody, and n is 0 to 6; or

(ii)




where the asterisk indicates the point of attachment to L^1 , the wavy line indicates the point of attachment to the antibody, n is 0 or 1, and m is 0 to 30.

100. A conjugate according to claim 1 of formula ConjA:




ConjA

ConjB:




ConjB

ConjC:




ConjC

ConjD:



ConjD


ConjE:



ConjE

;


ConjF:



ConjF

;


ConjG:



ConjG

; or

ConjH:



101. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 103, 106, and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14, 106, and 112 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or

a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 106 and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.

102. The conjugate according to claim 101 the cysteine at position 102 in SEQ ID NO: 120, if present, is also substituted by an amino acid that is not cysteine.

103. The conjugate according to either one of claims 101 or 102 wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110, the cysteine at position 14 of SEQ ID NO.120, the cysteine at position 103 of SEQ ID NO.120, the cysteine at position 14 of SEQ ID NO.130, or the cysteine at position 14 of SEQ ID NO.140.

104. The conjugate according to any one of claims 101 to 103 wherein the antibody comprises:

a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, wherein the cysteine at position 105, if present, is substituted by an amino acid that is not cysteine; or

a light chain comprising the amino acid sequence of SEQ ID NO. 160, or fragment thereof, wherein the cysteine at position 102, if present, is substituted by an amino acid that is not cysteine.

105. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.113 and a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.113.

106. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.114 and a light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.114.

107. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110 or fragment thereof, SEQ ID NO.120 or fragment thereof, SEQ ID NO.130 or fragment thereof, or SEQ ID NO.140 or fragment thereof.

108. The conjugate according to claim 107 wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110, the cysteine at position 14 of SEQ ID NO.120,

the cysteine at position 103 of SEQ ID NO.120, the cysteine at position 14 of SEQ ID NO.130, or the cysteine at position 14 of SEQ ID NO.140.

109. The conjugate according to either one of claims 107 or 108 wherein the antibody comprises:

a light chain comprising the amino acid sequence of SEQ ID NO. 150, or fragment thereof, wherein the cysteine at position 105, if present, is substituted by an amino acid that is not cysteine; or

a light chain comprising the amino acid sequence of SEQ ID NO. 160, or fragment thereof, wherein the cysteine at position 102, if present, is substituted by an amino acid that is not cysteine.

110. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.110 and light chain comprising the amino acid sequence of SEQ ID NO.151, SEQ ID NO.152, SEQ ID NO.153, SEQ ID NO.161, SEQ ID NO.162, or SEQ ID NO.163;

optionally wherein the drug moiety is conjugated to the cysteine at position 103 of SEQ ID NO.110.

111. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein the cysteine at position 103 of SEQ ID NO.110, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14 and 103 of SEQ ID NO.120, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or

a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein the cysteine at position 14 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.

112. The conjugate according to claim 111 wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

113. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.111 and a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160.

114. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.112 and a light chain comprising the amino acid sequence of SEQ ID NO.150 or SEQ ID NO.160.

115. The conjugate according to any one of claims 112 to 114 wherein the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, or the cysteine at position 102 of SEQ ID NO.160.

116. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises:

a heavy chain comprising the amino acid sequence of SEQ ID NO.110, or fragment thereof, wherein each of the cysteines at positions 103, 109 and 112 in SEQ ID NO: 110, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.120, or fragment thereof, wherein each of the cysteines at positions 14, 103, 106 and 109 in SEQ ID NO: 120, if present, is substituted by an amino acid that is not cysteine;

a heavy chain comprising the amino acid sequence of SEQ ID NO.130, or fragment thereof, wherein each of the cysteines at positions 14, 111, 114, 120, 126, 129, 135, 141, 144, 150, 156, and 159 in SEQ ID NO: 130, if present, is substituted by an amino acid that is not cysteine; or

a heavy chain comprising the amino acid sequence of SEQ ID NO.140, or fragment thereof, wherein each of the cysteines at positions 14, 106, and 109 in SEQ ID NO: 140, if present, is substituted by an amino acid that is not cysteine.

117. The conjugate according to claim 116 wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

118. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.115 and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

119. The conjugate according to any one of claims 1 to 100 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.116 and a light chain comprising the amino acid sequence of SEQ ID NO. 150 or SEQ ID NO. 160.

120. The conjugate according to claim 117 wherein the drug moiety is conjugated to the cysteine at position 105 of SEQ ID NO.150, the cysteine at position 102 of SEQ ID NO.160

121. The conjugate according to any one of claims 1 to 120 wherein the antibody comprises a heavy chain having a substitution of the amino acid at position 234 in the EU index set forth in Kabat and/or a substitution of the residue at position 235 in the EU index set forth in Kabat.

122. The conjugate according to claim 121 wherein the antibody comprises a heavy chain having a substitution of the amino acid at position 234 in the EU index set forth in Kabat and a substitution of the residue at position 235 in the EU index set forth in Kabat.

123. The conjugate according to any one of claims 121 to 122 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and wherein the leucine at position 117 and/or the leucine at position 118 is substituted by an amino acid that is not leucine.

124. The conjugate according to claim 123 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.110, and wherein the leucine at position 117 and the leucine at position 118 are substituted by an amino acid that is not leucine.

125. The conjugate according to any one of claims 121 to 122 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and wherein the leucine at position 164 and/or the leucine at position 165 is substituted by an amino acid that is not leucine.

126. The conjugate according to claim 125 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.130, and wherein the leucine at position 164 and the leucine at position 165 are substituted by an amino acid that is not leucine.

127. The conjugate according to claim 121 wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO.140, and wherein the leucine at position 115 is substituted by an amino acid that is not leucine.
128. The conjugate according to any one of claims 1 to 127 wherein the substituted amino acids are replaced by alanine, glycine, valine, or isoleucine.
129. The conjugate according to claim 128 wherein the substituted amino acids are replaced by alanine.
130. The conjugate according to any one of claims 1 to 129 wherein the antibody comprises a VH domain having the sequence according to any one of SEQ ID NOs. 1, 3, 5, 7, 8, 9, 10, 21, 22, 23, 24, 25, 26, or 27.
131. The conjugate according to claim 130 wherein the antibody further comprises a VL domain having the sequence according to any one of SEQ ID NOs. 2, 4, 6, 11, 12, 13, 14, 15, 16, 17, 18, 31, 32, 33, 34, 35, 36, or 37.
132. The conjugate according to any one of the preceding claims wherein the antibody comprises a VH domain having a sequence SEQ ID NO. 3;
and, optionally, further comprises a VL domain having a sequence SEQ ID NO. 4.
133. The conjugate according to any one of the preceding claims wherein the antibody comprises a VH domain having a sequence SEQ ID NO. 1;
and, optionally, further comprises a VL domain having a sequence SEQ ID NO. 2.
134. The conjugate according to any one of the preceding claims wherein the antibody in an intact antibody.
135. The conjugate according to any one of the preceding claims wherein the antibody is humanised, deimmunised or resurfaced.
136. The conjugate according to any one of the preceding claims wherein the conjugate has a maximum tolerated dose in rat at least 2.0 mg/kg delivered as a single-dose.
137. The conjugate according to any one of the preceding claims wherein the drug loading (p) of drugs (D) to antibody (Ab) is 2 or 4.

138. The conjugate according to any one of claims 1 to 137, for use in therapy.
139. The conjugate according to any one of claims 1 to 137, for use in the treatment of a proliferative disease in a subject.
140. The conjugate according to claim 139, wherein the disease is cancer.
141. A pharmaceutical composition comprising the conjugate of any one of claims 1 to 137 and a pharmaceutically acceptable diluent, carrier or excipient.
142. The pharmaceutical composition of claim 141 further comprising a therapeutically effective amount of a chemotherapeutic agent.
143. Use of a conjugate according to any one of claims 1 to 137 in the preparation of a medicament for use in the treatment of a proliferative disease in a subject.
144. A method of treating cancer comprising administering to a patient the pharmaceutical composition of claim 141.
145. The method of claim 144 wherein the patient is administered a chemotherapeutic agent, in combination with the conjugate.

Cynomolgus monkey Platelet data

- AbCJ591-ConjH (0.6 mg/kg)
- AbCJ591-ConjH (0.9 mg/kg)
- △ AbCJ591-ConjE (0.9 mg/kg)
- ◇ AbBJ591-ConjE (0.6 mg/kg)




Figure 1

eol f-seq
SEQUENCE LISTING

<110> van Berkel, Patricius HC
Howard, Philip W
<120> Site-Specific Antibody-Drug Conjugates
<130> RKA/LP7185689
<150> GB 1506394.4
<151> 2015-04-15
<160> 1166
<170> PatentIn version 3.3
<210> 1
<211> 115
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic J591 VH
<400> 1

Glu Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Lys Lys Pro Gly Thr
1 5 10 15

Ser Val Arg Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
20 25 30

Thr Ile His Trp Val Lys Gln Ser His Gly Lys Ser Leu Glu Trp Ile
35 40 45

Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe
50 55 60

Glu Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Arg Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
85 90 95

Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Thr Leu Thr
100 105 110

Val Ser Ser
115

<210> 2
<211> 107
<212> PRT
<213> Artificial sequence
<220>
<223> Synthetic J591 VL
<400> 2

Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Ser Ile Ile Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Asp Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Thr Asn Val Gln Ser
65 70 75 80

Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95

Thr Phe Gly Ala Gly Thr Met Leu Asp Leu Lys
100 105

<210> 3
<211> 115
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J591 VH Delm

<400> 3

Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
20 25 30

Thr Ile His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe
50 55 60

Glu Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Asp Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr
100 105 110

Val Ser Ser
115

eol f-seql

<210> 4
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J591 VK Delm
<400> 4

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Thr Leu Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Asp Trp Tyr Gln Gln Lys Pro Gly Pro Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Arg His Thr Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Asp Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu
85 90 95

Thr Phe Gly Pro Gly Thr Lys Val Asp Ile Lys
100 105

<210> 5
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415 VH
<400> 5

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

eol f-seql

Val Tyr Leu Gln Met Asn Asn Leu Arg Ala Glu Asp Thr Gly Ile Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Leu
100 105 110

Thr Val Ser Ser
115

<210> 6
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415 VL

<400> 6

Asn Ile Val Met Thr Gln Phe Pro Lys Ser Met Ser Ile Ser Val Gly
1 5 10 15

Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Ile Leu Thr Ile Ser Ser Val Gln Thr
65 70 75 80

Glu Asp Leu Val Asp Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105

<210> 7
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415-2 VH Delm

<400> 7

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Lys Ile Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

eol f-seq1

Trp Met Asn Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Leu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 8
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415-3 VH Delm

<400> 8

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Met Lys Ile Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Ser Ser
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

eol f-seql

<210> 9
 <211> 116
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic J415 VH Delm consensus

<400> 9

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Met Lys Ile Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30

Trp Met Asn Trp Val Arg Gln Thr Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
 50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Ser Ser
 65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
 100 105 110

Thr Val Ser Ser
 115

<210> 10
 <211> 123
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic J415 VH-MuVH consensus

<400> 10

Glu Val Lys Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Met Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser Asn Tyr
 20 25 30

Trp Met Asn Trp Val Arg Gln Ser Pro Glu Lys Gly Leu Glu Trp Val
 35 40 45

Ala Glu Ile Arg Leu Gln Ser Asp Asn Phe Ala Thr His Tyr Ala Glu
 50 55 60

eof-seq1

Glu Arg Met Thr₂₀ Leu Thr Cys Lys Ala₂₅ Ser Glu Asn Val Gly₃₀ Thr Tyr

Val Ser Trp₃₅ Tyr Gln Gln Lys Pro₄₀ Thr Gln Ser Pro Lys₄₅ Met Leu Ile

Tyr Gly₅₀ Ala Ser Asn Arg Phe₅₅ Thr Gly Val Pro Asp₆₀ Arg Phe Ser Gly

Ser Gly Ser Gly Thr Asp₇₀ Phe Ile Leu Thr Ala₇₅ Ser Ser Val Gln Ala₈₀

Glu Asp Leu Val Asp₈₅ Tyr Tyr Cys Gly Gln₉₀ Ser Tyr Thr Phe Pro Tyr₉₅

Thr Phe Gly₁₀₀ Gly Thr Lys Leu Glu₁₀₅ Met Lys

- <210> 13
- <211> 107
- <212> PRT
- <213> Artificial sequence

<220>
<223> Synthetic J415-4 VL Delm

<400> 13

Asn Ile Val Met₅ Thr Gln Ser Pro Lys₁₀ Ser Met Ser Ala Ser Ala₁₅ Gly

Glu Arg Met Thr₂₀ Leu Thr Cys Lys Ala₂₅ Ser Glu Asn Val Gly₃₀ Thr Tyr

Val Ser Trp₃₅ Tyr Gln Gln Lys Pro₄₀ Thr Gln Ser Pro Lys₄₅ Met Leu Ile

Tyr Gly₅₀ Ala Ser Asn Arg Phe₅₅ Thr Gly Val Pro Asp₆₀ Arg Phe Ser Gly

Ser Gly Ser Gly Thr Asp₇₀ Phe Ile Leu Thr Ile₇₅ Ser Ser Val Gln Ala₈₀

Glu Asp Leu Val Asp₈₅ Tyr Tyr Cys Gly Gln₉₀ Ser Tyr Thr Phe Pro Tyr₉₅

Thr Phe Gly₁₀₀ Gly Thr Lys Leu Glu₁₀₅ Met Lys

- <210> 14
- <211> 107
- <212> PRT
- <213> Artificial sequence

<220>

eol f-seq1

<223> Synthetic J415-6 VL Delm

<400> 14

Asn Ile Val Met Thr Gln Phe Pro Lys Ser Met Ser Ala Ser Ala Gly
1 5 10 15

Glu Arg Met Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80

Glu Asp Leu Val Asp Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105

<210> 15

<211> 107

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic J415-7 VL Delm

<400> 15

Asn Ile Val Met Thr Gln Phe Pro Lys Ser Met Ser Ala Ser Ala Gly
1 5 10 15

Glu Arg Val Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Thr Gln Ser Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80

Glu Asp Leu Val Asp Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105

eol f-seql

<210> 16
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415-8 VL Delm
<400> 16

Asn Ile Val Met Thr Gln Phe Pro Lys Ser Met Ser Ala Ser Ala Gly
1 5 10 15
Glu Arg Met Thr Leu Thr Cys Lys Ala Ser Glu Asn Ser Gly Thr Tyr
20 25 30
Val Ser Trp Tyr Gln Gln Lys Pro Glu Gln Ser Pro Lys Met Leu Ile
35 40 45
Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80
Glu Asp Leu Val Asp Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95
Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105

<210> 17
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415 VL consensus
<400> 17

Asn Ile Val Met Thr Gln Phe Pro Lys Ser Met Ser Ala Ser Ala Gly
1 5 10 15
Glu Arg Met Thr Leu Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30
Val Ser Trp Tyr Gln Gln Lys Pro Thr Gln Ser Pro Lys Met Leu Ile
35 40 45
Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr Ile Ser Ser Val Gln Ala
65 70 75 80

eol f-seql

Glu Asp Leu Val Asp Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gly Gly Thr Lys Leu Glu Met Lys
100 105

<210> 18
<211> 113
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415 VL-MuVL1 consensus

<400> 18

Asp Ile Val Met Thr Gln Ser Pro Ser Ser Leu Ala Val Ser Ala Gly
1 5 10 15

Glu Lys Val Thr Leu Ser Cys Lys Ala Ser Glu Ser Leu Leu Asn Val
20 25 30

Gly Asn Gln Lys Thr Tyr Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45

Ser Pro Lys Leu Leu Ile Tyr Gly Ala Ser Thr Arg Glu Ser Gly Val
50 55 60

Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Ile Leu Thr
65 70 75 80

Ile Ser Ser Val Gln Ala Glu Asp Leu Ala Val Tyr Tyr Cys Gly Asn
85 90 95

Ser Tyr Ser Phe Pro Leu Thr Phe Gly Gly Gly Thr Lys Leu Glu Leu
100 105 110

Lys

<210> 19
<211> 445
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J591 Delm heavy chain

<400> 19

Glu Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
1 5 10 15

Thr Val Lys Ile Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Glu Tyr
20 25 30

eol f-seql

Thr Ile His Trp Val Lys Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Asn Ile Asn Pro Asn Asn Gly Gly Thr Thr Tyr Asn Gln Lys Phe
 50 55 60

Glu Asp Lys Ala Thr Leu Thr Val Asp Lys Ser Thr Asp Thr Ala Tyr
 65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
 85 90 95

Ala Ala Gly Trp Asn Phe Asp Tyr Trp Gly Gln Gly Thr Leu Leu Thr
 100 105 110

Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro
 115 120 125

Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val
 130 135 140

Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala
 145 150 155 160

Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly
 165 170 175

Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly
 180 185 190

Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys
 195 200 205

Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys
 210 215 220

Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu
 225 230 235 240

Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu
 245 250 255

Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys
 260 265 270

Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
 275 280 285

Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu
 290 295 300

eol f-seq1

Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys
305 310 315 320

Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys
325 330 335

Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser
340 345 350

Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys
355 360 365

Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln
370 375 380

Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly
385 390 395 400

Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln
405 410 415

Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn
420 425 430

His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 20
<211> 214
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J591 Delm light chain

<400> 20

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Thr Ser Val Gly
1 5 10 15

Asp Arg Val Thr Leu Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala
20 25 30

Val Asp Trp Tyr Gln Gln Lys Pro Gly Pro Ser Pro Lys Leu Leu Ile
35 40 45

Tyr Trp Ala Ser Thr Arg His Thr Gly Ile Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

eol f-seql

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gl n Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 22
<211> 116
<212> PRT
<213> Arti fici al sequence

<220>
<223> Synthetic J415RHB

<400> 22

Gl u Val Lys Leu Val Gl u Ser Gly Gly Gly Leu Val Gl n Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gl n Ala Ser Gly Lys Gly Leu Gl u Trp Val
35 40 45

Ala Gl u Ile Arg Ser Gl n Ser Asn Asn Phe Ala Thr Hi s Tyr Ala Gl u
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Val Tyr Leu Gl n Met Asn Ser Leu Arg Thr Gl u Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gl n Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 23
<211> 116
<212> PRT
<213> Arti fici al sequence

<220>
<223> Synthetic J415RHC

<400> 23

Gl u Val Gl n Leu Val Gl u Ser Gly Gly Gly Leu Val Gl n Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

eol f-seq1

Trp Met Asn Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 24
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RHD

<400> 24

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Val Ile Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

eol f-seq1

<210> 25
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RHE

<400> 25

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asp Ser Lys Asn Thr
65 70 75 80

Val Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Thr Arg Arg Trp Asn Asn Phe Trp Gly Gln Gly Thr Thr Val
100 105 110

Thr Val Ser Ser
115

<210> 26
<211> 116
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RHF

<400> 26

Glu Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Asn Tyr
20 25 30

Trp Met Asn Trp Val Arg Gln Ala Ser Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Glu Ile Arg Ser Gln Ser Asn Asn Phe Ala Thr His Tyr Ala Glu
50 55 60

eol f-seq1

<210> 30

<400> 30
000

<210> 31

<211> 107

<212> PRT

<213> Arti f i c i a l s e q u e n c e

<220>

<223> Syntheti c J415RKA

<400> 31

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 32

<211> 107

<212> PRT

<213> Arti f i c i a l s e q u e n c e

<220>

<223> Syntheti c J415RKB

<400> 32

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

eol f-seq1

Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 33
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RKC

<400> 33

Asn Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Ile Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 34
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RKD

<400> 34

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

eol f-seq1

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Ile Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 35
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RKE

<400> 35

Asn Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Ile Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 36
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RKF

<400> 36

eol f-seq1

Asn Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Ile Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 37
<211> 107
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic J415RKG

<400> 37

Asn Ile Val Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Glu Asn Val Gly Thr Tyr
20 25 30

Val Ser Trp Tyr Gln Gln Lys Pro Gly Thr Ala Pro Lys Met Leu Ile
35 40 45

Tyr Gly Ala Ser Asn Arg Phe Thr Gly Val Pro Asp Arg Phe Thr Gly
50 55 60

Ser Gly Ser Ala Thr Asp Phe Thr Leu Thr Ile Asn Asn Leu Gln Pro
65 70 75 80

Glu Asp Phe Ala Thr Tyr Tyr Cys Gly Gln Ser Tyr Thr Phe Pro Tyr
85 90 95

Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 38

eol f-seq1

<400> 38
000

<210> 39

<400> 39
000

<210> 40

<400> 40
000

<210> 41

<400> 41
000

<210> 42

<400> 42
000

<210> 43

<400> 43
000

<210> 44

<400> 44
000

<210> 45

<400> 45
000

<210> 46

<400> 46
000

<210> 47

<400> 47
000

<210> 48

<400> 48
000

<210> 49

<400> 49
000

<210> 50

<400> 50
000

<210> 51

<400> 51
000

eol f-seq1

<210> 52

<400> 52
000

<210> 53

<400> 53
000

<210> 54

<400> 54
000

<210> 55

<400> 55
000

<210> 56

<400> 56
000

<210> 57

<400> 57
000

<210> 58

<400> 58
000

<210> 59

<400> 59
000

<210> 60

<400> 60
000

<210> 61

<400> 61
000

<210> 62

<400> 62
000

<210> 63

<400> 63
000

<210> 64

<400> 64
000

<210> 65

eol f-seq1

<400> 65
000

<210> 66

<400> 66
000

<210> 67

<400> 67
000

<210> 68

<400> 68
000

<210> 69

<400> 69
000

<210> 70

<400> 70
000

<210> 71

<400> 71
000

<210> 72

<400> 72
000

<210> 73

<400> 73
000

<210> 74

<400> 74
000

<210> 75

<400> 75
000

<210> 76

<400> 76
000

<210> 77

<400> 77
000

<210> 78

<400> 78
000

eol f-seq1

<210> 79

<400> 79
000

<210> 80

<400> 80
000

<210> 81

<400> 81
000

<210> 82

<400> 82
000

<210> 83

<400> 83
000

<210> 84

<400> 84
000

<210> 85

<400> 85
000

<210> 86

<400> 86
000

<210> 87

<400> 87
000

<210> 88

<400> 88
000

<210> 89

<400> 89
000

<210> 90

<400> 90
000

<210> 91

<400> 91
000

<210> 92

<400> 92

eol f-seq1

000

<210> 93

<400> 93
000

<210> 94

<400> 94
000

<210> 95

<400> 95
000

<210> 96

<400> 96
000

<210> 97

<400> 97
000

<210> 98

<400> 98
000

<210> 99

<400> 99
000

<210> 100

<400> 100
000

<210> 101

<400> 101
000

<210> 102

<400> 102
000

<210> 103

<400> 103
000

<210> 104

<400> 104
000

<210> 105

<400> 105
000

<210> 106

eol f-seql

<400> 106
000

<210> 107

<400> 107
000

<210> 108

<400> 108
000

<210> 109

<400> 109
000

<210> 110

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region

<400> 110

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

eol f-seql

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 111
 <211> 330
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, HJ C->S

<400> 111

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser

eol f-seq1
60

50

55

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Gl u Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Gl u Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Gl u Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Gl u Asp Pro Gl u Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Gl u Val His Asn Ala Lys Thr Lys Pro Arg Gl u
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Gl u Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Gl u Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Gl u Gl u
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Gl u Trp Gl u Ser Asn Gly Gl n Pro Gl u Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Gl u Ala Leu His Asn His Tyr Thr
305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys

325

eol f-seq1
330

<210> 112
<211> 330
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic IgG1 HC constant region, HJ C->V

<400> 112

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

eol f-seql

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 113
<211> 330
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic IgG1 HC constant region, BJ C->S
<400> 113

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
Page 32

eol f-seq1

115

120

125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

- <210> 114
- <211> 330
- <212> PRT
- <213> Arti ficial sequence

- <220>
- <223> Synthetic IgG1 HC constant region, BJ C->V

<400> 114

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

eol f-seq1

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

eol f-seql

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 115
 <211> 330
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, DJ C->S

<400> 115

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110

Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 Page 35

eol f-seq1

180

185

190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240 245

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 116
 <211> 330
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, DJ C->V

<400> 116

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

eol F-seq1

Tyr Ile Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys

Arg Val Glu 100 Pro Lys Ser Val Asp Lys 105 Thr His Thr Val Pro 110 Pro Val

Pro Ala Pro 115 Glu Leu Leu Gly 120 Gly Pro Ser Val Phe Leu 125 Phe Pro Pro

Lys Pro 130 Lys Asp Thr Leu Met 135 Ile Ser Arg Thr Pro 140 Glu Val Thr Cys

Val Val Val Asp Val Ser 150 His Glu Asp Pro Glu 155 Val Lys Phe Asn Trp 160

Tyr Val Asp Gly Val 165 Glu Val His Asn Ala 170 Lys Thr Lys Pro Arg Glu 175

Glu Gln Tyr Asn 180 Ser Thr Tyr Arg Val 185 Val Ser Val Leu Thr Val 190 Leu

His Gln Asp 195 Trp Leu Asn Gly Lys 200 Glu Tyr Lys Cys Lys 205 Val Ser Asn

Lys Ala 210 Leu Pro Ala Pro Ile 215 Glu Lys Thr Ile Ser 220 Lys Ala Lys Gly

Gln Pro Arg Glu Pro Gln 230 Val Tyr Thr Leu Pro 235 Pro Ser Arg Glu Glu 240

Met Thr Lys Asn Gln 245 Val Ser Leu Thr Cys 250 Leu Val Lys Gly Phe Tyr 255

Pro Ser Asp Ile 260 Ala Val Glu Trp Glu 265 Ser Asn Gly Gln Pro 270 Glu Asn

Asn Tyr Lys 275 Thr Thr Pro Pro Val 280 Leu Asp Ser Asp Gly 285 Ser Phe Phe

Leu Tyr Ser Lys Leu Thr Val 295 Asp Lys Ser Arg Trp 300 Gln Gln Gly Asn

Val Phe Ser Cys Ser Val 310 Met His Glu Ala Leu 315 His Asn His Tyr Thr 320

Gln Lys Ser Leu Ser 325 Leu Ser Pro Gly Lys 330

<210> 117

<400> 117

eol f-seql

000

<210> 118

<400> 118
000

<210> 119

<400> 119
000

<210> 120
<211> 326
<212> PRT
<213> Arti fici al sequence

<220>
<223> Syntheti c IgG2 HC constant regi on

<400> 120

Al a Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Al a Pro Cys Ser Arg
1 5 10 15

Ser Thr Ser Gl u Ser Thr Al a Al a Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gly Al a Leu Thr Ser
35 40 45

Gly Val Hi s Thr Phe Pro Al a Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Asn Phe Gly Thr Gl n Thr
65 70 75 80

Tyr Thr Cys Asn Val Asp Hi s Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Thr Val Gl u Arg Lys Cys Cys Val Gl u Cys Pro Pro Cys Pro Al a Pro
100 105 110

Pro Val Al a Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp
115 120 125

Thr Leu Met Il e Ser Arg Thr Pro Gl u Val Thr Cys Val Val Val Asp
130 135 140

Val Ser Hi s Gl u Asp Pro Gl u Val Gl n Phe Asn Trp Tyr Val Asp Gly
145 150 155 160

Val Gl u Val Hi s Asn Al a Lys Thr Lys Pro Arg Gl u Gl u Gl n Phe Asn
165 170 175

Ser Thr Phe Arg Val Val Ser Val Leu Thr Val Val Hi s Gl n Asp Trp
180 185 190

eol f-seql

Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro
 195 200 205

Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Glu Pro Arg Glu
 210 215 220

Pro Glu Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn
 225 230 235 240

Glu Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile
 245 250 255

Ala Val Glu Trp Glu Ser Asn Gly Glu Pro Glu Asn Asn Tyr Lys Thr
 260 265 270

Thr Pro Pro Met Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys
 275 280 285

Leu Thr Val Asp Lys Ser Arg Trp Glu Glu Gly Asn Val Phe Ser Cys
 290 295 300

Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Glu Lys Ser Leu
 305 310 315 320

Ser Leu Ser Pro Gly Lys
 325

<210> 121

<400> 121
 000

<210> 122

<400> 122
 000

<210> 123

<400> 123
 000

<210> 124

<400> 124
 000

<210> 125

<400> 125
 000

<210> 126

<400> 126
 000

eol f-seq1

<210> 127
 <400> 127
 000

<210> 128
 <400> 128
 000

<210> 129
 <400> 129
 000

<210> 130
 <211> 377
 <212> PRT
 <213> Arti fici al sequence

<220>
 <223> Synthetic IgG3 HC constant region

<400> 130

Al a Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Al a Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Gly Gly Thr Al a Al a Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gly Al a Leu Thr Ser
 35 40 45

Gly Val Hi s Thr Phe Pro Al a Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asn Hi s Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Gl u Leu Lys Thr Pro Leu Gly Asp Thr Thr Hi s Thr Cys Pro
 100 105 110

Arg Cys Pro Gl u Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
 115 120 125

Cys Pro Gl u Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
 130 135 140

Pro Gl u Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 145 150 155 160

Al a Pro Gl u Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 165 170 175

eol f-seql

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Glu Phe Asn Trp Tyr
 195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 210 215 220

Glu Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 225 230 235 240

Glu Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 245 250 255

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Glu
 260 265 270

Pro Arg Glu Pro Glu Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
 275 280 285

Thr Lys Asn Glu Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 290 295 300

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Glu Pro Glu Asn Asn
 305 310 315 320

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Glu Glu Gly Asn Ile
 340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Glu
 355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
 370 375

<210> 131
 <211> 377
 <212> PRT
 <213> Artificial sequence
 <220>
 <223> Synthetic IgG3 HC constant region, L164A
 <400> 131

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr

eol f-seq1

20

25

30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
 100 105 110

Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
 115 120 125

Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
 130 135 140

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 145 150 155 160

Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 165 170 175

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gl n Phe Asn Trp Tyr
 195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 210 215 220

Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 225 230 235 240

Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 245 250 255

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gl n
 260 265 270

Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
 275 280 285

Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro

eol f-seq1 300

290

295

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn
305 310 315 320

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile
340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Gln
355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
370 375

<210> 132
<211> 377
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic IgG3 HC constant region, L165A

<400> 132

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
100 105 110

Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
115 120 125

Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
130 135 140

eol f-seql

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
145 150 155 160

Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
165 170 175

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr
195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
210 215 220

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
225 230 235 240

Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
245 250 255

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln
260 265 270

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
275 280 285

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
290 295 300

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn
305 310 315 320

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile
340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Gln
355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
370 375

<210> 133
<211> 377
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic IgG3 HC constant region, L164A & L165A

eol f-seql

<400> 133

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
100 105 110Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
115 120 125Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
130 135 140Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
145 150 155 160Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
165 170 175Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
180 185 190Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr
195 200 205Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
210 215 220Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
225 230 235 240Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
245 250 255Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Gln
Page 45

eol f-seq1

260

265

270

Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
 275 280 285

Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 290 295 300

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Gln Pro Glu Asn Asn
 305 310 315 320

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Ile
 340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Gln
 355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
 370 375

<210> 134

<211> 377

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG3 HC constant region, L164G & L165G

<400> 134

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
 100 105 110

eol f-seql

Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
 115 120 125

Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
 130 135 140

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 145 150 155 160

Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 165 170 175

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Glu Phe Asn Trp Tyr
 195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 210 215 220

Glu Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His
 225 230 235 240

Glu Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys
 245 250 255

Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Thr Lys Gly Glu
 260 265 270

Pro Arg Glu Pro Glu Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met
 275 280 285

Thr Lys Asn Glu Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro
 290 295 300

Ser Asp Ile Ala Val Glu Trp Glu Ser Ser Gly Glu Pro Glu Asn Asn
 305 310 315 320

Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu
 325 330 335

Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Glu Glu Gly Asn Ile
 340 345 350

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Glu
 355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
 370 375

eol f-seql

<210> 135
 <211> 377
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG3 HC constant region, L164V & L165V

<400> 135

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Leu Lys Thr Pro Leu Gly Asp Thr Thr His Thr Cys Pro
 100 105 110

Arg Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg
 115 120 125

Cys Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys
 130 135 140

Pro Glu Pro Lys Ser Cys Asp Thr Pro Pro Pro Cys Pro Arg Cys Pro
 145 150 155 160

Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys
 165 170 175

Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val
 180 185 190

Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr
 195 200 205

Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu
 210 215 220

Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His

eol f-seql

Tyr Thr Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys
 Arg Val Glu Leu 100 Lys Thr Pro Leu Gly 105 Asp Thr Thr His Thr 110 Cys Pro
 Arg Cys Pro 115 Glu Pro Lys Ser Cys 120 Asp Thr Pro Pro Pro 125 Cys Pro Arg
 Cys Pro 130 Glu Pro Lys Ser Cys 135 Asp Thr Pro Pro Pro 140 Cys Pro Arg Cys
 Pro 145 Glu Pro Lys Ser Cys 150 Asp Thr Pro Pro Pro 155 Cys Pro Arg Cys Pro 160
 Ala Pro Glu Ile Ile 165 Gly Gly Pro Ser Val 170 Phe Leu Phe Pro Pro 175 Lys
 Pro Lys Asp Thr 180 Leu Met Ile Ser Arg 185 Thr Pro Glu Val Thr 190 Cys Val
 Val Val Asp 195 Val Ser His Glu Asp 200 Pro Glu Val Glu Phe 205 Asn Trp Tyr
 Val Asp 210 Gly Val Glu Val His 215 Asn Ala Lys Thr Lys 220 Pro Arg Glu Glu
 Glu 225 Tyr Asn Ser Thr Tyr 230 Arg Val Val Ser Val 235 Leu Thr Val Leu His 240
 Glu Asp Trp Leu Asn 245 Gly Lys Glu Tyr Lys 250 Cys Lys Val Ser Asn 255 Lys
 Ala Leu Pro Ala 260 Pro Ile Glu Lys Thr 265 Ile Ser Lys Thr Lys 270 Gly Glu
 Pro Arg Glu 275 Pro Glu Val Tyr Thr 280 Leu Pro Pro Ser Arg 285 Glu Glu Met
 Thr Lys 290 Asn Glu Val Ser Leu 295 Thr Cys Leu Val Lys 300 Gly Phe Tyr Pro
 Ser 305 Asp Ile Ala Val Glu 310 Trp Glu Ser Ser Gly 315 Glu Pro Glu Asn Asn 320
 Tyr Lys Thr Thr Pro 325 Pro Val Leu Asp Ser 330 Asp Gly Ser Phe Phe 335 Leu
 Tyr Ser Lys Leu 340 Thr Val Asp Lys Ser 345 Arg Trp Glu Glu 350 Gly Asn Ile

eol f-seql

Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Phe Thr Gln
 355 360 365

Lys Ser Leu Ser Leu Ser Pro Gly Lys
 370 375

<210> 137

<400> 137
 000

<210> 138

<400> 138
 000

<210> 139

<400> 139
 000

<210> 140

<211> 327

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG4 HC constant region

<400> 140

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
 100 105 110

Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 130 135 140

eol f-seql

Asp Val Ser Gl n Gl u Asp Pro Gl u Val Gl n Phe Asn Trp Tyr Val Asp
145 150 155 160

Gl y Val Gl u Val Hi s Asn Al a Lys Thr Lys Pro Arg Gl u Gl u Gl n Phe
165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Hi s Gl n Asp
180 185 190

Trp Leu Asn Gl y Lys Gl u Tyr Lys Cys Lys Val Ser Asn Lys Gl y Leu
195 200 205

Pro Ser Ser Il e Gl u Lys Thr Il e Ser Lys Al a Lys Gl y Gl n Pro Arg
210 215 220

Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Gl n Gl u Gl u Met Thr Lys
225 230 235 240

Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gl y Phe Tyr Pro Ser Asp
245 250 255

Il e Al a Val Gl u Trp Gl u Ser Asn Gl y Gl n Pro Gl u Asn Asn Tyr Lys
260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gl y Ser Phe Phe Leu Tyr Ser
275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl u Gl y Asn Val Phe Ser
290 295 300

Cys Ser Val Met Hi s Gl u Al a Leu Hi s Asn Hi s Tyr Thr Gl n Lys Ser
305 310 315 320

Leu Ser Leu Ser Leu Gl y Lys
325

<210> 141
<211> 327
<212> PRT
<213> Arti fici al sequence

<220>
<223> Synthetic IgG4 HC constant region, L115A

<400> 141

Al a Ser Thr Lys Gl y Pro Ser Val Phe Pro Leu Al a Pro Cys Ser Arg
1 5 10 15

Ser Thr Ser Gl u Ser Thr Al a Al a Leu Gl y Cys Leu Val Lys Asp Tyr
20 25 30

eol f-seq1

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
100 105 110

Glu Phe Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
130 135 140

Asp Val Ser Gl n Glu Asp Pro Glu Val Gl n Phe Asn Trp Tyr Val Asp
145 150 155 160

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gl n Phe
165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gl n Asp
180 185 190

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gl n Pro Arg
210 215 220

Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Gl n Glu Glu Met Thr Lys
225 230 235 240

Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255

Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn Asn Tyr Lys
260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gl n Glu Gly Asn Val Phe Ser
290 295 300

eo l f-seq l

Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gl n Lys Ser
 305 310 315 320

Leu Ser Leu Ser Leu Gly Lys
 325

<210> 142
 <211> 327
 <212> PRT
 <213> Arti fici al sequence

<220>
 <223> Synthetic IgG4 HC constant region, L115G

<400> 142

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro
 100 105 110

Glu Phe Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
 115 120 125

Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val
 130 135 140

Asp Val Ser Gl n Glu Asp Pro Glu Val Gl n Phe Asn Trp Tyr Val Asp
 145 150 155 160

Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gl n Phe
 165 170 175

Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gl n Asp
 180 185 190

Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
 195 200 205

eol f-seql

Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gl n Pro Arg
 210 215 220

Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Gl n Gl u Gl u Met Thr Lys
 225 230 235 240

Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
 245 250 255

Ile Ala Val Gl u Trp Gl u Ser Asn Gly Gl n Pro Gl u Asn Asn Tyr Lys
 260 265 270

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl u Gly Asn Val Phe Ser
 290 295 300

Cys Ser Val Met His Gl u Ala Leu His Asn His Tyr Thr Gl n Lys Ser
 305 310 315 320

Leu Ser Leu Ser Leu Gly Lys
 325

<210> 143
 <211> 327
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG4 HC constant region, L115V

<400> 143

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg
 1 5 10 15

Ser Thr Ser Gl u Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
 65 70 75 80

Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

eoI f-seqI

Arg Val Glu Ser₁₀₀ Lys Tyr Gly Pro Pro₁₀₅ Cys Pro Ser Cys Pro₁₁₀ Ala Pro

Glu Phe Val₁₁₅ Gly Gly Pro Ser Val₁₂₀ Phe Leu Phe Pro Pro₁₂₅ Lys Pro Lys

Asp Thr₁₃₀ Leu Met Ile Ser Arg₁₃₅ Thr Pro Glu Val Thr₁₄₀ Cys Val Val Val

Asp Val Ser Glu Glu Asp₁₅₀ Pro Glu Val Glu Phe₁₅₅ Asn Trp Tyr Val Asp₁₆₀

Gly Val Glu Val His₁₆₅ Asn Ala Lys Thr Lys₁₇₀ Pro Arg Glu Glu Glu Phe₁₇₅

Asn Ser Thr Tyr₁₈₀ Arg Val Val Ser Val₁₈₅ Leu Thr Val Leu His₁₉₀ Glu Asp

Trp Leu Asn₁₉₅ Gly Lys Glu Tyr Lys₂₀₀ Cys Lys Val Ser Asn₂₀₅ Lys Gly Leu

Pro Ser₂₁₀ Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys₂₂₀ Gly Glu Pro Arg

Glu Pro Glu Val Tyr Thr₂₃₀ Leu Pro Pro Ser Glu₂₃₅ Glu Glu Met Thr Lys₂₄₀

Asn Glu Val Ser₂₄₅ Leu Thr Cys Leu Val Lys₂₅₀ Gly Phe Tyr Pro Ser₂₅₅ Asp

Ile Ala Val Glu₂₆₀ Trp Glu Ser Asn Gly₂₆₅ Glu Pro Glu Asn Asn₂₇₀ Tyr Lys

Thr Thr Pro₂₇₅ Pro Val Leu Asp Ser₂₈₀ Asp Gly Ser Phe Phe₂₈₅ Leu Tyr Ser

Arg Leu Thr Val Asp Lys Ser₂₉₅ Arg Trp Glu Glu Gly₃₀₀ Asn Val Phe Ser

Cys Ser Val Met His Glu₃₁₀ Ala Leu His Asn His₃₁₅ Tyr Thr Glu Lys Ser₃₂₀

Leu Ser Leu Ser Leu Gly Lys₃₂₅

- <210> 144
- <211> 327
- <212> PRT
- <213> Artificial sequence

- <220>
- <223> Synthetic IgG4 HC constant region, L115I

eol f-seq1

<400> 144

Al a Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Al a Pro Cys Ser Arg
1 5 10 15Ser Thr Ser Gl u Ser Thr Al a Al a Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gly Al a Leu Thr Ser
35 40 45Gly Val Hi s Thr Phe Pro Al a Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr
65 70 75 80Tyr Thr Cys Asn Val Asp Hi s Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Gl u Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Al a Pro
100 105 110Gl u Phe Il e Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys
115 120 125Asp Thr Leu Met Il e Ser Arg Thr Pro Gl u Val Thr Cys Val Val Val
130 135 140Asp Val Ser Gl n Gl u Asp Pro Gl u Val Gl n Phe Asn Trp Tyr Val Asp
145 150 155 160Gly Val Gl u Val Hi s Asn Al a Lys Thr Lys Pro Arg Gl u Gl u Gl n Phe
165 170 175Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu Hi s Gl n Asp
180 185 190Trp Leu Asn Gly Lys Gl u Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu
195 200 205Pro Ser Ser Il e Gl u Lys Thr Il e Ser Lys Al a Lys Gly Gl n Pro Arg
210 215 220Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Gl n Gl u Gl u Met Thr Lys
225 230 235 240Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp
245 250 255Il e Al a Val Gl u Trp Gl u Ser Asn Gly Gl n Pro Gl u Asn Asn Tyr Lys
260 265 270

eol f-seql

Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser
 275 280 285

Arg Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl u Gly Asn Val Phe Ser
 290 295 300

Cys Ser Val Met His Gl u Ala Leu His Asn His Tyr Thr Gl n Lys Ser
 305 310 315 320

Leu Ser Leu Ser Leu Gly Lys
 325

<210> 145

<400> 145
 000

<210> 146

<400> 146
 000

<210> 147

<400> 147
 000

<210> 148

<400> 148
 000

<210> 149

<400> 149
 000

<210> 150

<211> 105

<212> PRT

<213> Arti fici al sequence

<220>

<223> kappa LC constant region

<400> 150

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Gl u Gl n Leu
 1 5 10 15

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
 20 25 30

Arg Gl u Ala Lys Val Gl n Trp Lys Val Asp Asn Ala Leu Gl n Ser Gly
 35 40 45

Asn Ser Gl n Gl u Ser Val Thr Gl u Gl n Asp Ser Lys Asp Ser Thr Tyr
 50 55 60

eol f-seq1

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
65 70 75 80

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
85 90 95

Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 151
<211> 105
<212> PRT
<213> Artificial sequence

<220>
<223> kappa LC constant region, C105S

<400> 151

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
1 5 10 15

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
20 25 30

Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
35 40 45

Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
50 55 60

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
65 70 75 80

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
85 90 95

Thr Lys Ser Phe Asn Arg Gly Glu Ser
100 105

<210> 152
<211> 105
<212> PRT
<213> Artificial sequence

<220>
<223> kappa LC constant region, C105V

<400> 152

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
1 5 10 15

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
20 25 30

eol f-seql

Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
35 40 45

Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
50 55 60

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
65 70 75 80

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
85 90 95

Thr Lys Ser Phe Asn Arg Gly Glu Val
100 105

<210> 153
<211> 104
<212> PRT
<213> Artificial sequence

<220>
<223> kappa LC constant region, C105del
<400> 153

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
1 5 10 15

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
20 25 30

Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
35 40 45

Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
50 55 60

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
65 70 75 80

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
85 90 95

Thr Lys Ser Phe Asn Arg Gly Glu
100

<210> 154
<400> 154
000

<210> 155
<400> 155
000

eol f-seql

<210> 156

<400> 156
000

<210> 157

<400> 157
000

<210> 158

<400> 158
000

<210> 159

<400> 159
000

<210> 160

<211> 103

<212> PRT

<213> Arti fici al sequence

<220>

<223> I am bda LC constant regi on

<400> 160

Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
1 5 10 15

Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
20 25 30

Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
35 40 45

Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
50 55 60

Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
65 70 75 80

Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
85 90 95

Val Ala Pro Thr Glu Cys Ser
100

<210> 161

<211> 103

<212> PRT

<213> Arti fici al sequence

<220>

<223> I am bda LC constant regi on, C102S

<400> 161

eol f-seql

Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
1 5 10 15

Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
20 25 30

Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
35 40 45

Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
50 55 60

Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
65 70 75 80

Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
85 90 95

Val Ala Pro Thr Glu Ser Ser
100

<210> 162
<211> 103
<212> PRT
<213> Artificial sequence

<220>
<223> lambda LC constant region, C102V

<400> 162

Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
1 5 10 15

Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
20 25 30

Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
35 40 45

Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
50 55 60

Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
65 70 75 80

Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
85 90 95

Val Ala Pro Thr Glu Val Ser
100

<210> 163

eol f-seqI

<211> 101
<212> PRT
<213> Arti f i c i a l s e q u e n c e

<220>
<223> I a m b d a L C c o n s t a n t r e g i o n , C 1 0 2 & S 1 0 3 d e l

<400> 163

Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu Leu
1 5 10 15

Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr Pro
20 25 30

Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys Ala
35 40 45

Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr Ala
50 55 60

Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His Arg
65 70 75 80

Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys Thr
85 90 95

Val Ala Pro Thr Glu
100

<210> 164

<400> 164
000

<210> 165

<400> 165
000

<210> 166

<400> 166
000

<210> 167

<400> 167
000

<210> 168

<400> 168
000

<210> 169

<400> 169
000

<210> 170

eol f-seqI

<400> 170
000

<210> 171

<400> 171
000

<210> 172

<400> 172
000

<210> 173

<400> 173
000

<210> 174

<400> 174
000

<210> 175

<400> 175
000

<210> 176

<400> 176
000

<210> 177

<400> 177
000

<210> 178

<400> 178
000

<210> 179

<400> 179
000

<210> 180

<400> 180
000

<210> 181

<400> 181
000

<210> 182

<400> 182
000

<210> 183

<400> 183
000

eol f-seqI

<210> 184
<400> 184
000
<210> 185
<400> 185
000
<210> 186
<400> 186
000
<210> 187
<400> 187
000
<210> 188
<400> 188
000
<210> 189
<400> 189
000
<210> 190
<400> 190
000
<210> 191
<400> 191
000
<210> 192
<400> 192
000
<210> 193
<400> 193
000
<210> 194
<400> 194
000
<210> 195
<400> 195
000
<210> 196
<400> 196
000
<210> 197

eol f-seq1

<400> 197
000
<210> 198
<400> 198
000
<210> 199
<400> 199
000
<210> 200
<400> 200
000
<210> 201
<400> 201
000
<210> 202
<400> 202
000
<210> 203
<400> 203
000
<210> 204
<400> 204
000
<210> 205
<400> 205
000
<210> 206
<400> 206
000
<210> 207
<400> 207
000
<210> 208
<400> 208
000
<210> 209
<400> 209
000
<210> 210
<400> 210
000

eol f-seq1

<210> 211

<400> 211
000

<210> 212

<400> 212
000

<210> 213

<400> 213
000

<210> 214

<400> 214
000

<210> 215

<400> 215
000

<210> 216

<400> 216
000

<210> 217

<400> 217
000

<210> 218

<400> 218
000

<210> 219

<400> 219
000

<210> 220

<400> 220
000

<210> 221

<400> 221
000

<210> 222

<400> 222
000

<210> 223

<400> 223
000

<210> 224

<400> 224

eol f-seq1

000

<210> 225

<400> 225
000

<210> 226

<400> 226
000

<210> 227

<400> 227
000

<210> 228

<400> 228
000

<210> 229

<400> 229
000

<210> 230

<400> 230
000

<210> 231

<400> 231
000

<210> 232

<400> 232
000

<210> 233

<400> 233
000

<210> 234

<400> 234
000

<210> 235

<400> 235
000

<210> 236

<400> 236
000

<210> 237

<400> 237
000

<210> 238

eol f-seq1

<400> 238
000

<210> 239

<400> 239
000

<210> 240

<400> 240
000

<210> 241

<400> 241
000

<210> 242

<400> 242
000

<210> 243

<400> 243
000

<210> 244

<400> 244
000

<210> 245

<400> 245
000

<210> 246

<400> 246
000

<210> 247

<400> 247
000

<210> 248

<400> 248
000

<210> 249

<400> 249
000

<210> 250

<400> 250
000

<210> 251

<400> 251
000

eol f-seqI

<210> 252
<400> 252
000
<210> 253
<400> 253
000
<210> 254
<400> 254
000
<210> 255
<400> 255
000
<210> 256
<400> 256
000
<210> 257
<400> 257
000
<210> 258
<400> 258
000
<210> 259
<400> 259
000
<210> 260
<400> 260
000
<210> 261
<400> 261
000
<210> 262
<400> 262
000
<210> 263
<400> 263
000
<210> 264
<400> 264
000
<210> 265

eol f-seq1

<400> 265
000

<210> 266

<400> 266
000

<210> 267

<400> 267
000

<210> 268

<400> 268
000

<210> 269

<400> 269
000

<210> 270

<400> 270
000

<210> 271

<400> 271
000

<210> 272

<400> 272
000

<210> 273

<400> 273
000

<210> 274

<400> 274
000

<210> 275

<400> 275
000

<210> 276

<400> 276
000

<210> 277

<400> 277
000

<210> 278

<400> 278
000

eol f-seq1

<210> 279

<400> 279
000

<210> 280

<400> 280
000

<210> 281

<400> 281
000

<210> 282

<400> 282
000

<210> 283

<400> 283
000

<210> 284

<400> 284
000

<210> 285

<400> 285
000

<210> 286

<400> 286
000

<210> 287

<400> 287
000

<210> 288

<400> 288
000

<210> 289

<400> 289
000

<210> 290

<400> 290
000

<210> 291

<400> 291
000

<210> 292

<400> 292

000

<210> 293

<400> 293
000

<210> 294

<400> 294
000

<210> 295

<400> 295
000

<210> 296

<400> 296
000

<210> 297

<400> 297
000

<210> 298

<400> 298
000

<210> 299

<400> 299
000

<210> 300

<400> 300
000

<210> 301

<400> 301
000

<210> 302

<400> 302
000

<210> 303

<400> 303
000

<210> 304

<400> 304
000

<210> 305

<400> 305
000

<210> 306

eol f-seq1

<400> 306
000

<210> 307

<400> 307
000

<210> 308

<400> 308
000

<210> 309

<400> 309
000

<210> 310

<400> 310
000

<210> 311

<400> 311
000

<210> 312

<400> 312
000

<210> 313

<400> 313
000

<210> 314

<400> 314
000

<210> 315

<400> 315
000

<210> 316

<400> 316
000

<210> 317

<400> 317
000

<210> 318

<400> 318
000

<210> 319

<400> 319
000

eol f-seqI

<210> 320

<400> 320
000

<210> 321

<400> 321
000

<210> 322

<400> 322
000

<210> 323

<400> 323
000

<210> 324

<400> 324
000

<210> 325

<400> 325
000

<210> 326

<400> 326
000

<210> 327

<400> 327
000

<210> 328

<400> 328
000

<210> 329

<400> 329
000

<210> 330

<400> 330
000

<210> 331

<400> 331
000

<210> 332

<400> 332
000

<210> 333

eol f-seq1

<400> 333
000

<210> 334

<400> 334
000

<210> 335

<400> 335
000

<210> 336

<400> 336
000

<210> 337

<400> 337
000

<210> 338

<400> 338
000

<210> 339

<400> 339
000

<210> 340

<400> 340
000

<210> 341

<400> 341
000

<210> 342

<400> 342
000

<210> 343

<400> 343
000

<210> 344

<400> 344
000

<210> 345

<400> 345
000

<210> 346

<400> 346
000

eol f-seqI

<210> 347

<400> 347
000

<210> 348

<400> 348
000

<210> 349

<400> 349
000

<210> 350

<400> 350
000

<210> 351

<400> 351
000

<210> 352

<400> 352
000

<210> 353

<400> 353
000

<210> 354

<400> 354
000

<210> 355

<400> 355
000

<210> 356

<400> 356
000

<210> 357

<400> 357
000

<210> 358

<400> 358
000

<210> 359

<400> 359
000

<210> 360

<400> 360

000

<210> 361

<400> 361
000

<210> 362

<400> 362
000

<210> 363

<400> 363
000

<210> 364

<400> 364
000

<210> 365

<400> 365
000

<210> 366

<400> 366
000

<210> 367

<400> 367
000

<210> 368

<400> 368
000

<210> 369

<400> 369
000

<210> 370

<400> 370
000

<210> 371

<400> 371
000

<210> 372

<400> 372
000

<210> 373

<400> 373
000

<210> 374

eol f-seq1

<400> 374
000

<210> 375

<400> 375
000

<210> 376

<400> 376
000

<210> 377

<400> 377
000

<210> 378

<400> 378
000

<210> 379

<400> 379
000

<210> 380

<400> 380
000

<210> 381

<400> 381
000

<210> 382

<400> 382
000

<210> 383

<400> 383
000

<210> 384

<400> 384
000

<210> 385

<400> 385
000

<210> 386

<400> 386
000

<210> 387

<400> 387
000

eol f-seqI

<210> 388

<400> 388
000

<210> 389

<400> 389
000

<210> 390

<400> 390
000

<210> 391

<400> 391
000

<210> 392

<400> 392
000

<210> 393

<400> 393
000

<210> 394

<400> 394
000

<210> 395

<400> 395
000

<210> 396

<400> 396
000

<210> 397

<400> 397
000

<210> 398

<400> 398
000

<210> 399

<400> 399
000

<210> 400

<400> 400
000

<210> 401

eol f-seq1

<400> 401
000

<210> 402

<400> 402
000

<210> 403

<400> 403
000

<210> 404

<400> 404
000

<210> 405

<400> 405
000

<210> 406

<400> 406
000

<210> 407

<400> 407
000

<210> 408

<400> 408
000

<210> 409

<400> 409
000

<210> 410

<400> 410
000

<210> 411

<400> 411
000

<210> 412

<400> 412
000

<210> 413

<400> 413
000

<210> 414

<400> 414
000

eol f-seq1

<210> 415

<400> 415
000

<210> 416

<400> 416
000

<210> 417

<400> 417
000

<210> 418

<400> 418
000

<210> 419

<400> 419
000

<210> 420

<400> 420
000

<210> 421

<400> 421
000

<210> 422

<400> 422
000

<210> 423

<400> 423
000

<210> 424

<400> 424
000

<210> 425

<400> 425
000

<210> 426

<400> 426
000

<210> 427

<400> 427
000

<210> 428

<400> 428

000

<210> 429

<400> 429
000

<210> 430

<400> 430
000

<210> 431

<400> 431
000

<210> 432

<400> 432
000

<210> 433

<400> 433
000

<210> 434

<400> 434
000

<210> 435

<400> 435
000

<210> 436

<400> 436
000

<210> 437

<400> 437
000

<210> 438

<400> 438
000

<210> 439

<400> 439
000

<210> 440

<400> 440
000

<210> 441

<400> 441
000

<210> 442

eol f-seq1

<400> 442
000

<210> 443

<400> 443
000

<210> 444

<400> 444
000

<210> 445

<400> 445
000

<210> 446

<400> 446
000

<210> 447

<400> 447
000

<210> 448

<400> 448
000

<210> 449

<400> 449
000

<210> 450

<400> 450
000

<210> 451

<400> 451
000

<210> 452

<400> 452
000

<210> 453

<400> 453
000

<210> 454

<400> 454
000

<210> 455

<400> 455
000

eol f-seq1

<210> 456

<400> 456
000

<210> 457

<400> 457
000

<210> 458

<400> 458
000

<210> 459

<400> 459
000

<210> 460

<400> 460
000

<210> 461

<400> 461
000

<210> 462

<400> 462
000

<210> 463

<400> 463
000

<210> 464

<400> 464
000

<210> 465

<400> 465
000

<210> 466

<400> 466
000

<210> 467

<400> 467
000

<210> 468

<400> 468
000

<210> 469

eol f-seq1

<400> 469
000
<210> 470
<400> 470
000
<210> 471
<400> 471
000
<210> 472
<400> 472
000
<210> 473
<400> 473
000
<210> 474
<400> 474
000
<210> 475
<400> 475
000
<210> 476
<400> 476
000
<210> 477
<400> 477
000
<210> 478
<400> 478
000
<210> 479
<400> 479
000
<210> 480
<400> 480
000
<210> 481
<400> 481
000
<210> 482
<400> 482
000

eol f-seq1

<210> 483

<400> 483
000

<210> 484

<400> 484
000

<210> 485

<400> 485
000

<210> 486

<400> 486
000

<210> 487

<400> 487
000

<210> 488

<400> 488
000

<210> 489

<400> 489
000

<210> 490

<400> 490
000

<210> 491

<400> 491
000

<210> 492

<400> 492
000

<210> 493

<400> 493
000

<210> 494

<400> 494
000

<210> 495

<400> 495
000

<210> 496

<400> 496

000

<210> 497

<400> 497
000

<210> 498

<400> 498
000

<210> 499

<400> 499
000

<210> 500

<400> 500
000

<210> 501

<400> 501
000

<210> 502

<400> 502
000

<210> 503

<400> 503
000

<210> 504

<400> 504
000

<210> 505

<400> 505
000

<210> 506

<400> 506
000

<210> 507

<400> 507
000

<210> 508

<400> 508
000

<210> 509

<400> 509
000

<210> 510

eol f-seq1

<400> 510
000

<210> 511

<400> 511
000

<210> 512

<400> 512
000

<210> 513

<400> 513
000

<210> 514

<400> 514
000

<210> 515

<400> 515
000

<210> 516

<400> 516
000

<210> 517

<400> 517
000

<210> 518

<400> 518
000

<210> 519

<400> 519
000

<210> 520

<400> 520
000

<210> 521

<400> 521
000

<210> 522

<400> 522
000

<210> 523

<400> 523
000

eol f-seqI

<210> 524

<400> 524
000

<210> 525

<400> 525
000

<210> 526

<400> 526
000

<210> 527

<400> 527
000

<210> 528

<400> 528
000

<210> 529

<400> 529
000

<210> 530

<400> 530
000

<210> 531

<400> 531
000

<210> 532

<400> 532
000

<210> 533

<400> 533
000

<210> 534

<400> 534
000

<210> 535

<400> 535
000

<210> 536

<400> 536
000

<210> 537

eol f-seq1

<400> 537
000

<210> 538

<400> 538
000

<210> 539

<400> 539
000

<210> 540

<400> 540
000

<210> 541

<400> 541
000

<210> 542

<400> 542
000

<210> 543

<400> 543
000

<210> 544

<400> 544
000

<210> 545

<400> 545
000

<210> 546

<400> 546
000

<210> 547

<400> 547
000

<210> 548

<400> 548
000

<210> 549

<400> 549
000

<210> 550

<400> 550
000

eol f-seq1

<210> 551

<400> 551
000

<210> 552

<400> 552
000

<210> 553

<400> 553
000

<210> 554

<400> 554
000

<210> 555

<400> 555
000

<210> 556

<400> 556
000

<210> 557

<400> 557
000

<210> 558

<400> 558
000

<210> 559

<400> 559
000

<210> 560

<400> 560
000

<210> 561

<400> 561
000

<210> 562

<400> 562
000

<210> 563

<400> 563
000

<210> 564

<400> 564

000

<210> 565

<400> 565
000

<210> 566

<400> 566
000

<210> 567

<400> 567
000

<210> 568

<400> 568
000

<210> 569

<400> 569
000

<210> 570

<400> 570
000

<210> 571

<400> 571
000

<210> 572

<400> 572
000

<210> 573

<400> 573
000

<210> 574

<400> 574
000

<210> 575

<400> 575
000

<210> 576

<400> 576
000

<210> 577

<400> 577
000

<210> 578

eol f-seq1

<400> 578
000

<210> 579

<400> 579
000

<210> 580

<400> 580
000

<210> 581

<400> 581
000

<210> 582

<400> 582
000

<210> 583

<400> 583
000

<210> 584

<400> 584
000

<210> 585

<400> 585
000

<210> 586

<400> 586
000

<210> 587

<400> 587
000

<210> 588

<400> 588
000

<210> 589

<400> 589
000

<210> 590

<400> 590
000

<210> 591

<400> 591
000

eol f-seqI

<210> 592

<400> 592
000

<210> 593

<400> 593
000

<210> 594

<400> 594
000

<210> 595

<400> 595
000

<210> 596

<400> 596
000

<210> 597

<400> 597
000

<210> 598

<400> 598
000

<210> 599

<400> 599
000

<210> 600

<400> 600
000

<210> 601

<400> 601
000

<210> 602

<400> 602
000

<210> 603

<400> 603
000

<210> 604

<400> 604
000

<210> 605

eol f-seq1

<400> 605
000

<210> 606

<400> 606
000

<210> 607

<400> 607
000

<210> 608

<400> 608
000

<210> 609

<400> 609
000

<210> 610

<400> 610
000

<210> 611

<400> 611
000

<210> 612

<400> 612
000

<210> 613

<400> 613
000

<210> 614

<400> 614
000

<210> 615

<400> 615
000

<210> 616

<400> 616
000

<210> 617

<400> 617
000

<210> 618

<400> 618
000

eol f-seq1

<210> 619

<400> 619
000

<210> 620

<400> 620
000

<210> 621

<400> 621
000

<210> 622

<400> 622
000

<210> 623

<400> 623
000

<210> 624

<400> 624
000

<210> 625

<400> 625
000

<210> 626

<400> 626
000

<210> 627

<400> 627
000

<210> 628

<400> 628
000

<210> 629

<400> 629
000

<210> 630

<400> 630
000

<210> 631

<400> 631
000

<210> 632

<400> 632

000

<210> 633

<400> 633
000

<210> 634

<400> 634
000

<210> 635

<400> 635
000

<210> 636

<400> 636
000

<210> 637

<400> 637
000

<210> 638

<400> 638
000

<210> 639

<400> 639
000

<210> 640

<400> 640
000

<210> 641

<400> 641
000

<210> 642

<400> 642
000

<210> 643

<400> 643
000

<210> 644

<400> 644
000

<210> 645

<400> 645
000

<210> 646

eol f-seq1

<400> 646
000

<210> 647

<400> 647
000

<210> 648

<400> 648
000

<210> 649

<400> 649
000

<210> 650

<400> 650
000

<210> 651

<400> 651
000

<210> 652

<400> 652
000

<210> 653

<400> 653
000

<210> 654

<400> 654
000

<210> 655

<400> 655
000

<210> 656

<400> 656
000

<210> 657

<400> 657
000

<210> 658

<400> 658
000

<210> 659

<400> 659
000

eol f-seq1

<210> 660

<400> 660
000

<210> 661

<400> 661
000

<210> 662

<400> 662
000

<210> 663

<400> 663
000

<210> 664

<400> 664
000

<210> 665

<400> 665
000

<210> 666

<400> 666
000

<210> 667

<400> 667
000

<210> 668

<400> 668
000

<210> 669

<400> 669
000

<210> 670

<400> 670
000

<210> 671

<400> 671
000

<210> 672

<400> 672
000

<210> 673

eol f-seq1

<400> 673
000

<210> 674

<400> 674
000

<210> 675

<400> 675
000

<210> 676

<400> 676
000

<210> 677

<400> 677
000

<210> 678

<400> 678
000

<210> 679

<400> 679
000

<210> 680

<400> 680
000

<210> 681

<400> 681
000

<210> 682

<400> 682
000

<210> 683

<400> 683
000

<210> 684

<400> 684
000

<210> 685

<400> 685
000

<210> 686

<400> 686
000

<210> 687

<400> 687
000

<210> 688

<400> 688
000

<210> 689

<400> 689
000

<210> 690

<400> 690
000

<210> 691

<400> 691
000

<210> 692

<400> 692
000

<210> 693

<400> 693
000

<210> 694

<400> 694
000

<210> 695

<400> 695
000

<210> 696

<400> 696
000

<210> 697

<400> 697
000

<210> 698

<400> 698
000

<210> 699

<400> 699
000

<210> 700

<400> 700

000

<210> 701

<400> 701
000

<210> 702

<400> 702
000

<210> 703

<400> 703
000

<210> 704

<400> 704
000

<210> 705

<400> 705
000

<210> 706

<400> 706
000

<210> 707

<400> 707
000

<210> 708

<400> 708
000

<210> 709

<400> 709
000

<210> 710

<400> 710
000

<210> 711

<400> 711
000

<210> 712

<400> 712
000

<210> 713

<400> 713
000

<210> 714

eol f-seq1

<400> 714
000

<210> 715

<400> 715
000

<210> 716

<400> 716
000

<210> 717

<400> 717
000

<210> 718

<400> 718
000

<210> 719

<400> 719
000

<210> 720

<400> 720
000

<210> 721

<400> 721
000

<210> 722

<400> 722
000

<210> 723

<400> 723
000

<210> 724

<400> 724
000

<210> 725

<400> 725
000

<210> 726

<400> 726
000

<210> 727

<400> 727
000

eol f-seqI

<210> 728

<400> 728
000

<210> 729

<400> 729
000

<210> 730

<400> 730
000

<210> 731

<400> 731
000

<210> 732

<400> 732
000

<210> 733

<400> 733
000

<210> 734

<400> 734
000

<210> 735

<400> 735
000

<210> 736

<400> 736
000

<210> 737

<400> 737
000

<210> 738

<400> 738
000

<210> 739

<400> 739
000

<210> 740

<400> 740
000

<210> 741

eol f-seq1

<400> 741
000

<210> 742

<400> 742
000

<210> 743

<400> 743
000

<210> 744

<400> 744
000

<210> 745

<400> 745
000

<210> 746

<400> 746
000

<210> 747

<400> 747
000

<210> 748

<400> 748
000

<210> 749

<400> 749
000

<210> 750

<400> 750
000

<210> 751

<400> 751
000

<210> 752

<400> 752
000

<210> 753

<400> 753
000

<210> 754

<400> 754
000

eol f-seq1

<210> 755

<400> 755
000

<210> 756

<400> 756
000

<210> 757

<400> 757
000

<210> 758

<400> 758
000

<210> 759

<400> 759
000

<210> 760

<400> 760
000

<210> 761

<400> 761
000

<210> 762

<400> 762
000

<210> 763

<400> 763
000

<210> 764

<400> 764
000

<210> 765

<400> 765
000

<210> 766

<400> 766
000

<210> 767

<400> 767
000

<210> 768

<400> 768

000

<210> 769

<400> 769
000

<210> 770

<400> 770
000

<210> 771

<400> 771
000

<210> 772

<400> 772
000

<210> 773

<400> 773
000

<210> 774

<400> 774
000

<210> 775

<400> 775
000

<210> 776

<400> 776
000

<210> 777

<400> 777
000

<210> 778

<400> 778
000

<210> 779

<400> 779
000

<210> 780

<400> 780
000

<210> 781

<400> 781
000

<210> 782

eol f-seq1

<400> 782
000

<210> 783

<400> 783
000

<210> 784

<400> 784
000

<210> 785

<400> 785
000

<210> 786

<400> 786
000

<210> 787

<400> 787
000

<210> 788

<400> 788
000

<210> 789

<400> 789
000

<210> 790

<400> 790
000

<210> 791

<400> 791
000

<210> 792

<400> 792
000

<210> 793

<400> 793
000

<210> 794

<400> 794
000

<210> 795

<400> 795
000

eol f-seq1

<210> 796

<400> 796
000

<210> 797

<400> 797
000

<210> 798

<400> 798
000

<210> 799

<400> 799
000

<210> 800

<400> 800
000

<210> 801

<400> 801
000

<210> 802

<400> 802
000

<210> 803

<400> 803
000

<210> 804

<400> 804
000

<210> 805

<400> 805
000

<210> 806

<400> 806
000

<210> 807

<400> 807
000

<210> 808

<400> 808
000

<210> 809

eol f-seq1

<400> 809
000

<210> 810

<400> 810
000

<210> 811

<400> 811
000

<210> 812

<400> 812
000

<210> 813

<400> 813
000

<210> 814

<400> 814
000

<210> 815

<400> 815
000

<210> 816

<400> 816
000

<210> 817

<400> 817
000

<210> 818

<400> 818
000

<210> 819

<400> 819
000

<210> 820

<400> 820
000

<210> 821

<400> 821
000

<210> 822

<400> 822
000

<210> 823
<400> 823
000
<210> 824
<400> 824
000
<210> 825
<400> 825
000
<210> 826
<400> 826
000
<210> 827
<400> 827
000
<210> 828
<400> 828
000
<210> 829
<400> 829
000
<210> 830
<400> 830
000
<210> 831
<400> 831
000
<210> 832
<400> 832
000
<210> 833
<400> 833
000
<210> 834
<400> 834
000
<210> 835
<400> 835
000
<210> 836
<400> 836

000

<210> 837

<400> 837
000

<210> 838

<400> 838
000

<210> 839

<400> 839
000

<210> 840

<400> 840
000

<210> 841

<400> 841
000

<210> 842

<400> 842
000

<210> 843

<400> 843
000

<210> 844

<400> 844
000

<210> 845

<400> 845
000

<210> 846

<400> 846
000

<210> 847

<400> 847
000

<210> 848

<400> 848
000

<210> 849

<400> 849
000

<210> 850

eol f-seq1

<400> 850
000

<210> 851

<400> 851
000

<210> 852

<400> 852
000

<210> 853

<400> 853
000

<210> 854

<400> 854
000

<210> 855

<400> 855
000

<210> 856

<400> 856
000

<210> 857

<400> 857
000

<210> 858

<400> 858
000

<210> 859

<400> 859
000

<210> 860

<400> 860
000

<210> 861

<400> 861
000

<210> 862

<400> 862
000

<210> 863

<400> 863
000

eol f-seqI

<210> 864

<400> 864
000

<210> 865

<400> 865
000

<210> 866

<400> 866
000

<210> 867

<400> 867
000

<210> 868

<400> 868
000

<210> 869

<400> 869
000

<210> 870

<400> 870
000

<210> 871

<400> 871
000

<210> 872

<400> 872
000

<210> 873

<400> 873
000

<210> 874

<400> 874
000

<210> 875

<400> 875
000

<210> 876

<400> 876
000

<210> 877

eol f-seq1

<400> 877
000

<210> 878

<400> 878
000

<210> 879

<400> 879
000

<210> 880

<400> 880
000

<210> 881

<400> 881
000

<210> 882

<400> 882
000

<210> 883

<400> 883
000

<210> 884

<400> 884
000

<210> 885

<400> 885
000

<210> 886

<400> 886
000

<210> 887

<400> 887
000

<210> 888

<400> 888
000

<210> 889

<400> 889
000

<210> 890

<400> 890
000

<210> 891

<400> 891
000

<210> 892

<400> 892
000

<210> 893

<400> 893
000

<210> 894

<400> 894
000

<210> 895

<400> 895
000

<210> 896

<400> 896
000

<210> 897

<400> 897
000

<210> 898

<400> 898
000

<210> 899

<400> 899
000

<210> 900

<400> 900
000

<210> 901

<400> 901
000

<210> 902

<400> 902
000

<210> 903

<400> 903
000

<210> 904

<400> 904

000

<210> 905

<400> 905
000

<210> 906

<400> 906
000

<210> 907

<400> 907
000

<210> 908

<400> 908
000

<210> 909

<400> 909
000

<210> 910

<400> 910
000

<210> 911

<400> 911
000

<210> 912

<400> 912
000

<210> 913

<400> 913
000

<210> 914

<400> 914
000

<210> 915

<400> 915
000

<210> 916

<400> 916
000

<210> 917

<400> 917
000

<210> 918

eol f-seq1

<400> 918
000

<210> 919

<400> 919
000

<210> 920

<400> 920
000

<210> 921

<400> 921
000

<210> 922

<400> 922
000

<210> 923

<400> 923
000

<210> 924

<400> 924
000

<210> 925

<400> 925
000

<210> 926

<400> 926
000

<210> 927

<400> 927
000

<210> 928

<400> 928
000

<210> 929

<400> 929
000

<210> 930

<400> 930
000

<210> 931

<400> 931
000

eol f-seqI

<210> 932

<400> 932
000

<210> 933

<400> 933
000

<210> 934

<400> 934
000

<210> 935

<400> 935
000

<210> 936

<400> 936
000

<210> 937

<400> 937
000

<210> 938

<400> 938
000

<210> 939

<400> 939
000

<210> 940

<400> 940
000

<210> 941

<400> 941
000

<210> 942

<400> 942
000

<210> 943

<400> 943
000

<210> 944

<400> 944
000

<210> 945

eol f-seq1

<400> 945
000

<210> 946

<400> 946
000

<210> 947

<400> 947
000

<210> 948

<400> 948
000

<210> 949

<400> 949
000

<210> 950

<400> 950
000

<210> 951

<400> 951
000

<210> 952

<400> 952
000

<210> 953

<400> 953
000

<210> 954

<400> 954
000

<210> 955

<400> 955
000

<210> 956

<400> 956
000

<210> 957

<400> 957
000

<210> 958

<400> 958
000

eol f-seq1

<210> 959

<400> 959
000

<210> 960

<400> 960
000

<210> 961

<400> 961
000

<210> 962

<400> 962
000

<210> 963

<400> 963
000

<210> 964

<400> 964
000

<210> 965

<400> 965
000

<210> 966

<400> 966
000

<210> 967

<400> 967
000

<210> 968

<400> 968
000

<210> 969

<400> 969
000

<210> 970

<400> 970
000

<210> 971

<400> 971
000

<210> 972

<400> 972

000

<210> 973

<400> 973
000

<210> 974

<400> 974
000

<210> 975

<400> 975
000

<210> 976

<400> 976
000

<210> 977

<400> 977
000

<210> 978

<400> 978
000

<210> 979

<400> 979
000

<210> 980

<400> 980
000

<210> 981

<400> 981
000

<210> 982

<400> 982
000

<210> 983

<400> 983
000

<210> 984

<400> 984
000

<210> 985

<400> 985
000

<210> 986

eol f-seq1

<400> 986
000

<210> 987

<400> 987
000

<210> 988

<400> 988
000

<210> 989

<400> 989
000

<210> 990

<400> 990
000

<210> 991

<400> 991
000

<210> 992

<400> 992
000

<210> 993

<400> 993
000

<210> 994

<400> 994
000

<210> 995

<400> 995
000

<210> 996

<400> 996
000

<210> 997

<400> 997
000

<210> 998

<400> 998
000

<210> 999

<400> 999
000

eol f-seqI

<210> 1000
<400> 1000
000
<210> 1001
<400> 1001
000
<210> 1002
<400> 1002
000
<210> 1003
<400> 1003
000
<210> 1004
<400> 1004
000
<210> 1005
<400> 1005
000
<210> 1006
<400> 1006
000
<210> 1007
<400> 1007
000
<210> 1008
<400> 1008
000
<210> 1009
<400> 1009
000
<210> 1010
<400> 1010
000
<210> 1011
<400> 1011
000
<210> 1012
<400> 1012
000
<210> 1013

eol f-seq1

<400> 1013
000

<210> 1014

<400> 1014
000

<210> 1015

<400> 1015
000

<210> 1016

<400> 1016
000

<210> 1017

<400> 1017
000

<210> 1018

<400> 1018
000

<210> 1019

<400> 1019
000

<210> 1020

<400> 1020
000

<210> 1021

<400> 1021
000

<210> 1022

<400> 1022
000

<210> 1023

<400> 1023
000

<210> 1024

<400> 1024
000

<210> 1025

<400> 1025
000

<210> 1026

<400> 1026
000

eol f-seq1

<210> 1027

<400> 1027
000

<210> 1028

<400> 1028
000

<210> 1029

<400> 1029
000

<210> 1030

<400> 1030
000

<210> 1031

<400> 1031
000

<210> 1032

<400> 1032
000

<210> 1033

<400> 1033
000

<210> 1034

<400> 1034
000

<210> 1035

<400> 1035
000

<210> 1036

<400> 1036
000

<210> 1037

<400> 1037
000

<210> 1038

<400> 1038
000

<210> 1039

<400> 1039
000

<210> 1040

<400> 1040

000

<210> 1041

<400> 1041
000

<210> 1042

<400> 1042
000

<210> 1043

<400> 1043
000

<210> 1044

<400> 1044
000

<210> 1045

<400> 1045
000

<210> 1046

<400> 1046
000

<210> 1047

<400> 1047
000

<210> 1048

<400> 1048
000

<210> 1049

<400> 1049
000

<210> 1050

<400> 1050
000

<210> 1051

<400> 1051
000

<210> 1052

<400> 1052
000

<210> 1053

<400> 1053
000

<210> 1054

eol f-seqI

<400> 1054
000

<210> 1055

<400> 1055
000

<210> 1056

<400> 1056
000

<210> 1057

<400> 1057
000

<210> 1058

<400> 1058
000

<210> 1059

<400> 1059
000

<210> 1060

<400> 1060
000

<210> 1061

<400> 1061
000

<210> 1062

<400> 1062
000

<210> 1063

<400> 1063
000

<210> 1064

<400> 1064
000

<210> 1065

<400> 1065
000

<210> 1066

<400> 1066
000

<210> 1067

<400> 1067
000

eol f-seq1

<210> 1068
<400> 1068
000
<210> 1069
<400> 1069
000
<210> 1070
<400> 1070
000
<210> 1071
<400> 1071
000
<210> 1072
<400> 1072
000
<210> 1073
<400> 1073
000
<210> 1074
<400> 1074
000
<210> 1075
<400> 1075
000
<210> 1076
<400> 1076
000
<210> 1077
<400> 1077
000
<210> 1078
<400> 1078
000
<210> 1079
<400> 1079
000
<210> 1080
<400> 1080
000
<210> 1081

eol f-seq1

<400> 1081
000

<210> 1082

<400> 1082
000

<210> 1083

<400> 1083
000

<210> 1084

<400> 1084
000

<210> 1085

<400> 1085
000

<210> 1086

<400> 1086
000

<210> 1087

<400> 1087
000

<210> 1088

<400> 1088
000

<210> 1089

<400> 1089
000

<210> 1090

<400> 1090
000

<210> 1091

<400> 1091
000

<210> 1092

<400> 1092
000

<210> 1093

<400> 1093
000

<210> 1094

<400> 1094
000

eol f-seql

<210> 1095

<400> 1095
000

<210> 1096

<400> 1096
000

<210> 1097

<400> 1097
000

<210> 1098

<400> 1098
000

<210> 1099

<400> 1099
000

<210> 1100

<400> 1100
000

<210> 1101

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, L117A

<400> 1101

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

eol f-seq1

Pro Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1102

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, L118A

<400> 1102

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

eol f-seql

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

eol f-seql

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gl y Asn
 290 295 300

Val Phe Ser Cys Ser Val Met Hi s Gl u Al a Leu Hi s Asn Hi s Tyr Thr
 305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gl y Lys
 325 330

<210> 1103
 <211> 330
 <212> PRT
 <213> Arti fi ci al sequence

<220>
 <223> Synthetic IgG1 HC constant region, L117A & L118A

<400> 1103

Al a Ser Thr Lys Gl y Pro Ser Val Phe Pro Leu Al a Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gl y Gl y Thr Al a Al a Leu Gl y Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gl y Al a Leu Thr Ser
 35 40 45

Gl y Val Hi s Thr Phe Pro Al a Val Leu Gl n Ser Ser Gl y Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gl y Thr Gl n Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn Hi s Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Gl u Pro Lys Ser Cys Asp Lys Thr Hi s Thr Cys Pro Pro Cys
 100 105 110

Pro Al a Pro Gl u Al a Al a Gl y Gl y Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Gl u Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser Hi s Gl u Asp Pro Gl u Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gl y Val Gl u Val Hi s Asn Al a Lys Thr Lys Pro Arg Gl u
 165 170 175

eol f-seql

Tyr Ile Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys

Arg Val Glu Pro 100 Lys Ser Cys Asp Lys 105 Thr His Thr Cys Pro 110 Pro Cys

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu 125 Phe Pro Pro 115

Lys Pro 130 Lys Asp Thr Leu Met 135 Ile Ser Arg Thr Pro Glu Val Thr Cys 140

Val 145 Val Val Asp Val Ser 150 His Glu Asp Pro Glu 155 Val Lys Phe Asn Trp 160

Tyr Val Asp Gly Val 165 Glu Val His Asn Ala 170 Lys Thr Lys Pro Arg Glu 175

Glu Gln Tyr Asn 180 Ser Thr Tyr Arg Val 185 Val Ser Val Leu Thr Val Leu 190

His Gln Asp 195 Trp Leu Asn Gly Lys 200 Glu Tyr Lys Cys Lys 205 Val Ser Asn

Lys Ala 210 Leu Pro Ala Pro Ile 215 Glu Lys Thr Ile Ser 220 Lys Ala Lys Gly

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 235 Pro Ser Arg Glu Glu 240 225

Met Thr Lys Asn Gln Val Ser Leu Thr Cys 250 Leu Val Lys Gly Phe Tyr 255 245

Pro Ser Asp Ile 260 Ala Val Glu Trp Glu 265 Ser Asn Gly Gln Pro Glu Asn 270

Asn Tyr Lys 275 Thr Thr Pro Pro Val 280 Leu Asp Ser Asp Gly 285 Ser Phe Phe

Leu Tyr 290 Ser Lys Leu Thr Val 295 Asp Lys Ser Arg Trp Gln Gln Gly Asn 300

Val 305 Phe Ser Cys Ser Val 310 Met His Glu Ala Leu 315 His Asn His Tyr Thr 320

Gln Lys Ser Leu Ser 325 Leu Ser Pro Gly Lys 330

<210> 1105

<211> 330

eol f-seql

<212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, L117V & L118V

<400> 1105

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

eol f-seq1

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1106
<211> 330
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic IgG1 HC constant region, L117I & L118I

<400> 1106

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

eol f-seql

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1107

<400> 1107
 000

<210> 1108

<400> 1108
 000

<210> 1109

<400> 1109
 000

<210> 1110

<400> 1110

eol f-seq1

000

<210> 1111

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->S, L117A

<400> 1111

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110Pro Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

eol f-seql

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1113

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->S, L117A & L118A

<400> 1113

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

eol f-seq1

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

eol F-seq1

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1114

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->S, L117G & L118G

<400> 1114

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

eol f-seql

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1115

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->S, L117V & L118V

<400> 1115

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys
 Arg Val Glu Pro 100 Lys Ser Ser Asp Lys 105 Thr His Thr Cys Pro 110 Pro Cys
 Pro Ala Pro 115 Glu Val Val Gly Gly 120 Pro Ser Val Phe Leu 125 Phe Pro Pro
 Lys Pro 130 Lys Asp Thr Leu Met 135 Ile Ser Arg Thr Pro 140 Glu Val Thr Cys
 Val 145 Val Val Asp Val Ser 150 His Glu Asp Pro Glu 155 Val Lys Phe Asn Trp 160
 Tyr Val Asp Gly Val 165 Glu Val His Asn Ala 170 Lys Thr Lys Pro Arg 175 Glu
 Glu Gln Tyr Asn 180 Ser Thr Tyr Arg Val 185 Val Ser Val Leu Thr 190 Val Leu
 His Gln Asp 195 Trp Leu Asn Gly Lys 200 Glu Tyr Lys Cys Lys 205 Val Ser Asn
 Lys Ala 210 Leu Pro Ala Pro Ile 215 Glu Lys Thr Ile Ser 220 Lys Ala Lys Gly
 Gln Pro Arg Glu Pro 230 Gln Val Tyr Thr Leu Pro 235 Pro Ser Arg Glu Glu 240
 Met Thr Lys Asn 245 Gln Val Ser Leu Thr Cys 250 Leu Val Lys Gly Phe Tyr 255
 Pro Ser Asp Ile 260 Ala Val Glu Trp Glu 265 Ser Asn Gly Gln Pro Glu Asn 270
 Asn Tyr Lys 275 Thr Thr Pro Pro Val 280 Leu Asp Ser Asp Gly 285 Ser Phe Phe
 Leu Tyr 290 Ser Lys Leu Thr Val 295 Asp Lys Ser Arg Trp 300 Gln Gln Gly Asn
 Val 305 Phe Ser Cys Ser Val 310 Met His Glu Ala Leu 315 His Asn His Tyr Thr 320
 Gln Lys Ser Leu Ser 325 Leu Ser Pro Gly Lys 330

<210> 1116
 <211> 330
 <212> PRT
 <213> Artificial sequence

eof-seq1

<220>

<223> Synthetic IgG1 HC constant region, HJ C->S, L117I & L118I

<400> 1116

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

eol f-seql

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Gl u Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1117

<400> 1117
 000

<210> 1118

<400> 1118
 000

<210> 1119

<400> 1119
 000

<210> 1120

<400> 1120
 000

<210> 1121

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L117A

<400> 1121

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

eol f-seq1

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Gl u Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Gl u Ala Leu Gly Gl y Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Gl u Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Gl u Asp Pro Gl u Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Gl u Val His Asn Ala Lys Thr Lys Pro Arg Gl u
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Gl u Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Gl u Lys Thr Ile Ser Lys Ala Lys Gl y
210 215 220

Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Gl u Gl u
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Gl u Trp Gl u Ser Asn Gly Gl n Pro Gl u Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gl y Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Gl u Ala Leu His Asn His Tyr Thr
305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

eol f-seq1

<210> 1122

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L118A

<400> 1122

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

eol f-seql

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1123

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L117A & L118A

<400> 1123

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

eof-seq1

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1124

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L117G & L118G

<400> 1124

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

eol f-seql

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80
 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110
 Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240
 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

eol f-seql

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1125

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L117V & L118V

<400> 1125

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
 100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205 eol f-seqI

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1126

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, HJ C->V, L117I & L118I

<400> 1126

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

eol f-seql

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Cys Pro Pro Cys
100 105 110

Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1127

<400> 1127
000

<210> 1128

eol f-seq1

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

Hi s Gl n Asp Trp Leu Asn Gly Lys Gl u Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Gl u Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gl n Pro Arg Gl u Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Gl u Gl u
 225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Gl u Trp Gl u Ser Asn Gly Gl n Pro Gl u Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met Hi s Gl u Ala Leu Hi s Asn Hi s Tyr Thr
 305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1132

<211> 330

<212> PRT

<213> Arti ficial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->S, L118A

<400> 1132

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Gl u Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val Hi s Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

eol f-seql

Tyr Ile Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys
 Arg Val Glu Pro 100 Lys Ser Cys Asp Lys 105 Thr His Thr Ser Pro 110 Pro Ser
 Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu 125 Phe Pro Pro
 Lys Pro 130 Lys Asp Thr Leu Met 135 Ile Ser Arg Thr Pro Glu Val Thr Cys
 Val 145 Val Val Asp Val Ser 150 His Glu Asp Pro Glu 155 Val Lys Phe Asn Trp 160
 Tyr Val Asp Gly Val 165 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 175
 Glu Gln Tyr Asn 180 Ser Thr Tyr Arg Val 185 Val Ser Val Leu Thr Val Leu
 His Gln Asp 195 Trp Leu Asn Gly Lys 200 Glu Tyr Lys Cys Lys 205 Val Ser Asn
 Lys Ala 210 Leu Pro Ala Pro Ile 215 Glu Lys Thr Ile Ser 220 Lys Ala Lys Gly
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 235 Pro Ser Arg Glu Glu 240
 Met Thr Lys Asn Gln 245 Val Ser Leu Thr Cys 250 Leu Val Lys Gly Phe Tyr 255
 Pro Ser Asp Ile 260 Ala Val Glu Trp Glu 265 Ser Asn Gly Gln Pro Glu Asn 270
 Asn Tyr Lys 275 Thr Thr Pro Pro Val 280 Leu Asp Ser Asp Gly 285 Ser Phe Phe
 Leu Tyr 290 Ser Lys Leu Thr Val 295 Asp Lys Ser Arg Trp 300 Gln Gln Gly Asn
 Val 305 Phe Ser Cys Ser Val 310 Met His Glu Ala Leu 315 His Asn His Tyr Thr 320
 Gln Lys Ser Leu Ser 325 Leu Ser Pro Gly Lys 330

<210> 1133

<211> 330

eol f-seql

<212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, BJ C->S, L117A & L118A

<400> 1133

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1134

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->S, L117G & L118G

<400> 1134

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

eol f-seql

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1135

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->S, L117V & L118V

<400> 1135

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

eol f-seq1

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
290 295 300

eof-seq1

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1136

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->S, L117I & L118I

<400> 1136

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110

Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

eol f-seql

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1137

<400> 1137
 000

<210> 1138

<400> 1138
 000

<210> 1139

<400> 1139
 000

<210> 1140

<400> 1140
 000

<210> 1141

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->V, L117A

<400> 1141

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

eol f-seq1

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
100 105 110

Pro Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160 165

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

eof-seq1

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1142
 <211> 330
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, BJ C->V, L118A

<400> 1142

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

eol f-seql

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1143

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->V, L117A & L118A

<400> 1143

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

eol f-seq1

Tyr Ile Cys Asn Val 85 Asn His Lys Pro Ser 90 Asn Thr Lys Val Asp 95 Lys

Arg Val Glu Pro 100 Lys Ser Cys Asp Lys 105 Thr His Thr Val Pro 110 Pro Val

Pro Ala Pro 115 Glu Ala Ala Gly Gly 120 Pro Ser Val Phe Leu 125 Phe Pro Pro

Lys Pro 130 Lys Asp Thr Leu Met 135 Ile Ser Arg Thr Pro 140 Glu Val Thr Cys

Val Val Val Asp Val Ser 150 His Glu Asp Pro Glu 155 Val Lys Phe Asn Trp 160

Tyr Val Asp Gly Val 165 Glu Val His Asn Ala 170 Lys Thr Lys Pro Arg 175 Glu

Glu Gln Tyr Asn 180 Ser Thr Tyr Arg Val 185 Val Ser Val Leu Thr 190 Val Leu

His Gln Asp 195 Trp Leu Asn Gly Lys 200 Glu Tyr Lys Cys Lys 205 Val Ser Asn

Lys Ala 210 Leu Pro Ala Pro Ile 215 Glu Lys Thr Ile Ser 220 Lys Ala Lys Gly

Gln Pro Arg Glu Pro Gln 230 Val Tyr Thr Leu Pro 235 Pro Ser Arg Glu Glu 240

Met Thr Lys Asn 245 Gln Val Ser Leu Thr Cys 250 Leu Val Lys Gly Phe Tyr 255

Pro Ser Asp Ile 260 Ala Val Glu Trp Glu 265 Ser Asn Gly Gln Pro 270 Glu Asn

Asn Tyr Lys 275 Thr Thr Pro Pro Val 280 Leu Asp Ser Asp Gly 285 Ser Phe Phe

Leu Tyr 290 Ser Lys Leu Thr Val 295 Asp Lys Ser Arg Trp 300 Gln Gln Gly Asn

Val Phe Ser Cys Ser Val 310 Met His Glu Ala Leu 315 His Asn His Tyr Thr 320

Gln Lys Ser Leu Ser 325 Leu Ser Pro Gly Lys 330

<210> 1144
 <211> 330
 <212> PRT
 <213> Artificial sequence

eof-seq1

<220>

<223> Synthetic IgG1 HC constant region, BJ C->V, L117G & L118G

<400> 1144

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
100 105 110

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

eol f-seql

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Gl u Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gl n Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1145

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->V, L117V & L118V

<400> 1145

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

eol f-seq1

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1146

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, BJ C->V, L117I & L118I

<400> 1146

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

eol f-seql

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80
 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110
 Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240
 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300
 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

eol f-seql

Gln Lys Ser Leu Ser₃₂₅ Leu Ser Pro Gly Lys₃₃₀

<210> 1147

<400> 1147
000

<210> 1148

<400> 1148
000

<210> 1149

<400> 1149
000

<210> 1150

<400> 1150
000

<210> 1151

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->S, L117A

<400> 1151

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

eof-seq1

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1152

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->S, L118A

<400> 1152

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

eof-seq1

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45
 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60
 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80
 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95
 Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110
 Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125
 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140
 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160
 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175
 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190
 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205
 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220
 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240
 Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255
 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270
 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285
 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

eol f-seql

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1153
 <211> 330
 <212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, DJ C->S, L117A & L118A
 <400> 1153

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205 eol f-seq1

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1154

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->S, L117G & L118G

<400> 1154

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

eol f-seql

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1155
<211> 330
<212> PRT
<213> Artificial sequence

<220>

eol f-seq1

<223> Synthetic IgG1 HC constant region, DJ C->S, L117V & L118V

<400> 1155

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

eof-seq1

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1156

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->S, L117I & L118I

<400> 1156

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Ser Asp Lys Thr His Thr Ser Pro Pro Ser
 100 105 110

Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

eol f-seql

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1157

<400> 1157
 000

<210> 1158

<400> 1158
 000

<210> 1159

<400> 1159
 000

<210> 1160

<400> 1160
 000

<210> 1161

<211> 330

eol f-seql

<212> PRT
 <213> Artificial sequence

<220>
 <223> Synthetic IgG1 HC constant region, DJ C->V, L117A

<400> 1161

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Ala Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

eof-seq1

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1162

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->V, L118A

<400> 1162

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Leu Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

eol f-seq1

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1163

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->V, L117A & L118A

<400> 1163

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

eol f-seq1

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gl n Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gl n Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
100 105 110

Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Gl u Gl n Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gl n Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gl n Pro Arg Glu Pro Gl n Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gl n Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gl n Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gl n Gl n Gly Asn
290 295 300

eol f-seq1

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1164

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->V, L117G & L118G

<400> 1164

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
 100 105 110

Pro Ala Pro Glu Gly Gly Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
 115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
 130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
 145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
 165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
 180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
 195 200 205

eol f-seql

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
 210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
 225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
 245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
 260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
 275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
 290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
 305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
 325 330

<210> 1165

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->V, L117V & L118V

<400> 1165

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
 1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
 20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
 35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
 50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
 65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
 85 90 95

eol f-seq1

Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
100 105 110

Pro Ala Pro Glu Val Val Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125

Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140

Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160

Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175

Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190

His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205

Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220

Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240

Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255

Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330

<210> 1166

<211> 330

<212> PRT

<213> Artificial sequence

<220>

<223> Synthetic IgG1 HC constant region, DJ C->V, L117I & L118I

eol f-seq1

<400> 1166

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95Arg Val Glu Pro Lys Ser Val Asp Lys Thr His Thr Val Pro Pro Val
100 105 110Pro Ala Pro Glu Ile Ile Gly Gly Pro Ser Val Phe Leu Phe Pro Pro
115 120 125Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys
130 135 140Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp
145 150 155 160Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu
165 170 175Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu
180 185 190His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn
195 200 205Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly
210 215 220Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Glu Glu
225 230 235 240Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr
245 250 255Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn
260 265 270

eol f-seq1

Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe
275 280 285

Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn
290 295 300

Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr
305 310 315 320

Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
325 330